PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 12383199-2 2002 While RA (10(-8) m) alone did not alter STAT-1 activation or expression in THP-1 cells, RA enhanced or prolonged STAT-1 activation (tyrosine 701 phosphorylation) and gene expression (mRNA and protein) induced by either IFN-beta or IFN-gamma. Tretinoin 88-90 interferon beta 1 Homo sapiens 219-227 12356687-5 2002 In response to lipopolysaccharide (LPS), IFN-beta gene expression was augmented in both wild-type and MyD88-deficient BMDC. bmdc 118-122 interferon beta 1 Homo sapiens 41-49 12425473-1 2002 PURPOSE: An integrated receptor-based pharmacokinetic/pharmacodynamic (PK/PD) model of interferon-beta la (IFN-beta la) previously developed for monkeys was used to capture the time-course of drug and induced neopterin concentrations after intravenous (IV) and subcutaneous (SC) dosing in humans. Neopterin 209-218 interferon beta 1 Homo sapiens 107-115 12349849-0 2002 Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Interferon-beta and glatiramer acetate (GA) are the two main groups of drugs used in the treatment of MS. glatiramer aetate 57-74 interferon beta 1 Homo sapiens 82-97 12349849-0 2002 Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Interferon-beta and glatiramer acetate (GA) are the two main groups of drugs used in the treatment of MS. Glatiramer Acetate 102-120 interferon beta 1 Homo sapiens 37-52 12349849-0 2002 Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Interferon-beta and glatiramer acetate (GA) are the two main groups of drugs used in the treatment of MS. Glatiramer Acetate 122-124 interferon beta 1 Homo sapiens 37-52 12220840-0 2002 Liver targeting of human interferon-beta with pullulan based on metal coordination. Metals 64-69 interferon beta 1 Homo sapiens 25-40 12220840-4 2002 A chelating residue, diethylenetriaminepentaacetic acid (DTPA), was introduced to pullulan, a water-soluble polysaccharide with a high affinity to the liver (DTPA-pullulan) and natural human IFN-beta was coordinately conjugated with the DTPA-pullulan by mixing in an aqueous solution containing zinc ions (Zn(2+)). Pentetic Acid 21-55 interferon beta 1 Homo sapiens 191-199 12220840-4 2002 A chelating residue, diethylenetriaminepentaacetic acid (DTPA), was introduced to pullulan, a water-soluble polysaccharide with a high affinity to the liver (DTPA-pullulan) and natural human IFN-beta was coordinately conjugated with the DTPA-pullulan by mixing in an aqueous solution containing zinc ions (Zn(2+)). Pentetic Acid 57-61 interferon beta 1 Homo sapiens 191-199 12220840-7 2002 Moreover, the duration of the liver 2-5AS induction by the IFN-beta-DTPA-pullulan conjugate was longer than that by free natural IFN-beta. Pentetic Acid 68-72 interferon beta 1 Homo sapiens 59-67 12564806-6 2002 Preliminary results indicated significantly greater efficacy for IFN beta-1a (Rebif, Serono) 44 microg administered subcutaneously three times weekly (t.i.w. serono 85-91 interferon beta 1 Homo sapiens 65-73 12186889-6 2002 poly(C)] and encephalomyocarditis virus were greatly enhanced by IFN-gamma pretreatment (priming) of wild-type cells or of mutant cells lacking an IFN-alpha/beta response; these include the primary induction of dsRNA-inducible mRNAs, including IFN-beta mRNA, and, to a lesser extent, the dsRNA-mediated activation of the p38 mitogen-activated protein (MAP) kinase(s). Poly C 0-7 interferon beta 1 Homo sapiens 244-252 12054664-3 2002 Here, we show the mAb to TLR3 suppressed poly(I):poly(C)-mediated IFN-beta production by human fibroblasts naturally expressing TLR3 on their surface. Poly I 41-48 interferon beta 1 Homo sapiens 66-74 12396726-4 2002 In this report, we characterized the viability of various human tumor cells in vitro after combination treatment with IFN-beta protein and the chemotherapeutic drugs, cis-platinum (II) diamine dichloride (cisplatin), 5-fluorouracil (5-FU), paclitaxel (Taxol) and gemcitabine. Cisplatin 205-214 interferon beta 1 Homo sapiens 118-126 12396726-4 2002 In this report, we characterized the viability of various human tumor cells in vitro after combination treatment with IFN-beta protein and the chemotherapeutic drugs, cis-platinum (II) diamine dichloride (cisplatin), 5-fluorouracil (5-FU), paclitaxel (Taxol) and gemcitabine. Fluorouracil 217-231 interferon beta 1 Homo sapiens 118-126 12396726-4 2002 In this report, we characterized the viability of various human tumor cells in vitro after combination treatment with IFN-beta protein and the chemotherapeutic drugs, cis-platinum (II) diamine dichloride (cisplatin), 5-fluorouracil (5-FU), paclitaxel (Taxol) and gemcitabine. Fluorouracil 233-237 interferon beta 1 Homo sapiens 118-126 12396726-4 2002 In this report, we characterized the viability of various human tumor cells in vitro after combination treatment with IFN-beta protein and the chemotherapeutic drugs, cis-platinum (II) diamine dichloride (cisplatin), 5-fluorouracil (5-FU), paclitaxel (Taxol) and gemcitabine. Paclitaxel 240-250 interferon beta 1 Homo sapiens 118-126 12396726-4 2002 In this report, we characterized the viability of various human tumor cells in vitro after combination treatment with IFN-beta protein and the chemotherapeutic drugs, cis-platinum (II) diamine dichloride (cisplatin), 5-fluorouracil (5-FU), paclitaxel (Taxol) and gemcitabine. Paclitaxel 252-257 interferon beta 1 Homo sapiens 118-126 12396726-4 2002 In this report, we characterized the viability of various human tumor cells in vitro after combination treatment with IFN-beta protein and the chemotherapeutic drugs, cis-platinum (II) diamine dichloride (cisplatin), 5-fluorouracil (5-FU), paclitaxel (Taxol) and gemcitabine. gemcitabine 263-274 interferon beta 1 Homo sapiens 118-126 12195454-5 2002 Patients were to continue treatment with IFNB-1b (8 MIU qod, subcutaneous) and received AZA (50 mg tid, oral). 1b 46-48 interferon beta 1 Homo sapiens 41-45 12144572-0 2002 Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Steroids 84-91 interferon beta 1 Homo sapiens 51-66 12184914-6 2002 Furthermore, viral spread in nonIL-1-treated cultures was inhibited by the addition of recombinant IFN-beta. nonil-1 29-36 interferon beta 1 Homo sapiens 99-107 12068083-12 2002 IFNbeta induced AP-1 nuclear binding activity in microglia and this was suppressed by PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 86-93 interferon beta 1 Homo sapiens 0-7 12068083-13 2002 Additionally, IFNbeta induced Stat1 phosphorylation at both tyrosine 701 (Y701) and serine 727 (S727) residues. Tyrosine 60-68 interferon beta 1 Homo sapiens 14-21 12068083-13 2002 Additionally, IFNbeta induced Stat1 phosphorylation at both tyrosine 701 (Y701) and serine 727 (S727) residues. Serine 84-90 interferon beta 1 Homo sapiens 14-21 12152786-6 2002 Co-treatment with either cytokine increased H2O2 effects whereas IFN-beta reversed H2O2-induced effects. Hydrogen Peroxide 83-87 interferon beta 1 Homo sapiens 65-73 12161037-8 2002 Secondly, in untreated patients with stable MS, culture with IFN-beta induced excessive tyrosine phosphorylation of STAT1, and this correlated with low SHP1 tyrosine phosphatase levels. Tyrosine 88-96 interferon beta 1 Homo sapiens 61-69 12096086-4 2002 Because interferon beta (IFN-beta) has antitumor effects and increases expression of some membrane receptors, we examined whether it may enhance the effects of NO-Cbl. no-cbl 160-166 interferon beta 1 Homo sapiens 8-23 12096086-4 2002 Because interferon beta (IFN-beta) has antitumor effects and increases expression of some membrane receptors, we examined whether it may enhance the effects of NO-Cbl. no-cbl 160-166 interferon beta 1 Homo sapiens 25-33 12096086-15 2002 The increased expression of TC II-R induced by IFN-beta resulted in enhanced antitumor effects with NO-Cbl both in vitro and in vivo. no-cbl 100-106 interferon beta 1 Homo sapiens 47-55 12144572-13 2002 CONCLUSION: Although this open pilot study included only a small number of patients, the high response rate suggests that interferon-beta may be a safe and effective treatment for steroid-refractory active ulcerative colitis. Steroids 180-187 interferon beta 1 Homo sapiens 122-137 12011292-0 2002 A one-year study on the pharmacodynamic profile of interferon-beta1a in MS. Interferon (IFN)-beta1a induction of neopterin and beta2-microglobulin (beta2-MG) were evaluated over 1 year in patients with MS. Neopterin and beta2-MG levels peaked 24 to 48 hours after weekly injections of IFNbeta1a over the entire study period. Neopterin 113-122 interferon beta 1 Homo sapiens 76-98 12168834-7 2002 When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of liposome-entrapped-gene, the rate of growth inhibition of these cells increased over that caused by either 5-FU or hIFN-beta gene entrapped in the liposomes alone. Fluorouracil 51-65 interferon beta 1 Homo sapiens 230-239 12168834-7 2002 When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of liposome-entrapped-gene, the rate of growth inhibition of these cells increased over that caused by either 5-FU or hIFN-beta gene entrapped in the liposomes alone. Fluorouracil 67-71 interferon beta 1 Homo sapiens 230-239 11956580-7 2002 Analysis of [35S]methionine incorporation into cells confirmed a more pronounced inhibitory effect elicited by IFN-beta and onconase; IFN-beta and 1 microg/ml onconase each decreased de novo protein synthesis by 23-25%, while the combination resulted in 59% suppression. Sulfur-35 13-16 interferon beta 1 Homo sapiens 111-119 11956580-7 2002 Analysis of [35S]methionine incorporation into cells confirmed a more pronounced inhibitory effect elicited by IFN-beta and onconase; IFN-beta and 1 microg/ml onconase each decreased de novo protein synthesis by 23-25%, while the combination resulted in 59% suppression. Methionine 17-27 interferon beta 1 Homo sapiens 111-119 12054664-3 2002 Here, we show the mAb to TLR3 suppressed poly(I):poly(C)-mediated IFN-beta production by human fibroblasts naturally expressing TLR3 on their surface. Poly C 49-56 interferon beta 1 Homo sapiens 66-74 12096926-7 2002 When melanocytes and melanoma cells were treated with a potent IFN inducer, polyinosinic:polycytidylic acid (poly I:C), the mRNA expression of both IFN-alpha and IFN-beta was significantly upregulated. Poly I-C 109-117 interferon beta 1 Homo sapiens 162-170 12096926-8 2002 Poly I:C was not able to induce melanocytes or melanoma cells to produce detectable amounts of IFN-alpha protein, but able to induce a significant amount of IFN-beta in melanocytes and two of the melanoma cell lines: MMAc and VMRC-MELG. Poly I-C 0-8 interferon beta 1 Homo sapiens 157-165 11955727-7 2002 Betaseron (recombinant human interferon beta(ser), rHuIFN-beta(ser),) was the chosen preparation of beta-interferon. Serine 4-7 interferon beta 1 Homo sapiens 29-44 11846976-3 2002 In infected cells, these factors are activated by phosphorylation on the serine residues, transported to the nucleus, where they bind to the promoters of IFNA and IFNB genes and tether histone transacetylases to the transcription complex enhanceosome. Serine 73-79 interferon beta 1 Homo sapiens 163-167 12096926-7 2002 When melanocytes and melanoma cells were treated with a potent IFN inducer, polyinosinic:polycytidylic acid (poly I:C), the mRNA expression of both IFN-alpha and IFN-beta was significantly upregulated. polyinosinic 76-88 interferon beta 1 Homo sapiens 162-170 12096926-7 2002 When melanocytes and melanoma cells were treated with a potent IFN inducer, polyinosinic:polycytidylic acid (poly I:C), the mRNA expression of both IFN-alpha and IFN-beta was significantly upregulated. Poly C 89-107 interferon beta 1 Homo sapiens 162-170 11884587-6 2002 A neutralizing antibody against beta interferon (IFN-beta) blunted Ser(727) phosphorylation and apoptosis after 7kchol treatment; cells deficient in an IFN-beta receptor subunit exhibited blunted apoptosis. Serine 67-70 interferon beta 1 Homo sapiens 32-57 11884587-6 2002 A neutralizing antibody against beta interferon (IFN-beta) blunted Ser(727) phosphorylation and apoptosis after 7kchol treatment; cells deficient in an IFN-beta receptor subunit exhibited blunted apoptosis. Serine 67-70 interferon beta 1 Homo sapiens 49-57 11884587-6 2002 A neutralizing antibody against beta interferon (IFN-beta) blunted Ser(727) phosphorylation and apoptosis after 7kchol treatment; cells deficient in an IFN-beta receptor subunit exhibited blunted apoptosis. 7-ketocholesterol 112-118 interferon beta 1 Homo sapiens 32-57 11884587-6 2002 A neutralizing antibody against beta interferon (IFN-beta) blunted Ser(727) phosphorylation and apoptosis after 7kchol treatment; cells deficient in an IFN-beta receptor subunit exhibited blunted apoptosis. 7-ketocholesterol 112-118 interferon beta 1 Homo sapiens 49-57 11884587-7 2002 IFN-beta alone did not induce apoptosis; thus, 7kchol-induced release of IFN-beta was necessary but not sufficient for optimal apoptosis. 7-ketocholesterol 47-53 interferon beta 1 Homo sapiens 0-8 11884587-7 2002 IFN-beta alone did not induce apoptosis; thus, 7kchol-induced release of IFN-beta was necessary but not sufficient for optimal apoptosis. 7-ketocholesterol 47-53 interferon beta 1 Homo sapiens 73-81 11867606-4 2002 Based on metal coordination, conjugation of IFNbeta with DTPA-dextran resulted from simply mixing both substances in an aqueous solution containing Zn(2+). Metals 9-14 interferon beta 1 Homo sapiens 44-51 11867606-4 2002 Based on metal coordination, conjugation of IFNbeta with DTPA-dextran resulted from simply mixing both substances in an aqueous solution containing Zn(2+). dtpa-dextran 57-69 interferon beta 1 Homo sapiens 44-51 11867606-4 2002 Based on metal coordination, conjugation of IFNbeta with DTPA-dextran resulted from simply mixing both substances in an aqueous solution containing Zn(2+). Zinc 148-150 interferon beta 1 Homo sapiens 44-51 11867606-16 2002 CONCLUSIONS: In this study, human IFNbeta was successfully used to target CNV, an enhanced antiangiogenic effect was achieved by combining it with dextran, based on metal coordination. Dextrans 147-154 interferon beta 1 Homo sapiens 34-41 11867606-16 2002 CONCLUSIONS: In this study, human IFNbeta was successfully used to target CNV, an enhanced antiangiogenic effect was achieved by combining it with dextran, based on metal coordination. Metals 165-170 interferon beta 1 Homo sapiens 34-41 11807004-6 2002 Finally, IL-3-IFN-beta DCs were found to produce much higher levels of IFN-alpha than IL-4-GM-CSF DCs in response to Poly (I:C) but not to influenza virus. poly 117-121 interferon beta 1 Homo sapiens 14-22 11911803-3 2002 The frequency of developing NAb and BAb to IFN-beta varied according to the IFN-beta given. bab 36-39 interferon beta 1 Homo sapiens 43-51 11911803-3 2002 The frequency of developing NAb and BAb to IFN-beta varied according to the IFN-beta given. bab 36-39 interferon beta 1 Homo sapiens 76-84 11911803-5 2002 Analysis of BAb seroconversion frequency in the same patients revealed that different IFN-beta preparations may also have different capability to induce BAb development and that BAb are produced during IFN-beta therapy at a significantly higher rate than NAb. bab 12-15 interferon beta 1 Homo sapiens 86-94 11911803-5 2002 Analysis of BAb seroconversion frequency in the same patients revealed that different IFN-beta preparations may also have different capability to induce BAb development and that BAb are produced during IFN-beta therapy at a significantly higher rate than NAb. bab 153-156 interferon beta 1 Homo sapiens 86-94 11911803-5 2002 Analysis of BAb seroconversion frequency in the same patients revealed that different IFN-beta preparations may also have different capability to induce BAb development and that BAb are produced during IFN-beta therapy at a significantly higher rate than NAb. bab 153-156 interferon beta 1 Homo sapiens 86-94 11798194-4 2002 We further studied the effect of the DP-conditioned medium and found that interferon beta, a predominant interferon secreted by the fibroblasts, is expressed by the DP cells. dp 37-39 interferon beta 1 Homo sapiens 74-89 12405292-4 2002 Using DNA microarrays, we compared expression between MIP-101 cells, a poorly metastatic human colon cancer cell line, with an interferon-beta (IFN-beta) resistant subline of MIP-101 (beta-MIP) that is metastatic to the liver. (2-benzoylethyl)trimethylammonium 138-142 interferon beta 1 Homo sapiens 144-152 11747625-0 2001 Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. Alanine 149-156 interferon beta 1 Homo sapiens 11-19 11741104-3 2001 Effects of short (3 h) or prolonged (48 h) exposure of RPE cells to natural human IFN-beta were assessed by (3)H-thymidine uptake. h-thymidine 111-122 interferon beta 1 Homo sapiens 82-90 11498771-7 2001 These data suggest that intratumoral delivery of the IFN-beta gene with adenoviral vectors could be an effective therapy for prostate cancer and that tumor suppression by AdIFN-beta correlated with up-regulation of iNOS and down-regulation of angiogenesis. adifn-beta 171-181 interferon beta 1 Homo sapiens 53-61 11498590-3 2001 We show that the accurate execution of the IFN-beta transcriptional switch depends on the ordered acetylation of the high-mobility group I protein HMGI(Y) by PCAF/GCN5 and CBP, which acetylate HMGI(Y) at distinct lysine residues on endogenous promoters. Lysine 213-219 interferon beta 1 Homo sapiens 43-51 11848487-6 2001 When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of hIFN-beta, the effectiveness of 5-FU was markedly enhanced. Fluorouracil 51-65 interferon beta 1 Homo sapiens 115-124 11848487-6 2001 When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of hIFN-beta, the effectiveness of 5-FU was markedly enhanced. Fluorouracil 67-71 interferon beta 1 Homo sapiens 115-124 11848487-6 2001 When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of hIFN-beta, the effectiveness of 5-FU was markedly enhanced. Fluorouracil 147-151 interferon beta 1 Homo sapiens 115-124 11337497-7 2001 A mutant IP6K2 with substitutions in the putative inositol phosphate binding domain abrogates IFN-beta-induced apoptosis. Inositol Phosphates 50-68 interferon beta 1 Homo sapiens 94-102 11389809-3 2001 Interferon beta 1-a, which has been demonstrated to significantly reduce the 3-year probability of the development of CDMS and the development of clinically silent MRI lesions in high-risk patients with acute optic neuritis, should be considered following IV methylprednisolone treatment (30 &mgr;g intramuscularly weekly). Methylprednisolone 259-277 interferon beta 1 Homo sapiens 0-17 11389809-3 2001 Interferon beta 1-a, which has been demonstrated to significantly reduce the 3-year probability of the development of CDMS and the development of clinically silent MRI lesions in high-risk patients with acute optic neuritis, should be considered following IV methylprednisolone treatment (30 &mgr;g intramuscularly weekly). Adenosine Monophosphate 293-296 interferon beta 1 Homo sapiens 0-17 11449369-4 2001 Here we describe distinct CpG-containing oligonucleotide sequences which, in contrast to previously described CpG ODN, induced high amounts of IFN-alpha and IFN-beta in peripheral blood mononuclear cells (PBMC). Oligonucleotides 41-56 interferon beta 1 Homo sapiens 157-165 11410525-7 2001 Caspase inhibitors benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl keton or benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl keton, inhibited IFN-beta-induced apoptosis. benzyloxycarbonyl-val-ala-asp-fluoromethyl keton 19-67 interferon beta 1 Homo sapiens 135-143 11410525-7 2001 Caspase inhibitors benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl keton or benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl keton, inhibited IFN-beta-induced apoptosis. benzyloxycarbonyl-asp-glu 71-96 interferon beta 1 Homo sapiens 135-143 11410525-7 2001 Caspase inhibitors benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl keton or benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl keton, inhibited IFN-beta-induced apoptosis. val-asp-fluoromethyl keton 97-123 interferon beta 1 Homo sapiens 135-143 11381057-7 2001 An image analysis system was used to determine the production of IFNbeta by either untreated or MMC-treated HTF. Mitomycin 96-99 interferon beta 1 Homo sapiens 65-72 11381057-10 2001 Both untreated and growth-arrested HTF secrete IFNbeta, and MMC at 0.4 mg/ml appeared to increase IFNbeta production. Mitomycin 60-63 interferon beta 1 Homo sapiens 98-105 11050025-9 2000 The different pattern seen in patients with and without baseline gadolinium enhancement suggests that part of the cerebral volume reduction observed in IFNbeta-treated patients may be due to the anti-inflammatory/antioedematous effect of the drug. Gadolinium 65-75 interferon beta 1 Homo sapiens 152-159 11389189-6 2001 IFN-beta decreased HO-1 expression and mitochondrial iron sequestration in IL-1beta- and TNF-alpha-challenged astroglia. Iron 53-57 interferon beta 1 Homo sapiens 0-8 11389189-9 2001 In MS, IFN-beta may attenuate glial HO-1 gene induction and aberrant mitochondrial iron deposition accruing from exposure to proinflammatory cytokines. Iron 83-87 interferon beta 1 Homo sapiens 7-15 11437159-5 2001 A bioassay was used to detect and quantify the NABs to IFN-beta, measuring the capacity of NABs to block the antiviral resistance induced by IFNs. nabs 47-51 interferon beta 1 Homo sapiens 55-63 11176940-0 2001 Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis. Etretinate 0-10 interferon beta 1 Homo sapiens 20-35 11176940-4 2001 OBJECTIVE: To determine whether retinoid administration to patients with MS who are being treated with interferon beta-1b augments their CD8 suppressor cell function. Retinoids 32-40 interferon beta 1 Homo sapiens 103-118 11176940-14 2001 CONCLUSIONS: Etretinate treatment at a dose of 10 mg twice or three times daily augments suppressor cell function in patients with MS receiving interferon beta-1b. Etretinate 13-23 interferon beta 1 Homo sapiens 144-159 11176940-17 2001 Whether pulse therapy or administration of retinoid restricted to the day of interferon beta dosing will also augment suppressor function, while being better tolerated, remains to be determined. Retinoids 43-51 interferon beta 1 Homo sapiens 77-92 11152576-10 2000 Induction of apoptosis by either 2-5A alone or by the combination of 2-5A and IFN-beta was effectively blocked with either the pancaspase inhibitor, Z-VAD-fmk, or with the caspase 3 inhibitor, DEVD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 149-158 interferon beta 1 Homo sapiens 78-86 11152576-10 2000 Induction of apoptosis by either 2-5A alone or by the combination of 2-5A and IFN-beta was effectively blocked with either the pancaspase inhibitor, Z-VAD-fmk, or with the caspase 3 inhibitor, DEVD-fmk. devd-fmk 193-201 interferon beta 1 Homo sapiens 78-86 11282166-3 2001 We previously demonstrated that serum sVCAM levels are increased in multiple sclerosis (MS) patients treated with interferon beta 1b (IFNbeta1b), which correlated with a reduction in gadolinium enhancing lesions on magnetic resonance imaging. Gadolinium 183-193 interferon beta 1 Homo sapiens 114-129 11603629-11 2001 MTX is inexpensive and, given its anti-inflammatory and immunomodulatory properties, may be used as add-on therapy in non-responders to interferon beta, although hepatic toxicity may be a problem in long-term treatment. Methotrexate 0-3 interferon beta 1 Homo sapiens 136-151 12687205-5 2001 The effect of rIFN-alpha administration on blood cell sensitivity to in vitro IFN-beta treatment was manifested by augmentation of PBL response in patient with the remitting MS. rifn-alpha 14-24 interferon beta 1 Homo sapiens 78-86 11169057-0 2000 A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. AIMS: Interferon alpha monotherapy induces a sustained response in less than 20% of patients treated for chronic hepatitis C. Interferon beta represents a potential therapeutic alternative for the treatment of chronic hepatitis C. The aim of this pilot study was to evaluate the efficacy and tolerance of recombinant interferon beta-la administered subcutaneously. beta-la 418-425 interferon beta 1 Homo sapiens 216-231 11169057-7 2000 CONCLUSIONS: The results of this pilot study indicate that interferon beta-la administered subcutaneously is an effective therapy for some patients with chronic hepatitis C, and suggest that interferon beta-1a deserves further evaluations in larger trials especially in combination with ribavirin. Ribavirin 287-296 interferon beta 1 Homo sapiens 59-74 11094104-4 2000 RESULTS: Pretreatment of T cells with IFN-beta potentiates the production of IL-10 when they interact with adult human microglia, human fetal microglia, or U937 cells treated with phorbol-12-myristate-13-acetate (PMA) and IFN-gamma. Tetradecanoylphorbol Acetate 180-211 interferon beta 1 Homo sapiens 38-46 11071509-2 2000 injection of interferon beta-1a on the secretion of the cytokines interleukin-6, tumor necrosis factor-alpha, soluble tumor necrosis factor receptor I, and interleukin-1 receptor antagonist and its relation to peripheral concentrations of adrenocorticotropic hormone (ACTH) and cortisol in patients with MS were investigated, as well as the influence of cotreatment with indomethacin on these parameters. Indomethacin 371-383 interferon beta 1 Homo sapiens 13-28 11096454-5 2000 The receptor blockade by mAb 51.44 and 234.28 resulted in the inhibition of IFN-alpha2a and IFN-beta-induced tyrosine phosphorylation of Jak1, Tyk2, Stat1/2/3, and IFNAR-1/2 and inhibition of IFN-stimulated gene factor 3 (ISGF3) formation. Tyrosine 109-117 interferon beta 1 Homo sapiens 92-100 11071509-3 2000 After interferon beta injection we found an acute rise in plasma cytokine levels and an increase in plasma hormone concentrations, both of which were modulated by indomethacin comedication. Indomethacin 163-175 interferon beta 1 Homo sapiens 6-21 11042692-3 2000 In combination treatment RA potentiates IFN-beta effect in SCC ME-180 but not in SiHa cell line, partially resistant to RA antiproliferative action. Tretinoin 25-27 interferon beta 1 Homo sapiens 40-48 19003391-7 2000 This is explained by the fact that the optimalsuppressed growth of NB1-RGB cells on the cast films leads tothe enhanced production of interferon-beta on the cast filmscompared to those on the LB films prepared by the same polymer. Polymers 222-229 interferon beta 1 Homo sapiens 134-149 11006365-8 2000 As compared with the patients in the placebo group, patients in the interferon beta-1a group had a relative reduction in the volume of brain lesions (P<0.001), fewer new or enlarging lesions (P<0.001), and fewer gadolinium-enhancing lesions (P<0.001) at 18 months. Gadolinium 212-222 interferon beta 1 Homo sapiens 68-83 10918594-0 2000 IFN-beta induces serine phosphorylation of Stat-1 in Ewing"s sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Serine 17-23 interferon beta 1 Homo sapiens 0-8 10925286-4 2000 IFN-beta induced inhibitory 16-kDa C/EBPbeta in macrophages, but had no effect on C/EBPbeta expression in monocytes. 16-kda 28-34 interferon beta 1 Homo sapiens 0-8 10918594-3 2000 Analysis of the early signals triggered by IFN-alpha and IFN-beta demonstrated that the two IFNs were similarly effective in inducing tyrosine phosphorylation of the Jak-1 and Tyk-2 kinases and the transcription factors Stat-1 and Stat-2. Tyrosine 134-142 interferon beta 1 Homo sapiens 57-65 10918594-4 2000 Interestingly, an additional rapid phosphorylation of Stat-1 on serine was observed after IFN-beta treatment, with concomitant activation of p38 mitogen-activated protein kinase. Serine 64-70 interferon beta 1 Homo sapiens 90-98 10918594-5 2000 In these cells, Stat-1 Ser727 phosphorylation in response to IFN-beta was found to be impaired by p38 MAPkinase inhibitor (SB203580). SB 203580 123-131 interferon beta 1 Homo sapiens 61-69 10926209-4 2000 One such gene, gene associated with retinoid-interferon-induced mortality-19 (GRIM-19), is essential for tumor cell death induced by interferon-beta (IFN-beta) and retinoic acid (RA). Retinoids 36-44 interferon beta 1 Homo sapiens 133-148 10926209-4 2000 One such gene, gene associated with retinoid-interferon-induced mortality-19 (GRIM-19), is essential for tumor cell death induced by interferon-beta (IFN-beta) and retinoic acid (RA). Retinoids 36-44 interferon beta 1 Homo sapiens 150-158 10926209-4 2000 One such gene, gene associated with retinoid-interferon-induced mortality-19 (GRIM-19), is essential for tumor cell death induced by interferon-beta (IFN-beta) and retinoic acid (RA). Tretinoin 179-181 interferon beta 1 Homo sapiens 133-148 10926209-4 2000 One such gene, gene associated with retinoid-interferon-induced mortality-19 (GRIM-19), is essential for tumor cell death induced by interferon-beta (IFN-beta) and retinoic acid (RA). Tretinoin 179-181 interferon beta 1 Homo sapiens 150-158 10860892-8 2000 The ability of cp-52, which does not express the SH and G proteins, to induce IFN-beta levels similar to those of its parent strain suggests that these viral proteins may not have a role in the induction of IFN-beta in the host. 1-(3-ETHOXYPROPYL)-3-HYDROXY-2-METHYLPYRIDIN-4-ONE 15-20 interferon beta 1 Homo sapiens 78-86 10802778-1 2000 OBJECTIVE: The authors examined the effect of 6.0 MIU interferon beta-1a (IFNbeta-1a) administered IM each week on the evolution of monthly magnetization transfer ratio (MTR) within new gadolinium-enhancing (Gd+) lesions in patients with very early relapsing-remitting (RR) MS. BACKGROUND: IFNbeta is an effective disease-modifying treatment for patients with RRMS. Gadolinium 186-196 interferon beta 1 Homo sapiens 74-81 10319275-15 1999 While in MTBE + Benzene exposed cells anti IFN-beta reduced the activity of these enzymes by 40% and anti-HSP70 by more than 90%. Benzene 16-23 interferon beta 1 Homo sapiens 43-51 10704203-2 2000 The crystal structure of IFN-beta-1a was used to design a panel of 15 mutant proteins, in each of which a contiguous group of 2-8 surface residues was mutated, in most instances to alanine. Alanine 181-188 interferon beta 1 Homo sapiens 25-33 10733102-0 2000 Phosphatidylinositol 3-kinase and mTOR mediate lipopolysaccharide-stimulated nitric oxide production in macrophages via interferon-beta. Nitric Oxide 77-89 interferon beta 1 Homo sapiens 120-135 10705228-3 2000 The anti-rspg41 antisera after adsorption by IFN-beta sepharose column lost the activity of interaction with both synthetic peptides. Sepharose 54-63 interferon beta 1 Homo sapiens 45-53 10705228-3 2000 The anti-rspg41 antisera after adsorption by IFN-beta sepharose column lost the activity of interaction with both synthetic peptides. Peptides 124-132 interferon beta 1 Homo sapiens 45-53 10705228-4 2000 In another experiment, rsgp41 could bind to sepharose column conjugated with anti-IFN-beta polyclonal antibodies (IgG). Sepharose 44-53 interferon beta 1 Homo sapiens 82-90 10606259-1 1999 Interferons (IFN)-alpha, -beta, and -gamma enhance the activity of 5-fluorouracil (5-FU) in vitro and in vivo. Fluorouracil 67-81 interferon beta 1 Homo sapiens 0-42 10606259-1 1999 Interferons (IFN)-alpha, -beta, and -gamma enhance the activity of 5-fluorouracil (5-FU) in vitro and in vivo. Fluorouracil 83-87 interferon beta 1 Homo sapiens 0-42 10450805-0 1999 Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C. We report the case of a 53-year-old female patient, who developed bilateral blepharoptosis, limb weakness, dysphagia, and dyspnea several days after human natural interferon-beta (IFN-beta) treatment for chronic active hepatitis C. A positive edrophonium test, an elevated anti-acetylcholine receptor antibody titer, and decrements in the amplitude of muscle action potentials evoked by repetitive stimulation confirmed the diagnosis of myasthenia gravis (MG). Edrophonium 354-365 interferon beta 1 Homo sapiens 53-68 10450805-0 1999 Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C. We report the case of a 53-year-old female patient, who developed bilateral blepharoptosis, limb weakness, dysphagia, and dyspnea several days after human natural interferon-beta (IFN-beta) treatment for chronic active hepatitis C. A positive edrophonium test, an elevated anti-acetylcholine receptor antibody titer, and decrements in the amplitude of muscle action potentials evoked by repetitive stimulation confirmed the diagnosis of myasthenia gravis (MG). Acetylcholine 389-402 interferon beta 1 Homo sapiens 53-68 10732833-2 2000 While IFN-beta therapy was continued in our outpatient clinic, his blood glucose level increased gradually, and he was admitted to our hospital for hyperglycemia. Glucose 73-80 interferon beta 1 Homo sapiens 6-14 10754403-6 2000 The anti-inflammatory cytokine IFN-beta blocked cytokine (IL-1beta plus IFN-gamma)-induced inhibition of glutamate uptake with a corresponding reduction in nitric oxide generation. Glutamic Acid 105-114 interferon beta 1 Homo sapiens 31-39 10754403-6 2000 The anti-inflammatory cytokine IFN-beta blocked cytokine (IL-1beta plus IFN-gamma)-induced inhibition of glutamate uptake with a corresponding reduction in nitric oxide generation. Nitric Oxide 156-168 interferon beta 1 Homo sapiens 31-39 10754403-7 2000 Taken together, these findings suggest that proinflammatory cytokines inhibit astrocyte glutamate uptake by a mechanism involving nitric oxide, and that IFN-beta may exert a therapeutically beneficial effect by blocking cytokine-induced nitric oxide production in inflammatory diseases of the brain. Nitric Oxide 237-249 interferon beta 1 Homo sapiens 153-161 10563614-1 1999 OBJECTIVE: To define the in vitro effects of interferon beta la (IFN-beta1a) on myelin basic protein (MBP)-reactive T cells and to determine its regulatory mechanism on cytokine networks in patients with MS. METHODS: The proliferation and cytokine production of MBP-reactive T-cell clones were measured in thymidine uptake assays and ELISA respectively. Thymidine 306-315 interferon beta 1 Homo sapiens 45-60 10496181-4 1999 After IFNbeta therapy, the production of interleukin-4 was decreased in MBP-stimulated TCL while the secretion of interferon-gamma was increased in unstimulated TCL. Triclosan 87-90 interferon beta 1 Homo sapiens 6-13 10496181-4 1999 After IFNbeta therapy, the production of interleukin-4 was decreased in MBP-stimulated TCL while the secretion of interferon-gamma was increased in unstimulated TCL. Triclosan 161-164 interferon beta 1 Homo sapiens 6-13 10428508-3 1999 In the present study, we provide evidence that the related CrkII protein is also rapidly phosphorylated on tyrosine during treatment of U-266 and Daudi cells with IFNalpha or IFNbeta. Tyrosine 107-115 interferon beta 1 Homo sapiens 175-182 10454351-4 1999 Consistent with this, tyrosine phosphorylation of Stat1 and Stat2 and formation of the IFN-stimulated gene factor 3 (ISGF3) complex occurred to a much higher degree in response to IFN-beta stimulation. Tyrosine 22-30 interferon beta 1 Homo sapiens 180-188 10229237-3 1999 Because the asialoglycoprotein (ASGP) receptor is specifically expressed in the liver at high density, the ASGP receptor-binding domain was generated within an N-glycosylated human IFN-beta molecule by the removal of sialic acid to direct this cytokine to the liver. Nitrogen 160-161 interferon beta 1 Homo sapiens 181-189 9916720-3 1999 Inhibition by IFN-gamma, and to a lesser extent IFN-beta, was almost completely reversed by addition of L-tryptophan to the culture medium, strongly implicating the indoleamine 2,3 dioxygenase (IDO) pathway. Tryptophan 104-116 interferon beta 1 Homo sapiens 48-56 10204571-10 1999 MS patients who demonstrate a pro-inflammatory response to IFN-beta (e.g., increased QUIN) may be less likely to benefit from this therapy. Quinolinic Acid 85-89 interferon beta 1 Homo sapiens 59-67 10049744-0 1999 Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Tyrosine 187-195 interferon beta 1 Homo sapiens 69-84 9920723-0 1999 Stimulation side-dependent asymmetrical secretion of poly I:poly C-induced interferon-beta from polarized epithelial cell lines. Poly I 53-59 interferon beta 1 Homo sapiens 75-90 9920723-0 1999 Stimulation side-dependent asymmetrical secretion of poly I:poly C-induced interferon-beta from polarized epithelial cell lines. Poly C 60-66 interferon beta 1 Homo sapiens 75-90 10074115-5 1999 Endogenous IFN-beta RNA production was also inhibited in Tet-inducible TD-IkappaBalpha-expressing cells. tetramethylenedisulfotetramine 57-60 interferon beta 1 Homo sapiens 11-19 9889406-4 1998 The two cell lines differ in their sensitivity to the anti-proliferative effects of the different agents and their combination: i) both cell lines were more responsive to IFN-beta than to IFN-alpha2b; ii) combined treatment with RA increases the growth inhibitory effect of the single agents in ME180, but not in SiHa; iii) the antiproliferative effect correlates with the induction of apoptosis. Tretinoin 229-231 interferon beta 1 Homo sapiens 171-179 10363567-13 1999 The maximal sensitizing enhancement ratio (SER) obtained with n-IFN-beta or r-IFN-beta1a at 3000 IU/ml was 1.66 and 1.51, respectively. Serine 43-46 interferon beta 1 Homo sapiens 64-72 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Serine 100-103 interferon beta 1 Homo sapiens 84-99 9774665-5 1998 We have previously reported that IFN-beta-all-trans-retinoic acid (RA) combination is a more potent growth suppressor of human tumor xenografts in vivo than either agent alone. Radium 67-69 interferon beta 1 Homo sapiens 33-41 9777250-7 1998 Expression of IFN-beta and MHC class I antigens was suppressed in ONS-76 cells during the dcAMP-induced differentiation. Bucladesine 90-95 interferon beta 1 Homo sapiens 14-22 9768684-4 1998 Six million international units of IFN-beta dissolved in glucose solution was injected for 30 min. Glucose 57-64 interferon beta 1 Homo sapiens 35-43 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Serine 100-103 interferon beta 1 Homo sapiens 105-113 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Fluorouracil 158-172 interferon beta 1 Homo sapiens 84-99 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Fluorouracil 158-172 interferon beta 1 Homo sapiens 105-113 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Fluorouracil 174-178 interferon beta 1 Homo sapiens 84-99 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Fluorouracil 174-178 interferon beta 1 Homo sapiens 105-113 9815298-15 1998 CONCLUSIONS: The combination of 5-FU and IFN beta ser was active in patients with advanced colorectal carcinoma, and survival with this regimen was comparable to or better than that with other modulating regimens. Serine 50-53 interferon beta 1 Homo sapiens 41-49 9557213-14 1998 IFN-beta is well tolerated in patients with AIDS-related Kaposi"s sarcoma when used in conjunction with zidovudine. Zidovudine 104-114 interferon beta 1 Homo sapiens 0-8 9649118-5 1998 In the presence of cycloheximide, virally induced IFN-beta gene expression of C-76 cells was suppressed, whereas R1 and R2 cells produced IFN-beta 7.5- and 2.2-fold higher than C-76 cells respectively. Cycloheximide 19-32 interferon beta 1 Homo sapiens 50-58 9649118-5 1998 In the presence of cycloheximide, virally induced IFN-beta gene expression of C-76 cells was suppressed, whereas R1 and R2 cells produced IFN-beta 7.5- and 2.2-fold higher than C-76 cells respectively. Cycloheximide 19-32 interferon beta 1 Homo sapiens 138-146 9525899-3 1998 For example, IFN-beta, but not IFN-alpha, induces the association of tyrosine-phosphorylated receptor components ifnar1 and ifnar2, and has activity in cells lacking the IFN receptor-associated, Janus kinase tyk2. Tyrosine 69-77 interferon beta 1 Homo sapiens 13-21 9780644-0 1998 Growth inhibition of experimental glioma by human interferon-beta superinduced by cationic liposomes entrapping polyinosilic:polycytidilic acid. polyinosilic: 112-125 interferon beta 1 Homo sapiens 50-65 9780644-0 1998 Growth inhibition of experimental glioma by human interferon-beta superinduced by cationic liposomes entrapping polyinosilic:polycytidilic acid. polycytidilic acid 125-143 interferon beta 1 Homo sapiens 50-65 9595973-7 1998 RESULTS: In patients in the open-label study, development of NAB to IFN-beta-1a resulted in a titer-dependent reduction in neopterin induction after interferon injections. Neopterin 123-132 interferon beta 1 Homo sapiens 68-76 9525899-5 1998 IFN-beta mutants with charged residues (N86K, N86E, or Y92D) introduced at two positions in the C helix lost the ability to induce the association of tyrosine-phosphorylated receptor chains and had reduced activity on tyk2-deficient cells. Tyrosine 150-158 interferon beta 1 Homo sapiens 0-8 9585809-0 1998 Interferon-beta-1-b (IFN-B) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. Nitric Oxide 46-58 interferon beta 1 Homo sapiens 0-19 9585809-0 1998 Interferon-beta-1-b (IFN-B) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. Nitric Oxide 46-58 interferon beta 1 Homo sapiens 21-26 9585809-4 1998 L-NMMA and aminoguanidine, competitive inhibitors of iNOS suppressed NO production as measured by the NO byproduct, nitrite, as did IFN-B. omega-N-Methylarginine 0-6 interferon beta 1 Homo sapiens 132-137 9585809-4 1998 L-NMMA and aminoguanidine, competitive inhibitors of iNOS suppressed NO production as measured by the NO byproduct, nitrite, as did IFN-B. pimagedine 11-25 interferon beta 1 Homo sapiens 132-137 9506459-4 1998 Concomitant treatment with (1000 U/ml) IFN-beta counteracted the inhibitory effect of etoposide and camptothecin but had no consistent effect on the inhibition mediated by the other drugs. Etoposide 86-95 interferon beta 1 Homo sapiens 39-47 9506459-4 1998 Concomitant treatment with (1000 U/ml) IFN-beta counteracted the inhibitory effect of etoposide and camptothecin but had no consistent effect on the inhibition mediated by the other drugs. Camptothecin 100-112 interferon beta 1 Homo sapiens 39-47 21533466-4 1997 However, all NSCLC lines were resistant to the antiproliferative effects of IFN alpha 2 and IFN beta ser. Serine 101-104 interferon beta 1 Homo sapiens 92-100 9489531-4 1998 METHODS: A 1H MRS study was performed on five patients with relapsing-remitting multiple sclerosis who were being treated with intramuscular IFN beta-1a (6 million units/week) for six months and on five untreated patients. Hydrogen 11-13 interferon beta 1 Homo sapiens 141-149 9489531-9 1998 A slight but not significant rise in the Cho peak was also found in normal appearing white matter in the patient group undergoing treatment with IFN beta-1a. Choline 41-44 interferon beta 1 Homo sapiens 145-153 9422392-8 1998 In view of these results, we suggest that a possible mechanism of action of interferon-beta in the treatment of multiple sclerosis is that it prevents astrocytic nitric oxide production, thereby limiting damage to neighbouring cells, such as neurones. Nitric Oxide 162-174 interferon beta 1 Homo sapiens 76-91 9452359-6 1997 However, those from KC activated with the potent IFN inducer, polyriboinosinic:polriboycytidylic acid (poly rI:rC), had appreciable antiviral activity, which studies with neutralizing sera showed to be caused by IFN-beta. polyriboinosinic 62-78 interferon beta 1 Homo sapiens 212-220 9452359-6 1997 However, those from KC activated with the potent IFN inducer, polyriboinosinic:polriboycytidylic acid (poly rI:rC), had appreciable antiviral activity, which studies with neutralizing sera showed to be caused by IFN-beta. polriboycytidylic acid 79-101 interferon beta 1 Homo sapiens 212-220 22358897-7 1997 The IFN-beta expression level reached in the presence of dexamethasone was about three times higher than in the absence of inducer. Dexamethasone 57-70 interferon beta 1 Homo sapiens 4-12 22358899-1 1997 Two hundreds species of marine algae were investigated for in vitro promoting activity of human interferon beta (IFN-beta) production by poly(I:C)-induced human osteosarcoma cell line, MG-63. Poly I-C 137-146 interferon beta 1 Homo sapiens 96-111 22358899-1 1997 Two hundreds species of marine algae were investigated for in vitro promoting activity of human interferon beta (IFN-beta) production by poly(I:C)-induced human osteosarcoma cell line, MG-63. Poly I-C 137-146 interferon beta 1 Homo sapiens 113-121 9199317-4 1997 In HeLa cells, both IFN-beta and oncostatin M (OSM) stimulated MAPK and Raf-1 enzyme activity, in addition to Stat1 and Stat3 tyrosine phosphorylation. Tyrosine 126-134 interferon beta 1 Homo sapiens 20-28 9181462-0 1997 Chemotherapeutic purine analogs alter the level of interferon-beta mRNA induced by poly I-poly C in cultured osteosarcoma cells. purine 17-23 interferon beta 1 Homo sapiens 51-66 9181462-0 1997 Chemotherapeutic purine analogs alter the level of interferon-beta mRNA induced by poly I-poly C in cultured osteosarcoma cells. Poly I-C 83-96 interferon beta 1 Homo sapiens 51-66 9181462-5 1997 Northern blot analysis showed a dose-dependent inhibition of IFN-B mRNA accumulation in response to a known inducer (Poly I-Poly C) all three purine analogs. Poly I-C 117-130 interferon beta 1 Homo sapiens 61-66 9181462-5 1997 Northern blot analysis showed a dose-dependent inhibition of IFN-B mRNA accumulation in response to a known inducer (Poly I-Poly C) all three purine analogs. purine 142-148 interferon beta 1 Homo sapiens 61-66 9181462-6 1997 Hybridization analysis also revealed that inhibition of IFN-beta mRNA accumulation by the purine analogs is not a result of decreased mRNA stability. purine 90-96 interferon beta 1 Homo sapiens 56-64 9397161-5 1998 IFN-alpha and IFN-beta were as effective as IFN-gamma in RPMI-8226 cells, but less than IFN-gamma in KG-1 cells. rpmi 57-61 interferon beta 1 Homo sapiens 14-22 9453454-1 1997 A long-term pretreatment (72 h) of bovine adrenal chromaffin cells with recombinant human interferon (IFN) -alpha-2b (1500 units/ml) produced a decrease in the secretion of catecholamines from the cells stimulated by acetylcholine (ACh) (25 micromol/l) but not that with human fibloblast IFN-beta (3000 units/ml) or recombinant human IFN-gamma (3000 units/ml). chromaffin 50-60 interferon beta 1 Homo sapiens 288-296 9453454-1 1997 A long-term pretreatment (72 h) of bovine adrenal chromaffin cells with recombinant human interferon (IFN) -alpha-2b (1500 units/ml) produced a decrease in the secretion of catecholamines from the cells stimulated by acetylcholine (ACh) (25 micromol/l) but not that with human fibloblast IFN-beta (3000 units/ml) or recombinant human IFN-gamma (3000 units/ml). Catecholamines 173-187 interferon beta 1 Homo sapiens 288-296 9402106-10 1997 Tamoxifen as a single agent had little effect (up to 2.0 microM) but caused enhanced antiproliferative activity when added to IFN-beta. Tamoxifen 0-9 interferon beta 1 Homo sapiens 126-134 9385476-7 1997 IFN-beta reduces the number of new T2-weighted lesions, as well as the number and volume of gadolinium-enhanced lesions. Gadolinium 92-102 interferon beta 1 Homo sapiens 0-8 10684111-22 1997 Similarly, in agreement with a very recent report from David, M et al in NIH, in which they indicated that forskolin (30 mumol/L) inhibited IFN-beta-stimulated ERK activity by U 266 cells (J. Biol. Colforsin 107-116 interferon beta 1 Homo sapiens 140-148 9067644-6 1997 Furthermore, morphine significantly inhibited both IFN-alpha and IFN-beta production by normal lymphocytes and fibroblasts but induced apoptosis of normal lymphocytes. Morphine 13-21 interferon beta 1 Homo sapiens 65-73 9287241-8 1997 Comparison with results from other studies suggests that CHO-derived IFN-beta 1a induces less neutralizing antibody than IFN-beta 1b produced in E. coli. cho 57-60 interferon beta 1 Homo sapiens 69-77 9041346-7 1997 In ECs, the constitutive production of interferon-beta, but not of other cytokines, appeared to confer resistance to CVBs. PVB protocol 117-121 interferon beta 1 Homo sapiens 39-54 9164531-2 1997 However, after completion of interferon-beta administration for 6 weeks, urinary excretion of uroporphyrin and coproporphyrin, serum enzymes and ferritin were significantly decreased correspondent with diminished hepatitis C virus RNA titer. Uroporphyrins 94-106 interferon beta 1 Homo sapiens 29-44 9164531-2 1997 However, after completion of interferon-beta administration for 6 weeks, urinary excretion of uroporphyrin and coproporphyrin, serum enzymes and ferritin were significantly decreased correspondent with diminished hepatitis C virus RNA titer. Coproporphyrins 111-125 interferon beta 1 Homo sapiens 29-44 9061569-3 1997 We report on treatment with interferon-beta in 8 patients with cerebral ALD, who additionally received glycerol trioleate/glycerol trierucate. Triolein 103-121 interferon beta 1 Homo sapiens 28-43 9061569-3 1997 We report on treatment with interferon-beta in 8 patients with cerebral ALD, who additionally received glycerol trioleate/glycerol trierucate. trierucate 122-141 interferon beta 1 Homo sapiens 28-43 9059994-3 1997 Treatment with the combination of IFN-beta and tamoxifen enhanced the expression of several IFN-beta-inducible genes in human breast carcinoma cell lines relative to levels induced by IFN-beta alone. Tamoxifen 47-56 interferon beta 1 Homo sapiens 92-100 9059994-3 1997 Treatment with the combination of IFN-beta and tamoxifen enhanced the expression of several IFN-beta-inducible genes in human breast carcinoma cell lines relative to levels induced by IFN-beta alone. Tamoxifen 47-56 interferon beta 1 Homo sapiens 92-100 9059994-9 1997 In tamoxifen treated cells, IFN-beta and IFN-gamma readily activated transcription factors ISGF-3 and GAF, respectively. Tamoxifen 3-12 interferon beta 1 Homo sapiens 28-36 22358527-5 1997 The production of interferon-beta (IFN-beta) by MG-63 cells super-induced by Poly (I): Poly (C) was shown to decrease in a dose dependent manner upon the addition of 0.01-10 mug/ml of cortisol or noradrenaline (NA). Poly I 77-85 interferon beta 1 Homo sapiens 18-33 8978300-4 1997 Prior treatment of U266 cells with IFN-beta downregulated IL-6-induced tyrosine phosphorylation of gp130, Jak2, PTP1D/Syp, Shc, and Erk2, and GTP-loading of p21ras. Tyrosine 71-79 interferon beta 1 Homo sapiens 35-43 8978300-4 1997 Prior treatment of U266 cells with IFN-beta downregulated IL-6-induced tyrosine phosphorylation of gp130, Jak2, PTP1D/Syp, Shc, and Erk2, and GTP-loading of p21ras. Guanosine Triphosphate 142-145 interferon beta 1 Homo sapiens 35-43 8978300-5 1997 Further analysis indicated that treatment with IFN-beta disrupted IL-6-induced binding of PTP1D/Syp to gp130 and the adaptor protein Grb2; IFN-beta pretreatment also interfered with IL-6-induced interaction of Shc with Grb2 and a 145-kD tyrosine-phosphorylated protein. Tyrosine 237-245 interferon beta 1 Homo sapiens 47-55 8978300-5 1997 Further analysis indicated that treatment with IFN-beta disrupted IL-6-induced binding of PTP1D/Syp to gp130 and the adaptor protein Grb2; IFN-beta pretreatment also interfered with IL-6-induced interaction of Shc with Grb2 and a 145-kD tyrosine-phosphorylated protein. Tyrosine 237-245 interferon beta 1 Homo sapiens 139-147 22358527-10 1997 These results suggest that DG, lipids from kefir and kefiran may be equated as anti-stress food component.Abbreviations DG - diacylglycerol; IFN-beta - interferon-beta; NA - noradrenaline; PC - phosphatidylcholine; Poly (I):Poly (C) - polyinosinic polycytidylic acid. kefir grain polysaccharide 53-60 interferon beta 1 Homo sapiens 141-149 22358527-10 1997 These results suggest that DG, lipids from kefir and kefiran may be equated as anti-stress food component.Abbreviations DG - diacylglycerol; IFN-beta - interferon-beta; NA - noradrenaline; PC - phosphatidylcholine; Poly (I):Poly (C) - polyinosinic polycytidylic acid. kefir grain polysaccharide 53-60 interferon beta 1 Homo sapiens 152-167 22358527-5 1997 The production of interferon-beta (IFN-beta) by MG-63 cells super-induced by Poly (I): Poly (C) was shown to decrease in a dose dependent manner upon the addition of 0.01-10 mug/ml of cortisol or noradrenaline (NA). Poly I 77-85 interferon beta 1 Homo sapiens 35-43 22358527-5 1997 The production of interferon-beta (IFN-beta) by MG-63 cells super-induced by Poly (I): Poly (C) was shown to decrease in a dose dependent manner upon the addition of 0.01-10 mug/ml of cortisol or noradrenaline (NA). Poly C 87-95 interferon beta 1 Homo sapiens 18-33 22358527-5 1997 The production of interferon-beta (IFN-beta) by MG-63 cells super-induced by Poly (I): Poly (C) was shown to decrease in a dose dependent manner upon the addition of 0.01-10 mug/ml of cortisol or noradrenaline (NA). Poly C 87-95 interferon beta 1 Homo sapiens 35-43 22358527-5 1997 The production of interferon-beta (IFN-beta) by MG-63 cells super-induced by Poly (I): Poly (C) was shown to decrease in a dose dependent manner upon the addition of 0.01-10 mug/ml of cortisol or noradrenaline (NA). Hydrocortisone 184-192 interferon beta 1 Homo sapiens 18-33 22358527-5 1997 The production of interferon-beta (IFN-beta) by MG-63 cells super-induced by Poly (I): Poly (C) was shown to decrease in a dose dependent manner upon the addition of 0.01-10 mug/ml of cortisol or noradrenaline (NA). Hydrocortisone 184-192 interferon beta 1 Homo sapiens 35-43 22358527-5 1997 The production of interferon-beta (IFN-beta) by MG-63 cells super-induced by Poly (I): Poly (C) was shown to decrease in a dose dependent manner upon the addition of 0.01-10 mug/ml of cortisol or noradrenaline (NA). Norepinephrine 196-209 interferon beta 1 Homo sapiens 18-33 22358527-5 1997 The production of interferon-beta (IFN-beta) by MG-63 cells super-induced by Poly (I): Poly (C) was shown to decrease in a dose dependent manner upon the addition of 0.01-10 mug/ml of cortisol or noradrenaline (NA). Norepinephrine 196-209 interferon beta 1 Homo sapiens 35-43 22358527-8 1997 Kefiran, a polysaccharide secreted from L. kafiranofasiens GKL-28 diminished the cortisol or NA influenced IFN-beta production. kefir grain polysaccharide 0-7 interferon beta 1 Homo sapiens 107-115 22358527-8 1997 Kefiran, a polysaccharide secreted from L. kafiranofasiens GKL-28 diminished the cortisol or NA influenced IFN-beta production. Polysaccharides 11-25 interferon beta 1 Homo sapiens 107-115 8989922-5 1997 In particular, the finding that in estrogen receptor-negative MDA-MB231 cells 4-HPR (which at 1 microM was singly ineffective) in combination with TAM at 1 microM or any concentration of IFN-beta produced a synergistic effect suggests that the compound could act through a pathway independent of specific receptors for retinoids. Tamoxifen 147-150 interferon beta 1 Homo sapiens 187-195 8989922-5 1997 In particular, the finding that in estrogen receptor-negative MDA-MB231 cells 4-HPR (which at 1 microM was singly ineffective) in combination with TAM at 1 microM or any concentration of IFN-beta produced a synergistic effect suggests that the compound could act through a pathway independent of specific receptors for retinoids. Retinoids 319-328 interferon beta 1 Homo sapiens 187-195 8910760-3 1996 In the IFN-beta sequence, there are five potential N-glycosylation sites and four cysteine residues. Cysteine 82-90 interferon beta 1 Homo sapiens 7-15 8969169-5 1996 Both IFNAR1 and IFNAR2.2 undergo tyrosine phosphorylation upon induction by either IFN-alpha or IFN-beta. Tyrosine 33-41 interferon beta 1 Homo sapiens 96-104 8892645-9 1996 Both single and multiple doses of IFN-beta(ser) increased serum ISG15 levels significantly (p < 0.01) over baseline. Serine 43-46 interferon beta 1 Homo sapiens 34-42 8892645-10 1996 A maximum 7.3-fold enhancement of serum ISG15 was obtained after multiple injections of 8 million units of IFN-beta(ser). Serine 34-37 interferon beta 1 Homo sapiens 107-115 8980894-3 1996 During IFN-beta administration (4th to 8th week of treatment), both serum free thyroxine (FT4) and free triiodothyronine (FT3) concentrations decreased significantly (P < 0.0005 and P < 0.05, respectively): FT4, 1.37 +/- 0.17 to 1.09 +/- 0.12 ng/dl, and FT3, 3.71 +/- 0.45 to 3.28 +/- 0.34 pg/ml. Thyroxine 79-88 interferon beta 1 Homo sapiens 7-15 8980894-3 1996 During IFN-beta administration (4th to 8th week of treatment), both serum free thyroxine (FT4) and free triiodothyronine (FT3) concentrations decreased significantly (P < 0.0005 and P < 0.05, respectively): FT4, 1.37 +/- 0.17 to 1.09 +/- 0.12 ng/dl, and FT3, 3.71 +/- 0.45 to 3.28 +/- 0.34 pg/ml. Triiodothyronine 104-120 interferon beta 1 Homo sapiens 7-15 8980894-3 1996 During IFN-beta administration (4th to 8th week of treatment), both serum free thyroxine (FT4) and free triiodothyronine (FT3) concentrations decreased significantly (P < 0.0005 and P < 0.05, respectively): FT4, 1.37 +/- 0.17 to 1.09 +/- 0.12 ng/dl, and FT3, 3.71 +/- 0.45 to 3.28 +/- 0.34 pg/ml. CHEMBL240806 122-125 interferon beta 1 Homo sapiens 7-15 8980894-4 1996 On the other hand, serum TSH increased significantly from a baseline of 1.70 +/- 0.82 to 3.34 +/- 1.98 microU/ml during IFN-beta administration (P < 0.005). Thyrotropin 25-28 interferon beta 1 Homo sapiens 120-128 8938568-4 1996 However, when present on both sides of the micropore membrane, all the IFN (1000 U/ml IFN-alpha and IFN-beta, 100 U/ml IFN-gamma) inhibited both random and directed migration toward zymosan-activated serum (ZAS). Zymosan 182-189 interferon beta 1 Homo sapiens 100-108 8862132-0 1996 Methylprednisolone attenuates interferon-beta induced expression of HLA-DR on monocytes. Methylprednisolone 0-18 interferon beta 1 Homo sapiens 30-45 8862132-1 1996 The effect of methylprednisolone on constitutive and interferon-beta (IFN-beta) induced HLA-DR expression on monocytes from multiple sclerosis (MS) patients was investigated. Methylprednisolone 14-32 interferon beta 1 Homo sapiens 70-78 8862132-5 1996 Experiments in which monocytes from normal subjects and MS patients were pre-treated in vitro with methylprednisolone prior to IFN-beta stimulation revealed that induction of HLA-DR was significantly inhibited; in contrast, IFN-beta induced HLA-DR expression was not down-regulated following subsequent in vitro treatment with methylprednisolone. Methylprednisolone 99-117 interferon beta 1 Homo sapiens 224-232 8862132-5 1996 Experiments in which monocytes from normal subjects and MS patients were pre-treated in vitro with methylprednisolone prior to IFN-beta stimulation revealed that induction of HLA-DR was significantly inhibited; in contrast, IFN-beta induced HLA-DR expression was not down-regulated following subsequent in vitro treatment with methylprednisolone. Methylprednisolone 327-345 interferon beta 1 Homo sapiens 224-232 8662521-4 1996 Human monocytes transfected with pDNA or double-stranded oligonucleotides containing the ISS, but not those transfected with ISS-deficient pDNA or oligonucleotides, transcribed large amounts of interferon-alpha, interferon-beta, and interleukin-12. double-stranded oligonucleotides 41-73 interferon beta 1 Homo sapiens 212-227 8757052-0 1996 The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis. Pentoxifylline 32-46 interferon beta 1 Homo sapiens 77-94 8857714-3 1996 First, we validated the IFNB NAB assay used in the multicenter trial by having representative stored serum samples reanalyzed by an independent laboratory. nab 29-32 interferon beta 1 Homo sapiens 24-28 8662521-4 1996 Human monocytes transfected with pDNA or double-stranded oligonucleotides containing the ISS, but not those transfected with ISS-deficient pDNA or oligonucleotides, transcribed large amounts of interferon-alpha, interferon-beta, and interleukin-12. ISS 89-92 interferon beta 1 Homo sapiens 212-227 8662521-4 1996 Human monocytes transfected with pDNA or double-stranded oligonucleotides containing the ISS, but not those transfected with ISS-deficient pDNA or oligonucleotides, transcribed large amounts of interferon-alpha, interferon-beta, and interleukin-12. Oligonucleotides 57-73 interferon beta 1 Homo sapiens 212-227 8676386-13 1996 In addition, helix A", which is interdigitated into the helical bundle in a manner similar to the helices in the CD loop of interferon-beta and interferon-gamma, exists in a region where short stretches of beta-structure are found at analogous positions in GM-CSF and IL-5. Cadmium 113-115 interferon beta 1 Homo sapiens 124-139 8602746-9 1996 Patients treated with interferon beta-1a also had significantly fewer exacerbations (p = 0.03) and a significantly lower number and volume of gadolinium-enhanced brain lesions on magnetic resonance images (p-values ranging between 0.02 and 0.05). Gadolinium 142-152 interferon beta 1 Homo sapiens 22-37 8727074-7 1996 Superoxide production was enhanced to the greatest degree by IFN-gamma, followed by IFN-beta and then IFN-gamma. Superoxides 0-10 interferon beta 1 Homo sapiens 84-92 9345430-4 1996 The counteracting effect of IFN-alpha/IFN-beta against IFN-gamma-induced astrocytic proliferation was verified by the DNA content distribution analysis of propidium iodide-labeled cells. Propidium 155-171 interferon beta 1 Homo sapiens 38-46 8631848-5 1996 Pretreatment of cells with retinoic acid (RA) for 16 h followed by IFN-beta, but not the converse, induced cytotoxic effects in the cells. Tretinoin 27-40 interferon beta 1 Homo sapiens 67-75 8631848-5 1996 Pretreatment of cells with retinoic acid (RA) for 16 h followed by IFN-beta, but not the converse, induced cytotoxic effects in the cells. Tretinoin 42-44 interferon beta 1 Homo sapiens 67-75 8602746-12 1996 Interferon beta-1a had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium-enhanced lesions on brain magnetic resonance images. Gadolinium 216-226 interferon beta 1 Homo sapiens 0-15 8615603-7 1996 The addition of low concentrations of IFN-beta to the culture medium determined a significant increase (p < 0.02) in PgF2 alpha and a parallel increase in the above ratio in neoplastic tissue, while no variation was found in normal endometrium. Dinoprost 120-130 interferon beta 1 Homo sapiens 38-46 8552072-7 1996 Sucrose gradient analysis of cytoplasmic extracts showed that IFN-beta transcripts with elongated poly(A) tails were found in the nonpolysomal fractions, whereas the shorter transcripts could be detected in both polysomal and nonpolysomal fractions. Sucrose 0-7 interferon beta 1 Homo sapiens 62-70 8552072-7 1996 Sucrose gradient analysis of cytoplasmic extracts showed that IFN-beta transcripts with elongated poly(A) tails were found in the nonpolysomal fractions, whereas the shorter transcripts could be detected in both polysomal and nonpolysomal fractions. poly 98-102 interferon beta 1 Homo sapiens 62-70 8707485-9 1996 These observations infer that the thermoregulatory pathway in the brain becomes conditioned and points to a common pathway of communication in which interferon-beta, prostaglandin E2, CRH and ACTH appear to play a role in modulating both Tc and NK cell activity. Technetium 238-240 interferon beta 1 Homo sapiens 149-164 8548878-4 1996 The study also revealed two distinct metabolic patterns in which the urinary recoveries of (R)-2-DCE-IFF and (R)-3-DCE-IFF were linked as were those of (S)-2-DCE-IFF and (S)-3-DCE-IFF. (s)-3-dce 170-179 interferon beta 1 Homo sapiens 101-104 8548878-3 1996 The results indicated an enantioselective excretion of the parent and N-dechloroethylated metabolites: the urinary recovery of (R)-IFF was significantly greater than that of (S)-IFF (1.73 +/- 0.45 vs 1.43 +/- 0.41 mmol, P < 0.0001); the excretion of (S)-2-DCE-IFF (0.75 +/- 0.53 mmol) was greater than that of (R)-2-DCE-IFF (0.42 +/- 0.22 mmol, P = 0.071) while the excretion of (R)-3-DCE-IFF (1.64 +/- 0.76 mmol) was greater than that of (S)-3-DCE-IFF (0.77 +/- 0.59 mmol, P = 0.012). Nitrogen 70-71 interferon beta 1 Homo sapiens 131-134 8548878-4 1996 The study also revealed two distinct metabolic patterns in which the urinary recoveries of (R)-2-DCE-IFF and (R)-3-DCE-IFF were linked as were those of (S)-2-DCE-IFF and (S)-3-DCE-IFF. (s)-3-dce 170-179 interferon beta 1 Homo sapiens 119-122 8548878-3 1996 The results indicated an enantioselective excretion of the parent and N-dechloroethylated metabolites: the urinary recovery of (R)-IFF was significantly greater than that of (S)-IFF (1.73 +/- 0.45 vs 1.43 +/- 0.41 mmol, P < 0.0001); the excretion of (S)-2-DCE-IFF (0.75 +/- 0.53 mmol) was greater than that of (R)-2-DCE-IFF (0.42 +/- 0.22 mmol, P = 0.071) while the excretion of (R)-3-DCE-IFF (1.64 +/- 0.76 mmol) was greater than that of (S)-3-DCE-IFF (0.77 +/- 0.59 mmol, P = 0.012). Nitrogen 70-71 interferon beta 1 Homo sapiens 178-181 8548878-3 1996 The results indicated an enantioselective excretion of the parent and N-dechloroethylated metabolites: the urinary recovery of (R)-IFF was significantly greater than that of (S)-IFF (1.73 +/- 0.45 vs 1.43 +/- 0.41 mmol, P < 0.0001); the excretion of (S)-2-DCE-IFF (0.75 +/- 0.53 mmol) was greater than that of (R)-2-DCE-IFF (0.42 +/- 0.22 mmol, P = 0.071) while the excretion of (R)-3-DCE-IFF (1.64 +/- 0.76 mmol) was greater than that of (S)-3-DCE-IFF (0.77 +/- 0.59 mmol, P = 0.012). Nitrogen 70-71 interferon beta 1 Homo sapiens 178-181 8548878-3 1996 The results indicated an enantioselective excretion of the parent and N-dechloroethylated metabolites: the urinary recovery of (R)-IFF was significantly greater than that of (S)-IFF (1.73 +/- 0.45 vs 1.43 +/- 0.41 mmol, P < 0.0001); the excretion of (S)-2-DCE-IFF (0.75 +/- 0.53 mmol) was greater than that of (R)-2-DCE-IFF (0.42 +/- 0.22 mmol, P = 0.071) while the excretion of (R)-3-DCE-IFF (1.64 +/- 0.76 mmol) was greater than that of (S)-3-DCE-IFF (0.77 +/- 0.59 mmol, P = 0.012). Nitrogen 70-71 interferon beta 1 Homo sapiens 178-181 8548878-3 1996 The results indicated an enantioselective excretion of the parent and N-dechloroethylated metabolites: the urinary recovery of (R)-IFF was significantly greater than that of (S)-IFF (1.73 +/- 0.45 vs 1.43 +/- 0.41 mmol, P < 0.0001); the excretion of (S)-2-DCE-IFF (0.75 +/- 0.53 mmol) was greater than that of (R)-2-DCE-IFF (0.42 +/- 0.22 mmol, P = 0.071) while the excretion of (R)-3-DCE-IFF (1.64 +/- 0.76 mmol) was greater than that of (S)-3-DCE-IFF (0.77 +/- 0.59 mmol, P = 0.012). Nitrogen 70-71 interferon beta 1 Homo sapiens 178-181 8548878-3 1996 The results indicated an enantioselective excretion of the parent and N-dechloroethylated metabolites: the urinary recovery of (R)-IFF was significantly greater than that of (S)-IFF (1.73 +/- 0.45 vs 1.43 +/- 0.41 mmol, P < 0.0001); the excretion of (S)-2-DCE-IFF (0.75 +/- 0.53 mmol) was greater than that of (R)-2-DCE-IFF (0.42 +/- 0.22 mmol, P = 0.071) while the excretion of (R)-3-DCE-IFF (1.64 +/- 0.76 mmol) was greater than that of (S)-3-DCE-IFF (0.77 +/- 0.59 mmol, P = 0.012). Nitrogen 70-71 interferon beta 1 Homo sapiens 178-181 8548878-4 1996 The study also revealed two distinct metabolic patterns in which the urinary recoveries of (R)-2-DCE-IFF and (R)-3-DCE-IFF were linked as were those of (S)-2-DCE-IFF and (S)-3-DCE-IFF. (s)-3-dce 170-179 interferon beta 1 Homo sapiens 119-122 8548878-3 1996 The results indicated an enantioselective excretion of the parent and N-dechloroethylated metabolites: the urinary recovery of (R)-IFF was significantly greater than that of (S)-IFF (1.73 +/- 0.45 vs 1.43 +/- 0.41 mmol, P < 0.0001); the excretion of (S)-2-DCE-IFF (0.75 +/- 0.53 mmol) was greater than that of (R)-2-DCE-IFF (0.42 +/- 0.22 mmol, P = 0.071) while the excretion of (R)-3-DCE-IFF (1.64 +/- 0.76 mmol) was greater than that of (S)-3-DCE-IFF (0.77 +/- 0.59 mmol, P = 0.012). (r)-3-dce 382-391 interferon beta 1 Homo sapiens 131-134 8548878-4 1996 The study also revealed two distinct metabolic patterns in which the urinary recoveries of (R)-2-DCE-IFF and (R)-3-DCE-IFF were linked as were those of (S)-2-DCE-IFF and (S)-3-DCE-IFF. (r)-2-dce 91-100 interferon beta 1 Homo sapiens 101-104 8548878-4 1996 The study also revealed two distinct metabolic patterns in which the urinary recoveries of (R)-2-DCE-IFF and (R)-3-DCE-IFF were linked as were those of (S)-2-DCE-IFF and (S)-3-DCE-IFF. (s)-3-dce 170-179 interferon beta 1 Homo sapiens 119-122 8548878-4 1996 The study also revealed two distinct metabolic patterns in which the urinary recoveries of (R)-2-DCE-IFF and (R)-3-DCE-IFF were linked as were those of (S)-2-DCE-IFF and (S)-3-DCE-IFF. (r)-3-dce 109-118 interferon beta 1 Homo sapiens 119-122 7479825-9 1995 However, of type I IFNs, IFN-beta uniquely induced the tyrosine phosphorylation of a 105-kDa protein associated with the IFNAR chain in two lymphoblastoid cell lines (Daudi and U266), demonstrating the specificity of transmembrane signaling for IFN-beta and IFN-alpha through the IFNAR chain. Tyrosine 55-63 interferon beta 1 Homo sapiens 25-33 8548878-4 1996 The study also revealed two distinct metabolic patterns in which the urinary recoveries of (R)-2-DCE-IFF and (R)-3-DCE-IFF were linked as were those of (S)-2-DCE-IFF and (S)-3-DCE-IFF. (r)-3-dce 109-118 interferon beta 1 Homo sapiens 119-122 8548878-4 1996 The study also revealed two distinct metabolic patterns in which the urinary recoveries of (R)-2-DCE-IFF and (R)-3-DCE-IFF were linked as were those of (S)-2-DCE-IFF and (S)-3-DCE-IFF. (r)-3-dce 109-118 interferon beta 1 Homo sapiens 119-122 7479825-9 1995 However, of type I IFNs, IFN-beta uniquely induced the tyrosine phosphorylation of a 105-kDa protein associated with the IFNAR chain in two lymphoblastoid cell lines (Daudi and U266), demonstrating the specificity of transmembrane signaling for IFN-beta and IFN-alpha through the IFNAR chain. Tyrosine 55-63 interferon beta 1 Homo sapiens 245-253 7569900-3 1995 Treatment of cells with IFN-beta induced tyrosine phosphorylation and activation of MAPK and caused MAPK and Stat1 alpha to coimmunoprecipitate. Tyrosine 41-49 interferon beta 1 Homo sapiens 24-32 9815929-3 1995 A strong synergism (P < 0.002) was observed when a short-term (1-h), high-concentration exposure to fluoropyrimidine (300 or 1000 microM) was followed by IFN-beta given continuously. 2-fluoropyrimidine 103-119 interferon beta 1 Homo sapiens 157-165 9815929-5 1995 Longer exposures to the fluoropyrimidine (24 h, 7 days) produced less than additive effects with IFN-beta, indicating strong schedule dependency for this synergism. 2-fluoropyrimidine 24-40 interferon beta 1 Homo sapiens 97-105 9815929-8 1995 When the prolonged infusion of IFN-beta followed a 1-h exposure to FUra, the observed TS inhibition and recovery, at each time point, were very similar to the expected values, indicating that the interactions between these drugs at the level of TS are not the determinant of the synergism. Fluorouracil 67-71 interferon beta 1 Homo sapiens 31-39 9815929-10 1995 During the continuous exposure to IFN-beta, a significant accumulation of HCT-8 cells in S-phase was observed at 24, 48, and 72 h compared to untreated controls (P = 0.003); however, under the same experimental conditions producing synergy in the clonogenic assay, no significant cell cycle perturbations were produced by the combination of FUra followed by IFN-beta compared to those caused by each agent alone. Fluorouracil 341-345 interferon beta 1 Homo sapiens 34-42 9815929-15 1995 These results suggest that the mechanism of this synergism may be related to the ability of IFN-beta to promote the incorporation of intracellular FUra metabolites into nucleic acids and/or to inhibit the cleavage of FUra nucleotides from RNA/DNA. Fluorouracil 147-151 interferon beta 1 Homo sapiens 92-100 9815929-15 1995 These results suggest that the mechanism of this synergism may be related to the ability of IFN-beta to promote the incorporation of intracellular FUra metabolites into nucleic acids and/or to inhibit the cleavage of FUra nucleotides from RNA/DNA. fura nucleotides 217-233 interferon beta 1 Homo sapiens 92-100 8534972-0 1995 Enhancement of production of IgM and interferon-beta in human cell lines by poly-lysine. Polylysine 76-87 interferon beta 1 Homo sapiens 37-52 8534972-5 1995 epsilon-Poly-lysine also enhanced interferon-beta (IFN-beta) production of human osteosarcoma MG-63 cells, but this stimulatory effect was reduced by the trypsin digestion. Polylysine 0-19 interferon beta 1 Homo sapiens 34-49 8534972-5 1995 epsilon-Poly-lysine also enhanced interferon-beta (IFN-beta) production of human osteosarcoma MG-63 cells, but this stimulatory effect was reduced by the trypsin digestion. Polylysine 0-19 interferon beta 1 Homo sapiens 51-59 7776650-1 1995 In our previous study on liposome-mediated transfection of the human interferon-beta (HuIFN-beta) gene into subcutaneously implanted human gliomas in nude mice, we found that HuIFN-beta was produced and secreted by the tumor cells and that the growth of solid tumors was completely inhibited. huifn 86-91 interferon beta 1 Homo sapiens 69-84 8572622-3 1995 In a previous paper we reported that in a subset of patients (pts) with metastatic breast cancer the resistance to the antiestrogen could be overcome by pretreatment with natural interferon-beta (nIFN-beta) followed by the association of nIFN-beta and T. In the present study we adopted a treatment schedule employing nIFN-beta (3 x 10(6) IU/day im three times a week) and T (60 mg/day) concurrently in 30 pts with ABC progressive to previous treatment with T (30 mg/day). nifn-beta 196-205 interferon beta 1 Homo sapiens 179-194 8588979-4 1995 This suggests that a synergistic involvement of phosphatidylinositol-bis-phosphate (PIP2) hydrolysis and phosphatidylcholine (PC) breakdown provide early molecular events upon the interaction between interferon beta and its cell surface receptors. Phosphatidylinositol 4,5-Diphosphate 84-88 interferon beta 1 Homo sapiens 200-215 8588979-4 1995 This suggests that a synergistic involvement of phosphatidylinositol-bis-phosphate (PIP2) hydrolysis and phosphatidylcholine (PC) breakdown provide early molecular events upon the interaction between interferon beta and its cell surface receptors. Phosphatidylcholines 105-124 interferon beta 1 Homo sapiens 200-215 8588979-4 1995 This suggests that a synergistic involvement of phosphatidylinositol-bis-phosphate (PIP2) hydrolysis and phosphatidylcholine (PC) breakdown provide early molecular events upon the interaction between interferon beta and its cell surface receptors. Phosphatidylcholines 126-128 interferon beta 1 Homo sapiens 200-215 7648442-2 1995 Fibroblast-derived natural human interferon-beta is a glycoprotein having a single asparagine-linked sugar chain. Asparagine 83-93 interferon beta 1 Homo sapiens 33-48 7648442-2 1995 Fibroblast-derived natural human interferon-beta is a glycoprotein having a single asparagine-linked sugar chain. Sugars 101-106 interferon beta 1 Homo sapiens 33-48 7648442-9 1995 The results also suggested that the terminal sialic acid of the sugar chains in natural human interferon-beta significantly affects its pharmacokinetics and biologic activities. N-Acetylneuraminic Acid 45-56 interferon beta 1 Homo sapiens 94-109 7648442-9 1995 The results also suggested that the terminal sialic acid of the sugar chains in natural human interferon-beta significantly affects its pharmacokinetics and biologic activities. Sugars 64-69 interferon beta 1 Homo sapiens 94-109 7640344-3 1995 The effects of TNF and IFN-beta were further distinguished by the action of the protein synthesis inhibitor cycloheximide, which reduced MT-II mRNA stimulation by TNF but enhanced IFN-beta-induced MT-II mRNA. Cycloheximide 108-121 interferon beta 1 Homo sapiens 180-188 7553067-8 1995 Pre-exposure in vivo to IFN-beta ser seems to prime the PBMs to respond to in vitro stimulation by IFN-gamma, which otherwise had no effect. Serine 33-36 interferon beta 1 Homo sapiens 24-32 7762995-0 1995 IFN-beta inhibition of etoposide resistance acquisition in vitro: studies using a human glioblastoma cell line. Etoposide 23-32 interferon beta 1 Homo sapiens 0-8 7762995-1 1995 The inhibition by IFN-beta of acquired resistance to the epipodophillotoxin etoposide was studied using a human glioblastoma cell line, T98G. Etoposide 76-85 interferon beta 1 Homo sapiens 18-26 7762995-8 1995 The present results show that resistant cells have less topoisomerase II than sensitive cells, suggesting that IFN-beta inhibits the acquisition of resistance to etoposide by suppressing the alteration in topoisomerase II. Etoposide 162-171 interferon beta 1 Homo sapiens 111-119 7762995-9 1995 The inhibition of acquired resistance to etoposide by IFN-beta suggests that continuous and repeated chemotherapy for glioblastoma and other malignant tumors may be clinically advantageous. Etoposide 41-50 interferon beta 1 Homo sapiens 54-62 9363235-2 1995 Polyriboinosinic/polyribocytidylic acid [poly(I:C)] induced exclusively IFN-beta in trophoblast cultures, whereas viruses induced mixtures of IFN-alpha subtypes and -beta. Poly I-C 0-39 interferon beta 1 Homo sapiens 72-80 9363235-2 1995 Polyriboinosinic/polyribocytidylic acid [poly(I:C)] induced exclusively IFN-beta in trophoblast cultures, whereas viruses induced mixtures of IFN-alpha subtypes and -beta. Poly I-C 41-50 interferon beta 1 Homo sapiens 72-80 7532663-5 1995 Pretreatment of the three melanoma cell lines with the tyrosine kinase inhibitors, Herbimycin A or Genistein, produced a dose-dependent inhibition of the antiviral action of IFN-alpha, -beta, and -gamma and the induction of OAS by IFN-beta. herbimycin 83-95 interferon beta 1 Homo sapiens 231-239 7532663-5 1995 Pretreatment of the three melanoma cell lines with the tyrosine kinase inhibitors, Herbimycin A or Genistein, produced a dose-dependent inhibition of the antiviral action of IFN-alpha, -beta, and -gamma and the induction of OAS by IFN-beta. Genistein 99-108 interferon beta 1 Homo sapiens 231-239 7720088-1 1995 The tryptophan decyclizing enzyme indoleamine 2,3-dioxygenase (IDO) was induced in human monocyte-derived macrophages (MDM) treated with human recombinant interferon-beta (IFN-beta) or interferon-gamma (IFN-gamma). Tryptophan 4-14 interferon beta 1 Homo sapiens 155-170 7720088-1 1995 The tryptophan decyclizing enzyme indoleamine 2,3-dioxygenase (IDO) was induced in human monocyte-derived macrophages (MDM) treated with human recombinant interferon-beta (IFN-beta) or interferon-gamma (IFN-gamma). Tryptophan 4-14 interferon beta 1 Homo sapiens 172-180 7720088-4 1995 When IFN-beta-treated cells were incubated in the presence of specified amounts of bacterial lipopolysaccharide (LPS) or liposome-encapsulated muramyl tripeptide (MTP), peak IDO activity increased such that enzyme activity was comparable to maximal activity observed with IFN-gamma-treated cells. muramyl tripeptide 143-161 interferon beta 1 Homo sapiens 5-13 7553067-10 1995 All the NK activity responding to IFN-beta ser was found in the CD16+ enriched population of PBM, suggesting that it is unlikely that in vivo redistribution of CD16+ subsets representative of NK cells has occurred in the peripheral blood. Serine 43-46 interferon beta 1 Homo sapiens 34-42 7883780-7 1995 At higher carboplatin: IFN beta molar ratios (20,000:1 and 60,000:1) an additive interaction was observed (I = 1.07 and 1.20). Carboplatin 10-21 interferon beta 1 Homo sapiens 23-31 7648432-5 1995 Zwittergent 3-14 was used in combination with urea to produce a urea/Zwittergent 3-14 washed inclusion body preparation enriched in human interferon-beta Ser17 (Betaseron). Urea 64-68 interferon beta 1 Homo sapiens 138-153 7883780-4 1995 IFN beta was found to be 10,000 times more active in inhibiting cell growth of SK-MEL 28 cells than carboplatin on the basis of IC50 values (IFN beta: IC50 = 1.24 nM, carboplatin: IC50 = 18.2 microM). Carboplatin 100-111 interferon beta 1 Homo sapiens 0-8 7883780-4 1995 IFN beta was found to be 10,000 times more active in inhibiting cell growth of SK-MEL 28 cells than carboplatin on the basis of IC50 values (IFN beta: IC50 = 1.24 nM, carboplatin: IC50 = 18.2 microM). Carboplatin 100-111 interferon beta 1 Homo sapiens 141-149 7883780-4 1995 IFN beta was found to be 10,000 times more active in inhibiting cell growth of SK-MEL 28 cells than carboplatin on the basis of IC50 values (IFN beta: IC50 = 1.24 nM, carboplatin: IC50 = 18.2 microM). Carboplatin 167-178 interferon beta 1 Homo sapiens 0-8 7883780-5 1995 The addition of IFN beta at 0.5 nM reduced the IC50 value of carboplatin 18.0-fold; with IFN beta at 0.05 nM a dose reduction of 1.84 was measured. Carboplatin 61-72 interferon beta 1 Homo sapiens 16-24 7648432-5 1995 Zwittergent 3-14 was used in combination with urea to produce a urea/Zwittergent 3-14 washed inclusion body preparation enriched in human interferon-beta Ser17 (Betaseron). zwittergent 3-14 0-16 interferon beta 1 Homo sapiens 138-153 7783683-0 1995 Carbohydrate-dependent biological activities of glycosylated human interferon-beta on human hepatoblastoma cells in vitro. Carbohydrates 0-12 interferon beta 1 Homo sapiens 67-82 7783683-3 1995 These results showed that the sugar chain structure of human interferon-beta affects its biological activity on human hepatoblastoma cells. Sugars 30-35 interferon beta 1 Homo sapiens 61-76 7909434-1 1994 Addition of IFN-beta resulted in a dose-dependent reduction of growth, a drop in [3H]thymidine incorporation into DNA, and a concurrent 69% and 15% increase in the S and G2/M phases, of the human prostatic JCA-1 cells. Tritium 82-84 interferon beta 1 Homo sapiens 12-20 7813427-0 1994 Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta. Tyrosine 13-21 interferon beta 1 Homo sapiens 157-165 7813427-3 1994 We show that the IFNAR protein becomes tyrosine phosphorylated within 5 min after treatment of human myeloma U266 cells with IFN-alpha 2, IFN-alpha 8 or IFN-beta. Tyrosine 39-47 interferon beta 1 Homo sapiens 153-161 7813427-6 1994 After IFN-beta treatment for 5 min, a tyrosine-phosphorylated protein of approximately 95 kDa (beta-PTyr) is found bound to IFNAR, but can be dissociated by denaturation. Tyrosine 38-46 interferon beta 1 Homo sapiens 6-14 7813427-6 1994 After IFN-beta treatment for 5 min, a tyrosine-phosphorylated protein of approximately 95 kDa (beta-PTyr) is found bound to IFNAR, but can be dissociated by denaturation. beta-ptyr 95-104 interferon beta 1 Homo sapiens 6-14 7813427-8 1994 The ratio of beta-PTyr to IFNAR tyrosine phosphorylation is much higher with IFN-beta than with IFN-alpha 2 or 8. beta-ptyr 13-22 interferon beta 1 Homo sapiens 77-85 7813427-8 1994 The ratio of beta-PTyr to IFNAR tyrosine phosphorylation is much higher with IFN-beta than with IFN-alpha 2 or 8. Tyrosine 32-40 interferon beta 1 Homo sapiens 77-85 7523403-3 1994 In mammary cells or hybridoma B9 cells, four distinct tyrosine-phosphorylated transcription complexes activated by interleukin-6 (IL-6) and IFN-beta were observed: pIRFA and complexes I, II, and III (of increasing electrophoretic mobility). Tyrosine 54-62 interferon beta 1 Homo sapiens 140-148 8063804-7 1994 The protein synthesis inhibitor cycloheximide inhibited collagenase mRNA induction by TNF or IFN-beta, suggesting that induction by both agents is indirect. Cycloheximide 32-45 interferon beta 1 Homo sapiens 93-101 8027027-1 1994 Interferon-beta selectively induces tyrosine phosphorylation of an alpha subunit-associated protein. Tyrosine 36-44 interferon beta 1 Homo sapiens 0-15 8027027-3 1994 Both IFN-alpha and IFN-beta induced tyrosine phosphorylation of the beta subunit of the receptor. Tyrosine 36-44 interferon beta 1 Homo sapiens 19-27 8027027-6 1994 Interestingly, IFN-beta, but not IFN-alpha or IFN-omega, induced tyrosine phosphorylation of an alpha subunit-associated protein with an apparent molecular mass of approximately 100 kDa (p100). Tyrosine 65-73 interferon beta 1 Homo sapiens 15-23 8027027-8 1994 However, differences between the signaling pathways of different Type I IFNs exist, as suggested by tyrosine phosphorylation of an alpha subunit-associated protein only in response to IFN-beta. Tyrosine 100-108 interferon beta 1 Homo sapiens 184-192 8078205-3 1994 However, scores of SDS were more increased in the patients treated with IFN-alpha (32.7 +/- 7.4 to 38.9 +/- 8.4, n = 26, p < 0.001) than in those treated with IFN-beta (33.7 +/- 9.8 to 36.0 +/- 12.4, n = 18, not significant), suggesting subclinical psychiatric abnormalities caused by IFN therapy. Sodium Dodecyl Sulfate 19-22 interferon beta 1 Homo sapiens 162-170 7523670-7 1994 Interferon beta ser had weak IDO stimulatory activity that was in a few cases additive to that of IFN-gamma. Serine 16-19 interferon beta 1 Homo sapiens 0-15 8069001-1 1994 OBJECTIVE: To introduce readers to the use of a new agent, interferon beta-1b (IFN beta ser), in the treatment of relapsing-remitting multiple sclerosis (RRMS). Serine 88-91 interferon beta 1 Homo sapiens 59-74 8069001-1 1994 OBJECTIVE: To introduce readers to the use of a new agent, interferon beta-1b (IFN beta ser), in the treatment of relapsing-remitting multiple sclerosis (RRMS). Serine 88-91 interferon beta 1 Homo sapiens 79-87 8069001-2 1994 Therapeutic and economic issues surrounding IFN beta ser are discussed, as are its pharmacology, clinical efficacy, adverse effects, and dosage guidelines. Serine 53-56 interferon beta 1 Homo sapiens 44-52 8069001-6 1994 DATA SYNTHESIS: IFN beta ser has recently been approved by the Food and Drug Administration for the treatment of RRMS. Serine 25-28 interferon beta 1 Homo sapiens 16-24 8069001-14 1994 CONCLUSIONS: IFN beta ser is not a cure for MS, but it is well tolerated and patients with RRMS have shown significant improvements in exacerbation rates and burden of central nervous system disease. Serine 22-25 interferon beta 1 Homo sapiens 13-21 7510292-4 1994 Moreover, in MCF-7 cells natural IFN beta (nIFN beta) combined with aqua[meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(II) (meso-6-Pt) resulted in synergistic inhibition. meso-6-pt 154-163 interferon beta 1 Homo sapiens 33-41 10319138-5 1994 Taken together, these data indicate that interferon-beta produced in response to poly I:C acts in an autocrine manner to activate the 2"-5" oligoadenylate synthetase and to induce resistance to HSV-1. Poly I 81-87 interferon beta 1 Homo sapiens 41-56 7508909-7 1994 Tyrosine phosphorylation of p95vav in U-266 and HL-60 cells was also induced by two other Type I IFNs, IFN beta and IFN omega. Tyrosine 0-8 interferon beta 1 Homo sapiens 103-125 7527303-2 1994 Results obtained in the in vitro study indicate that combinations of interferon-beta/-gamma with cepharanthin show synergistic and, occasionally, additive antiproliferative effects in a dose-dependent manner on tumor viable cell-staining assay. cepharanthine 97-109 interferon beta 1 Homo sapiens 69-84 7527303-3 1994 Interferon-gamma combined with cepharanthin suppressed the growth of all four human tumor cell lines (RPMI 4788, PC 10, HeLa, ZR-75-1), and this enhanced antiproliferative effect was not dependent on the interferon species involved, including interferon-beta and -gamma. cepharanthine 31-43 interferon beta 1 Homo sapiens 243-269 7527303-7 1994 These studies indicate that due to their therapeutic potential, combinations of recombinant human interferon-beta or -gamma with cepharanthin might be a promising therapy for pulmonary metastasis of human cancers. cepharanthine 129-141 interferon beta 1 Homo sapiens 98-113 7684500-4 1993 However, translational efficiency was considerably improved when the poly(A) tract was shortened (11 A residues) or when the 3" AU-rich sequence was deleted, indicating that interaction between these two regions was responsible for the reduced translation of the poly(A)-rich hu-IFN beta mRNA. Poly A 263-270 interferon beta 1 Homo sapiens 279-287 8344280-9 1993 An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. fuc(alpha 1-6) 222-236 interferon beta 1 Homo sapiens 60-75 8344280-9 1993 An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. 2-acetamido-2-deoxy-4-O-(beta-2-acetamid-2-deoxyglucopyranosyl)glucopyranose 215-221 interferon beta 1 Homo sapiens 60-75 8344280-9 1993 An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. man2glcnac 247-257 interferon beta 1 Homo sapiens 60-75 8344280-9 1993 An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. 2-acetamido-2-deoxy-4-O-(beta-2-acetamid-2-deoxyglucopyranosyl)glucopyranose 237-243 interferon beta 1 Homo sapiens 60-75 8077347-1 1993 When interferons (IFN-alpha-2a, IFN-alpha-2b, natural IFN-alpha and IFN-beta) were cultured with human thyroid follicles, each IFN inhibited TSH-induced thyroid function (125I incorporation and release of 125I-T4) in a concentration-dependent manner. Thyrotropin 141-144 interferon beta 1 Homo sapiens 68-76 8077347-1 1993 When interferons (IFN-alpha-2a, IFN-alpha-2b, natural IFN-alpha and IFN-beta) were cultured with human thyroid follicles, each IFN inhibited TSH-induced thyroid function (125I incorporation and release of 125I-T4) in a concentration-dependent manner. Iodine-125 171-175 interferon beta 1 Homo sapiens 68-76 8077347-1 1993 When interferons (IFN-alpha-2a, IFN-alpha-2b, natural IFN-alpha and IFN-beta) were cultured with human thyroid follicles, each IFN inhibited TSH-induced thyroid function (125I incorporation and release of 125I-T4) in a concentration-dependent manner. 125i-t4 205-212 interferon beta 1 Homo sapiens 68-76 8301155-5 1993 Sixty to 120 min after IFN-beta ser injection median levels of cortisol, adrenocorticotropin (ACTH), prolactin (PRL), and growth hormone (GH) rose two-fold. Serine 32-35 interferon beta 1 Homo sapiens 23-31 8301155-6 1993 Urinary free cortisol excretion increased significantly during the day following IFN-beta ser administration. Serine 90-93 interferon beta 1 Homo sapiens 81-89 8100486-5 1993 This study demonstrates that IFN beta is able to inhibit HTLV-I infection of CBMC through a mechanism that does not necessarily involve cell-mediated natural or antigen-dependent immunity afforded by CBMC subpopulations distinct from targets of HTLV-I infection. cbmc 77-81 interferon beta 1 Homo sapiens 29-37 8344280-9 1993 An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. Polysaccharides 202-209 interferon beta 1 Homo sapiens 60-75 8344280-9 1993 An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins. Man3GlcNAc 211-221 interferon beta 1 Homo sapiens 60-75 8390537-8 1993 Primary amines also inhibited IL-1-induced increases in ELAM-1, ICAM-1, and VCAM-1 measured 4 to 6 h after treatment and inhibited IFN-beta- and IFN-gamma-mediated induction of class I MHC molecules and IFN-gamma-mediated induction of class II MHC molecules measured 72 h after treatment with cytokine. Amines 8-14 interferon beta 1 Homo sapiens 131-139 8517649-0 1993 Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Fluorouracil 48-62 interferon beta 1 Homo sapiens 0-15 8483840-0 1993 Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Serine 54-57 interferon beta 1 Homo sapiens 38-53 8483840-0 1993 Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Neopterin 104-113 interferon beta 1 Homo sapiens 38-53 8483840-1 1993 The pharmacokinetics of and biologic response modification by recombinant human interferon-beta ser (rIFN-beta ser) were evaluated in 12 healthy male volunteers. Serine 96-99 interferon beta 1 Homo sapiens 80-95 8483840-1 1993 The pharmacokinetics of and biologic response modification by recombinant human interferon-beta ser (rIFN-beta ser) were evaluated in 12 healthy male volunteers. Serine 111-114 interferon beta 1 Homo sapiens 80-95 8517649-1 1993 The modulating effect of human fibroblast-derived interferon beta (IFN-beta) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. Fluorouracil 104-118 interferon beta 1 Homo sapiens 50-65 8517649-1 1993 The modulating effect of human fibroblast-derived interferon beta (IFN-beta) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. Fluorouracil 104-118 interferon beta 1 Homo sapiens 67-75 8517649-1 1993 The modulating effect of human fibroblast-derived interferon beta (IFN-beta) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. Fluorouracil 120-124 interferon beta 1 Homo sapiens 50-65 8517649-1 1993 The modulating effect of human fibroblast-derived interferon beta (IFN-beta) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. Fluorouracil 120-124 interferon beta 1 Homo sapiens 67-75 7803191-0 1993 Enhancement of interferon-beta production with sphingomyelin from fermented milk. Sphingomyelins 47-60 interferon beta 1 Homo sapiens 15-30 1289413-4 1992 In the second study, patients received IFN-beta ser 180 million units t.i.w. Serine 48-51 interferon beta 1 Homo sapiens 39-47 1447187-4 1992 In addition, the mRNA levels for the cytokines interleukin-1 alpha (IL-1 alpha) and interferon-beta 1 are induced in poly(I.C)-treated cells. Poly I-C 117-126 interferon beta 1 Homo sapiens 84-101 1289413-6 1992 Severe or life-threatening fatigue with decline in performance status complicated treatment of 37% of patients receiving IFN-alpha 2b and 17% of patients receiving IFN-beta ser. Serine 173-176 interferon beta 1 Homo sapiens 164-172 1368953-0 1992 Stimulation of interferon beta production of cultured cells by phospholipids in foodstuffs. Phospholipids 63-76 interferon beta 1 Homo sapiens 15-30 1448916-2 1992 In cells treated with poly rl:rC and cycloheximide, appearance of TH3 DNA-binding activity was inversely proportional to the disappearance of a constitutive complex TH1 and coincided temporally with induction of IFN-beta gene transcription. Cycloheximide 37-50 interferon beta 1 Homo sapiens 212-220 1431312-1 1992 The clinical tolerance of and the effects recombinant human interferon-beta (rHuIFN-beta) obtained from mammalian cells (Chinese hamster ovary cells) exerts on 2",5"-oligoadenyl (2-5A) synthetase activity, human-Mx protein, neopterin, beta 2-microglobulin, interleukin-1 (IL-1) alpha and beta synthesis were compared to those of natural IFN-beta in 12 healthy volunteers. Neopterin 224-233 interferon beta 1 Homo sapiens 60-75 1431312-1 1992 The clinical tolerance of and the effects recombinant human interferon-beta (rHuIFN-beta) obtained from mammalian cells (Chinese hamster ovary cells) exerts on 2",5"-oligoadenyl (2-5A) synthetase activity, human-Mx protein, neopterin, beta 2-microglobulin, interleukin-1 (IL-1) alpha and beta synthesis were compared to those of natural IFN-beta in 12 healthy volunteers. Neopterin 224-233 interferon beta 1 Homo sapiens 80-88 1431312-5 1992 Moreover, rHuIFN-beta and natural IFN-beta induced significant and similar increases in 2"-5" adenylates, human Mx protein, and neopterin levels, but neither modulated beta 2-microglobulin, IL-1 alpha or beta synthesis. Neopterin 128-137 interferon beta 1 Homo sapiens 13-21 1431317-0 1992 Tandem repeat polymers of a critical region of the human interferon-beta promoter exhibit a marked constitutive activity and enhanced responsiveness to transcriptional regulators in transfected HeLa cells. Polymers 14-22 interferon beta 1 Homo sapiens 57-72 1525120-5 1992 In normal subjects, IFN-beta serine reduced LDL cholesterol and apolipoprotein (apo) B levels by 25% and 27%, respectively (p less than 0.05); LDL apo B synthesis was decreased by 59% (p less than 0.05). Serine 29-35 interferon beta 1 Homo sapiens 20-28 1525120-5 1992 In normal subjects, IFN-beta serine reduced LDL cholesterol and apolipoprotein (apo) B levels by 25% and 27%, respectively (p less than 0.05); LDL apo B synthesis was decreased by 59% (p less than 0.05). Cholesterol 48-59 interferon beta 1 Homo sapiens 20-28 1525120-6 1992 In hypercholesterolemic subjects, IFN-beta serine reduced LDL cholesterol levels by 38% (p less than 0.05); however, apo B concentrations and production rates were not significantly decreased. Serine 43-49 interferon beta 1 Homo sapiens 34-42 1384719-1 1992 The double-stranded RNA polyinosinic acid-polycytidylic acid (PolyIC) is an inducer of interferons alpha and beta (IFN) genes. Poly I-C 24-60 interferon beta 1 Homo sapiens 87-113 1384719-1 1992 The double-stranded RNA polyinosinic acid-polycytidylic acid (PolyIC) is an inducer of interferons alpha and beta (IFN) genes. polyic 62-68 interferon beta 1 Homo sapiens 87-113 21584536-8 1992 The antiproliferative and toxic effect of FLU was increased in GBM-MDR cells by simultaneous growth in IFN-B and the toxic effect of FLU could be blocked in a dose-dependent manner by the simultaneous addition of deoxycytidine. fludarabine phosphate 42-45 interferon beta 1 Homo sapiens 103-108 1499452-8 1992 These results suggest that interferon-beta injures endoplasmic reticulum and glycogen areas and damages the cholinesterase activity in the early stage of treatment and protein synthesis in patients with hepatitis B e antigen-positive chronic active hepatitis. Glycogen 77-85 interferon beta 1 Homo sapiens 27-42 1377102-3 1992 Interferon-alpha-2a and interferon-beta also exerted synergistic effects with azidothymidine, but the potentiation was weaker than that by the combination of interferon-gamma and aziodthymidine. aziodthymidine 179-193 interferon beta 1 Homo sapiens 24-39 1568161-1 1992 The author has studied the effects of alpha-difluoromethylornithine (alpha DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase; human fibroblast interferon (IFN beta); and their combination on human gastric cancer cell growth in vitro. Eflornithine 69-79 interferon beta 1 Homo sapiens 182-190 1568161-4 1992 When alpha DFMO (0.1 mmol/l) was administered in combination with IFN beta (100 and 1000 IU/ml), synergistic antiproliferative activity was observed 7 days after continuous exposure. Eflornithine 5-15 interferon beta 1 Homo sapiens 66-74 1584209-0 1992 Conversion of human interferon-beta from a secreted to a phosphatidylinositol anchored protein by fusion of a 17 amino acid sequence to its carboxyl terminus. Phosphatidylinositols 57-77 interferon beta 1 Homo sapiens 20-35 1592362-0 1992 Effects of recombinant human interferon-alpha, beta and gamma on the antiproliferative activity of cytarabine in K562 human myeloid leukemia clonogenic cells. Cytarabine 99-109 interferon beta 1 Homo sapiens 29-61 1592362-1 1992 The effects of recombinant human interferon-alpha, beta and gamma (IFN) on the antiproliferative activity of cytarabine (ara-C) in K562 human myeloid leukemia clonogenic cells were studied in an agar capillary microassay. Cytarabine 109-119 interferon beta 1 Homo sapiens 33-71 1592362-1 1992 The effects of recombinant human interferon-alpha, beta and gamma (IFN) on the antiproliferative activity of cytarabine (ara-C) in K562 human myeloid leukemia clonogenic cells were studied in an agar capillary microassay. Cytarabine 121-126 interferon beta 1 Homo sapiens 33-71 1592362-6 1992 The significant reduction of the desired antiproliferative activity of ara-C by the three interferons was reproduced in liquid suspension cultures of K562 cells on day 4 in the following order: IFN-gamma greater than IFN-beta greater than IFN-alpha. Cytarabine 71-76 interferon beta 1 Homo sapiens 217-225 1591013-6 1992 Both interferon-gamma (IFN-gamma) and interferon-beta (IFN-beta) induced neopterin production and tryptophan degradation by AM with corresponding inhibition of intracellular replication by Chlamydia psittaci in AM, but IFN-gamma was a more potent inducer of these responses than IFN-beta. Neopterin 73-82 interferon beta 1 Homo sapiens 55-63 1591013-6 1992 Both interferon-gamma (IFN-gamma) and interferon-beta (IFN-beta) induced neopterin production and tryptophan degradation by AM with corresponding inhibition of intracellular replication by Chlamydia psittaci in AM, but IFN-gamma was a more potent inducer of these responses than IFN-beta. Tryptophan 98-108 interferon beta 1 Homo sapiens 55-63 1602741-9 1992 Vascular SMC treated with poly(I):poly(C) or tumor necrosis factor-alpha expressed IFN-beta mRNA. Poly I 26-33 interferon beta 1 Homo sapiens 83-91 1602741-9 1992 Vascular SMC treated with poly(I):poly(C) or tumor necrosis factor-alpha expressed IFN-beta mRNA. poly 26-30 interferon beta 1 Homo sapiens 83-91 1602741-10 1992 SMC treated with poly(I):poly(C) or Newcastle Disease virus elaborated biologically active IFN-beta as well. Poly I 17-24 interferon beta 1 Homo sapiens 91-99 1602741-10 1992 SMC treated with poly(I):poly(C) or Newcastle Disease virus elaborated biologically active IFN-beta as well. Poly C 25-32 interferon beta 1 Homo sapiens 91-99 1373138-7 1992 Affinity-purified anti-UCRP antibodies detected the induction of UCRP in interferon-beta-treated A549 cells and recognized a group of high molecular weight UCRP conjugates on immunoblots of sodium dodecyl sulfate-polyacrylamide gel electrophoresis-resolved cell extracts. Sodium Dodecyl Sulfate 190-212 interferon beta 1 Homo sapiens 73-88 1377102-3 1992 Interferon-alpha-2a and interferon-beta also exerted synergistic effects with azidothymidine, but the potentiation was weaker than that by the combination of interferon-gamma and aziodthymidine. Zidovudine 78-92 interferon beta 1 Homo sapiens 24-39 1583063-0 1992 Recombinant human interferons alpha, beta and gamma reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells. Cytarabine 91-101 interferon beta 1 Homo sapiens 18-51 1352313-0 1992 The effects of interferon-beta on phorbol ester or calcium ionophore-induced intercellular adhesion molecule-I expression in epidermal carcinoma cells. Phorbol Esters 34-47 interferon beta 1 Homo sapiens 15-30 1586975-4 1992 Cotreatment of these cells with IFN-beta ser17 and the anticancer agent N-methylformamide leads to the partial abrogation of 2",5"-oligo (A) synthetase activity and the stabilization of c-myc mRNA. methylformamide 72-89 interferon beta 1 Homo sapiens 32-40 1370149-10 1992 However, indomethacin, a well known inhibitor of prostaglandin synthesis, prevented the increase in lipolysis induced by TNF, IL-1, IFN alpha, IFN beta, or IFN gamma. Indomethacin 9-21 interferon beta 1 Homo sapiens 143-151 1583063-1 1992 The effects of recombinant human interferons alpha, beta and gamma (IFN) on the antiproliferative activity of cytarabine in K562 human myeloid leukaemia clonogenic cells were studied in an agar capillary microassay. Cytarabine 110-120 interferon beta 1 Homo sapiens 33-72 1357650-3 1992 In human melanoma cells, the combination of mezerein (MEZ) and fibroblast interferon (IFN-beta), results in a rapid and irreversible suppression of cell growth with a concomitant increase in the synthesis of melanin. Melanins 208-215 interferon beta 1 Homo sapiens 86-94 1666117-0 1991 Production of human interferon-beta by Sendai virus and poly(rI).poly(rC): inhibition by neomycin. Neomycin 89-97 interferon beta 1 Homo sapiens 20-35 1666117-1 1991 Neomycin inhibits the production of interferon-beta (IFN-beta) in human fibroblast cells in response to Sendai virus or to poly(rI).poly(rC) in a concentration-dependent manner, and to the greatest extent effective when added prior to or up to 2 h after induction. Neomycin 0-8 interferon beta 1 Homo sapiens 36-51 1666117-1 1991 Neomycin inhibits the production of interferon-beta (IFN-beta) in human fibroblast cells in response to Sendai virus or to poly(rI).poly(rC) in a concentration-dependent manner, and to the greatest extent effective when added prior to or up to 2 h after induction. Neomycin 0-8 interferon beta 1 Homo sapiens 53-61 1666117-3 1991 These results suggest that in human cells both virus and poly(rI).poly(rC) utilize an early neomycin-sensitive signal transduction step for the production of IFN-beta; because neomycin binds specific phosphatidylinositol phosphates, both of these inducers very likely require hydrolysis of these phosphates. Neomycin 92-100 interferon beta 1 Homo sapiens 158-166 1666117-3 1991 These results suggest that in human cells both virus and poly(rI).poly(rC) utilize an early neomycin-sensitive signal transduction step for the production of IFN-beta; because neomycin binds specific phosphatidylinositol phosphates, both of these inducers very likely require hydrolysis of these phosphates. Neomycin 176-184 interferon beta 1 Homo sapiens 158-166 1666117-3 1991 These results suggest that in human cells both virus and poly(rI).poly(rC) utilize an early neomycin-sensitive signal transduction step for the production of IFN-beta; because neomycin binds specific phosphatidylinositol phosphates, both of these inducers very likely require hydrolysis of these phosphates. Phosphatidylinositol Phosphates 200-231 interferon beta 1 Homo sapiens 158-166 1666117-3 1991 These results suggest that in human cells both virus and poly(rI).poly(rC) utilize an early neomycin-sensitive signal transduction step for the production of IFN-beta; because neomycin binds specific phosphatidylinositol phosphates, both of these inducers very likely require hydrolysis of these phosphates. Phosphates 221-231 interferon beta 1 Homo sapiens 158-166 1666118-2 1991 The protein synthesis inhibitor cycloheximide (CHX) totally prevented the appearance of both IFN-alpha and IFN-beta mRNA, also in cultures supplemented with a conditioned medium (CM) assumed to contain soluble factors necessary for the IFN induction. Cycloheximide 32-45 interferon beta 1 Homo sapiens 107-115 1666118-2 1991 The protein synthesis inhibitor cycloheximide (CHX) totally prevented the appearance of both IFN-alpha and IFN-beta mRNA, also in cultures supplemented with a conditioned medium (CM) assumed to contain soluble factors necessary for the IFN induction. Cycloheximide 47-50 interferon beta 1 Homo sapiens 107-115 1660913-0 1991 Poly I:C-induced anti-herpes simplex virus type 1 activity in inflammatory macrophages is mediated by induction of interferon-beta. Poly I-C 0-8 interferon beta 1 Homo sapiens 115-130 1660913-2 1991 We show that Poly I:C-induced antiviral activity is completely abrogated by antibodies to interferon-beta (IFN-beta) whereas antibodies to other interferons or to other cytokines have no effect. Poly I 13-19 interferon beta 1 Homo sapiens 90-105 1660913-2 1991 We show that Poly I:C-induced antiviral activity is completely abrogated by antibodies to interferon-beta (IFN-beta) whereas antibodies to other interferons or to other cytokines have no effect. Poly I 13-19 interferon beta 1 Homo sapiens 107-115 1660913-2 1991 We show that Poly I:C-induced antiviral activity is completely abrogated by antibodies to interferon-beta (IFN-beta) whereas antibodies to other interferons or to other cytokines have no effect. Carbon 20-21 interferon beta 1 Homo sapiens 90-105 1660913-2 1991 We show that Poly I:C-induced antiviral activity is completely abrogated by antibodies to interferon-beta (IFN-beta) whereas antibodies to other interferons or to other cytokines have no effect. Carbon 20-21 interferon beta 1 Homo sapiens 107-115 1660913-4 1991 In addition, we demonstrate that supernatants from macrophages treated with Poly I:C contain IFN-beta but not IFN-alpha. Poly I-C 76-84 interferon beta 1 Homo sapiens 93-101 1660913-5 1991 Taken together these data indicate that the antiviral effects of Poly I:C in inflammatory macrophages are mediated solely by IFN-beta, which acts in an autocrine manner to induce resistance to HSV-1. Poly I-C 65-73 interferon beta 1 Homo sapiens 125-133 1774470-5 1991 Increased [3H]TdR uptake was observed in 5 patients and was suppressed by the addition of IFN-beta. Tritium 11-13 interferon beta 1 Homo sapiens 90-98 1718390-10 1991 However, the addition of the following cytokines to retinoids potentiated the retinoid-induced differentiation: IFN alpha, IFN beta, IFN gamma, TNF alpha, G-CSF, IL-1 alpha and IL-4. Retinoids 52-61 interferon beta 1 Homo sapiens 123-131 1662459-1 1991 Addition of the calmodulin-antagonist, trifluoperazine (TFP), to human cell cultures producing biologically active IFN-beta in response to Sendai virus, results in a significant increase in IFN-beta production. Trifluoperazine 39-54 interferon beta 1 Homo sapiens 115-123 1907881-5 1991 IFN-gamma and IFN-beta ser alone or in combination significantly increased serum TAG-72 or CEA in approximately 65% of those patients. Serine 23-26 interferon beta 1 Homo sapiens 14-22 1662459-1 1991 Addition of the calmodulin-antagonist, trifluoperazine (TFP), to human cell cultures producing biologically active IFN-beta in response to Sendai virus, results in a significant increase in IFN-beta production. Trifluoperazine 39-54 interferon beta 1 Homo sapiens 190-198 1899864-10 1991 This IFN-gamma induced factor also binds to an oligonucleotide corresponding to -91 to -62 bp of the interferon-beta (IFN-beta) gene promoter, a region necessary for the induction of the IFN-beta gene by virus and double-stranded RNA. Oligonucleotides 47-62 interferon beta 1 Homo sapiens 101-116 1919072-1 1991 Human interferon-alpha (IFN-alpha) or IFN-beta has been shown to induce a 17-kD membrane protein in human cells which when eluted from SDS gels inhibited the multiplication of cells of different human cell lines. Sodium Dodecyl Sulfate 135-138 interferon beta 1 Homo sapiens 38-46 1919073-9 1991 Inhibition by 2-aminopurine of the induction of IFN-inducible mRNAs by IFN-beta or dsRNA suggests the participation of a protein kinase in their mechanism of action. 2-Aminopurine 14-27 interferon beta 1 Homo sapiens 71-79 1919075-0 1991 Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. Zidovudine 57-67 interferon beta 1 Homo sapiens 37-52 1919075-9 1991 The rate of metabolism of AZT was diminished from 1.43 h-1 prior to IFN-beta therapy, to 0.4 h-1 and 0.05 h-1 at days 3 and 15, respectively. Zidovudine 26-29 interferon beta 1 Homo sapiens 68-76 1708891-1 1991 The location of biologically relevant epitopes on recombinant human beta interferon in which Ser-17 replaces Cys-17 (rh[Ser17]IFN-beta) was evaluated by testing the immunoreactivity of antibodies against 159 sequential, overlapping octamer peptides. Serine 93-96 interferon beta 1 Homo sapiens 126-134 1369307-1 1991 We screened for foodstuffs affecting interferon-beta (IFN-beta) production of human foreskin diploid fibroblasts, in the presence of poly I.poly C, cycloheximide, and actinomycin D. alpha- and beta-caseins stimulated IFN-beta production dose-dependently, but kappa-casein inhibited it. poly 133-137 interferon beta 1 Homo sapiens 37-52 1369307-1 1991 We screened for foodstuffs affecting interferon-beta (IFN-beta) production of human foreskin diploid fibroblasts, in the presence of poly I.poly C, cycloheximide, and actinomycin D. alpha- and beta-caseins stimulated IFN-beta production dose-dependently, but kappa-casein inhibited it. poly 133-137 interferon beta 1 Homo sapiens 54-62 1899864-10 1991 This IFN-gamma induced factor also binds to an oligonucleotide corresponding to -91 to -62 bp of the interferon-beta (IFN-beta) gene promoter, a region necessary for the induction of the IFN-beta gene by virus and double-stranded RNA. Oligonucleotides 47-62 interferon beta 1 Homo sapiens 118-126 1899864-10 1991 This IFN-gamma induced factor also binds to an oligonucleotide corresponding to -91 to -62 bp of the interferon-beta (IFN-beta) gene promoter, a region necessary for the induction of the IFN-beta gene by virus and double-stranded RNA. Oligonucleotides 47-62 interferon beta 1 Homo sapiens 187-195 2124247-0 1990 Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. Melanins 141-148 interferon beta 1 Homo sapiens 24-57 2086672-7 1990 When assessed 24 h after IFN-beta ser at 4.5 x 10(6) units, significant (p less than 0.05) augmentation had occurred in beta 2-microglobulin, HLA-DR, and HLA-DQ expression on monocytes, 2",5"-oligoadenylate (2-5A) synthetase in peripheral mononuclear cells, and natural killer (NK) and K cells functional activity. Serine 34-37 interferon beta 1 Homo sapiens 25-33 1988537-5 1991 The synthetic glucocorticoid dexamethasone was previously shown to increase the turnover of IFN-beta mRNA. Dexamethasone 29-42 interferon beta 1 Homo sapiens 92-100 1988537-6 1991 This activity of dexamethasone was clearly observed only in cells expressing IFN-beta mRNA with AU-rich sequences in the 3" UTR. Dexamethasone 17-30 interferon beta 1 Homo sapiens 77-85 1857683-4 1991 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot experiments showed that the tro-IFN-beta was present as a 24 kDa protein. sodium dodecyl sulfate-polyacrylamide 0-37 interferon beta 1 Homo sapiens 116-124 1857683-4 1991 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot experiments showed that the tro-IFN-beta was present as a 24 kDa protein. Sodium Dodecyl Sulfate 59-62 interferon beta 1 Homo sapiens 116-124 2086672-0 1990 Biological and clinical effects of interferon-beta ser at two doses. Serine 51-54 interferon beta 1 Homo sapiens 35-50 2273299-4 1990 IFN-beta ser at this dose and schedule does not appear to be an active single agent for patients with refractory malignant mesothelioma. Serine 9-12 interferon beta 1 Homo sapiens 0-8 2226642-7 1990 Since the inhibition of mitogenic stimulation by poly(I:C) is completely overcome by antisera recognizing interferon-beta (IFN-beta) and interleukin-6 (IL-6), we tested the effect of IL-6 and IFN-beta on EGF mitogenicity. Poly I-C 49-58 interferon beta 1 Homo sapiens 106-121 2226642-7 1990 Since the inhibition of mitogenic stimulation by poly(I:C) is completely overcome by antisera recognizing interferon-beta (IFN-beta) and interleukin-6 (IL-6), we tested the effect of IL-6 and IFN-beta on EGF mitogenicity. Poly I-C 49-58 interferon beta 1 Homo sapiens 123-131 2120284-4 1990 IFN-beta ser was more effective than IFN-gamma in enhancing 2-5A synthetase activity (P = 0.001). Serine 9-12 interferon beta 1 Homo sapiens 0-8 2120284-5 1990 IFN-gamma was more effective than IFN-beta ser in enhancing serum beta 2 microglobulin expression (P = 0.05) and indoleamine dioxygenase activity, as assessed by decreased serum tryptophan (P = 0.03). Tryptophan 178-188 interferon beta 1 Homo sapiens 34-42 2120284-6 1990 The combination enhanced tryptophan catabolism more effectively than IFN-beta ser in a dose-dependent manner (P less than 0.03). Serine 78-81 interferon beta 1 Homo sapiens 69-77 2120284-8 1990 IFN-beta ser/IFN-gamma enhanced monocyte guanylate cyclase activity, as assessed by serum neopterin, more effectively than IFN-gamma alone (P = 0.005). Neopterin 90-99 interferon beta 1 Homo sapiens 0-8 2120284-13 1990 Thus, IFN-beta ser and IFN-gamma each resulted in effective and essentially equivalent patterns of induction of induced proteins. Serine 15-18 interferon beta 1 Homo sapiens 6-14 2129033-6 1990 In addition, cellular response to IFN-beta was documented by increased B2-microglobulin and neopterin levels, even as early as 24 hours after the 1st IFN injection of the 1st and 2nd cycles. Neopterin 92-101 interferon beta 1 Homo sapiens 34-42 2118972-4 1990 In the present work, the uptake of rhodamine 123 by Molt 16 cells stimulated by IFN-gamma or IFN-beta was measured by flow cytometry. Rhodamines 35-44 interferon beta 1 Homo sapiens 93-101 1698636-1 1990 The use of a panel of monoclonal antibodies (mAb) raised against recombinant (serine-17) human interferon-beta (rHuIFN-beta ser) has permitted the identification of three epitopes on HuIFN-beta, designated as sites I, II and III, based solely on functional differences, i.e., the neutralization of antiviral and antiproliferative activities of natural and recombinant HuIFN-beta (Redlich, P.N. Serine 78-84 interferon beta 1 Homo sapiens 95-110 1698636-1 1990 The use of a panel of monoclonal antibodies (mAb) raised against recombinant (serine-17) human interferon-beta (rHuIFN-beta ser) has permitted the identification of three epitopes on HuIFN-beta, designated as sites I, II and III, based solely on functional differences, i.e., the neutralization of antiviral and antiproliferative activities of natural and recombinant HuIFN-beta (Redlich, P.N. Serine 78-81 interferon beta 1 Homo sapiens 95-110 2129033-9 1990 The low toxicity and the modulation of B2-microglobulin and neopterin should encourage studies aimed at defining the optimal antitumor dose of IFN-beta that could be used in combination with conventional chemotherapeutic regimens to improve the response rate in multiple myeloma patients. Neopterin 60-69 interferon beta 1 Homo sapiens 143-151 2370859-4 1990 Induction of the intact IFN-beta promoter linked to a reporter plasmid was achieved in lymphoid and epithelioid cellular backgrounds by a triple transfection with IRF-1 and Tax expression plasmids or a combination of IRF-1 and phorbol ester, indicating that at least two trans-activating events and the association of two proteins on the promoter template are required for IFN-beta activation. Phorbol Esters 227-240 interferon beta 1 Homo sapiens 24-32 2395002-7 1990 The p78 protein was induced in a dose-dependent manner by IFN-alpha and IFN-beta ser. Serine 81-84 interferon beta 1 Homo sapiens 72-80 2395002-8 1990 IFN-gamma enhanced the expression of p78 induction by IFN-alpha or IFN-beta ser, even at concentrations of IFN-gamma that did not induce the protein when administered as a single agent. Serine 76-79 interferon beta 1 Homo sapiens 67-75 2395002-9 1990 The combination of IFN-alpha and IFN-beta ser, which results in an antagonistic antiproliferative effect, also resulted in an antagonistic induction of p78. Serine 42-45 interferon beta 1 Homo sapiens 33-41 2395002-11 1990 Thus, the synergistic antiproliferative effect produced by IFN-beta ser and IFN-gamma in SKCO 1 cells could not be correlated with a synergistic enhancement in 2-5A synthetase or IDO activity, or with a perturbation in the cell cycle. Serine 68-71 interferon beta 1 Homo sapiens 59-67 2395002-12 1990 In contrast, the combination of IFN-gamma and IFN-alpha or IFN-beta ser synergistically enhanced the expression of p78 protein in these cells. Serine 68-71 interferon beta 1 Homo sapiens 59-67 2082958-8 1990 IFN-beta ser appears to have activity in human glioma and is well tolerated at this dosage and schedule. Serine 9-12 interferon beta 1 Homo sapiens 0-8 2395002-5 1990 IDO activity was induced by IFN-gamma and the combination of IFN-beta ser and IFN-gamma, but not IFN-beta ser alone. Serine 70-73 interferon beta 1 Homo sapiens 61-69 2135379-2 1990 We found that in monocytes from patients with HIV infection, the defective OB response could be partially restored by pretreatment with IFN-beta when the cells were challenged with zymosan. Zymosan 181-188 interferon beta 1 Homo sapiens 136-144 2135379-4 1990 In monocyte-derived macrophages, both IFN-alpha and IFN-beta stimulated the phorbol myristate acetate (PMA) induced OB response in the patient group as well as in the blood donor control group. Tetradecanoylphorbol Acetate 76-101 interferon beta 1 Homo sapiens 52-60 2135379-4 1990 In monocyte-derived macrophages, both IFN-alpha and IFN-beta stimulated the phorbol myristate acetate (PMA) induced OB response in the patient group as well as in the blood donor control group. Tetradecanoylphorbol Acetate 103-106 interferon beta 1 Homo sapiens 52-60 2341750-4 1990 Both helicity and antiviral activity of the IFN-beta decrease in parallel with denaturation by urea, heat, and/or by repeated cycles of freezing and thawing. Urea 95-99 interferon beta 1 Homo sapiens 44-52 2140395-11 1990 These data do suggest that, for human glioma cells in culture, type I IFN receptors may display a subtle architectural variation that allows equivalent binding of both IFN-alpha and IFN-beta ser, but allows an enhanced signal transduction and biological effect only after binding a specific IFN subtype. Serine 191-194 interferon beta 1 Homo sapiens 182-190 1692865-4 1990 Although a corresponding sequence of amino acids in the IFN-beta molecule was localized to the region 134-139 and shows only a 66% homology with the assumed IFN-alpha 2 binding site, lysine at position 132 in IFN-alpha 2 and at position 134 in IFN-beta seems to be crucial for establishment of the common epitope. Lysine 183-189 interferon beta 1 Homo sapiens 56-64 2157136-4 1990 This transcriptional repression can be blocked with cycloheximide, suggesting that the synthesis of a virus-inducible repressor is necessary for the postinduction turnoff of the IFN-beta gene. Cycloheximide 52-65 interferon beta 1 Homo sapiens 178-186 2153928-5 1990 IFN treatment of either Daudi or HeLa cells transfected with the human IFN-beta promoter (-282 to -37) linked to the chloramphenicol acetyltransferase (CAT) gene resulted in an increase in CAT activity after induction with poly(I)-poly(C) or Sendai virus. Poly I-C 223-237 interferon beta 1 Homo sapiens 71-79 2405777-0 1990 [Randomized study of initial treatment with radiation.MCNU or radiation.MCNU.interferon-beta for malignant glioma. ranimustine 72-76 interferon beta 1 Homo sapiens 77-92 2153928-6 1990 A synthetic double-stranded oligonucleotide corresponding to an authentic 30-base-pair (bp) region of the human IFN-beta promoter between positions -91 and -62 was found to confer virus inducibility upon the reporter CAT gene in HeLa cells. Oligonucleotides 28-43 interferon beta 1 Homo sapiens 112-120 2293873-2 1990 We administered doses of 5 to 180 x 10(6) IU of beta-serine-interferon (IFN-beta ser17) twice weekly to 20 patients with recurrent malignant gliomas in a Phase I study. beta-serine 48-59 interferon beta 1 Homo sapiens 72-80 2136700-1 1990 Combination treatment of SKCO1 human colon carcinoma cells with beta ser-interferon (IFN-beta ser) and gamma-interferon (IFN-gamma) results in a synergistic antiproliferative effect. Serine 69-72 interferon beta 1 Homo sapiens 85-93 2136700-2 1990 The role of IFN-beta ser and IFN-gamma receptor modulation was investigated as a possible mechanism for this response. Serine 21-24 interferon beta 1 Homo sapiens 12-20 2136700-3 1990 IFN-gamma (0.05-50 ng/ml) pretreatment of SKCO1 cells for 24 h decreased specific binding of 125I-IFN-beta ser by 35-60%. Serine 107-110 interferon beta 1 Homo sapiens 98-106 2136700-5 1990 In contrast, pretreatment of SKCO1 cells with IFN-beta ser (5 ng/ml) resulted in slight (10-35%) increases in 125I-IFN-gamma-specific binding. Serine 55-58 interferon beta 1 Homo sapiens 46-54 1690591-4 1990 The levels of these two induced activities after VIP treatment are comparable to those induced by the poly (I).poly (C), an inducer of IFN beta/alpha in mammalian cells. Poly I 102-110 interferon beta 1 Homo sapiens 135-143 1690591-4 1990 The levels of these two induced activities after VIP treatment are comparable to those induced by the poly (I).poly (C), an inducer of IFN beta/alpha in mammalian cells. Poly C 111-118 interferon beta 1 Homo sapiens 135-143 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 91-94 interferon beta 1 Homo sapiens 82-90 2136700-8 1990 However, it is unlikely that differences in binding and internalization of this magnitude play a primary role in the synergistic antiproliferative effect of IFN-gamma with IFN-beta ser in SKCO1 cells. Serine 181-184 interferon beta 1 Homo sapiens 172-180 2163462-4 1990 In this study, the interaction between human fibroblast interferon (HuIFN-beta) and anti-herpetic agents, 5-iodo-2"-deoxyuridine (IDU), aciclovir (ACV) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), was studied in vitro using VERO cells. Ganciclovir 198-202 interferon beta 1 Homo sapiens 45-66 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 91-94 interferon beta 1 Homo sapiens 167-175 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 91-94 interferon beta 1 Homo sapiens 167-175 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 82-90 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 167-175 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 167-175 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 82-90 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 167-175 2136700-6 1990 Scatchard analysis of binding data obtained following 24-h treatment with 5 ng/ml IFN-beta ser showed a decrease in binding affinity (control cells, Kd = 28 +/- 7 pM; IFN-beta ser-treated cells, Kd = 38 +/- 7 pM, n = 2) and a 32% increase in IFN-gamma receptor sites (receptor number/control cell = 4257 +/- 464, receptor number/IFN-beta ser-treated cell = 5570 +/- 730; n = 2). Serine 176-179 interferon beta 1 Homo sapiens 167-175 2136700-7 1990 125I-IFN-gamma internalization studies performed at 37 degrees C confirmed the cell surface binding assays; IFN-beta ser-treated cells internalized 30-50% more labeled IFN-gamma than untreated cells. Serine 117-120 interferon beta 1 Homo sapiens 108-116 2163462-4 1990 In this study, the interaction between human fibroblast interferon (HuIFN-beta) and anti-herpetic agents, 5-iodo-2"-deoxyuridine (IDU), aciclovir (ACV) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), was studied in vitro using VERO cells. Acyclovir 147-150 interferon beta 1 Homo sapiens 45-66 2163462-4 1990 In this study, the interaction between human fibroblast interferon (HuIFN-beta) and anti-herpetic agents, 5-iodo-2"-deoxyuridine (IDU), aciclovir (ACV) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), was studied in vitro using VERO cells. Ganciclovir 156-196 interferon beta 1 Homo sapiens 45-66 33770100-7 2021 It is preceded by an increase in IFNB1 mRNA levels and can be blocked by siRNA targeting the type I IFN receptor IFNAR1 and by inhibition of Janus kinases by Ruxolitinib. ruxolitinib 158-169 interferon beta 1 Homo sapiens 33-38 2232850-10 1990 Therefore IFN-beta may be suggested as an alternative treatment for HCL. Hydrochloric Acid 68-71 interferon beta 1 Homo sapiens 10-18 33814892-3 2021 Recent Findings: Observational data support the safety of injectable DMTs (glatiramer acetate, interferon-beta) for use in pregnancy, while some oral DMTs might be associated with fetal risk. N,N-Dimethyltryptamine 69-73 interferon beta 1 Homo sapiens 95-110 34911669-7 2022 Importantly, domain I of nsp4 inhibited Sendai virus-induced interferon beta production, and this inhibitory effect was eliminated by Lovastatin, an HMGCR inhibitor, indicating that the upregulation of cellular cholesterol by nsp4 is a strategy used by PRRSV to suppress the antiviral innate immunity of its host. Lovastatin 134-144 interferon beta 1 Homo sapiens 61-76 1895445-2 1991 IFN beta ser inhibited growth of anchorage dependent semiconfluent monolayers and anchorage dependent colony formation of both DU-145 and PC-3 in a dose dependent manner but had no effect on LNCaP. Serine 9-12 interferon beta 1 Homo sapiens 0-8 1895445-4 1991 The combination of TGF beta 1 and IFN beta ser was additive in its effects on growth. Serine 43-46 interferon beta 1 Homo sapiens 34-42 1895445-7 1991 The potential use of IFN beta ser in combination with hormonal therapy to delay the development of hormone refractory tumors is discussed. Serine 30-33 interferon beta 1 Homo sapiens 21-29 34911669-7 2022 Importantly, domain I of nsp4 inhibited Sendai virus-induced interferon beta production, and this inhibitory effect was eliminated by Lovastatin, an HMGCR inhibitor, indicating that the upregulation of cellular cholesterol by nsp4 is a strategy used by PRRSV to suppress the antiviral innate immunity of its host. Cholesterol 211-222 interferon beta 1 Homo sapiens 61-76 34695651-5 2021 PU.1 expression also primes the cells to develop a strong immune response against the dsRNA virus mimic polyinosinic:polycytidylic acid (poly I:C) by significantly up-regulating Interferon-beta (14.9 fold change with p-value <0.0001). Poly C 117-135 interferon beta 1 Homo sapiens 178-193 34695651-5 2021 PU.1 expression also primes the cells to develop a strong immune response against the dsRNA virus mimic polyinosinic:polycytidylic acid (poly I:C) by significantly up-regulating Interferon-beta (14.9 fold change with p-value <0.0001). Poly I 137-143 interferon beta 1 Homo sapiens 178-193 34695651-5 2021 PU.1 expression also primes the cells to develop a strong immune response against the dsRNA virus mimic polyinosinic:polycytidylic acid (poly I:C) by significantly up-regulating Interferon-beta (14.9 fold change with p-value <0.0001). Carbon 144-145 interferon beta 1 Homo sapiens 178-193 34583098-10 2021 Arginine methylation of TLR4 on R812 or PRMT2 enhanced interferon-beta (IFN-beta) production. Arginine 0-8 interferon beta 1 Homo sapiens 55-70 34591979-0 2021 MEK/ERK MAP kinase limits poly I:C-induced antiviral gene expression in RAW264.7 macrophages by reducing interferon-beta expression. Poly I 26-32 interferon beta 1 Homo sapiens 105-120 34739556-7 2022 Poly IC activated the TLR3 pathway, whereas knockdown of SMPDL3b attenuated poly IC-induced interferon-beta/chemokine C-X-C ligand 10 expression in podocytes. poly 76-80 interferon beta 1 Homo sapiens 92-107 34585989-8 2021 Furthermore, AG205 treatment or PGRMC1 knockout significantly inhibited the retinoic acid-inducible gene I (RIG-I)-mediated interferon beta (IFN-beta) signaling pathway and reduced the levels of several antiviral proteins (Mx1 and ISG15). AG205 13-18 interferon beta 1 Homo sapiens 124-139 34093539-5 2021 RDV also inhibited other pro-inflammatory genes including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-12, IL-1beta, and interferon-beta (IFN-beta), leading to the reduction of inflammatory factors release. remdesivir 0-3 interferon beta 1 Homo sapiens 142-157 35595822-4 2022 Compared to the clinical CDN STING agonist ADU-S100, SHR1032 has much higher activity in human cells with different STING haplotypes and robustly induces interferon beta (IFNbeta) production. shr1032 53-60 interferon beta 1 Homo sapiens 154-169 35020157-5 2022 Interferon beta (30.7%) was the most common pre-fingolimod treatment. Fingolimod Hydrochloride 48-58 interferon beta 1 Homo sapiens 0-15 35220042-8 2022 Animals treated with SCFA-acetate intranasally recovered significantly faster, with reduction in the RSV clinical isolates viral load, and increased lung expression of IFNB1 and the RIG-I. scfa-acetate 21-33 interferon beta 1 Homo sapiens 168-173 2514233-0 1989 Recombinant human interferon-beta suppresses the replication of HIV and acts synergistically with AZT. Zidovudine 98-101 interferon beta 1 Homo sapiens 18-33 2514233-1 1989 The in vitro effects of recombinant human interferon-beta ser (rIFN-beta ser) and 3"-azido-3"-deoxythymidine (AZT) alone and in combination on human immunodeficiency virus (HIV) replication were examined. Serine 58-61 interferon beta 1 Homo sapiens 42-57 2790060-1 1989 Human interferon-beta 1 is extremely stable is a low ionic strength solution of pH 2 such as 10 mM HCl at 37 degrees C. However, the presence of 0.15 M NaCl led to a remarkable loss of antiviral activity. Hydrochloric Acid 99-102 interferon beta 1 Homo sapiens 6-23 2557635-6 1989 In FS-4 cells an increase in IFN-beta mRNA (examined by the polymerase chain reaction) was seen after treatment with TNF, IL-1, A23187, or poly(I).poly(C), but not with IFN-beta, epidermal growth factor, dibutyryl-cAMP, or forskolin. Bucladesine 204-218 interferon beta 1 Homo sapiens 29-37 2557635-6 1989 In FS-4 cells an increase in IFN-beta mRNA (examined by the polymerase chain reaction) was seen after treatment with TNF, IL-1, A23187, or poly(I).poly(C), but not with IFN-beta, epidermal growth factor, dibutyryl-cAMP, or forskolin. Colforsin 223-232 interferon beta 1 Homo sapiens 29-37 2509363-5 1989 Antibodies to IFN-beta blocked the augmentation of tryptophan degradation by TNF and decreased but did not fully eliminate the antichlamydial effect of TNF. Tryptophan 51-61 interferon beta 1 Homo sapiens 14-22 2509363-7 1989 This study suggests that the inhibition of chlamydial growth by TNF is mediated partly through an autocrine function of IFN-beta which, in synergism with TNF, enhances the activity of a tryptophan-degrading enzyme(s) and partly by some other activities of TNF which can be blocked by tryptophan. Tryptophan 186-196 interferon beta 1 Homo sapiens 120-128 2509363-7 1989 This study suggests that the inhibition of chlamydial growth by TNF is mediated partly through an autocrine function of IFN-beta which, in synergism with TNF, enhances the activity of a tryptophan-degrading enzyme(s) and partly by some other activities of TNF which can be blocked by tryptophan. Tryptophan 284-294 interferon beta 1 Homo sapiens 120-128 2513475-6 1989 A recessive mutant, selected in 6-thioguanine plus IFN, was completely resistant to IFN-alpha but responded normally to IFN-gamma and, unexpectedly, partially to IFN-beta. Thioguanine 32-45 interferon beta 1 Homo sapiens 162-170 2790060-1 1989 Human interferon-beta 1 is extremely stable is a low ionic strength solution of pH 2 such as 10 mM HCl at 37 degrees C. However, the presence of 0.15 M NaCl led to a remarkable loss of antiviral activity. Sodium Chloride 152-156 interferon beta 1 Homo sapiens 6-23 2790060-7 1989 Monomerization of the oligomeric human interferon-beta 1 by treatment with 1% SDS, fully regenerated its antiviral activity. Sodium Dodecyl Sulfate 78-81 interferon beta 1 Homo sapiens 39-56 2790060-8 1989 These results suggest that the inactivation of the human interferon-beta 1 preparation was caused by its oligomerization via hydrophobic interactions without the formation of intermolecular disulphide bonds. disulphide 190-200 interferon beta 1 Homo sapiens 57-74 2681875-10 1989 Their results suggested that IFN-beta with ACNU was a promising regimen as a chemical modifier in radiotherapy for patients with malignant gliomas. Nimustine 43-47 interferon beta 1 Homo sapiens 29-37 2478362-3 1989 We have investigated whether an inhibitor of interferon-beta gene activation, 2-aminopurine, would block this induction process. 2-Aminopurine 78-91 interferon beta 1 Homo sapiens 45-60 2476404-1 1989 Effect of human interferon beta (IFN beta) or interferon gamma (IFN gamma) on cellular uptake of adriamycin (ADM) was measured in 3 in vitro-cultured human tumor cell lines. Doxorubicin 97-107 interferon beta 1 Homo sapiens 16-31 2476404-1 1989 Effect of human interferon beta (IFN beta) or interferon gamma (IFN gamma) on cellular uptake of adriamycin (ADM) was measured in 3 in vitro-cultured human tumor cell lines. Doxorubicin 97-107 interferon beta 1 Homo sapiens 33-41 2513306-0 1989 Enhancement of cytotoxicity of cisplatin in vitro by recombinant human tumor necrosis factor and/or recombinant human interferon-alpha, -beta and -gamma. Cisplatin 31-40 interferon beta 1 Homo sapiens 118-152 2809278-0 1989 Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. Serine 91-94 interferon beta 1 Homo sapiens 75-90 2731537-3 1989 Each mammalian-cell-derived recombinant human interferon-beta 1 represented a single band of 23 kDa on sodium dodecyl sulphate/polyacrylamide gel electrophoresis, the same molecular mass as fibroblast-derived natural human interferon-beta 1. Sodium Dodecyl Sulfate 103-126 interferon beta 1 Homo sapiens 46-63 2472488-8 1989 These alterations after sc administration were similar quantitatively to those resulting from the same dose of IFN-beta ser given iv. Serine 120-123 interferon beta 1 Homo sapiens 111-119 2624146-3 1989 While cells in FBS-SM show a substantially greater increase in 2-5A synthetase by IFN-beta ser than cells in SFN-SM, the latter culture condition is significantly more effective in elevating synthetase activity with the addition of IFN-alpha 2. Serine 91-94 interferon beta 1 Homo sapiens 82-90 2549667-1 1989 Preliminary results of adjuvant human fibroblasts interferon (IFN beta) given after CO2 laser excision in recurrent laryngeal papillomatosis in 7 adult patients are reported. N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide 84-87 interferon beta 1 Homo sapiens 62-70 2731537-3 1989 Each mammalian-cell-derived recombinant human interferon-beta 1 represented a single band of 23 kDa on sodium dodecyl sulphate/polyacrylamide gel electrophoresis, the same molecular mass as fibroblast-derived natural human interferon-beta 1. polyacrylamide 127-141 interferon beta 1 Homo sapiens 46-63 2731537-8 1989 These results indicate that mammalian-cell-derived recombinant human interferon-beta 1s have identical polypeptides to those of natural human interferon-beta 1 but their carbohydrate moieties, including unusual N-linked oligosaccharides, are individually different from natural ones and depend on the host cell. Carbohydrates 170-182 interferon beta 1 Homo sapiens 69-86 2731537-8 1989 These results indicate that mammalian-cell-derived recombinant human interferon-beta 1s have identical polypeptides to those of natural human interferon-beta 1 but their carbohydrate moieties, including unusual N-linked oligosaccharides, are individually different from natural ones and depend on the host cell. n-linked oligosaccharides 211-236 interferon beta 1 Homo sapiens 69-86 2647497-2 1989 Human fibroblasts were synchronized with mitotic detachment and, at different stages of the cell cycle, poly(I):poly(C) was added for induction of interferon-beta. Poly C 112-119 interferon beta 1 Homo sapiens 147-162 2501084-8 1989 An oligonucleotide derived from the virus- and double-stranded RNA-inducible promoter of the interferon-beta 1 gene is able to bind IBP-1. Oligonucleotides 3-18 interferon beta 1 Homo sapiens 93-110 2610595-5 1989 Furthermore, higher antiviral activity was consistently obtained when RA (0.1-10 microM) was added prior to either IFN-alpha or IFN-beta comparing to cultures with IFN alone. Tretinoin 70-72 interferon beta 1 Homo sapiens 128-136 2785576-0 1989 Enhancement of indoleamine 2,3-dioxygenase activity in cancer patients receiving interferon-beta Ser. Serine 97-100 interferon beta 1 Homo sapiens 81-96 2785576-1 1989 Degradation of tryptophan to kynurenine, catalyzed by indoleamine 2,3-dioxygenase (IDO), has been shown previously to be augmented in human peripheral blood mononuclear cells (PBMCs) treated in vitro with interferons-alpha, -beta, and -gamma (IFNs), and in human epithelial cells treated with IFN-gamma. Tryptophan 15-25 interferon beta 1 Homo sapiens 205-241 2785576-1 1989 Degradation of tryptophan to kynurenine, catalyzed by indoleamine 2,3-dioxygenase (IDO), has been shown previously to be augmented in human peripheral blood mononuclear cells (PBMCs) treated in vitro with interferons-alpha, -beta, and -gamma (IFNs), and in human epithelial cells treated with IFN-gamma. Kynurenine 29-39 interferon beta 1 Homo sapiens 205-241 2785576-4 1989 bolus injection of 90 X 10(6) units or 180 X 10(6) units of IFN-beta Ser, were cultivated in medium containing [3H]tryptophan. Serine 69-72 interferon beta 1 Homo sapiens 60-68 2785576-6 1989 Significantly enhanced IDO activity was observed after IFN-beta Ser treatment, with a mean paired increase of 43% of maximum inducible activity. Serine 64-67 interferon beta 1 Homo sapiens 55-63 2488591-1 1989 Recombinant human interferon-beta (IFN-beta), a highly basic and hydrophobic protein, has been isoelectric focused using the nonionic detergent polyoxyethylene 12 lauryl ether (laureth 12). Polyethylene Glycols 144-159 interferon beta 1 Homo sapiens 18-33 2488591-1 1989 Recombinant human interferon-beta (IFN-beta), a highly basic and hydrophobic protein, has been isoelectric focused using the nonionic detergent polyoxyethylene 12 lauryl ether (laureth 12). Polyethylene Glycols 144-159 interferon beta 1 Homo sapiens 35-43 2488591-1 1989 Recombinant human interferon-beta (IFN-beta), a highly basic and hydrophobic protein, has been isoelectric focused using the nonionic detergent polyoxyethylene 12 lauryl ether (laureth 12). Ether 170-175 interferon beta 1 Homo sapiens 18-33 2488591-1 1989 Recombinant human interferon-beta (IFN-beta), a highly basic and hydrophobic protein, has been isoelectric focused using the nonionic detergent polyoxyethylene 12 lauryl ether (laureth 12). Ether 170-175 interferon beta 1 Homo sapiens 35-43 2647497-0 1989 Production of interferon-beta upon induction with polyinosinic acid:polycytidylic acid during the cell cycle of human fibroblasts. Poly I 50-67 interferon beta 1 Homo sapiens 14-29 2647497-0 1989 Production of interferon-beta upon induction with polyinosinic acid:polycytidylic acid during the cell cycle of human fibroblasts. Poly C 68-86 interferon beta 1 Homo sapiens 14-29 2647497-1 1989 The production of interferon-beta was examined at various stages of the cell cycle in synchronized and unsynchronized cell populations induced by poly(I):poly(C). Poly I 146-153 interferon beta 1 Homo sapiens 18-33 2647497-1 1989 The production of interferon-beta was examined at various stages of the cell cycle in synchronized and unsynchronized cell populations induced by poly(I):poly(C). Poly C 154-161 interferon beta 1 Homo sapiens 18-33 2494120-1 1989 Recombinant human interferon beta (rIFN-beta) inhibited in a time- and dose-dependent manner the proliferation of 18/18 human colon carcinoma cell lines in monolayer culture and 8/9 lines in a soft agar assay but had no effect on 4 human fibroblast cell lines. Agar 198-202 interferon beta 1 Homo sapiens 18-33 2537976-3 1989 In addition, we show that viral infection coinduces the expression of TNF-alpha and interferon beta mRNA and that viral induction of both genes is blocked by the kinase inhibitor 2-aminopurine. 2-Aminopurine 179-192 interferon beta 1 Homo sapiens 84-99 2537976-6 1989 However, in a third cell line (JY), cycloheximide blocked viral induction of the interferon beta gene but not the TNF-alpha gene. Cycloheximide 36-49 interferon beta 1 Homo sapiens 81-96 2783367-1 1989 Regional cerebral glucose metabolism was studied in a 15-year-old boy with subacute sclerosing panencephalitis before and after therapy with human interferon beta, using positron emission tomography of fluorine 18-2-fluoro-2-deoxyglucose. fluorine 18-2-fluoro-2-deoxyglucose 202-237 interferon beta 1 Homo sapiens 147-162 2488591-2 1989 Laureth 12 preserved the solubility of IFN-beta during isoelectric focusing (IEF) under conditions where other nonionic reagents were ineffective. Polidocanol 0-10 interferon beta 1 Homo sapiens 39-47 2975600-7 1988 The addition of either unlabeled IFN-alpha or IFN-beta, but not IFN-gamma, abolished the binding of 125I-rIFN-alpha A to p95. 125i-rifn-alpha a 100-117 interferon beta 1 Homo sapiens 46-54 2463322-10 1989 Monocyte-derived macrophages were found to retain their capacity to be induced by IFN-gamma and IFN-beta to degrade tryptophan after differentiation, and to possess seven times more IDO activity per cell than IFN-induced monocytes. Tryptophan 116-126 interferon beta 1 Homo sapiens 96-104 3203696-4 1988 However, subsequent to treatment with the weaker viral inducer Newcastle disease virus (NDV) both IFN-beta and the 12S RNA transcripts are induced to a higher level in the presence of cycloheximide. Cycloheximide 184-197 interferon beta 1 Homo sapiens 98-106 2504627-0 1989 Differences in intracellular calcium mobilization by interferon-beta and interferon-gamma in RPMI-4788 cells. Calcium 29-36 interferon beta 1 Homo sapiens 53-68 2504627-0 1989 Differences in intracellular calcium mobilization by interferon-beta and interferon-gamma in RPMI-4788 cells. rpmi 93-97 interferon beta 1 Homo sapiens 53-68 2504627-4 1989 The increased [Ca2+]i gradually returned to its resting level within 60 s. The addition of EGTA (0.5-10 mM) to medium induced a marked decrease in the amount of [Ca2+]i mobilized by IFN-beta and a partial decrease by IFN-gamma. Egtazic Acid 91-95 interferon beta 1 Homo sapiens 182-190 2504627-6 1989 While IFN-beta-induced mobilization may be mainly from an influx of the extracellular calcium ion ([Ca2+]o), IFN-gamma-induced mobilization may be a summation of an influx of [Ca2+]o and a release from intracellular Ca2+ stores. Calcium 86-93 interferon beta 1 Homo sapiens 6-14 2732096-5 1989 Induction in the presence of cycloheximide and actinomycin D (superinduction conditions) exhibited an enhanced level of IFN-beta mRNA with a maximum at 4-8 h. The kinetics of the IFN-beta mRNA expression in the cytoplasm as revealed by in situ hybridization proved to be compatible with the results of Northern blotting experiments of total cellular RNA. Cycloheximide 29-42 interferon beta 1 Homo sapiens 120-128 2732096-5 1989 Induction in the presence of cycloheximide and actinomycin D (superinduction conditions) exhibited an enhanced level of IFN-beta mRNA with a maximum at 4-8 h. The kinetics of the IFN-beta mRNA expression in the cytoplasm as revealed by in situ hybridization proved to be compatible with the results of Northern blotting experiments of total cellular RNA. Cycloheximide 29-42 interferon beta 1 Homo sapiens 179-187 2732096-5 1989 Induction in the presence of cycloheximide and actinomycin D (superinduction conditions) exhibited an enhanced level of IFN-beta mRNA with a maximum at 4-8 h. The kinetics of the IFN-beta mRNA expression in the cytoplasm as revealed by in situ hybridization proved to be compatible with the results of Northern blotting experiments of total cellular RNA. Dactinomycin 47-60 interferon beta 1 Homo sapiens 120-128 2732096-5 1989 Induction in the presence of cycloheximide and actinomycin D (superinduction conditions) exhibited an enhanced level of IFN-beta mRNA with a maximum at 4-8 h. The kinetics of the IFN-beta mRNA expression in the cytoplasm as revealed by in situ hybridization proved to be compatible with the results of Northern blotting experiments of total cellular RNA. Dactinomycin 47-60 interferon beta 1 Homo sapiens 179-187 3221257-1 1988 This paper describes the determination of the effect of IFN-beta on U-251 MG cells using the bromodeoxyuridine (BrdU/DNA) analysis technique. Bromodeoxyuridine 93-110 interferon beta 1 Homo sapiens 56-64 3230332-2 1988 These were used to study the in vitro anti-proliferative effects of a recombinant DNA human interferon-beta (rIFN-beta ser). Serine 119-122 interferon beta 1 Homo sapiens 92-107 3068316-11 1988 After single weekly IFN-beta injections, maximum induction of neopterin was observed 24 h after administration, then the levels of this molecule slowly declined towards the baseline levels, but 96 h after, its levels were still significantly elevated (p less than 0.00001). Neopterin 62-71 interferon beta 1 Homo sapiens 20-28 2459591-2 1988 Poly(I).poly(C), poly(A).poly(U) and rln.r(C13,U)n at 5 to 100 micrograms/ml produced 20 to 60% growth inhibition, whereas poly(ICLC) produced 40 to 80% growth inhibition at 0.05 to 25 micrograms/ml.Poly(I).poly(C) did not cause the secretion of interferon (IFN) into the medium, and addition of polyclonal antibodies to IFN-alpha and IFN-beta did not block the growth inhibition produced by poly(I).poly(C). Poly I 0-7 interferon beta 1 Homo sapiens 335-343 3182859-1 1988 The asparagine-linked sugar chains of natural interferon-beta 1 secreted from human foreskin fibroblasts by poly I:poly C induction and of three recombinant human interferon-beta 1 produced by Chinese hamster ovary cells, mouse epithelial cells (C127), and human lung adenocarcinoma cells (PC8) were released quantitatively as oligosaccharides by hydrazinolysis followed by N-acetylation. Oligosaccharides 327-343 interferon beta 1 Homo sapiens 46-63 3182859-3 1988 More than 80% of the sugar chains of natural interferon-beta 1 occur as biantennary complex-type sugar chains, approximately 10% of which contain N-acetyllactosamine repeating structure in their outer chain moieties. Sugars 21-26 interferon beta 1 Homo sapiens 45-62 3182859-3 1988 More than 80% of the sugar chains of natural interferon-beta 1 occur as biantennary complex-type sugar chains, approximately 10% of which contain N-acetyllactosamine repeating structure in their outer chain moieties. Sugars 97-102 interferon beta 1 Homo sapiens 45-62 3182859-3 1988 More than 80% of the sugar chains of natural interferon-beta 1 occur as biantennary complex-type sugar chains, approximately 10% of which contain N-acetyllactosamine repeating structure in their outer chain moieties. N-acetyllactosamine 146-165 interferon beta 1 Homo sapiens 45-62 3182859-9 1988 In contrast, the sialic acid residues of other interferon-beta 1 occur as the Sia alpha 2----3Gal group only. N-Acetylneuraminic Acid 17-28 interferon beta 1 Homo sapiens 47-64 2459591-2 1988 Poly(I).poly(C), poly(A).poly(U) and rln.r(C13,U)n at 5 to 100 micrograms/ml produced 20 to 60% growth inhibition, whereas poly(ICLC) produced 40 to 80% growth inhibition at 0.05 to 25 micrograms/ml.Poly(I).poly(C) did not cause the secretion of interferon (IFN) into the medium, and addition of polyclonal antibodies to IFN-alpha and IFN-beta did not block the growth inhibition produced by poly(I).poly(C). Poly A 17-23 interferon beta 1 Homo sapiens 335-343 2459591-2 1988 Poly(I).poly(C), poly(A).poly(U) and rln.r(C13,U)n at 5 to 100 micrograms/ml produced 20 to 60% growth inhibition, whereas poly(ICLC) produced 40 to 80% growth inhibition at 0.05 to 25 micrograms/ml.Poly(I).poly(C) did not cause the secretion of interferon (IFN) into the medium, and addition of polyclonal antibodies to IFN-alpha and IFN-beta did not block the growth inhibition produced by poly(I).poly(C). Poly I 0-6 interferon beta 1 Homo sapiens 335-343 3182859-0 1988 Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells. Asparagine 25-35 interferon beta 1 Homo sapiens 73-90 3182859-0 1988 Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells. Asparagine 25-35 interferon beta 1 Homo sapiens 113-130 3182859-0 1988 Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells. Sugars 43-48 interferon beta 1 Homo sapiens 73-90 3182859-1 1988 The asparagine-linked sugar chains of natural interferon-beta 1 secreted from human foreskin fibroblasts by poly I:poly C induction and of three recombinant human interferon-beta 1 produced by Chinese hamster ovary cells, mouse epithelial cells (C127), and human lung adenocarcinoma cells (PC8) were released quantitatively as oligosaccharides by hydrazinolysis followed by N-acetylation. Asparagine 4-14 interferon beta 1 Homo sapiens 46-63 3182859-1 1988 The asparagine-linked sugar chains of natural interferon-beta 1 secreted from human foreskin fibroblasts by poly I:poly C induction and of three recombinant human interferon-beta 1 produced by Chinese hamster ovary cells, mouse epithelial cells (C127), and human lung adenocarcinoma cells (PC8) were released quantitatively as oligosaccharides by hydrazinolysis followed by N-acetylation. Sugars 22-27 interferon beta 1 Homo sapiens 46-63 3182859-1 1988 The asparagine-linked sugar chains of natural interferon-beta 1 secreted from human foreskin fibroblasts by poly I:poly C induction and of three recombinant human interferon-beta 1 produced by Chinese hamster ovary cells, mouse epithelial cells (C127), and human lung adenocarcinoma cells (PC8) were released quantitatively as oligosaccharides by hydrazinolysis followed by N-acetylation. Poly I 108-114 interferon beta 1 Homo sapiens 46-63 3182859-1 1988 The asparagine-linked sugar chains of natural interferon-beta 1 secreted from human foreskin fibroblasts by poly I:poly C induction and of three recombinant human interferon-beta 1 produced by Chinese hamster ovary cells, mouse epithelial cells (C127), and human lung adenocarcinoma cells (PC8) were released quantitatively as oligosaccharides by hydrazinolysis followed by N-acetylation. Poly C 115-121 interferon beta 1 Homo sapiens 46-63 2466914-3 1988 An increase in O2 consumption after f-MLP-stimulation was seen when PMN had been incubated 2-4 h with either 1000 IU/ml IFN-alpha or 100 IU/ml IFN-gamma, but this increase in O2 consumption was not observed with 1000 IU/ml IFN-beta. Oxygen 15-17 interferon beta 1 Homo sapiens 223-231 2459271-8 1988 As suggested by SDS-polyacrylamide gel electrophoresis, other viral beta- and gamma-proteins of HSV were inhibited by IFN-alpha and IFN-beta as well. Sodium Dodecyl Sulfate 16-19 interferon beta 1 Homo sapiens 132-140 2459271-8 1988 As suggested by SDS-polyacrylamide gel electrophoresis, other viral beta- and gamma-proteins of HSV were inhibited by IFN-alpha and IFN-beta as well. polyacrylamide 20-34 interferon beta 1 Homo sapiens 132-140 3262700-7 1988 The inhibitory action of IL1 on poly(I).poly(C)-induced IFN-beta synthesis was abolished in the presence of cycloheximide, suggesting that it is mediated indirectly by an IL1-induced product in the FS-4 cells. Poly I 32-39 interferon beta 1 Homo sapiens 56-64 3262700-4 1988 To elucidate the mechanism of this inhibition, we examined the effect of IL1 on the synthesis of interferon-beta (IFN-beta), stimulated with polyinosinate.polycytidylate [poly(I).poly(C)]. polyinosinate 141-154 interferon beta 1 Homo sapiens 97-112 3262700-4 1988 To elucidate the mechanism of this inhibition, we examined the effect of IL1 on the synthesis of interferon-beta (IFN-beta), stimulated with polyinosinate.polycytidylate [poly(I).poly(C)]. polyinosinate 141-154 interferon beta 1 Homo sapiens 114-122 3262700-4 1988 To elucidate the mechanism of this inhibition, we examined the effect of IL1 on the synthesis of interferon-beta (IFN-beta), stimulated with polyinosinate.polycytidylate [poly(I).poly(C)]. Poly C 179-185 interferon beta 1 Homo sapiens 114-122 3262700-7 1988 The inhibitory action of IL1 on poly(I).poly(C)-induced IFN-beta synthesis was abolished in the presence of cycloheximide, suggesting that it is mediated indirectly by an IL1-induced product in the FS-4 cells. Poly C 40-47 interferon beta 1 Homo sapiens 56-64 3262700-5 1988 When added 2 h or more before poly(I).poly(C), both forms of IL1 had a strong inhibitory effect on IFN-beta synthesis, as determined by antiviral assay of the IFN-beta protein or by quantitation of IFN-beta mRNA levels in Northern blot analysis. Poly C 38-45 interferon beta 1 Homo sapiens 99-107 3262700-7 1988 The inhibitory action of IL1 on poly(I).poly(C)-induced IFN-beta synthesis was abolished in the presence of cycloheximide, suggesting that it is mediated indirectly by an IL1-induced product in the FS-4 cells. Cycloheximide 108-121 interferon beta 1 Homo sapiens 56-64 3262700-10 1988 Simultaneous addition of TNF and poly(I).poly(C) to FS-4 cells enhanced IFN-beta synthesis. Poly I 33-40 interferon beta 1 Homo sapiens 72-80 3262700-10 1988 Simultaneous addition of TNF and poly(I).poly(C) to FS-4 cells enhanced IFN-beta synthesis. poly 33-37 interferon beta 1 Homo sapiens 72-80 3220830-0 1988 Disulfide bond interchange in Escherichia coli-derived recombinant human interferon-beta 1 under denaturing conditions. Disulfides 0-9 interferon beta 1 Homo sapiens 73-90 3171246-0 1988 The long-term stability of recombinant (serine-17) human interferon-beta. Serine 40-46 interferon beta 1 Homo sapiens 57-72 3171246-1 1988 Escherichia coli-derived (Serine 17) human interferon-beta (HuIFN-beta SER) was formulated with SDS and placed at multiple isothermal temperatures (-70 degrees C to 37 degrees C). Serine 26-32 interferon beta 1 Homo sapiens 43-58 3171246-1 1988 Escherichia coli-derived (Serine 17) human interferon-beta (HuIFN-beta SER) was formulated with SDS and placed at multiple isothermal temperatures (-70 degrees C to 37 degrees C). Serine 71-74 interferon beta 1 Homo sapiens 43-58 3171246-1 1988 Escherichia coli-derived (Serine 17) human interferon-beta (HuIFN-beta SER) was formulated with SDS and placed at multiple isothermal temperatures (-70 degrees C to 37 degrees C). Sodium Dodecyl Sulfate 96-99 interferon beta 1 Homo sapiens 43-58 3220830-4 1988 The state of sulfhydryl groups of E. coli-derived recombinant human interferon-beta 1, which had been purified under nonreducing and nondenaturing conditions, was examined by using the N-(7-dimethylamino-4-methylcoumarinyl)maleimide (DACM) labeling technique. N-(7-dimethylamino-4-methylcoumarinyl)maleimide 185-232 interferon beta 1 Homo sapiens 68-85 3220830-4 1988 The state of sulfhydryl groups of E. coli-derived recombinant human interferon-beta 1, which had been purified under nonreducing and nondenaturing conditions, was examined by using the N-(7-dimethylamino-4-methylcoumarinyl)maleimide (DACM) labeling technique. N-(7-dimethylamino-4-methylcoumarinyl)maleimide 234-238 interferon beta 1 Homo sapiens 68-85 3220830-5 1988 Among the three cysteine residues in E. coli-derived human interferon-beta 1, the 17th cysteine was identified as being unpaired, as in the natural molecule. Cysteine 16-24 interferon beta 1 Homo sapiens 59-76 3220830-5 1988 Among the three cysteine residues in E. coli-derived human interferon-beta 1, the 17th cysteine was identified as being unpaired, as in the natural molecule. Cysteine 87-95 interferon beta 1 Homo sapiens 59-76 3220830-8 1988 These results indicate that disulfide bond interchange occurs in E. coli-derived recombinant human interferon-beta 1 under denaturing conditions in spite of the absence of a reducing agent. Disulfides 28-37 interferon beta 1 Homo sapiens 99-116 2453506-3 1988 A similar decrease in secretion of human IFN-beta was detected in dexamethasone-treated murine C127 cells that carry an IFN expression vector. Dexamethasone 66-79 interferon beta 1 Homo sapiens 41-49 2449288-4 1987 Fibroblast cells grown on microcarriers in the presence of glucocorticoid hormones maintained their ability to produce interferon (IFN)-beta in a superinduction method with poly I: poly C and antimetabolites. Poly I 173-179 interferon beta 1 Homo sapiens 119-140 2454270-5 1988 In all three mRNAs, as in mature IFN-beta 1 mRNA, the polyadenylation site was located within a few nucleotides downstream from the AAUAAA hexanucleotide consensus sequence. hexanucleotide 139-153 interferon beta 1 Homo sapiens 33-43 3154015-5 1988 The pretreatment of LGL with anti Leu-11 (CD16) plus complement abrogated the enhancing effect by IFN-beta or IL-2, but not with anti Leu-1 (CD5) plus complement. leu-11 34-40 interferon beta 1 Homo sapiens 98-106 3279118-9 1988 PCT-GF activity in supernatants of human FS-4 fibroblasts stimulated with TNF, IL-1 or poly(I).poly(C) was neutralized by antibody to rBSF-2, but not by antibodies neutralizing the antiviral activity of IFN-beta. Poly C 95-102 interferon beta 1 Homo sapiens 203-211 3045221-1 1988 Interferon-beta serine (IFN-beta ser) was administered intravenously (i.v.) Serine 16-22 interferon beta 1 Homo sapiens 0-15 3045221-1 1988 Interferon-beta serine (IFN-beta ser) was administered intravenously (i.v.) Serine 16-19 interferon beta 1 Homo sapiens 0-15 3045221-3 1988 In this Phase I trial, IFN-beta ser was tolerated without limiting fever or subjective toxicities. Serine 32-35 interferon beta 1 Homo sapiens 23-31 2839097-4 1988 IFN-beta ser induced a greater than or equal to 50% reduction in the 7 day growth of 6 of the 15 cultures. Serine 9-12 interferon beta 1 Homo sapiens 0-8 2839097-7 1988 In contrast, when treated with the combination of IFN-beta ser plus IFN-gamma, 1000 Units/ml of each interferon preparation, 12 of 15 cultures were inhibited by greater than or equal to 50% after 7 days growth. Serine 59-62 interferon beta 1 Homo sapiens 50-58 2839097-9 1988 One glioblastoma culture, G-7, was studied through 45 passages and displayed the same sensitivity at different passages to growth inhibition when exposed to IFN-beta ser, IFN-gamma or both interferons. Serine 166-169 interferon beta 1 Homo sapiens 157-165 2449288-4 1987 Fibroblast cells grown on microcarriers in the presence of glucocorticoid hormones maintained their ability to produce interferon (IFN)-beta in a superinduction method with poly I: poly C and antimetabolites. Poly C 181-187 interferon beta 1 Homo sapiens 119-140 2960673-0 1987 Binding of recombinant-produced interferon beta ser to human lymphoblastoid cells. Serine 48-51 interferon beta 1 Homo sapiens 32-47 2960673-2 1987 Human interferon beta (IFN beta ser), produced by recombinant DNA technology, was radiolabeled to approximately one atom of iodine-125/molecule of interferon without detectable loss of antiviral activity. Iodine 124-130 interferon beta 1 Homo sapiens 6-21 2960673-2 1987 Human interferon beta (IFN beta ser), produced by recombinant DNA technology, was radiolabeled to approximately one atom of iodine-125/molecule of interferon without detectable loss of antiviral activity. Iodine 124-130 interferon beta 1 Homo sapiens 23-31 2960673-3 1987 At 37 degrees C, binding of 125I IFN beta ser occurred rapidly (t1/2max less than or equal to 15 min) followed by internalization and degradation of bound ligand. Serine 42-45 interferon beta 1 Homo sapiens 33-41 2960673-5 1987 Dissociation of bound 125I IFN beta ser from Daudi cells was slow (t1/2 = 1.2 h) of bound radiolabeled ligand was observed in the presence of unlabeled IFN beta ser, naturally produced IFN beta, and IFN alpha 6, but was not observed with unlabeled IFN gamma or nonspecific proteins. Serine 36-39 interferon beta 1 Homo sapiens 27-35 2960673-5 1987 Dissociation of bound 125I IFN beta ser from Daudi cells was slow (t1/2 = 1.2 h) of bound radiolabeled ligand was observed in the presence of unlabeled IFN beta ser, naturally produced IFN beta, and IFN alpha 6, but was not observed with unlabeled IFN gamma or nonspecific proteins. Serine 36-39 interferon beta 1 Homo sapiens 152-160 2960673-5 1987 Dissociation of bound 125I IFN beta ser from Daudi cells was slow (t1/2 = 1.2 h) of bound radiolabeled ligand was observed in the presence of unlabeled IFN beta ser, naturally produced IFN beta, and IFN alpha 6, but was not observed with unlabeled IFN gamma or nonspecific proteins. Serine 36-39 interferon beta 1 Homo sapiens 152-160 2960673-5 1987 Dissociation of bound 125I IFN beta ser from Daudi cells was slow (t1/2 = 1.2 h) of bound radiolabeled ligand was observed in the presence of unlabeled IFN beta ser, naturally produced IFN beta, and IFN alpha 6, but was not observed with unlabeled IFN gamma or nonspecific proteins. Serine 116-119 interferon beta 1 Homo sapiens 27-35 2960673-6 1987 Concomitantly, equilibrium analysis indicated heterogeneous binding of 125I IFN beta ser to six cell lines of lymphoid origin consistent with either negative cooperativity or two populations of receptors. Serine 85-88 interferon beta 1 Homo sapiens 76-84 2960673-7 1987 Analysis of binding of 125I IFN beta ser to Daudi cell receptors in the presence of unlabeled IFN alpha 6 suggested that one receptor served both ligands. Serine 37-40 interferon beta 1 Homo sapiens 28-36 2960673-8 1987 The latter conclusion was supported by results of chemical cross-linking experiments in which an 125I IFN beta ser/receptor complex (Mr 120,000-130,000) was observed following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Sodium Dodecyl Sulfate 176-198 interferon beta 1 Homo sapiens 102-110 2960673-8 1987 The latter conclusion was supported by results of chemical cross-linking experiments in which an 125I IFN beta ser/receptor complex (Mr 120,000-130,000) was observed following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. polyacrylamide 199-213 interferon beta 1 Homo sapiens 102-110 2960673-9 1987 This complex was absent when binding occurred in the presence of either excess unlabeled IFN beta ser or IFN alpha 6. Serine 98-101 interferon beta 1 Homo sapiens 89-97 3667593-5 1987 NeuAc, which is alpha 2-3-linked to galactose in the human IFN-beta secreted by Chinese hamster ovary cells, can be re-incorporated with an alpha 2-6 linkage in vitro, into enzymatically desialylated IFN-beta using rat liver Gal beta 1-4GlcNAc alpha 2-6 sialyltransferase. Galactose 36-45 interferon beta 1 Homo sapiens 59-67 3667593-0 1987 Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line. Carbohydrates 17-29 interferon beta 1 Homo sapiens 46-61 3667593-5 1987 NeuAc, which is alpha 2-3-linked to galactose in the human IFN-beta secreted by Chinese hamster ovary cells, can be re-incorporated with an alpha 2-6 linkage in vitro, into enzymatically desialylated IFN-beta using rat liver Gal beta 1-4GlcNAc alpha 2-6 sialyltransferase. gal beta 1-4glcnac 225-243 interferon beta 1 Homo sapiens 59-67 3667593-1 1987 The carbohydrate structure of the major oligosaccharide of human interferon-beta (IFN-beta) synthesized by a genetically engineered Chinese hamster ovary cell line has been determined. Carbohydrates 4-16 interferon beta 1 Homo sapiens 65-80 3667593-1 1987 The carbohydrate structure of the major oligosaccharide of human interferon-beta (IFN-beta) synthesized by a genetically engineered Chinese hamster ovary cell line has been determined. Carbohydrates 4-16 interferon beta 1 Homo sapiens 82-90 3667593-1 1987 The carbohydrate structure of the major oligosaccharide of human interferon-beta (IFN-beta) synthesized by a genetically engineered Chinese hamster ovary cell line has been determined. Oligosaccharides 40-55 interferon beta 1 Homo sapiens 65-80 3667593-6 1987 The sugar chain is important for maintaining protein solubility as shown by the fact that IFN-beta protein precipitates after deglycosylation with glycopeptidase F. Sugars 4-9 interferon beta 1 Homo sapiens 90-98 3667593-1 1987 The carbohydrate structure of the major oligosaccharide of human interferon-beta (IFN-beta) synthesized by a genetically engineered Chinese hamster ovary cell line has been determined. Oligosaccharides 40-55 interferon beta 1 Homo sapiens 82-90 3308083-0 1987 Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer. Serine 68-71 interferon beta 1 Homo sapiens 58-66 3667593-2 1987 Analysis of the glycopeptidase F-released carbohydrates by sequential exoglycosidase treatment, methylation analysis, and fast atom bombardment-mass spectrometry revealed that 95% of the IFN-beta oligosaccharides had the following structure: (Formula: see text). Carbohydrates 42-55 interferon beta 1 Homo sapiens 187-195 3667593-4 1987 The major oligosaccharide of the recombinant IFN-beta is remarkably homogeneous with respect to terminal galactose sialylation. Oligosaccharides 10-25 interferon beta 1 Homo sapiens 45-53 3667593-4 1987 The major oligosaccharide of the recombinant IFN-beta is remarkably homogeneous with respect to terminal galactose sialylation. Galactose 105-114 interferon beta 1 Homo sapiens 45-53 3667593-5 1987 NeuAc, which is alpha 2-3-linked to galactose in the human IFN-beta secreted by Chinese hamster ovary cells, can be re-incorporated with an alpha 2-6 linkage in vitro, into enzymatically desialylated IFN-beta using rat liver Gal beta 1-4GlcNAc alpha 2-6 sialyltransferase. N-Acetylneuraminic Acid 0-5 interferon beta 1 Homo sapiens 59-67 3667593-5 1987 NeuAc, which is alpha 2-3-linked to galactose in the human IFN-beta secreted by Chinese hamster ovary cells, can be re-incorporated with an alpha 2-6 linkage in vitro, into enzymatically desialylated IFN-beta using rat liver Gal beta 1-4GlcNAc alpha 2-6 sialyltransferase. N-Acetylneuraminic Acid 0-5 interferon beta 1 Homo sapiens 200-208 3115570-11 1987 We conclude that combinations of IFN-beta ser and IFN-gamma can be safely administered on a chronic basis without enhanced or cumulative toxic effects. Serine 42-45 interferon beta 1 Homo sapiens 33-41 3675571-4 1987 This interferon-beta-induced protein is located on the exterior of Daudi cells for it can be labeled with [125I] iodine catalyzed by lactoperoxidase. Iodine 113-119 interferon beta 1 Homo sapiens 5-20 3079540-3 1987 IFN-beta ser affected lipoprotein lipids of patients in a dose dependent fashion. Serine 9-12 interferon beta 1 Homo sapiens 0-8 3079540-6 1987 The plasma total cholesterol concentration decrease resulted primarily from a decrease in LDL cholesterol of 28% and 50% for patients on low and high doses respectively of IFN-beta ser. Cholesterol 17-28 interferon beta 1 Homo sapiens 172-180 3079540-6 1987 The plasma total cholesterol concentration decrease resulted primarily from a decrease in LDL cholesterol of 28% and 50% for patients on low and high doses respectively of IFN-beta ser. Cholesterol 94-105 interferon beta 1 Homo sapiens 172-180 3079540-8 1987 A dose-related increase in plasma triglyceride concentration occurred during IFN-beta ser, increasing 74% for patients on low dose and 136% for patients on high doses. Triglycerides 34-46 interferon beta 1 Homo sapiens 77-85 3079540-8 1987 A dose-related increase in plasma triglyceride concentration occurred during IFN-beta ser, increasing 74% for patients on low dose and 136% for patients on high doses. Serine 86-89 interferon beta 1 Homo sapiens 77-85 3079540-9 1987 This increase was only observed after 9 days on IFN-beta ser. Serine 25-28 interferon beta 1 Homo sapiens 48-56 2957045-0 1987 Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro. Iodine-125 28-32 interferon beta 1 Homo sapiens 41-56 2957045-0 1987 Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro. Serine 57-60 interferon beta 1 Homo sapiens 41-56 2957045-1 1987 Studies of various established human bladder and renal carcinoma cell lines cultured in vitro demonstrated the presence of specific, saturable, high affinity binding sites for 125I-labeled human interferon Beta ser IFN-beta ser). Serine 211-214 interferon beta 1 Homo sapiens 215-223 2957045-1 1987 Studies of various established human bladder and renal carcinoma cell lines cultured in vitro demonstrated the presence of specific, saturable, high affinity binding sites for 125I-labeled human interferon Beta ser IFN-beta ser). Serine 224-227 interferon beta 1 Homo sapiens 215-223 2957045-3 1987 A single class of binding sites (1000-2000/cell) with an affinity constant of 10(10)-10(11) L/M was measured at 4 degrees C for cells exhibiting widely different sensitivity to the antiproliferative effect of IFN-beta ser. Serine 218-221 interferon beta 1 Homo sapiens 209-217 2957045-4 1987 Major fluctuations in the binding of 125I-labeled IFN-beta ser to cellular receptors were observed during in vitro proliferation of four of five cell lines examined. Serine 59-62 interferon beta 1 Homo sapiens 50-58 2957045-6 1987 Cell cycle analysis suggested that within the first 24 h and in the very late log and stationary phase of growth of ACHN (human renal carcinoma) cells, variations in the binding of 125I-labeled IFN-beta ser were partially attributable to binding fluctuations during the mitotic cycle. Serine 203-206 interferon beta 1 Homo sapiens 194-202 2957045-8 1987 T24 (human transitional cell carcinoma) and ACHN cells, synchronized by serum starvation, demonstrated increased binding of 125I-labeled IFN-beta ser 4-16 h following serum replenishment. Serine 72-75 interferon beta 1 Homo sapiens 137-145 2957045-13 1987 These changes in the biological activity of this interferon corresponded to growth related fluctuations in the IFN-beta ser binding. Serine 120-123 interferon beta 1 Homo sapiens 111-119 3040777-9 1987 Inhibition of IFN-beta synthesis is likely to be responsible for the inhibition of the TNF-induced antiviral state by dexamethasone. Dexamethasone 118-131 interferon beta 1 Homo sapiens 14-22 3040777-10 1987 Since IFNs suppress cell growth, inhibition of endogenous IFN-beta synthesis may also be responsible for the amplification by dexamethasone of the growth-stimulating action of TNF and IL-1. Dexamethasone 126-139 interferon beta 1 Homo sapiens 58-66 3496595-1 1987 A 26-kDa protein, originally described in human fibroblasts superinduced for interferon beta (IFN-beta) production, and termed IFN-beta 2 by other investigators, is induced by cycloheximide and by a 22-kDa, interleukin 1 (IL-1)-related factor. Cycloheximide 176-189 interferon beta 1 Homo sapiens 77-92 2444657-5 1987 The possibility that IFN-beta potentiates the antiproliferative effects of these free radical-generating agents in a different manner is also discussed. Free Radicals 81-93 interferon beta 1 Homo sapiens 21-29 3496595-1 1987 A 26-kDa protein, originally described in human fibroblasts superinduced for interferon beta (IFN-beta) production, and termed IFN-beta 2 by other investigators, is induced by cycloheximide and by a 22-kDa, interleukin 1 (IL-1)-related factor. Cycloheximide 176-189 interferon beta 1 Homo sapiens 94-102 3579676-7 1987 Low doses of indomethacin dramatically reduced the toxicity of interferon beta therapy and played an important role in successful double blinding. Indomethacin 13-25 interferon beta 1 Homo sapiens 63-78 3596615-6 1987 The purified monoclonal antibodies, YSB-1(5 micrograms/ml) and YSB-2(1 microgram/ml), neutralized IFN-beta from 10EU/ml to 1EU/ml. ysb-2 63-68 interferon beta 1 Homo sapiens 98-106 3567933-1 1987 Interferon-beta-serine (IFN-beta ser) is a recombinant genetically altered interferon with extensive in vitro antiproliferative, antiviral, and immunological effects. Serine 16-22 interferon beta 1 Homo sapiens 24-32 3596615-6 1987 The purified monoclonal antibodies, YSB-1(5 micrograms/ml) and YSB-2(1 microgram/ml), neutralized IFN-beta from 10EU/ml to 1EU/ml. ysb-1 36-41 interferon beta 1 Homo sapiens 98-106 3567933-1 1987 Interferon-beta-serine (IFN-beta ser) is a recombinant genetically altered interferon with extensive in vitro antiproliferative, antiviral, and immunological effects. Serine 16-19 interferon beta 1 Homo sapiens 24-32 3567933-3 1987 IFN-beta ser was given twice weekly (Monday/Thursday) by a 4-h i.v. Serine 9-12 interferon beta 1 Homo sapiens 0-8 3567933-7 1987 Preliminary studies with normal donor cells demonstrated that IFN-beta ser in vitro enhanced activity in a mononuclear-MBL-2 growth inhibition, NK-cell, and monocyte antibody-dependent cellular cytotoxicity assay. Serine 71-74 interferon beta 1 Homo sapiens 62-70 3567933-13 1987 In general changes in these assays were observed at low levels of IFN-beta ser, increased at 4-48 h, then returned toward base line. Serine 42-45 interferon beta 1 Homo sapiens 66-74 3567933-14 1987 We conclude that IFN-beta ser is an active biological agent in vitro and significantly modulated the biological responses in patients with renal cell carcinoma. Serine 26-29 interferon beta 1 Homo sapiens 17-25 3039014-0 1987 Potency stability of recombinant (Serine-17) human interferon-beta. Serine 34-40 interferon beta 1 Homo sapiens 51-66 3471521-1 1987 We have previously demonstrated that a combination of interferon beta and a differentiation agent, dimethyl sulfoxide (DMSO), is cytotoxic for HL-60 cells, a human promyelocytic leukemic cell line. Dimethyl Sulfoxide 99-117 interferon beta 1 Homo sapiens 54-69 3471521-1 1987 We have previously demonstrated that a combination of interferon beta and a differentiation agent, dimethyl sulfoxide (DMSO), is cytotoxic for HL-60 cells, a human promyelocytic leukemic cell line. Dimethyl Sulfoxide 119-123 interferon beta 1 Homo sapiens 54-69 3556111-0 1987 Chemical mutagenesis of human interferon-beta: construction, expression in E. coli, and biological activity of sodium bisulfite-induced mutations. sodium bisulfite 111-127 interferon beta 1 Homo sapiens 30-45 3556111-1 1987 A series of modified human interferon-beta (IFN-beta) genes was produced by sodium bisulfite treatment of the IFN-beta gene cloned in M13. sodium bisulfite 76-92 interferon beta 1 Homo sapiens 27-42 3556111-1 1987 A series of modified human interferon-beta (IFN-beta) genes was produced by sodium bisulfite treatment of the IFN-beta gene cloned in M13. sodium bisulfite 76-92 interferon beta 1 Homo sapiens 44-52 3556111-1 1987 A series of modified human interferon-beta (IFN-beta) genes was produced by sodium bisulfite treatment of the IFN-beta gene cloned in M13. sodium bisulfite 76-92 interferon beta 1 Homo sapiens 110-118 3039014-1 1987 The antiviral activity of Escherichia coli-derived (Serine-17) human interferon-beta, formulated with human serum albumin, is stable for 2 years when lyophilized and stored under refrigeration. Serine 52-58 interferon beta 1 Homo sapiens 69-84 3805129-2 1987 Poly(I).poly(C) is a potent inducer of interferon (IFN)-beta in human fibroblasts. Poly I 0-7 interferon beta 1 Homo sapiens 39-60 3805129-4 1987 Antiserum to interferon (IFN)-beta, added to poly(I).poly(C)-stimulated cultures in order to neutralize endogenously generated IFN, markedly amplified the mitogenic action. Poly I 45-52 interferon beta 1 Homo sapiens 13-34 3110053-4 1987 Unlabeled lung carcinoma A-549 cells block chromium release from labeled K-562 cells with non-boosted and IFN-gamma or IFN-beta-boosted effector cells. Chromium 43-51 interferon beta 1 Homo sapiens 119-127 3038690-7 1987 Full induction is achieved by shifting the incubation temperature to 42 degrees C. The combination of highly efficient transcriptional and translational signals on these vectors allowed high-level expression of sequences encoding human interferon beta and interleukin 2 and of the E. coli atpA, sucC and sucD genes. succinic semialdehyde 295-299 interferon beta 1 Homo sapiens 236-251 3038690-7 1987 Full induction is achieved by shifting the incubation temperature to 42 degrees C. The combination of highly efficient transcriptional and translational signals on these vectors allowed high-level expression of sequences encoding human interferon beta and interleukin 2 and of the E. coli atpA, sucC and sucD genes. succinyl dermatan sulfate 304-308 interferon beta 1 Homo sapiens 236-251 3805129-4 1987 Antiserum to interferon (IFN)-beta, added to poly(I).poly(C)-stimulated cultures in order to neutralize endogenously generated IFN, markedly amplified the mitogenic action. Poly C 53-60 interferon beta 1 Homo sapiens 13-34 3805129-2 1987 Poly(I).poly(C) is a potent inducer of interferon (IFN)-beta in human fibroblasts. Poly C 8-15 interferon beta 1 Homo sapiens 39-60 3756886-1 1986 Beta-interferon serine (IFN-beta ser) is a genetically altered recombinant IFN with a specific activity of 2 X 10(8) IU/mg protein. Serine 16-22 interferon beta 1 Homo sapiens 24-32 2437222-7 1986 Overall, however, none of the IFNs was markedly more effective in antiproliferative effects than any other, although there was a trend toward IFN-beta ser having more potent antiproliferative properties when compared to IFN-alpha 2 (p = 0.055). Serine 151-154 interferon beta 1 Homo sapiens 142-150 2437222-8 1986 Twelve of 13 tumors exposed to combinations of IFN-beta ser and IFN-gamma demonstrated a synergistic antiproliferative effect. Serine 56-59 interferon beta 1 Homo sapiens 47-55 2878272-6 1986 Low doses of indomethacin reduced the toxicity of IFN-B and played an important role in successful double-blinding. Indomethacin 13-25 interferon beta 1 Homo sapiens 50-55 3756886-1 1986 Beta-interferon serine (IFN-beta ser) is a genetically altered recombinant IFN with a specific activity of 2 X 10(8) IU/mg protein. Serine 16-19 interferon beta 1 Homo sapiens 24-32 3756886-3 1986 IFN-beta ser was given by a 4-h intravenous infusion twice weekly (Monday and Thursday). Serine 9-12 interferon beta 1 Homo sapiens 0-8 3756886-14 1986 We conclude that IFN-beta ser is a well tolerated IFN with minimal renal, hepatic, and bone marrow toxicity. Serine 26-29 interferon beta 1 Homo sapiens 17-25 2433366-0 1986 Interferon-beta inhibition of concanavalin A-stimulated calcium uptake and exchange in HeLa cells. Calcium 56-63 interferon beta 1 Homo sapiens 0-15 2433366-2 1986 Pretreatment of the cells with interferon-beta (IFN-beta) at a concentration of 640 U/ml for 24 h markedly inhibits this ConA-stimulated calcium exchange and uptake, but not the basal level of calcium exchange. Calcium 137-144 interferon beta 1 Homo sapiens 31-46 2433366-2 1986 Pretreatment of the cells with interferon-beta (IFN-beta) at a concentration of 640 U/ml for 24 h markedly inhibits this ConA-stimulated calcium exchange and uptake, but not the basal level of calcium exchange. Calcium 137-144 interferon beta 1 Homo sapiens 48-56 2433366-2 1986 Pretreatment of the cells with interferon-beta (IFN-beta) at a concentration of 640 U/ml for 24 h markedly inhibits this ConA-stimulated calcium exchange and uptake, but not the basal level of calcium exchange. Calcium 193-200 interferon beta 1 Homo sapiens 31-46 2433366-2 1986 Pretreatment of the cells with interferon-beta (IFN-beta) at a concentration of 640 U/ml for 24 h markedly inhibits this ConA-stimulated calcium exchange and uptake, but not the basal level of calcium exchange. Calcium 193-200 interferon beta 1 Homo sapiens 48-56 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Poly I 49-56 interferon beta 1 Homo sapiens 122-137 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Poly I 49-56 interferon beta 1 Homo sapiens 139-147 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Poly I 49-56 interferon beta 1 Homo sapiens 248-256 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Poly C 59-66 interferon beta 1 Homo sapiens 122-137 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Poly C 59-66 interferon beta 1 Homo sapiens 139-147 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Poly C 59-66 interferon beta 1 Homo sapiens 248-256 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Cycloheximide 86-99 interferon beta 1 Homo sapiens 122-137 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Cycloheximide 86-99 interferon beta 1 Homo sapiens 139-147 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Cycloheximide 86-99 interferon beta 1 Homo sapiens 248-256 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Adenosine Monophosphate 324-327 interferon beta 1 Homo sapiens 122-137 3758081-1 1986 When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. & Fiers, W. (1982) Proc. Adenosine Monophosphate 324-327 interferon beta 1 Homo sapiens 139-147 3489541-12 1986 Overall, these findings suggest that EC, either untreated or pretreated with IFN-beta or IL-2, significantly lose their lytic capabilities following interaction with K562 while retaining their ability to bind to the TC; IFN-beta acts predominantly on pre-NK cells, but not on ECi; and IL-2 appears to play an important role in restoring lytic potential to functionally inactive NK cells. ec 37-39 interferon beta 1 Homo sapiens 77-85 3489541-12 1986 Overall, these findings suggest that EC, either untreated or pretreated with IFN-beta or IL-2, significantly lose their lytic capabilities following interaction with K562 while retaining their ability to bind to the TC; IFN-beta acts predominantly on pre-NK cells, but not on ECi; and IL-2 appears to play an important role in restoring lytic potential to functionally inactive NK cells. ec 37-39 interferon beta 1 Homo sapiens 220-228 3489541-12 1986 Overall, these findings suggest that EC, either untreated or pretreated with IFN-beta or IL-2, significantly lose their lytic capabilities following interaction with K562 while retaining their ability to bind to the TC; IFN-beta acts predominantly on pre-NK cells, but not on ECi; and IL-2 appears to play an important role in restoring lytic potential to functionally inactive NK cells. Technetium 216-218 interferon beta 1 Homo sapiens 77-85 3489541-12 1986 Overall, these findings suggest that EC, either untreated or pretreated with IFN-beta or IL-2, significantly lose their lytic capabilities following interaction with K562 while retaining their ability to bind to the TC; IFN-beta acts predominantly on pre-NK cells, but not on ECi; and IL-2 appears to play an important role in restoring lytic potential to functionally inactive NK cells. Technetium 216-218 interferon beta 1 Homo sapiens 220-228 3732911-4 1986 The [3H]thymidine incorporation of both BeWo and HCCM-5 cells was suppressed in dose-dependent manner at 48 hr after treatment with 1 to 1,000 units (U)/ml of IFN-alpha or IFN-beta and the growth of them was also slightly inhibited when treated continuously with 1,000 U/ml for 6 days in vitro. Tritium 5-7 interferon beta 1 Homo sapiens 172-180 3016203-2 1986 Interferon beta ser, but not alpha 76, potentiated the destruction mediated by interleukin-2 (IL-2) dependent, long-term T cell cultures. Serine 16-19 interferon beta 1 Homo sapiens 0-15 2421645-3 1986 Treatment with IFN-beta combined with chemotherapy, e.g. DTIC, produced a clinical improvement in 2 of 5 patients with malignant melanoma (1CR, 1PR, 2NC and 1PD). Dacarbazine 57-61 interferon beta 1 Homo sapiens 15-23 2944474-1 1986 The combination of recombinant human fibroblast interferon (INF-delta) and the antileukemic compound mezerein (MEZ) results in a synergistic suppression in the growth of human melanoma cells and a concomitant increase in melanin synthesis. Melanins 221-228 interferon beta 1 Homo sapiens 37-69 3014018-0 1986 Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers. Serine 16-19 interferon beta 1 Homo sapiens 0-15 3014018-1 1986 The first test of intranasal recombinant human interferon-beta ser (IFN-beta ser) as prophylaxis against common colds is reported. Serine 63-66 interferon beta 1 Homo sapiens 47-62 3014018-1 1986 The first test of intranasal recombinant human interferon-beta ser (IFN-beta ser) as prophylaxis against common colds is reported. Serine 63-66 interferon beta 1 Homo sapiens 68-76 3014018-2 1986 IFN-beta ser was cleared from the nose like IFN-alpha. Serine 9-12 interferon beta 1 Homo sapiens 0-8 3014018-3 1986 A total of 10 volunteers were each given a total of 2.6 X 10(7) units of IFN-beta ser as 13 doses administered three times daily over 4 days and there were negligible symptoms that were not significantly different from those in 10 given placebo. Serine 82-85 interferon beta 1 Homo sapiens 73-81 3592940-3 1986 Further improvement of interferon beta affinity to CPG was obtained by rehydroxylation of boron enriched CPG surface. Boron 90-95 interferon beta 1 Homo sapiens 23-38 2416427-3 1986 In all cell lines except one, the addition of IFN-gamma to either IFN-alpha 54 or IFN-beta ser resulted in a synergistic antiproliferative effect, regardless of individual IFN sensitivities or tissue of origin. Serine 91-94 interferon beta 1 Homo sapiens 82-90 2416427-8 1986 The addition of IFN-alpha 54 to IFN-beta ser in the SKCO 1 cell line resulted in an antagonistic interaction. Serine 41-44 interferon beta 1 Homo sapiens 32-40 2416427-9 1986 Timing experiments with RT112 cells indicate that IFN-gamma and IFN-beta ser need not be in the media at the same time for the synergistic effect to occur. Serine 73-76 interferon beta 1 Homo sapiens 64-72 3484933-1 1986 Interferon-beta (GKT-beta) was administered to a patient with adult T-cell leukemia (ATL), presumably of acute type, with a marked organ infiltration and increases in serum calcium, LDH and bilirubin. Calcium 173-180 interferon beta 1 Homo sapiens 0-15 3484933-1 1986 Interferon-beta (GKT-beta) was administered to a patient with adult T-cell leukemia (ATL), presumably of acute type, with a marked organ infiltration and increases in serum calcium, LDH and bilirubin. Bilirubin 190-199 interferon beta 1 Homo sapiens 0-15 3511360-1 1986 "Molecular sandwiches" composed of two aromatic amino acids separated by a hydrophilic one were found on eleven subspecies of human interferon alpha, on murine interferon alpha 2, and human interferon beta 1. Amino Acids, Aromatic 39-59 interferon beta 1 Homo sapiens 190-207 3866799-5 1985 The combinations VP-16-213/IFN-beta and cis-platinum/IFN-beta produced the most pronounced synergistic effects. Etoposide 17-22 interferon beta 1 Homo sapiens 27-35 3016203-4 1986 In contrast to the potentiation of T cell-mediated cytotoxicity, IFN beta ser and alpha 76 did not modulate the cytotoxic activity of cytotoxic T cell clones that are specifically reactive to autologous EBV-LCL. Serine 74-77 interferon beta 1 Homo sapiens 65-73 3016203-6 1986 Rather, our results are consistent with IFN beta ser augmenting cytotoxic T cell reactivity indirectly, possibly via its influence on other immunoregulatory cells. Serine 49-52 interferon beta 1 Homo sapiens 40-48 3016203-7 1986 Although the precise mechanism whereby IFN beta ser may potentiate cytotoxicity is not yet defined, the synergistic action of IFN beta ser and IL-2 on long-term CTL cultures offers an alternate means to selectively enhance a desirable cytotoxic response. Serine 48-51 interferon beta 1 Homo sapiens 39-47 3016203-7 1986 Although the precise mechanism whereby IFN beta ser may potentiate cytotoxicity is not yet defined, the synergistic action of IFN beta ser and IL-2 on long-term CTL cultures offers an alternate means to selectively enhance a desirable cytotoxic response. Serine 135-138 interferon beta 1 Homo sapiens 126-134 3876934-5 1985 Addition of cycloheximide to the 22-kDa factor resulted in further significant increases in mRNA levels for both the 26-kDa-protein and IFN-beta. Cycloheximide 12-25 interferon beta 1 Homo sapiens 136-144 2998406-3 1985 The polynucleotide A includes a leader structure of the human fibroblast interferon gene. polynucleotide a 4-20 interferon beta 1 Homo sapiens 62-83 2410911-5 1985 Analysis by sodium dodecyl sulfate/polyacrylamide gel electrophoresis revealed the presence of IFN-alpha and IFN-beta with molecular masses between 15 and 80 kilodaltons. Sodium Dodecyl Sulfate 12-34 interferon beta 1 Homo sapiens 109-117 2410911-5 1985 Analysis by sodium dodecyl sulfate/polyacrylamide gel electrophoresis revealed the presence of IFN-alpha and IFN-beta with molecular masses between 15 and 80 kilodaltons. polyacrylamide 35-49 interferon beta 1 Homo sapiens 109-117 3986788-5 1985 Combinations of natural or recombinant IFN-beta with either polyriboinosinic acid.polyribocytidilic acid or r(I)n.r(C12,U)n gave an antagonistic effect regardless of tumor mass at the initiation of treatment. polyribocytidilic acid 82-104 interferon beta 1 Homo sapiens 39-47 3935515-5 1985 IFN-beta expression by these HRBS variants, as analyzed by antiviral activity and SDS-PAGE, shows both nucleotide sequence and spacer length effects. Sodium Dodecyl Sulfate 82-85 interferon beta 1 Homo sapiens 0-8 2985279-4 1985 Within this sequence, we note the presence of repetitious hexanucleotides (consensus: A-A-AG-TG-G-A), each of which may play a role in the maximum induction of the IFN-beta gene. hexanucleotides 58-73 interferon beta 1 Homo sapiens 164-172 3758650-3 1986 IFN-beta) either in saline, or in a human albumin (ALB) solution (10 and 13% final concentrations) modified the pharmacokinetic parameters calculated from the IFN plasma levels. Sodium Chloride 20-26 interferon beta 1 Homo sapiens 0-8 3989332-7 1985 When cell extracts were assayed for melanin content, a marker of melanoma cell differentiation, the combination of IFN-beta and MEZ resulted in higher levels of melanin than with either agent alone. Melanins 36-43 interferon beta 1 Homo sapiens 115-123 3989332-7 1985 When cell extracts were assayed for melanin content, a marker of melanoma cell differentiation, the combination of IFN-beta and MEZ resulted in higher levels of melanin than with either agent alone. Melanins 161-168 interferon beta 1 Homo sapiens 115-123 6091102-1 1984 Human fibroblast interferon has three cysteine residues, located at amino acid positions 17, 31, and 141. Cysteine 38-46 interferon beta 1 Homo sapiens 6-27 6441889-0 1984 Binding of 125I-labeled recombinant beta interferon (IFN-beta Ser17) to human cells. Iodine-125 11-15 interferon beta 1 Homo sapiens 53-61 6441889-1 1984 We investigated the binding of 125I-labeled beta interferon (IFN-beta Ser17), a nonglycosylated recombinant human fibroblast interferon in which cysteine at position 17 is replaced by serine by site-specific mutagenesis. Iodine-125 31-35 interferon beta 1 Homo sapiens 61-69 6441889-3 1984 Unlike the case with the chloramine T method, incorporation of a single mole of Bolton-Hunter reagent into a mole of IFN-beta Ser17 led to nearly complete loss of biological activity. chloramine-T 25-37 interferon beta 1 Homo sapiens 117-125 6441889-4 1984 125I-IFN-beta Ser17, prepared by the chloramine T method, bound specifically to human lymphoblastoid cells (Daudi) with a dissociation constant of 0.24 nM. chloramine-T 37-49 interferon beta 1 Homo sapiens 5-13 6091102-3 1984 The resulting interferon, IFN-beta Ser-17, retains the antiviral, natural killer cell activation, and antiproliferative activities of native fibroblast interferon. Serine 35-38 interferon beta 1 Homo sapiens 26-34 6091102-3 1984 The resulting interferon, IFN-beta Ser-17, retains the antiviral, natural killer cell activation, and antiproliferative activities of native fibroblast interferon. Serine 35-38 interferon beta 1 Homo sapiens 141-162 6091102-4 1984 The purified IFN-beta Ser-17 protein has an antiviral specific activity of 2 X 10(8) units/mg, similar to that of purified native fibroblast interferon. Serine 22-25 interferon beta 1 Homo sapiens 13-21 6584908-4 1984 Using a synthetic oligonucleotide complementary to the human c-myc mRNA as the probe, we detected a more than 75% reduction in the c-myc hybridizable poly(A)+ RNA in the IFN-beta-treated cells. Oligonucleotides 18-33 interferon beta 1 Homo sapiens 170-178 6715321-4 1984 The inhibition of proliferation of HeLa cells treated with IFN-beta is characterized by a 3-fold accumulation of newly synthesized DNA of Mr less than 56 X 10(6) compared to untreated cells as determined by alkaline sucrose gradient centrifugation. Sucrose 216-223 interferon beta 1 Homo sapiens 59-67 6733118-0 1984 Elution of interferon beta from blue sepharose by poly(vinylpyrrolidone). Sepharose 37-46 interferon beta 1 Homo sapiens 11-26 6733118-0 1984 Elution of interferon beta from blue sepharose by poly(vinylpyrrolidone). Povidone 50-72 interferon beta 1 Homo sapiens 11-26 6733118-1 1984 Interferon beta produced by a cell line (MRC-5) of human embryonic lung fibroblasts adsorbs to Blue Sepharose CL-6B and may be dissociated at neutral pH using a buffer containing poly(vinylpyrrolidone) and sodium chloride. Povidone 179-201 interferon beta 1 Homo sapiens 0-15 6733118-1 1984 Interferon beta produced by a cell line (MRC-5) of human embryonic lung fibroblasts adsorbs to Blue Sepharose CL-6B and may be dissociated at neutral pH using a buffer containing poly(vinylpyrrolidone) and sodium chloride. Sodium Chloride 206-221 interferon beta 1 Homo sapiens 0-15 6373201-1 1984 Ten recombinant plasmids were constructed which direct the synthesis of a mature human interferon-beta 1 (IFN-beta 1) under the control of the Escherichia coli tryptophan (trp) promoter. Tryptophan 172-175 interferon beta 1 Homo sapiens 87-104 6207796-3 1984 The affinity of Blue Dextran and its congeners to interferons were: IFN-beta greater than IFN-alpha greater than IFN-gamma. blue dextran 16-28 interferon beta 1 Homo sapiens 68-76 6373201-1 1984 Ten recombinant plasmids were constructed which direct the synthesis of a mature human interferon-beta 1 (IFN-beta 1) under the control of the Escherichia coli tryptophan (trp) promoter. Tryptophan 172-175 interferon beta 1 Homo sapiens 106-116 6538894-1 1984 Does the human "beta 2 interferon" (HuIFN-beta 2) mRNA of length 1.3 kb obtained from poly(I) X poly(C) and cycloheximide-induced human diploid fibroblasts (FS-4) code for an interferon per se, or for a protein which, in turn, induces IFN-beta in the cell culture assay that is usually used to detect the antiviral activity of the translation product (obtained from Xenopus laevis oocytes) of this mRNA? Cycloheximide 108-121 interferon beta 1 Homo sapiens 38-46 6193871-1 1983 Bleomycin, vincristine, or mitomycin C, when added to HeLa cells simultaneously with human fibroblast interferon (IFN-beta), caused a decrease in cell density and inhibited DNA synthesis compared with HeLa cells treated with IFN-beta alone. Bleomycin 0-9 interferon beta 1 Homo sapiens 114-122 6700582-3 1984 These cells were found to express high levels of human IFN-beta after polyriboinosinic acid-polyribocytidylic acid superinduction or NDV infection; this was a result of coamplification of the IFN-beta gene. Polyinosinic acid 70-91 interferon beta 1 Homo sapiens 55-63 6700582-3 1984 These cells were found to express high levels of human IFN-beta after polyriboinosinic acid-polyribocytidylic acid superinduction or NDV infection; this was a result of coamplification of the IFN-beta gene. Poly C 92-114 interferon beta 1 Homo sapiens 55-63 6700582-9 1984 Regulation of IFN-beta production by polyriboinosinic acid-polyribocytidylic acid or by cell density effects required the presence of DNA sequences 5" to the IFN-beta-coding sequences; replacement of these sequences with the simian virus 40 early promoter resulted in uninducible, density-independent production of IFN-beta. polyriboinosinic acid-polyribocytidylic acid 37-81 interferon beta 1 Homo sapiens 14-22 6193871-3 1983 HeLa cells treated with IFN-beta alone or with IFN-beta in combination with bleomycin, vincristine, or mitomycin C were able to induce the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and the double-stranded RNA-dependent protein kinase. Mitomycin 103-114 interferon beta 1 Homo sapiens 47-55 6193871-3 1983 HeLa cells treated with IFN-beta alone or with IFN-beta in combination with bleomycin, vincristine, or mitomycin C were able to induce the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and the double-stranded RNA-dependent protein kinase. Adenosine Triphosphate 169-191 interferon beta 1 Homo sapiens 24-32 6193871-3 1983 HeLa cells treated with IFN-beta alone or with IFN-beta in combination with bleomycin, vincristine, or mitomycin C were able to induce the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and the double-stranded RNA-dependent protein kinase. Adenosine Triphosphate 169-191 interferon beta 1 Homo sapiens 47-55 6193871-5 1983 These results indicate that, under these experimental conditions, the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase and protein kinase can be induced by IFN-beta in cells treated with bleomycin, vincristine, or mitomycin C. Adenosine Triphosphate 100-122 interferon beta 1 Homo sapiens 203-211 6193871-5 1983 These results indicate that, under these experimental conditions, the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase and protein kinase can be induced by IFN-beta in cells treated with bleomycin, vincristine, or mitomycin C. Bleomycin 234-243 interferon beta 1 Homo sapiens 203-211 6193871-5 1983 These results indicate that, under these experimental conditions, the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase and protein kinase can be induced by IFN-beta in cells treated with bleomycin, vincristine, or mitomycin C. Vincristine 245-256 interferon beta 1 Homo sapiens 203-211 6193871-5 1983 These results indicate that, under these experimental conditions, the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase and protein kinase can be induced by IFN-beta in cells treated with bleomycin, vincristine, or mitomycin C. Mitomycin 261-272 interferon beta 1 Homo sapiens 203-211 6193871-8 1983 The possibility that IFN-beta potentiates the cytotoxic effects of bleomycin and mitomycin C on HeLa cells is also discussed. Bleomycin 67-76 interferon beta 1 Homo sapiens 21-29 6193871-8 1983 The possibility that IFN-beta potentiates the cytotoxic effects of bleomycin and mitomycin C on HeLa cells is also discussed. Mitomycin 81-92 interferon beta 1 Homo sapiens 21-29 6193871-1 1983 Bleomycin, vincristine, or mitomycin C, when added to HeLa cells simultaneously with human fibroblast interferon (IFN-beta), caused a decrease in cell density and inhibited DNA synthesis compared with HeLa cells treated with IFN-beta alone. Bleomycin 0-9 interferon beta 1 Homo sapiens 225-233 6193871-1 1983 Bleomycin, vincristine, or mitomycin C, when added to HeLa cells simultaneously with human fibroblast interferon (IFN-beta), caused a decrease in cell density and inhibited DNA synthesis compared with HeLa cells treated with IFN-beta alone. Vincristine 11-22 interferon beta 1 Homo sapiens 114-122 6193871-1 1983 Bleomycin, vincristine, or mitomycin C, when added to HeLa cells simultaneously with human fibroblast interferon (IFN-beta), caused a decrease in cell density and inhibited DNA synthesis compared with HeLa cells treated with IFN-beta alone. Vincristine 11-22 interferon beta 1 Homo sapiens 225-233 6193871-1 1983 Bleomycin, vincristine, or mitomycin C, when added to HeLa cells simultaneously with human fibroblast interferon (IFN-beta), caused a decrease in cell density and inhibited DNA synthesis compared with HeLa cells treated with IFN-beta alone. Mitomycin 27-38 interferon beta 1 Homo sapiens 114-122 6193871-1 1983 Bleomycin, vincristine, or mitomycin C, when added to HeLa cells simultaneously with human fibroblast interferon (IFN-beta), caused a decrease in cell density and inhibited DNA synthesis compared with HeLa cells treated with IFN-beta alone. Mitomycin 27-38 interferon beta 1 Homo sapiens 225-233 6193871-3 1983 HeLa cells treated with IFN-beta alone or with IFN-beta in combination with bleomycin, vincristine, or mitomycin C were able to induce the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and the double-stranded RNA-dependent protein kinase. Bleomycin 76-85 interferon beta 1 Homo sapiens 24-32 6193871-3 1983 HeLa cells treated with IFN-beta alone or with IFN-beta in combination with bleomycin, vincristine, or mitomycin C were able to induce the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and the double-stranded RNA-dependent protein kinase. Bleomycin 76-85 interferon beta 1 Homo sapiens 47-55 6193871-3 1983 HeLa cells treated with IFN-beta alone or with IFN-beta in combination with bleomycin, vincristine, or mitomycin C were able to induce the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and the double-stranded RNA-dependent protein kinase. Vincristine 87-98 interferon beta 1 Homo sapiens 24-32 6193871-3 1983 HeLa cells treated with IFN-beta alone or with IFN-beta in combination with bleomycin, vincristine, or mitomycin C were able to induce the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and the double-stranded RNA-dependent protein kinase. Vincristine 87-98 interferon beta 1 Homo sapiens 47-55 6193871-3 1983 HeLa cells treated with IFN-beta alone or with IFN-beta in combination with bleomycin, vincristine, or mitomycin C were able to induce the double-stranded RNA-dependent adenosine triphosphate:2",5"-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and the double-stranded RNA-dependent protein kinase. Mitomycin 103-114 interferon beta 1 Homo sapiens 24-32 6357933-6 1983 Pretreatment of PBM with ReIFN-beta caused a significant increase in ADCC activity against both targets, and the enhancing activity of ReIFN-beta was similar to that of IFN-beta. pbm 16-19 interferon beta 1 Homo sapiens 27-35 6357933-7 1983 Phagocytic activity of adherent cells in PBM against CRBC was enhanced by ReIFN-beta and IFN-beta as determined by microscopical cytologic examination and by the 51Cr-labeled CRBC-uptake method. pbm 41-44 interferon beta 1 Homo sapiens 76-84 6357933-7 1983 Phagocytic activity of adherent cells in PBM against CRBC was enhanced by ReIFN-beta and IFN-beta as determined by microscopical cytologic examination and by the 51Cr-labeled CRBC-uptake method. crbc 53-57 interferon beta 1 Homo sapiens 76-84 6357933-7 1983 Phagocytic activity of adherent cells in PBM against CRBC was enhanced by ReIFN-beta and IFN-beta as determined by microscopical cytologic examination and by the 51Cr-labeled CRBC-uptake method. Chromium-51 162-166 interferon beta 1 Homo sapiens 76-84 6306284-0 1983 Cycloheximide induces expression of the human interferon beta 1 gene in mouse cells transformed by bovine papillomavirus-interferon beta 1 recombinants. Cycloheximide 0-13 interferon beta 1 Homo sapiens 46-63 6306284-0 1983 Cycloheximide induces expression of the human interferon beta 1 gene in mouse cells transformed by bovine papillomavirus-interferon beta 1 recombinants. Cycloheximide 0-13 interferon beta 1 Homo sapiens 121-138 6189584-12 1983 The associated changes in the (2",5")oligoadenylate [(2",5")oligo(A)] pathway produced by IFN-beta and IFL-alpha A were measured under growth-inhibitory conditions. 2',5'-oligoadenylate 30-51 interferon beta 1 Homo sapiens 90-98 6303787-6 1983 Treatment of the cells with butyrate or 5"-bromodeoxyuridine increased the amount of hybridizable IFN-alpha and IFN-beta mRNA about 15-fold and 4-fold respectively, again demonstrating coordinate control of IFN-alpha and IFN-beta production. Butyrates 28-36 interferon beta 1 Homo sapiens 112-120 6303787-6 1983 Treatment of the cells with butyrate or 5"-bromodeoxyuridine increased the amount of hybridizable IFN-alpha and IFN-beta mRNA about 15-fold and 4-fold respectively, again demonstrating coordinate control of IFN-alpha and IFN-beta production. Butyrates 28-36 interferon beta 1 Homo sapiens 221-229 6303787-6 1983 Treatment of the cells with butyrate or 5"-bromodeoxyuridine increased the amount of hybridizable IFN-alpha and IFN-beta mRNA about 15-fold and 4-fold respectively, again demonstrating coordinate control of IFN-alpha and IFN-beta production. Bromodeoxyuridine 40-60 interferon beta 1 Homo sapiens 112-120 6303787-6 1983 Treatment of the cells with butyrate or 5"-bromodeoxyuridine increased the amount of hybridizable IFN-alpha and IFN-beta mRNA about 15-fold and 4-fold respectively, again demonstrating coordinate control of IFN-alpha and IFN-beta production. Bromodeoxyuridine 40-60 interferon beta 1 Homo sapiens 221-229 6189584-12 1983 The associated changes in the (2",5")oligoadenylate [(2",5")oligo(A)] pathway produced by IFN-beta and IFL-alpha A were measured under growth-inhibitory conditions. (2",5")oligo 30-42 interferon beta 1 Homo sapiens 90-98 6189584-13 1983 A concentration-dependent induction of (2",5")oligo(A) synthetase was produced by IFN-beta or IFL-alpha A with a concomitant decrease in (2",5")oligo(A) phosphodiesterase. (2",5")oligo 39-51 interferon beta 1 Homo sapiens 82-90 6304240-2 1983 In the presence of tunicamycin, they produced non-glycosylated, biologically active, IFN-beta with a molecular weight of 17000. Tunicamycin 19-30 interferon beta 1 Homo sapiens 85-93 6856471-1 1983 Northern blot analysis reveals that total RNA from human fibroblastoid cells (MG 63) induced with poly(I).poly(C) under conditions of IFN-beta production, contains predominantly a +/- 1,200 nucleotide long poly (A) mRNA (mRNA.M) which hybridizes with a Hu IFN-beta cDNA specific probe. Poly I 98-105 interferon beta 1 Homo sapiens 134-142 6304727-3 1983 We have screened a human DNA library in lambda bacteriophage Charon 4A by using a 32P-labeled IFN-beta 1 insert cDNA (pD24) and thereby isolated six strongly positive human genomic DNA clones. Phosphorus-32 82-85 interferon beta 1 Homo sapiens 94-102 6856471-1 1983 Northern blot analysis reveals that total RNA from human fibroblastoid cells (MG 63) induced with poly(I).poly(C) under conditions of IFN-beta production, contains predominantly a +/- 1,200 nucleotide long poly (A) mRNA (mRNA.M) which hybridizes with a Hu IFN-beta cDNA specific probe. Poly I 98-105 interferon beta 1 Homo sapiens 256-264 6856471-1 1983 Northern blot analysis reveals that total RNA from human fibroblastoid cells (MG 63) induced with poly(I).poly(C) under conditions of IFN-beta production, contains predominantly a +/- 1,200 nucleotide long poly (A) mRNA (mRNA.M) which hybridizes with a Hu IFN-beta cDNA specific probe. Poly C 106-112 interferon beta 1 Homo sapiens 134-142 6856471-1 1983 Northern blot analysis reveals that total RNA from human fibroblastoid cells (MG 63) induced with poly(I).poly(C) under conditions of IFN-beta production, contains predominantly a +/- 1,200 nucleotide long poly (A) mRNA (mRNA.M) which hybridizes with a Hu IFN-beta cDNA specific probe. Poly C 106-112 interferon beta 1 Homo sapiens 256-264 6856471-4 1983 Furthermore, it also hybridizes to sequences, located downstream from the IFN-beta gene up to 2.5 kb beyond its poly A attachment site, while no hybridization to fragments located upstream of the IFN-beta mRNA cap site was observable. Poly A 112-118 interferon beta 1 Homo sapiens 74-82 6300659-3 1983 Mouse cells transformed by this hybrid DNA produced low levels of human IF-beta 1 constitutively and responded to induction with either inactivated Newcastle disease virus or polyriboinosinic acid-polyribocytidylic acid. polyriboinosinic acid-polyribocytidylic acid 175-219 interferon beta 1 Homo sapiens 72-81 6678936-2 1983 Different derivatives of polyethylene glycol (PEG)--liquid ion exchangers or affinity ligands--can be effectively used for the extraction of IFN-beta in combination with Dextran-T 500 or orthophosphate. Polyethylene Glycols 25-44 interferon beta 1 Homo sapiens 141-149 6678936-2 1983 Different derivatives of polyethylene glycol (PEG)--liquid ion exchangers or affinity ligands--can be effectively used for the extraction of IFN-beta in combination with Dextran-T 500 or orthophosphate. Polyethylene Glycols 46-49 interferon beta 1 Homo sapiens 141-149 6678936-4 1983 Systems containing polyethylene glycol-phosphate ester/orthophosphate/sodium chloride (1/19.5/2.9% w/w at pH 6.9 or 2/19/7.5% w/w at pH 5-5.9, respectively) resulted in up to 350-fold purified IFN-beta in the top phases with a yield of 74-100% and a specific activity of 3-7 X 10(6) units/mg. polyethylene glycol-phosphate ester 19-54 interferon beta 1 Homo sapiens 193-201 6814359-2 1982 When 100 units/ml of IFN-beta were preincubated with 30-80 microM of the gangliosides, all antiviral activity was abolished. Gangliosides 73-85 interferon beta 1 Homo sapiens 21-29 6205971-1 1983 Spleen cells from BALB/c mice, immunized with SDS-acrylamide gel purified human fibroblast interferon (HuIFN-beta) were fused with mouse myeloma cells. Sodium Dodecyl Sulfate 46-49 interferon beta 1 Homo sapiens 80-101 6205971-1 1983 Spleen cells from BALB/c mice, immunized with SDS-acrylamide gel purified human fibroblast interferon (HuIFN-beta) were fused with mouse myeloma cells. Acrylamide 50-60 interferon beta 1 Homo sapiens 80-101 6634760-6 1983 Catalase blocks SIRS or IFN beta action by consuming H2O2 and levamisole blocks SIRS or IFN beta by preventing activation or oxidation of SIRS by H2O2. Levamisole 62-72 interferon beta 1 Homo sapiens 24-32 6634760-6 1983 Catalase blocks SIRS or IFN beta action by consuming H2O2 and levamisole blocks SIRS or IFN beta by preventing activation or oxidation of SIRS by H2O2. Levamisole 62-72 interferon beta 1 Homo sapiens 88-96 6634760-6 1983 Catalase blocks SIRS or IFN beta action by consuming H2O2 and levamisole blocks SIRS or IFN beta by preventing activation or oxidation of SIRS by H2O2. Hydrogen Peroxide 146-150 interferon beta 1 Homo sapiens 24-32 6634760-7 1983 Other agents which block SIRS or IFN beta action include electron donors which can inactivate SIRSox. sirsox 94-100 interferon beta 1 Homo sapiens 33-41 6180119-2 1982 poly (C)-induced human diploid fibroblasts (FS-4) and from several similarly induced human-mouse somatic cell hybrids by electrophoresis through agarose-CH3HgOH tube gels led to the detection of at least five translationally active human IFN-beta mRNA species. Poly C 0-8 interferon beta 1 Homo sapiens 238-246 6814359-0 1982 Effect of glycolipids and glycophorin on the activity of human interferon-beta and -gamma. Glycolipids 10-21 interferon beta 1 Homo sapiens 63-89 6814359-6 1982 These results suggest that the terminal N-acetylneuraminic acid (NANA) residues of gangliosides and of glycophorin play an important role in the inhibition of IFN-beta, and that they may be similarly involved in the inhibition of IFN-gamma. N-Acetylneuraminic Acid 40-63 interferon beta 1 Homo sapiens 159-167 6814359-6 1982 These results suggest that the terminal N-acetylneuraminic acid (NANA) residues of gangliosides and of glycophorin play an important role in the inhibition of IFN-beta, and that they may be similarly involved in the inhibition of IFN-gamma. Gangliosides 83-95 interferon beta 1 Homo sapiens 159-167 7130759-1 1982 Human fibroblast-derived interferon-beta (IFN-beta) labeled in vivo with 35S-methionine and purified to greater than 90% radiochemical purity has been used to study the effect of glycosidases on its biological activity and its molecular weight. 35s-methionine 73-87 interferon beta 1 Homo sapiens 25-40 6178505-1 1982 Human interferon beta (IFN-beta) stimulated the synthesis of prostaglandin E (PGE) and prostaglandin F2 alpha in IFN-sensitive RSa and GM258 cell lines, but not in IFN-resistant HEC-1 cells. Prostaglandins E 78-81 interferon beta 1 Homo sapiens 23-31 6178505-1 1982 Human interferon beta (IFN-beta) stimulated the synthesis of prostaglandin E (PGE) and prostaglandin F2 alpha in IFN-sensitive RSa and GM258 cell lines, but not in IFN-resistant HEC-1 cells. Dinoprost 87-109 interferon beta 1 Homo sapiens 6-21 6178505-1 1982 Human interferon beta (IFN-beta) stimulated the synthesis of prostaglandin E (PGE) and prostaglandin F2 alpha in IFN-sensitive RSa and GM258 cell lines, but not in IFN-resistant HEC-1 cells. Dinoprost 87-109 interferon beta 1 Homo sapiens 23-31 6178505-1 1982 Human interferon beta (IFN-beta) stimulated the synthesis of prostaglandin E (PGE) and prostaglandin F2 alpha in IFN-sensitive RSa and GM258 cell lines, but not in IFN-resistant HEC-1 cells. rabbit sperm membrane autoantigen 127-130 interferon beta 1 Homo sapiens 6-21 6178505-1 1982 Human interferon beta (IFN-beta) stimulated the synthesis of prostaglandin E (PGE) and prostaglandin F2 alpha in IFN-sensitive RSa and GM258 cell lines, but not in IFN-resistant HEC-1 cells. rabbit sperm membrane autoantigen 127-130 interferon beta 1 Homo sapiens 23-31 6178505-1 1982 Human interferon beta (IFN-beta) stimulated the synthesis of prostaglandin E (PGE) and prostaglandin F2 alpha in IFN-sensitive RSa and GM258 cell lines, but not in IFN-resistant HEC-1 cells. gm258 135-140 interferon beta 1 Homo sapiens 6-21 6178505-1 1982 Human interferon beta (IFN-beta) stimulated the synthesis of prostaglandin E (PGE) and prostaglandin F2 alpha in IFN-sensitive RSa and GM258 cell lines, but not in IFN-resistant HEC-1 cells. gm258 135-140 interferon beta 1 Homo sapiens 23-31 6178505-2 1982 IFN-beta at a concentration of 1000 units/ml elicited 2- to 3-fold increases in PGE production in these cell lines. Prostaglandins E 80-83 interferon beta 1 Homo sapiens 0-8 6178110-1 1982 Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1. Cycloheximide 94-107 interferon beta 1 Homo sapiens 149-164 6178110-1 1982 Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1. Cycloheximide 94-107 interferon beta 1 Homo sapiens 166-174 6178110-1 1982 Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1. Cycloheximide 94-107 interferon beta 1 Homo sapiens 342-350 6178110-1 1982 Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1. Cycloheximide 94-107 interferon beta 1 Homo sapiens 342-350 6178110-1 1982 Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1. Dactinomycin 112-125 interferon beta 1 Homo sapiens 149-164 6178110-1 1982 Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1. Dactinomycin 112-125 interferon beta 1 Homo sapiens 166-174 6178110-1 1982 Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1. Dactinomycin 112-125 interferon beta 1 Homo sapiens 342-350 6178110-1 1982 Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1. Dactinomycin 112-125 interferon beta 1 Homo sapiens 342-350 7130759-1 1982 Human fibroblast-derived interferon-beta (IFN-beta) labeled in vivo with 35S-methionine and purified to greater than 90% radiochemical purity has been used to study the effect of glycosidases on its biological activity and its molecular weight. 35s-methionine 73-87 interferon beta 1 Homo sapiens 42-50 7130759-5 1982 We conclude that the carbohydrate of IFN-beta is not essential for its biological activity on cells in culture. Carbohydrates 21-33 interferon beta 1 Homo sapiens 37-45 6169643-4 1981 The amount of 125I-labeled anti-Hu IFN-beta bound to the complex was linearly proportional to the amount of antiviral activity present in the complex from 0 to 500 U of standard IFN-beta per ml; 1 U of antiviral activity was equivalent to about 40 cpm of 125I-labeled anti-IFN immunoglobulins in the radioimmunoassay. Iodine-125 14-18 interferon beta 1 Homo sapiens 35-43 6174973-6 1981 The degradation of interferon beta mRNA in the induced cells requires ongoing protein synthesis; accumulation of interferon beta mRNA was observed in the continuous presence of cycloheximide. Cycloheximide 177-190 interferon beta 1 Homo sapiens 113-128 6170583-7 1981 IFN produced after stimulation with TPA or mezerein, singly or in combination with phytohemagglutinin, had several properties characteristic of IFN-gamma, e.g., it was largely inactivated by dialysis at pH 2, or after exposure to sodium dodecyl sulfate, whereas it was not neutralized by antibody to IFN-alpha and IFN-beta. Tetradecanoylphorbol Acetate 36-39 interferon beta 1 Homo sapiens 314-322 6170583-7 1981 IFN produced after stimulation with TPA or mezerein, singly or in combination with phytohemagglutinin, had several properties characteristic of IFN-gamma, e.g., it was largely inactivated by dialysis at pH 2, or after exposure to sodium dodecyl sulfate, whereas it was not neutralized by antibody to IFN-alpha and IFN-beta. mezerein 43-51 interferon beta 1 Homo sapiens 314-322 6170512-2 1981 The antibody inhibits the antiviral activity of human fibroblast interferon in an antiviral assay using human FS4 fibroblast, reacts immunologically with interferon-beta separated by sodium dodecylsulfate/polyacrylamide gel electrophoresis and subsequent transfer to nitrocellulose and absorbs interferon-beta immunologically when bound to CNBr-activated Sepharose. Sodium Dodecyl Sulfate 183-204 interferon beta 1 Homo sapiens 54-75 6170512-2 1981 The antibody inhibits the antiviral activity of human fibroblast interferon in an antiviral assay using human FS4 fibroblast, reacts immunologically with interferon-beta separated by sodium dodecylsulfate/polyacrylamide gel electrophoresis and subsequent transfer to nitrocellulose and absorbs interferon-beta immunologically when bound to CNBr-activated Sepharose. Sodium Dodecyl Sulfate 183-204 interferon beta 1 Homo sapiens 154-169 6170512-2 1981 The antibody inhibits the antiviral activity of human fibroblast interferon in an antiviral assay using human FS4 fibroblast, reacts immunologically with interferon-beta separated by sodium dodecylsulfate/polyacrylamide gel electrophoresis and subsequent transfer to nitrocellulose and absorbs interferon-beta immunologically when bound to CNBr-activated Sepharose. polyacrylamide 205-219 interferon beta 1 Homo sapiens 54-75 6170512-2 1981 The antibody inhibits the antiviral activity of human fibroblast interferon in an antiviral assay using human FS4 fibroblast, reacts immunologically with interferon-beta separated by sodium dodecylsulfate/polyacrylamide gel electrophoresis and subsequent transfer to nitrocellulose and absorbs interferon-beta immunologically when bound to CNBr-activated Sepharose. polyacrylamide 205-219 interferon beta 1 Homo sapiens 154-169 6170512-2 1981 The antibody inhibits the antiviral activity of human fibroblast interferon in an antiviral assay using human FS4 fibroblast, reacts immunologically with interferon-beta separated by sodium dodecylsulfate/polyacrylamide gel electrophoresis and subsequent transfer to nitrocellulose and absorbs interferon-beta immunologically when bound to CNBr-activated Sepharose. Sepharose 355-364 interferon beta 1 Homo sapiens 54-75 6170512-2 1981 The antibody inhibits the antiviral activity of human fibroblast interferon in an antiviral assay using human FS4 fibroblast, reacts immunologically with interferon-beta separated by sodium dodecylsulfate/polyacrylamide gel electrophoresis and subsequent transfer to nitrocellulose and absorbs interferon-beta immunologically when bound to CNBr-activated Sepharose. Sepharose 355-364 interferon beta 1 Homo sapiens 154-169 6170512-2 1981 The antibody inhibits the antiviral activity of human fibroblast interferon in an antiviral assay using human FS4 fibroblast, reacts immunologically with interferon-beta separated by sodium dodecylsulfate/polyacrylamide gel electrophoresis and subsequent transfer to nitrocellulose and absorbs interferon-beta immunologically when bound to CNBr-activated Sepharose. Sepharose 355-364 interferon beta 1 Homo sapiens 294-309 6170512-3 1981 It also inhibits the antiviral activity of human fibroblast interferon-beta from which the sugar moiety has been cleaved off by enzymatic treatment. Sugars 91-96 interferon beta 1 Homo sapiens 60-75 6169643-4 1981 The amount of 125I-labeled anti-Hu IFN-beta bound to the complex was linearly proportional to the amount of antiviral activity present in the complex from 0 to 500 U of standard IFN-beta per ml; 1 U of antiviral activity was equivalent to about 40 cpm of 125I-labeled anti-IFN immunoglobulins in the radioimmunoassay. Iodine-125 255-259 interferon beta 1 Homo sapiens 35-43 6169644-7 1981 The effect of GA on IFN-beta could be reversed with 2-mercaptoethanol, suggesting a possible sulfhydryl involvement. Gallic Acid 14-16 interferon beta 1 Homo sapiens 20-28 6169644-7 1981 The effect of GA on IFN-beta could be reversed with 2-mercaptoethanol, suggesting a possible sulfhydryl involvement. Mercaptoethanol 52-69 interferon beta 1 Homo sapiens 20-28 6169643-4 1981 The amount of 125I-labeled anti-Hu IFN-beta bound to the complex was linearly proportional to the amount of antiviral activity present in the complex from 0 to 500 U of standard IFN-beta per ml; 1 U of antiviral activity was equivalent to about 40 cpm of 125I-labeled anti-IFN immunoglobulins in the radioimmunoassay. Iodine-125 14-18 interferon beta 1 Homo sapiens 178-186 6168400-3 1981 The effects of ammonia on the superinduction of human fibroblast interferon (IFN-beta) were also investigated. Ammonia 15-22 interferon beta 1 Homo sapiens 54-85 6160579-1 1980 The purification of human fibroblast interferon by chromatography on Blue Sepharose and high-performance liquid chromatography is described. Blue-Sepharose 69-83 interferon beta 1 Homo sapiens 26-47 6176485-2 1981 A comparative study of the production of IFN beta by human skin fibroblasts in monolayers was carried out using induction by NDV and poly I - poly C. Poly I-C 133-148 interferon beta 1 Homo sapiens 41-49 6176485-3 1981 The induction by polynucleotides produced significantly higher IFN beta titers. Polynucleotides 17-32 interferon beta 1 Homo sapiens 63-71 6178505-1 1982 Human interferon beta (IFN-beta) stimulated the synthesis of prostaglandin E (PGE) and prostaglandin F2 alpha in IFN-sensitive RSa and GM258 cell lines, but not in IFN-resistant HEC-1 cells. Prostaglandins E 61-76 interferon beta 1 Homo sapiens 6-21 6178505-1 1982 Human interferon beta (IFN-beta) stimulated the synthesis of prostaglandin E (PGE) and prostaglandin F2 alpha in IFN-sensitive RSa and GM258 cell lines, but not in IFN-resistant HEC-1 cells. Prostaglandins E 61-76 interferon beta 1 Homo sapiens 23-31 6178505-1 1982 Human interferon beta (IFN-beta) stimulated the synthesis of prostaglandin E (PGE) and prostaglandin F2 alpha in IFN-sensitive RSa and GM258 cell lines, but not in IFN-resistant HEC-1 cells. Prostaglandins E 78-81 interferon beta 1 Homo sapiens 6-21 6159580-1 1980 Using synthetic oligodeoxyribonucleotides to prime the transcription of interferon mRNA and cDNA, we recently determined the mRNA sequence coding for the 47 amino-terminal amino acids of mature human fibroblast interferon (1). Oligodeoxyribonucleotides 16-41 interferon beta 1 Homo sapiens 200-221 6159597-1 1980 From recently published data on the amino-terminal structures of human and mouse interferons, we have predicted and synthesised an oligonucleotide capable of priming specifically the reverse transcription of human fibroblast interferon mRNA present within a total mRNA population. Oligonucleotides 131-146 interferon beta 1 Homo sapiens 214-235 6155666-1 1980 Human fibroblast interferon was partially purified, about 4,000-fold, on a chromatographic tandem of columns: concanavalin A-agarose leads to phenyl-agarose, to a specific activity of ca 4 x 10(7). Sepharose 125-132 interferon beta 1 Homo sapiens 6-27 7352259-1 1980 The purification of human fibroblast interferon has been simplified to a two-step procedure consisting of affinity chromatography on Blue Sepharose and sodium dodecyl sulfate polyacrlamide gel electrophoresis. Sepharose 138-147 interferon beta 1 Homo sapiens 26-47 7352259-1 1980 The purification of human fibroblast interferon has been simplified to a two-step procedure consisting of affinity chromatography on Blue Sepharose and sodium dodecyl sulfate polyacrlamide gel electrophoresis. Sodium Dodecyl Sulfate 152-174 interferon beta 1 Homo sapiens 26-47 7352259-1 1980 The purification of human fibroblast interferon has been simplified to a two-step procedure consisting of affinity chromatography on Blue Sepharose and sodium dodecyl sulfate polyacrlamide gel electrophoresis. polyacrlamide 175-188 interferon beta 1 Homo sapiens 26-47 6155666-1 1980 Human fibroblast interferon was partially purified, about 4,000-fold, on a chromatographic tandem of columns: concanavalin A-agarose leads to phenyl-agarose, to a specific activity of ca 4 x 10(7). phenyl-sepharose 142-156 interferon beta 1 Homo sapiens 6-27 309487-1 1978 Purified polyribonucleotide-induced human fibroblast interferon (HFIF) was tested for its effects on proliferative and cytotoxic human T cell responses to alloantigens. Polyribonucleotides 9-27 interferon beta 1 Homo sapiens 42-70 467436-4 1979 Analysis of the immunoprecipitate by polyacrylamide gel electrophoresis in dodecylsulfate shows that the product of human fibroblast interferon mRNA is a 23000-Mr polypeptide. polyacrylamide 37-51 interferon beta 1 Homo sapiens 122-143 467436-4 1979 Analysis of the immunoprecipitate by polyacrylamide gel electrophoresis in dodecylsulfate shows that the product of human fibroblast interferon mRNA is a 23000-Mr polypeptide. dodecyl sulfate 75-89 interferon beta 1 Homo sapiens 122-143 225426-1 1979 The effects of human leukocyte interferon (Le-IF) and fibroblast interferon (F-IF) on the growth of the transformed human cell lines, RSa and RSb, were compared. rabbit sperm membrane autoantigen 134-137 interferon beta 1 Homo sapiens 77-81 309487-2 1978 The addition of HFIF (100 to 400 IFU/ml) to mixed leukocyte cultures decreased alloantigen-induced lymphocyte proliferative responses as determined by both recovery of responding cells and by 3H-thymidine incorporation into responding cells. 3h-thymidine 192-204 interferon beta 1 Homo sapiens 16-20 894267-0 1977 Reagents which inhibit disulphide bond formation stabilize human fibroblast interferon. disulphide 23-33 interferon beta 1 Homo sapiens 65-86 24432-1 1978 An efficient method for the purification of human fibroblast interferon (IF) based on binding via the N-acetyl neuraminic acid (N-ANA) residue of the IF molecules to the immobilized neuraminidase has been developed. N-Acetylneuraminic Acid 102-126 interferon beta 1 Homo sapiens 50-76 24432-1 1978 An efficient method for the purification of human fibroblast interferon (IF) based on binding via the N-acetyl neuraminic acid (N-ANA) residue of the IF molecules to the immobilized neuraminidase has been developed. N-Acetylneuraminic Acid 102-126 interferon beta 1 Homo sapiens 73-75 24432-3 1978 Specific activity of IF in the alkaline eluate was increased by a factor in excess of 200 and the IF thus recovered had probably retained most of the N-ANA moieties. Nitrogen 150-151 interferon beta 1 Homo sapiens 21-23 24432-3 1978 Specific activity of IF in the alkaline eluate was increased by a factor in excess of 200 and the IF thus recovered had probably retained most of the N-ANA moieties. Nitrogen 150-151 interferon beta 1 Homo sapiens 98-100 27163-0 1978 Stabilization of human fibroblast interferon purified on concanavalin A-agarose. Sepharose 72-79 interferon beta 1 Homo sapiens 23-44 27163-1 1978 Human fibroblast interferon, obtained by chromatography on concanavalin A-agarose, was stable for at least a month in 30--50 per cent ethylene glycol at 4 degrees, --20 degrees, and --70 degrees C. The succinct point of the present finding is that human fibroblast interferon may be stabilized by ethylene glycol alone without the addition of bovine serum albumin and "back-contamination" of the interferon preparation. Sepharose 74-81 interferon beta 1 Homo sapiens 6-27 27163-1 1978 Human fibroblast interferon, obtained by chromatography on concanavalin A-agarose, was stable for at least a month in 30--50 per cent ethylene glycol at 4 degrees, --20 degrees, and --70 degrees C. The succinct point of the present finding is that human fibroblast interferon may be stabilized by ethylene glycol alone without the addition of bovine serum albumin and "back-contamination" of the interferon preparation. Ethylene Glycol 134-149 interferon beta 1 Homo sapiens 6-27 27163-1 1978 Human fibroblast interferon, obtained by chromatography on concanavalin A-agarose, was stable for at least a month in 30--50 per cent ethylene glycol at 4 degrees, --20 degrees, and --70 degrees C. The succinct point of the present finding is that human fibroblast interferon may be stabilized by ethylene glycol alone without the addition of bovine serum albumin and "back-contamination" of the interferon preparation. Ethylene Glycol 297-312 interferon beta 1 Homo sapiens 6-27 894267-1 1977 Fibroblast interferon may be stabilized against many inactivating influences by the addition of certain simple sulphydryl reagents. Sulfhydryl Compounds 111-121 interferon beta 1 Homo sapiens 0-21 34057708-3 2021 In RRMS patients who are treatment-naive or were previously treated with interferon-beta or glatiramer acetate, diroximel fumarate reduces annualized relapse rates, with most patients experiencing no relapses during treatment, and reduces the formation of new MS-associated brain lesions. Diroximel fumarate 112-130 interferon beta 1 Homo sapiens 73-88 265081-6 1977 Enamel fluorosis can be avoided or minimized in areas with up to at least 1.2 mgF/l water if F-supply, e.g. water-diluted gruel and/or supplementary fluoride, is not commenced until 6 months of age when body weight is higher. Water 84-89 interferon beta 1 Homo sapiens 90-94 956190-1 1976 Human fibroblast interferon binds to L-tryptophan, D-tryptophan, L-phenylalanine, and L-tyrosine, all immobilized directly to cyanogen bromide-activated agarose, as well as to L-tryptophan and D-tryptophan methyl ester, both immobilized via molecular arms. Tryptophan 37-49 interferon beta 1 Homo sapiens 6-27 956190-1 1976 Human fibroblast interferon binds to L-tryptophan, D-tryptophan, L-phenylalanine, and L-tyrosine, all immobilized directly to cyanogen bromide-activated agarose, as well as to L-tryptophan and D-tryptophan methyl ester, both immobilized via molecular arms. D-Tryptophan 51-63 interferon beta 1 Homo sapiens 6-27 956190-1 1976 Human fibroblast interferon binds to L-tryptophan, D-tryptophan, L-phenylalanine, and L-tyrosine, all immobilized directly to cyanogen bromide-activated agarose, as well as to L-tryptophan and D-tryptophan methyl ester, both immobilized via molecular arms. Phenylalanine 65-80 interferon beta 1 Homo sapiens 6-27 956190-1 1976 Human fibroblast interferon binds to L-tryptophan, D-tryptophan, L-phenylalanine, and L-tyrosine, all immobilized directly to cyanogen bromide-activated agarose, as well as to L-tryptophan and D-tryptophan methyl ester, both immobilized via molecular arms. Tyrosine 86-96 interferon beta 1 Homo sapiens 6-27 956190-1 1976 Human fibroblast interferon binds to L-tryptophan, D-tryptophan, L-phenylalanine, and L-tyrosine, all immobilized directly to cyanogen bromide-activated agarose, as well as to L-tryptophan and D-tryptophan methyl ester, both immobilized via molecular arms. Cyanogen Bromide 126-142 interferon beta 1 Homo sapiens 6-27 956190-1 1976 Human fibroblast interferon binds to L-tryptophan, D-tryptophan, L-phenylalanine, and L-tyrosine, all immobilized directly to cyanogen bromide-activated agarose, as well as to L-tryptophan and D-tryptophan methyl ester, both immobilized via molecular arms. Sepharose 153-160 interferon beta 1 Homo sapiens 6-27 956190-1 1976 Human fibroblast interferon binds to L-tryptophan, D-tryptophan, L-phenylalanine, and L-tyrosine, all immobilized directly to cyanogen bromide-activated agarose, as well as to L-tryptophan and D-tryptophan methyl ester, both immobilized via molecular arms. Tryptophan 176-188 interferon beta 1 Homo sapiens 6-27 956190-1 1976 Human fibroblast interferon binds to L-tryptophan, D-tryptophan, L-phenylalanine, and L-tyrosine, all immobilized directly to cyanogen bromide-activated agarose, as well as to L-tryptophan and D-tryptophan methyl ester, both immobilized via molecular arms. (R)-methyl 2-amino-3-(1H-indol-3-yl)propanoate 193-218 interferon beta 1 Homo sapiens 6-27 863511-1 1977 There is a minor fraction of human fibroblast interferon that resembles human leukocyte interferon in being renaturable after treatment with guanidine hydrochloride. Guanidine 141-164 interferon beta 1 Homo sapiens 35-56 33675790-0 2021 Myeloid dendritic cells are major producers of interferon-beta in dermatomyositis and may contribute to hydroxychloroquine refractoriness. Hydroxychloroquine 104-122 interferon beta 1 Homo sapiens 47-62 34001091-11 2021 Transcript abundance of IFNB following poly I:C stimulation was not significantly altered by ORMDL3 knockdown or over-expression. Poly I-C 39-47 interferon beta 1 Homo sapiens 24-28 33522144-4 2021 In this work, it is uncovered that metal-protein nanoparticles designated GSTP1-MT3(Fe2+ ) (MPNP) can polarize macrophages toward the M1 phenotype and activate immune responses to induce Interferon-beta (IFN-beta) production in vesicular stomatitis virus (VSV)-infected macrophages. Metals 35-40 interferon beta 1 Homo sapiens 187-202 33597189-6 2021 Based on an analysis of individual treatments (interferon-beta, glatiramer acetate, fingolimod, and natalizumab), interferon-beta was associated with inferior RGC preservation, relative to the other drugs. Glatiramer Acetate 64-82 interferon beta 1 Homo sapiens 114-129 33352008-0 2021 Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon beta Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study. pf-06823859 46-57 interferon beta 1 Homo sapiens 67-82 33352008-12 2021 In conclusion, PF-06823859 demonstrated an acceptable safety, tolerability, and PK profile that supports clinical development for treating disorders associated with increased interferon beta levels, such as dermatomyositis or systemic lupus erythematosus. pf-06823859 15-26 interferon beta 1 Homo sapiens 175-190 33597189-6 2021 Based on an analysis of individual treatments (interferon-beta, glatiramer acetate, fingolimod, and natalizumab), interferon-beta was associated with inferior RGC preservation, relative to the other drugs. Fingolimod Hydrochloride 84-94 interferon beta 1 Homo sapiens 114-129 33176874-6 2020 Moreover, pUL47 significantly inhibited polyriboinosinic:polyribocytidylic acid [poly(I:C)]-induced interferon beta (IFN-beta) production and downregulated interferon-stimulated gene (ISG) expression, such as Mx and oligoadenylate synthetase-like (OASL), by interacting with signal transducer and activator of transcription-1 (STAT1). 4-chloro-2-cresol 57-79 interferon beta 1 Homo sapiens 100-115 33603735-5 2020 O-GlcNAcylation of the serine-rich region of MAVS also suppresses its interaction with TRAF3; this prevents IRF3 activation and production of interferon-beta. Serine 23-29 interferon beta 1 Homo sapiens 142-157 33614913-5 2021 Intratumoral injection of vanadyl sulfate, a pan-inhibitor of protein tyrosine phosphatases, in combination with NDV significantly increased the number and activation status of natural killer (NK) cells in the tumor microenvironment, concomitant with increased expression of interferon-beta, granulocyte-macrophage colony-stimulating factor, and monocyte chemoattractant protein-1, leading to rapid tumor regression and long-term cures in mice bearing syngeneic B16-F10 melanomas. vanadyl sulfate 26-41 interferon beta 1 Homo sapiens 275-290 33201170-1 2020 Following the detection of cytosolic double-stranded DNA from viral or bacterial infection in mammalian cells, cyclic dinucleotide activation of STING induces interferon beta expression to initiate innate immune defenses. cyclic dinucleotide 111-130 interferon beta 1 Homo sapiens 159-174 33247831-4 2020 This review summarizes the clinical development program for cladribine tablets in patients with MS, including the efficacy endpoints and results from the 2-year phase III CLARITY study in patients with relapsing-remitting MS (RRMS), the 2-year CLARITY EXTENSION study, and the phase III ORACLE-MS study in patients with a first clinical demyelinating event at risk for developing MS. Efficacy results from the phase II ONWARD study, in which cladribine tablets were administered as an add-on to interferon-beta therapy in patients with RRMS, are also summarized. Cladribine 60-70 interferon beta 1 Homo sapiens 495-510 33176874-6 2020 Moreover, pUL47 significantly inhibited polyriboinosinic:polyribocytidylic acid [poly(I:C)]-induced interferon beta (IFN-beta) production and downregulated interferon-stimulated gene (ISG) expression, such as Mx and oligoadenylate synthetase-like (OASL), by interacting with signal transducer and activator of transcription-1 (STAT1). Poly I-C 81-90 interferon beta 1 Homo sapiens 100-115 33143745-2 2020 Up to 40% of multiple sclerosis patients treated with interferon beta (IFNbeta) develop ADA, for which a genetic predisposition exists. N-(2-acetamido)iminodiacetic acid 88-91 interferon beta 1 Homo sapiens 54-69 33189062-3 2020 In this longitudinal study, we aim to quantify the concentration of plasma cytokines of MS patients treated with Fingolimod alone or after Glatiramer Acetate (GA) or Interferon-beta (IFN-beta), in order to compeer both treatments and describes if it is possible to use them as biomarkers. Fingolimod Hydrochloride 113-123 interferon beta 1 Homo sapiens 166-181 31625434-8 2020 Results: We found that poly IC-induced Fkn expression in GECs, and that this involved NF-kappaB, IFN-beta, and IRF3. Poly I-C 23-30 interferon beta 1 Homo sapiens 97-105 32562561-7 2020 Hydroxychloroquine was administered in 11 patients, associated with lopinavir/ritonavir and interferon beta in 2 cases each. Hydroxychloroquine 0-18 interferon beta 1 Homo sapiens 92-107 32415989-6 2020 In addition, we showed that 1,25-dihydroxyvitamin D3 inhibited genomic DNA fragment-induced TNFA and interleukin-1beta (IFNB) expression in human keratinocytes, and an intact function of cathelicidin anti-microbial peptide (CAMP) was required for this effect. Calcitriol 28-52 interferon beta 1 Homo sapiens 120-124 32707230-6 2020 A single dose of 10 U/mL interferon-beta (IFNbeta) pretreatment potently protected both Calu3 and Caco2 against SARS-CoV-2 infection. caco2 98-103 interferon beta 1 Homo sapiens 25-40 32943610-0 2020 Novel insights into stress-induced susceptibility to influenza: corticosterone impacts interferon-beta responses by Mfn2-mediated ubiquitin degradation of MAVS. Corticosterone 64-78 interferon beta 1 Homo sapiens 87-102 32967656-0 2020 Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer. gemcitabine 40-51 interferon beta 1 Homo sapiens 0-15 32694786-7 2020 This correlates with their immunosuppressive phenotype: dimethyl itaconate and 4-octyl itaconate inhibited IkappaBzeta and pro-interleukin (IL)-1beta induction, as well as IL-6, IL-10 and interferon-beta secretion, in an NRF2-independent manner. dimethyl itaconate 56-74 interferon beta 1 Homo sapiens 188-203 32694786-7 2020 This correlates with their immunosuppressive phenotype: dimethyl itaconate and 4-octyl itaconate inhibited IkappaBzeta and pro-interleukin (IL)-1beta induction, as well as IL-6, IL-10 and interferon-beta secretion, in an NRF2-independent manner. 4-Octyl Itaconate 79-96 interferon beta 1 Homo sapiens 188-203 32694786-8 2020 In contrast, itaconate treatment suppressed IL-1beta secretion but not pro-IL-1beta levels and, surprisingly, strongly enhanced lipopolysaccharide-induced interferon-beta secretion. itaconic acid 13-22 interferon beta 1 Homo sapiens 155-170 32218815-0 2020 Interferon-beta sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02. 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 94-98 interferon beta 1 Homo sapiens 0-15 32321279-8 2020 Transfection of miR-887-3p into HPMECs altered gene expression, including the upregulation of several genes previously associated with ARDS (e.g., CXCL10, CCL5, CX3CL1, VCAM1, CASP1, IL1B, IFNB, and TLR2), and activation of cellular pathways relevant to the response to infection. mir-887-3p 16-26 interferon beta 1 Homo sapiens 189-193 32414131-6 2020 The number of CD56bright NK cells increases upon treatment with interferon-beta, alemtuzumab, dimethyl fumarate, after autologous hematopoietic stem cell transplantation, and is higher in those who respond to fingolimod. Fingolimod Hydrochloride 209-219 interferon beta 1 Homo sapiens 64-79 32152082-5 2020 In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors lopinavir/ritonavir and interferon beta (LPV/RTV-IFN-beta) was shown to be effective in patients infected with SARS-CoV. lpv/rtv 139-146 interferon beta 1 Homo sapiens 122-137 31589278-12 2020 The crude rate of infections was higher in patients with MS taking interferon beta and GA than the general population (incidence rate, 8.9 [95% CI, 6.4-12.1] vs 5.2 [95% CI, 4.8-5.5] per 1000 person-years), and higher still in patients taking fingolimod (incidence rate, 14.3 [95% CI, 10.8-18.5] per 1000 person-years), natalizumab (incidence rate, 11.4 [95% CI, 8.3-15.3] per 1000 person-years), and rituximab (incidence rate, 19.7 [95% CI, 16.4-23.5] per 1000 person-years). fingolimod 243-253 interferon beta 1 Homo sapiens 67-82 31916113-5 2020 In contrast, dipotassium glycyrrhizate (GK2), a soluble analogue of HMGB1-blocker Glycyrrhizin, down-regulated interferon-beta, a typical inflammatory cytokine induced by secreted HMGB1, and accelerated differentiation responses to the calcium treatment in these cells. glycyrrhizic acid methyl ester 13-38 interferon beta 1 Homo sapiens 111-126 31916113-5 2020 In contrast, dipotassium glycyrrhizate (GK2), a soluble analogue of HMGB1-blocker Glycyrrhizin, down-regulated interferon-beta, a typical inflammatory cytokine induced by secreted HMGB1, and accelerated differentiation responses to the calcium treatment in these cells. Calcium 236-243 interferon beta 1 Homo sapiens 111-126 31512776-8 2020 In Western blot assay, ROS, and apoptosis-related genes were increased in SNU-80 cells when they were cocultured with HB1.F3.CD and HB1.F3.CD.IFN-beta cells. Reactive Oxygen Species 23-26 interferon beta 1 Homo sapiens 142-150 31996953-2 2020 The addition of interferon beta/interleukin-2 immunotherapy to first-line salvage hormone therapy (HT) prolonged progression-free (PFS) and overall survivals (OS) in 26 patients, as compared with 30 historical controls and literature data. 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine 131-134 interferon beta 1 Homo sapiens 16-31 31996953-13 2020 Interferon beta-interleukin-2 immunotherapy added to first-line salvage hormone therapy prolonged progression-free (PFS) and overall (OS) survivals in 26 patients of a pilot study as compared with 30 historical controls. 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine 116-119 interferon beta 1 Homo sapiens 0-15 31806367-6 2020 The inhibition of SUMOylation by Ginkgolic acid or Ubc9 siRNA was found to inhibit the poly(dA:dT)-induced secretion of IFN-beta, suggesting that the SUMOylation is required for the poly(dA:dT)-activated RIG-I/MAVS pathway, which drives the secretion of IFN-beta. ginkgolic acid 33-47 interferon beta 1 Homo sapiens 120-128 31806367-6 2020 The inhibition of SUMOylation by Ginkgolic acid or Ubc9 siRNA was found to inhibit the poly(dA:dT)-induced secretion of IFN-beta, suggesting that the SUMOylation is required for the poly(dA:dT)-activated RIG-I/MAVS pathway, which drives the secretion of IFN-beta. ginkgolic acid 33-47 interferon beta 1 Homo sapiens 254-262 31821828-4 2020 Using chemical crosslinking, intrinsic fluorescence and surface plasmon resonance spectroscopies, we show that S100P protein interacts with interferon beta (IFN-beta) depending on calcium level and oligomeric state of S100P. Calcium 180-187 interferon beta 1 Homo sapiens 157-165 31708102-7 2020 Inhibition of Erk1/2 phosphorylation induced the expression of Ifn-beta mRNA, and IFN-beta promoted nitric oxide production in microglia. Nitric Oxide 100-112 interferon beta 1 Homo sapiens 82-90 31708102-9 2020 These findings indicated that the enhancement of nitric oxide production by Sema4D is involved in partial Erk1/2 inhibition and upregulation of IFN-beta. Nitric Oxide 49-61 interferon beta 1 Homo sapiens 144-152 31821828-5 2020 Dimeric Ca2+-loaded S100P binds IFN-beta with equilibrium dissociation constants, Kd, of 0.05-0.6 muM. Calcium 8-12 interferon beta 1 Homo sapiens 32-40 31821828-7 2020 Calcium depletion drastically lowers S100P affinity to IFN-beta. Calcium 0-7 interferon beta 1 Homo sapiens 55-63 31662325-5 2020 Thus, convergence of PTEN loss and TBK1/IKKepsilon activation on Rab7-S72 phosphorylation limited STING turnover and increased downstream production of IRF3 targets including CXL10, CCL5, and IFN-b. Ts-72 70-73 interferon beta 1 Homo sapiens 192-197 31733580-8 2020 Sophoridine-treated TAMs exhibited stronger pro-inflammatory function through upregulation the expression of INOS, IFN-beta and IL-12alpha, and downregulation the expression of Arg-1, CD206 and IL-10. matrine 0-11 interferon beta 1 Homo sapiens 115-123 31851971-8 2020 We show for the first time that Mal is engaged in TLR9-de-pendent expression of genes encoding IFNbeta and TNFalpha in HSV-1-infected or CpG-C-treated macrophages and requires a noncanonical NF-kappaB pathway. cytidylyl-(3'-5')-cytidine 137-142 interferon beta 1 Homo sapiens 95-115 31884382-0 2019 Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-beta. glatiramer acetate 17-35 interferon beta 1 Homo sapiens 103-118 31898253-3 2020 IE86 amino acids (aa) 136-289 were sufficient to promote STING degradation and further induced down-regulation of 2"3"-cyclic GMP-AMP (cGAMP)-mediated IFN-beta promoter activation. cyclic guanosine monophosphate-adenosine monophosphate 114-133 interferon beta 1 Homo sapiens 151-159 31898253-3 2020 IE86 amino acids (aa) 136-289 were sufficient to promote STING degradation and further induced down-regulation of 2"3"-cyclic GMP-AMP (cGAMP)-mediated IFN-beta promoter activation. cyclic guanosine monophosphate-adenosine monophosphate 135-140 interferon beta 1 Homo sapiens 151-159 31884382-11 2019 CONCLUSION: While on GA, patients switched from IFNbeta in the context of disease activity and no NAbs had the highest risk of future disease activity, while NAb positive patients without previous activity had the lowest. glatiramer acetate 21-23 interferon beta 1 Homo sapiens 48-55 31849956-10 2019 Further, poly(I:C)-induced IFNbeta gene expression was reduced after pre-treatment with H2O2. Water 88-92 interferon beta 1 Homo sapiens 27-34 31822637-3 2019 Here, we demonstrated that NiCl2 activated nuclear factor kappa B (NF-kappaB), mitogen-activated protein kinases (MAPKs) and interferon regulatory factor 3 (IRF3) signaling pathways in primary bone marrow-derived macrophages (BMDMs), leading to the altered transcription levels of interleukin-1beta (IL-1beta), -6, -8, -18, tumor necrosis factor-alpha (TNF-alpha) and interferon beta (INF-beta). Nickel 27-32 interferon beta 1 Homo sapiens 368-383 31288047-5 2019 Overexpression of goTRAF6 caused NF-kappaB activation in a dose-dependent manner and substantially upregulated IFN-beta expression in HEK293T cells. gotraf6 18-25 interferon beta 1 Homo sapiens 111-119 31849956-12 2019 Pre-treatment with H2O2 did not alter antioxidant responses in COPD bronchial epithelial cells and, more modestly than in asthma, reduced poly(I:C)-induced IFNbeta gene expression. Water 19-23 interferon beta 1 Homo sapiens 156-163 31849956-13 2019 Knockdown of TLR3 but not RIG-I/MDA5 abrogated impairment of poly(I:C)-induced IFNbeta gene expression by H2O2. Water 106-110 interferon beta 1 Homo sapiens 79-86 31582399-0 2019 Vitamin D enhances responses to interferon-beta in MS. Vitamin D 0-9 interferon beta 1 Homo sapiens 32-47 31323223-8 2019 Additionally, ergosterol peroxide inhibited the activation of RIG-I downstream signaling pathways, including p38 MAP kinase and NF-kappaB, which ultimately resulted in the reduced production of an array of pro-inflammatory mediators and interferons (IFN-beta and IFN-lambda1). ergosterol-5,8-peroxide 14-33 interferon beta 1 Homo sapiens 250-258 31323223-10 2019 On the other hand, ergosterol peroxide effectively abolished the amplified production of pro-inflammatory mediators in cells pretreated with IFN-beta (500 ng/ml) prior to IAV infection. ergosterol-5,8-peroxide 19-38 interferon beta 1 Homo sapiens 141-149 31582399-1 2019 OBJECTIVE: To determine the effect of vitamin D3 on interferon-beta (IFN-beta) response and immune regulation in MS mononuclear cells (MNCs). Cholecalciferol 38-48 interferon beta 1 Homo sapiens 52-67 31582399-1 2019 OBJECTIVE: To determine the effect of vitamin D3 on interferon-beta (IFN-beta) response and immune regulation in MS mononuclear cells (MNCs). Cholecalciferol 38-48 interferon beta 1 Homo sapiens 69-77 31582399-6 2019 The combination of vitamin D plus IFN-beta reduced Th1 and Th17 cytokines, and increased Th2 responses, reversing the effect of IFN-beta alone. Vitamin D 19-28 interferon beta 1 Homo sapiens 128-136 31582399-9 2019 CONCLUSION: Vitamin D enhances IFN-beta induction of multiple proteins and also reverses the Th1/Th2 bias in MS seen with IFN-beta alone. Vitamin D 12-21 interferon beta 1 Homo sapiens 31-39 30610351-7 2019 RESULTS: EtOH induced TLR3, IFNbeta, and IFNgamma in SH-SY5Y neurons and U373 astrocytes, but not in BV2 microglia. Ethanol 9-13 interferon beta 1 Homo sapiens 28-35 31551774-3 2019 The MDCK cellular research results showed that, among nine predominant ingredients of MHT, L-methylephedrin (LMEP), L-ephedrine (LEP) and D-pseudo- ephedrine (DPEP) significantly inhibited the proliferation of influenza A virus in vitro, and the inhibitory effect at 24 h after the treatment was more obvious than that at 48 h. They also significantly inhibited the mRNA expression levels of related genes in the TLR3, TLR4 and TLR7 signaling pathways, which were accompanied with the down-regulation of TNF-alpha level and the up-regulation of IFN-beta level in the cell supernatant. parathyroid hormone (1-34), bovine 109-113 interferon beta 1 Homo sapiens 545-553 31582399-9 2019 CONCLUSION: Vitamin D enhances IFN-beta induction of multiple proteins and also reverses the Th1/Th2 bias in MS seen with IFN-beta alone. Vitamin D 12-21 interferon beta 1 Homo sapiens 122-130 31551774-3 2019 The MDCK cellular research results showed that, among nine predominant ingredients of MHT, L-methylephedrin (LMEP), L-ephedrine (LEP) and D-pseudo- ephedrine (DPEP) significantly inhibited the proliferation of influenza A virus in vitro, and the inhibitory effect at 24 h after the treatment was more obvious than that at 48 h. They also significantly inhibited the mRNA expression levels of related genes in the TLR3, TLR4 and TLR7 signaling pathways, which were accompanied with the down-regulation of TNF-alpha level and the up-regulation of IFN-beta level in the cell supernatant. Ephedrine 116-127 interferon beta 1 Homo sapiens 545-553 31551774-3 2019 The MDCK cellular research results showed that, among nine predominant ingredients of MHT, L-methylephedrin (LMEP), L-ephedrine (LEP) and D-pseudo- ephedrine (DPEP) significantly inhibited the proliferation of influenza A virus in vitro, and the inhibitory effect at 24 h after the treatment was more obvious than that at 48 h. They also significantly inhibited the mRNA expression levels of related genes in the TLR3, TLR4 and TLR7 signaling pathways, which were accompanied with the down-regulation of TNF-alpha level and the up-regulation of IFN-beta level in the cell supernatant. parathyroid hormone (1-34), bovine 91-107 interferon beta 1 Homo sapiens 545-553 31551774-3 2019 The MDCK cellular research results showed that, among nine predominant ingredients of MHT, L-methylephedrin (LMEP), L-ephedrine (LEP) and D-pseudo- ephedrine (DPEP) significantly inhibited the proliferation of influenza A virus in vitro, and the inhibitory effect at 24 h after the treatment was more obvious than that at 48 h. They also significantly inhibited the mRNA expression levels of related genes in the TLR3, TLR4 and TLR7 signaling pathways, which were accompanied with the down-regulation of TNF-alpha level and the up-regulation of IFN-beta level in the cell supernatant. Ephedrine 129-132 interferon beta 1 Homo sapiens 545-553 31551774-3 2019 The MDCK cellular research results showed that, among nine predominant ingredients of MHT, L-methylephedrin (LMEP), L-ephedrine (LEP) and D-pseudo- ephedrine (DPEP) significantly inhibited the proliferation of influenza A virus in vitro, and the inhibitory effect at 24 h after the treatment was more obvious than that at 48 h. They also significantly inhibited the mRNA expression levels of related genes in the TLR3, TLR4 and TLR7 signaling pathways, which were accompanied with the down-regulation of TNF-alpha level and the up-regulation of IFN-beta level in the cell supernatant. Ephedrine 118-127 interferon beta 1 Homo sapiens 545-553 30325468-9 2019 There was a cereal type x PA interaction (P < 0.05), as expression of IFNB was downregulated in the birds fed PA supplemented MC but not WC. Protactinium 26-28 interferon beta 1 Homo sapiens 70-74 30325468-9 2019 There was a cereal type x PA interaction (P < 0.05), as expression of IFNB was downregulated in the birds fed PA supplemented MC but not WC. Protactinium 110-112 interferon beta 1 Homo sapiens 70-74 31358054-11 2019 Both CCK8 and colony forming assay showed that GMSCs/IFN-beta significantly inhibited the proliferation of CAL27 cells compared with the GMSCs, GMSCs/vector, or DMEM group. dmem 161-165 interferon beta 1 Homo sapiens 53-61 31358054-12 2019 Flow cytometry analysis demonstrated that the CAL27 cell apoptosis rate was higher in the GMSCs/IFN-beta group than in the other three groups. gmscs 90-95 interferon beta 1 Homo sapiens 96-104 31358054-14 2019 There were smaller tumor volume and lower number of Ki67-positive cells in the GMSCs/IFN-beta group than in the GMSCs, GMSCs/vector, or phosphate-buffered saline (PBS) group. gmscs 79-84 interferon beta 1 Homo sapiens 85-93 31358054-17 2019 These results provide evidence that delivery of IFN-beta by GMSCs may be a promising approach to develop an effective treatment option for TSCC therapy. gmscs 60-65 interferon beta 1 Homo sapiens 48-56 31332169-4 2019 Oral administration of acetate mediated interferon-beta (IFN-beta) response by increasing expression of interferon-stimulated genes in the lung. Acetates 23-30 interferon beta 1 Homo sapiens 40-55 31332169-4 2019 Oral administration of acetate mediated interferon-beta (IFN-beta) response by increasing expression of interferon-stimulated genes in the lung. Acetates 23-30 interferon beta 1 Homo sapiens 57-65 31332169-9 2019 Our findings reveal antiviral effects of acetate involving IFN-beta in lung epithelial cells and engagement of GPR43 and IFNAR. Acetates 41-48 interferon beta 1 Homo sapiens 59-67 31333667-4 2019 PolyI:C increased the expression of interferon-beta (IFN-beta), interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant protein (MCP-1), and interleukin-1beta (IL-1beta) in HCT116 cells, and these up-regulations were significantly altered when cells were pre-stimulated with LAB isolated from Korean fermented foods. Poly I-C 0-7 interferon beta 1 Homo sapiens 36-51 31486403-10 2019 Combined dsDNA + chloroquine treatment has a synergistic effect on transcription of only one of the genes tested, with the pro-inflammatory cytokine IFN-beta displaying the strongest fold induction by 24 hours. Chloroquine 17-28 interferon beta 1 Homo sapiens 149-157 30820880-0 2019 Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy. Hydrogen 100-102 interferon beta 1 Homo sapiens 78-95 30546090-7 2019 Presence of IFN-beta in the circulation of ER- breast cancer patients treated with neoadjuvant Epirubicin chemotherapy correlated with a significantly longer distant metastasis-free survival. Epirubicin 95-105 interferon beta 1 Homo sapiens 12-20 30944180-2 2019 A previous study suggested that PRRSV nsp4, a 3C-like protease, antagonizes interferon beta (IFN-beta) production by cleaving the NF-kappaB essential modulator (NEMO) at a single site, glutamate 349 (E349). Glutamic Acid 185-194 interferon beta 1 Homo sapiens 76-91 31064978-6 2019 Furthermore, we present epigenetic biomarkers for current interferon-beta treatment, and extensive validation shows that the ZBTB16 DMP is a signature for prior glucocorticoid treatment. dmp 132-135 interferon beta 1 Homo sapiens 58-73 30864696-0 2019 Interferon-beta sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy. Temozolomide 61-73 interferon beta 1 Homo sapiens 0-15 30864696-10 2019 We also demonstrated that a combination of TMZ and IFN-beta enhanced apoptosis and autophagy more efficiently compared with TMZ treatment alone. Temozolomide 124-127 interferon beta 1 Homo sapiens 51-59 30387134-9 2019 In conclusion, our studies demonstrate that poly I:C reinforces the potency of cytotoxic chemotherapeutics in PTX-resistant cell line through the TLR3-UNC93B1-IFN-beta signaling pathway, which supplies a novel mechanism of poly I:C for the chemotherapy sensitizing effect in a PTX-resistant tumor. Poly C 223-231 interferon beta 1 Homo sapiens 159-167 30387134-9 2019 In conclusion, our studies demonstrate that poly I:C reinforces the potency of cytotoxic chemotherapeutics in PTX-resistant cell line through the TLR3-UNC93B1-IFN-beta signaling pathway, which supplies a novel mechanism of poly I:C for the chemotherapy sensitizing effect in a PTX-resistant tumor. Paclitaxel 277-280 interferon beta 1 Homo sapiens 159-167 30867299-12 2019 Here, we show that 2Apro, but not 3Cpro, of all four human EV species (EV-A to EV-D) inhibits SG formation and IFN-beta gene transcription. ev-a 71-75 interferon beta 1 Homo sapiens 111-119 30867299-12 2019 Here, we show that 2Apro, but not 3Cpro, of all four human EV species (EV-A to EV-D) inhibits SG formation and IFN-beta gene transcription. ev-d 79-83 interferon beta 1 Homo sapiens 111-119 30387134-0 2019 Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-beta signaling axis in paclitaxel-resistant colon cancer. Poly I 29-35 interferon beta 1 Homo sapiens 108-116 30387134-0 2019 Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-beta signaling axis in paclitaxel-resistant colon cancer. Carbon 36-37 interferon beta 1 Homo sapiens 108-116 30387134-0 2019 Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-beta signaling axis in paclitaxel-resistant colon cancer. Paclitaxel 135-145 interferon beta 1 Homo sapiens 108-116 30387134-6 2019 In addition, when TLR3 was overexpressed in HCT-8/PTX cells, we found that TLR3 contributed to the production of IFN-beta that reduced cell viability, and poly I:C preferentially activated the TLR3-UNC93B1 signaling pathway to mediate this effect. Paclitaxel 50-53 interferon beta 1 Homo sapiens 113-121 30387134-7 2019 Moreover, cotreatment of poly I:C and PTX acted synergistically to induce cell apoptosis of HCT-8/PTX via upregulating the expression of TLR3 and its molecular chaperone UNC93B1, assisting in the secretion of IFN-beta. Poly C 25-33 interferon beta 1 Homo sapiens 209-217 30387134-7 2019 Moreover, cotreatment of poly I:C and PTX acted synergistically to induce cell apoptosis of HCT-8/PTX via upregulating the expression of TLR3 and its molecular chaperone UNC93B1, assisting in the secretion of IFN-beta. Paclitaxel 38-41 interferon beta 1 Homo sapiens 209-217 30387134-7 2019 Moreover, cotreatment of poly I:C and PTX acted synergistically to induce cell apoptosis of HCT-8/PTX via upregulating the expression of TLR3 and its molecular chaperone UNC93B1, assisting in the secretion of IFN-beta. Paclitaxel 98-101 interferon beta 1 Homo sapiens 209-217 30387134-9 2019 In conclusion, our studies demonstrate that poly I:C reinforces the potency of cytotoxic chemotherapeutics in PTX-resistant cell line through the TLR3-UNC93B1-IFN-beta signaling pathway, which supplies a novel mechanism of poly I:C for the chemotherapy sensitizing effect in a PTX-resistant tumor. Poly C 44-52 interferon beta 1 Homo sapiens 159-167 30387134-9 2019 In conclusion, our studies demonstrate that poly I:C reinforces the potency of cytotoxic chemotherapeutics in PTX-resistant cell line through the TLR3-UNC93B1-IFN-beta signaling pathway, which supplies a novel mechanism of poly I:C for the chemotherapy sensitizing effect in a PTX-resistant tumor. Paclitaxel 110-113 interferon beta 1 Homo sapiens 159-167 32010894-9 2019 Interferon beta can be a treatment of choice in patients with coincident FMF and MS and can be used in colchicine-resistant patients after being studied in systematic clinical studies. Colchicine 103-113 interferon beta 1 Homo sapiens 0-15 29553138-7 2019 Interferon-beta was induced by gp120 in upper GECs through Toll-like receptor 2 signaling and required presence of heparan sulfate on epithelial cell surface. Heparitin Sulfate 115-130 interferon beta 1 Homo sapiens 0-15 31097999-5 2019 In THP1 cells, GSK8612 was able to inhibit secretion of interferon beta (IFNbeta) in response to dsDNA and cGAMP, the natural ligand for STING. GSK8612 15-22 interferon beta 1 Homo sapiens 56-71 30178232-13 2019 Additionally, IFN-gamma production by Th1 cells was decreased after treatment silymarin in newly diagnosed patients; however, in IFN-beta treated after 48-h treatment with silymarin, IFN-gamma concentration was decreased at concentrations of 100 and 150 muM, and after 120 h, a significant increase was observed in the IFN-gamma level at a concentration of 100 muM in comparison with DMSO. Silymarin 172-181 interferon beta 1 Homo sapiens 129-137 30178232-10 2019 In vitro cultured Th1 cells showed that silymarin suppresses Th1 cell proliferation dose and time dependently in newly diagnosed and IFN-beta-treated MS patients in comparison to DMSO control. Silymarin 40-49 interferon beta 1 Homo sapiens 133-141 30644981-13 2019 Conclusions and Relevance: Among patients with relapsing-remitting MS, initial treatment with fingolimod, alemtuzumab, or natalizumab was associated with a lower risk of conversion to secondary progressive MS vs initial treatment with glatiramer acetate or interferon beta. Fingolimod Hydrochloride 94-104 interferon beta 1 Homo sapiens 257-272 30178232-13 2019 Additionally, IFN-gamma production by Th1 cells was decreased after treatment silymarin in newly diagnosed patients; however, in IFN-beta treated after 48-h treatment with silymarin, IFN-gamma concentration was decreased at concentrations of 100 and 150 muM, and after 120 h, a significant increase was observed in the IFN-gamma level at a concentration of 100 muM in comparison with DMSO. Dimethyl Sulfoxide 384-388 interferon beta 1 Homo sapiens 129-137 30178232-12 2019 T-bet gene expression was significantly decreased in Th1 cells isolated from newly diagnosed and IFN-beta-treated RRMS patients after treatment with silymarin compared to DMSO control. Silymarin 149-158 interferon beta 1 Homo sapiens 97-105 30178232-12 2019 T-bet gene expression was significantly decreased in Th1 cells isolated from newly diagnosed and IFN-beta-treated RRMS patients after treatment with silymarin compared to DMSO control. Dimethyl Sulfoxide 171-175 interferon beta 1 Homo sapiens 97-105 30619284-3 2018 We found that LX-2 cells expressed the functional Toll-like receptor 3 (TLR3), activation of which by PolyI:C resulted in the selective induction of interferon-beta (IFN-beta) and IFN-lambdas, the phosphorylation of IFN regulatory factor 3 (IRF3) and IRF7. Poly I-C 102-109 interferon beta 1 Homo sapiens 149-164 30808838-5 2019 RESULTS: We found that poly IC induced the expression of RIG-I, MDA5 and IL-6 via TLR3/IFN-beta signaling in GECs. Poly I-C 23-30 interferon beta 1 Homo sapiens 87-95 31626182-3 2019 The development of the pegylated form of IFN-beta (PEG-IFN-beta) is aimed at resolving these issues. pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate 51-54 interferon beta 1 Homo sapiens 41-49 31626182-3 2019 The development of the pegylated form of IFN-beta (PEG-IFN-beta) is aimed at resolving these issues. pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate 51-54 interferon beta 1 Homo sapiens 55-63 31626182-4 2019 This article reviewed the mechanism of action, efficacy, safety and tolerability of PEG-IFN-beta in the treatment of MS. pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate 84-87 interferon beta 1 Homo sapiens 88-96 29882169-8 2018 The IFNbeta patients with OCMB+ presented the poorest response, 31.3% RF vs. 48.1% in IFNbeta without OCMB, p = 0.03. ocmb 26-30 interferon beta 1 Homo sapiens 4-11 29870688-8 2018 Pretreatment with polyinosinic-polycytidylic acid alone or plus the antimicrobial peptide, LL37 enhanced IFN-beta production and suppressed viral replication. Poly I-C 18-49 interferon beta 1 Homo sapiens 105-113 30142694-12 2018 Collectively, it is suggested that iPS-ML/IFN-beta therapy offers a new approach for the treatment of patients with advanced ovarian cancer. IPS 35-38 interferon beta 1 Homo sapiens 42-50 30176558-4 2018 Within the type I interferon family the Asn-Gly-Arg (NGR) sequence motif is unique to interferon-beta and, together with its deamidated variants Asp-Gly-Arg (DGR) and iso-Asp-Gly-Arg (iso-DGR), imparts additional binding specificities that go beyond that of the canonical IFNAR1/IFNAR2. NGR peptide 40-51 interferon beta 1 Homo sapiens 86-101 30025984-5 2018 Overexpression of duDDX41 triggered the activation of transcription factors IRF1 and NF-kappaB, as well as IFN-beta expression in DEFs. duddx41 18-25 interferon beta 1 Homo sapiens 107-115 30025984-7 2018 Knockdown of duDDX41 by siRNA silencing dramatically decreased IFN-beta expression stimulated by poly(dA:dT) or duck enteritis virus (DEV). duddx41 13-20 interferon beta 1 Homo sapiens 63-71 30025984-7 2018 Knockdown of duDDX41 by siRNA silencing dramatically decreased IFN-beta expression stimulated by poly(dA:dT) or duck enteritis virus (DEV). poly 97-101 interferon beta 1 Homo sapiens 63-71 30025984-7 2018 Knockdown of duDDX41 by siRNA silencing dramatically decreased IFN-beta expression stimulated by poly(dA:dT) or duck enteritis virus (DEV). amsonic acid 102-104 interferon beta 1 Homo sapiens 63-71 30025984-7 2018 Knockdown of duDDX41 by siRNA silencing dramatically decreased IFN-beta expression stimulated by poly(dA:dT) or duck enteritis virus (DEV). Thymidine 105-107 interferon beta 1 Homo sapiens 63-71 30409294-5 2018 We found that cisplatin could be a potential activator of TLR3 and cisplatin treatment results in activation of PRRs" signaling and down-stream associated cytokine/chemokine, IFNbeta, and CCL5 in TLR3High OC2 cells, but not in TLR3Low FaDu cells. Cisplatin 14-23 interferon beta 1 Homo sapiens 175-182 30409294-5 2018 We found that cisplatin could be a potential activator of TLR3 and cisplatin treatment results in activation of PRRs" signaling and down-stream associated cytokine/chemokine, IFNbeta, and CCL5 in TLR3High OC2 cells, but not in TLR3Low FaDu cells. Cisplatin 67-76 interferon beta 1 Homo sapiens 175-182 30075406-12 2018 The treatment with interferon-beta (IFN-beta) and glatiramer acetate (GA) was safe and patients treated with high dose IFN-beta and GA had a statistically significant reduction in disability progression. Glatiramer Acetate 50-68 interferon beta 1 Homo sapiens 119-127 29974307-9 2018 Conversely, patients treated with fingolimod following IFN-beta did not have significant BVL. Fingolimod Hydrochloride 34-44 interferon beta 1 Homo sapiens 55-63 29974307-10 2018 These results indicate that evaluation of NEDA-4 is encouraged especially in patients with IFN-beta therapy in MS clinical practice in Japan although Japanese MS patients have generally been thought to possess a milder disease including brain atrophy compared to their Western counterparts. neda-4 42-48 interferon beta 1 Homo sapiens 91-99 29981256-5 2018 Indeed, IFN-beta gene induction by SINCRO is abolished in STING-deficient cells. SINCRO 35-41 interferon beta 1 Homo sapiens 8-16 30373255-4 2018 By using our data as independent validation, we reanalysed selected genes that were reported to be altered from previous studies of workers being exposed to sub-ppm benzene levels Four out of six genes previously proposed as marker genes in chronically exposed workers separated benzene exposed workers from unexposed referents (CLEC5, ACSL1, PRG2, IFNB1). Benzene 165-172 interferon beta 1 Homo sapiens 349-354 30373255-4 2018 By using our data as independent validation, we reanalysed selected genes that were reported to be altered from previous studies of workers being exposed to sub-ppm benzene levels Four out of six genes previously proposed as marker genes in chronically exposed workers separated benzene exposed workers from unexposed referents (CLEC5, ACSL1, PRG2, IFNB1). Benzene 279-286 interferon beta 1 Homo sapiens 349-354 30217172-9 2018 More patients treated with IFN beta-1a SC tiw achieved NEDA status, versus placebo, regardless of relapse severity (p <= 0.006). neda 55-59 interferon beta 1 Homo sapiens 27-35 29526079-8 2018 After DAA treatment, a significant decrease in the expression levels of IFN-beta, IFI44, and CXCL10 was observed in the PBMCs. daa 6-9 interferon beta 1 Homo sapiens 72-80 29526079-10 2018 CONCLUSION: Pretreatment activation of IFN-beta response is rapidly normalized after DAA treatment. daa 85-88 interferon beta 1 Homo sapiens 39-47 28559152-7 2018 Hsp70 down-regulation by quercetin significantly recovered IFN-beta-induced apoptosis of NS5-expressing cells, correlating with the increase in the phosphorylation of ERK2, p38 MAPK, and STAT1. Quercetin 25-34 interferon beta 1 Homo sapiens 59-67 29882169-8 2018 The IFNbeta patients with OCMB+ presented the poorest response, 31.3% RF vs. 48.1% in IFNbeta without OCMB, p = 0.03. ocmb 26-30 interferon beta 1 Homo sapiens 86-93 30027104-6 2018 Patients treated with cladribine tablets 3.5 mg/kg/IFN-beta were 63% less likely to have a qualifying relapse than placebo/IFN-beta recipients, and cladribine tablets 3.5 mg/kg/IFN-beta reduced most MRI measures of disease activity. Cladribine 22-32 interferon beta 1 Homo sapiens 51-59 30027104-7 2018 Conclusions: In patients with active relapsing MS despite IFN-beta treatment, cladribine tablets 3.5 mg/kg/IFN-beta reduced relapses and MRI lesion activity over 96 weeks compared with placebo/IFN-beta but led to an increased incidence of lymphopenia. Cladribine 78-88 interferon beta 1 Homo sapiens 58-66 30027104-7 2018 Conclusions: In patients with active relapsing MS despite IFN-beta treatment, cladribine tablets 3.5 mg/kg/IFN-beta reduced relapses and MRI lesion activity over 96 weeks compared with placebo/IFN-beta but led to an increased incidence of lymphopenia. Cladribine 78-88 interferon beta 1 Homo sapiens 107-115 30027104-7 2018 Conclusions: In patients with active relapsing MS despite IFN-beta treatment, cladribine tablets 3.5 mg/kg/IFN-beta reduced relapses and MRI lesion activity over 96 weeks compared with placebo/IFN-beta but led to an increased incidence of lymphopenia. Cladribine 78-88 interferon beta 1 Homo sapiens 107-115 29875313-2 2018 IFN-beta is an established treatment for MS; however, up to 30% of IFN-beta-treated MS patients develop neutralizing antidrug antibodies (nADA), leading to reduced drug bioactivity and efficacy. arachidonyl dopamine 138-142 interferon beta 1 Homo sapiens 0-8 29875313-2 2018 IFN-beta is an established treatment for MS; however, up to 30% of IFN-beta-treated MS patients develop neutralizing antidrug antibodies (nADA), leading to reduced drug bioactivity and efficacy. arachidonyl dopamine 138-142 interferon beta 1 Homo sapiens 67-75 29875313-4 2018 Using high-throughput flow cytometry, NOTCH2 expression on CD14+ monocytes and increased frequency of proinflammatory monocyte subsets were identified as baseline predictors of nADA development in MS patients treated with IFN-beta. arachidonyl dopamine 177-181 interferon beta 1 Homo sapiens 222-230 29875313-8 2018 Thus, nADA development was driven by a proinflammatory environment that triggered activation of the NOTCH2 signaling pathway prior to first IFN-beta administration. arachidonyl dopamine 6-10 interferon beta 1 Homo sapiens 140-148 29915590-11 2018 ACh was significantly higher in the IFN-beta-treated than HC and non-treated MS patients (p < 0.001). Acetylcholine 0-3 interferon beta 1 Homo sapiens 36-44 29673589-4 2018 Here, we show, paradoxically, that both BAPTA-AM-mediated calcium depletion and ionomycin-induced calcium elevation suppress STING translocation and STING-mediated IFN-beta production. 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester 40-48 interferon beta 1 Homo sapiens 164-172 29673589-4 2018 Here, we show, paradoxically, that both BAPTA-AM-mediated calcium depletion and ionomycin-induced calcium elevation suppress STING translocation and STING-mediated IFN-beta production. Ionomycin 80-89 interferon beta 1 Homo sapiens 164-172 29673589-4 2018 Here, we show, paradoxically, that both BAPTA-AM-mediated calcium depletion and ionomycin-induced calcium elevation suppress STING translocation and STING-mediated IFN-beta production. Calcium 98-105 interferon beta 1 Homo sapiens 164-172 29673589-5 2018 We demonstrate that the mitochondria fission mediator DRP1 is crucial for ionomycin-induced inhibition of IFN-beta production. Ionomycin 74-83 interferon beta 1 Homo sapiens 106-114 29558821-0 2018 Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-beta levels. Suramin 0-7 interferon beta 1 Homo sapiens 74-82 29558821-5 2018 Addition of suramin to THP1 cells reduced the levels of IFN-beta mRNA and protein. Suramin 12-19 interferon beta 1 Homo sapiens 56-64 29445009-5 2018 In vivo and in vitro binge alcohol exposure significantly inhibited the TLR4-MyD88 cytokines TNF-alpha and IL-6, as well as the TLR4-TRIF cytokines/chemokines IFN-beta, IP-10, and RANTES, in human monocytes, but not TLR3-TRIF-induced cytokines/chemokines, as detected by quantitative PCR and ELISA. Alcohols 27-34 interferon beta 1 Homo sapiens 159-167 29555588-10 2018 Furthermore, Cappariloside A strongly inhibited phosphorylated STAT1 levels and IFN-beta and IL-29 expressions induced by PR8/H1N1. Cappariloside A 13-28 interferon beta 1 Homo sapiens 80-88 29555588-11 2018 Cappariloside A also inhibited IP-10 and CCL-5/RANTES expressions induced by exogenous human recombinant IFN-beta. Cappariloside A 0-15 interferon beta 1 Homo sapiens 105-113 29488605-2 2018 Gene associated with retinoid-interferon (IFN)-induced mortality-19 (Grim-19) is reported to be a cell death activator that may be used to define mechanisms involved in IFN-beta- and retinoic acid-induced cell death and apoptosis in a number of tumor cell lines. Retinoids 21-29 interferon beta 1 Homo sapiens 169-177 29504299-11 2018 CONCLUSIONS: These results further support that persistent NAb positivity is associated with disease activity in MS patients treated with IFN-beta. nab 59-62 interferon beta 1 Homo sapiens 138-146 29962372-7 2018 HOSCN decreased polyI:C-induced apoptosis and the expression levels of IFNB1, IFNL1, IFNL2 and IFNL3 mRNAs. Carbon 3-4 interferon beta 1 Homo sapiens 71-76 29521113-0 2018 Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. Fingolimod Hydrochloride 78-88 interferon beta 1 Homo sapiens 18-26 29512705-5 2018 Poly(I:C) transfection in NSCLC cells triggered apoptosis via the extrinsic apoptotic pathway, and activated the innate immune response by promoting interferon-beta and C-X-C motif chemokine ligand 10 expression. Poly I-C 0-8 interferon beta 1 Homo sapiens 149-164 29686117-10 2018 In people with CIS, glatiramer acetate and IFN-beta-1a subcutaneous 3 times per week are more effective than placebo in decreasing risk of conversion to MS. Cladribine, immunoglobulins, IFN-beta-1a 30 mug intramuscular weekly, IFN-beta-1b subcutaneous alternate day, and teriflunomide are probably more effective than placebo in decreasing risk of conversion to MS. teriflunomide 271-284 interferon beta 1 Homo sapiens 43-51 29414325-3 2018 One differentiating factor of interferon-beta (IFN-beta) from other type I interferons is the presence of theAsn-Gly-Arg (NGR) sequence motif, which, upon deamidation, converts to Asp-Gly-Arg (DGR) and iso-Asp-Gly-Arg (iso-DGR) motifs. -gly-arg 112-120 interferon beta 1 Homo sapiens 30-45 29414325-3 2018 One differentiating factor of interferon-beta (IFN-beta) from other type I interferons is the presence of theAsn-Gly-Arg (NGR) sequence motif, which, upon deamidation, converts to Asp-Gly-Arg (DGR) and iso-Asp-Gly-Arg (iso-DGR) motifs. -gly-arg 112-120 interferon beta 1 Homo sapiens 47-55 29414325-3 2018 One differentiating factor of interferon-beta (IFN-beta) from other type I interferons is the presence of theAsn-Gly-Arg (NGR) sequence motif, which, upon deamidation, converts to Asp-Gly-Arg (DGR) and iso-Asp-Gly-Arg (iso-DGR) motifs. Asp-Gly-Arg 180-191 interferon beta 1 Homo sapiens 30-45 29414325-3 2018 One differentiating factor of interferon-beta (IFN-beta) from other type I interferons is the presence of theAsn-Gly-Arg (NGR) sequence motif, which, upon deamidation, converts to Asp-Gly-Arg (DGR) and iso-Asp-Gly-Arg (iso-DGR) motifs. Asp-Gly-Arg 180-191 interferon beta 1 Homo sapiens 47-55 29414325-3 2018 One differentiating factor of interferon-beta (IFN-beta) from other type I interferons is the presence of theAsn-Gly-Arg (NGR) sequence motif, which, upon deamidation, converts to Asp-Gly-Arg (DGR) and iso-Asp-Gly-Arg (iso-DGR) motifs. iso-asp-gly-arg 202-217 interferon beta 1 Homo sapiens 30-45 29414325-3 2018 One differentiating factor of interferon-beta (IFN-beta) from other type I interferons is the presence of theAsn-Gly-Arg (NGR) sequence motif, which, upon deamidation, converts to Asp-Gly-Arg (DGR) and iso-Asp-Gly-Arg (iso-DGR) motifs. iso-asp-gly-arg 202-217 interferon beta 1 Homo sapiens 47-55 29451469-0 2018 Evaluation of the warming sensation, acceptability, and local tolerability of an acetylcysteine oral solution containing the flavoring agent IFF flavor 316282 in the treatment of productive cough : . Acetylcysteine 81-95 interferon beta 1 Homo sapiens 141-144 29451469-1 2018 OBJECTIVE: This open-label study sought to evaluate the warming sensation produced by IFF flavor 316282 in an acetylcysteine oral solution in subjects with productive cough. Acetylcysteine 110-124 interferon beta 1 Homo sapiens 86-89 29451469-2 2018 MATERIALS: 2% ace-tylcysteine oral solution (200 mg per 10 mL) containing IFF flavor 316282. Acetylcysteine 14-29 interferon beta 1 Homo sapiens 74-77 29451469-10 2018 CONCLUSION: The addition of IFF flavor 316282 to a 2% acetylcysteine oral solution produced a warming sensation with rapid onset and relatively short duration, which the majority of subjects found acceptable. Acetylcysteine 54-68 interferon beta 1 Homo sapiens 28-31 29408707-9 2018 Moreover, Poly-I:C treatment induced a marked antiviral response including increases of interferons IFNB, IL-28B and a group of interferon-stimulated genes. Poly I-C 10-18 interferon beta 1 Homo sapiens 100-104 28884930-1 2018 AIM: To improve the therapeutic efficacy of sofosbuvir/ledipasvir (SOF/LDV) for the retreatment of patients after daclatasvir/asunaprevir (DCV/ASV), a customized therapy with or without lead-in interferon (IFN)-beta injections was formulated according to the types of resistance-associated substitutions (RAS) in the non-structural protein (NS)5A region of genotype 1b hepatitis C virus (HCV). Sofosbuvir 44-54 interferon beta 1 Homo sapiens 194-215 29317357-5 2018 Results from this comprehensive study revealed two novel pathways to become activated upon monocyte stimulation with Al(OH)3: the first pathway was IFNbeta signaling possibly induced by DAMP sensing pathways like TLR or NOD1 activation, and second the HLA class I antigen processing and presentation pathway. Aluminum Hydroxide 117-124 interferon beta 1 Homo sapiens 148-155 28884930-1 2018 AIM: To improve the therapeutic efficacy of sofosbuvir/ledipasvir (SOF/LDV) for the retreatment of patients after daclatasvir/asunaprevir (DCV/ASV), a customized therapy with or without lead-in interferon (IFN)-beta injections was formulated according to the types of resistance-associated substitutions (RAS) in the non-structural protein (NS)5A region of genotype 1b hepatitis C virus (HCV). ledipasvir 55-65 interferon beta 1 Homo sapiens 194-215 28884930-1 2018 AIM: To improve the therapeutic efficacy of sofosbuvir/ledipasvir (SOF/LDV) for the retreatment of patients after daclatasvir/asunaprevir (DCV/ASV), a customized therapy with or without lead-in interferon (IFN)-beta injections was formulated according to the types of resistance-associated substitutions (RAS) in the non-structural protein (NS)5A region of genotype 1b hepatitis C virus (HCV). sof 67-70 interferon beta 1 Homo sapiens 194-215 29066027-7 2018 ADA positive patients showed higher T cell responses to IFN-beta protein than ADA negative patients and untreated controls. N-(2-acetamido)iminodiacetic acid 0-3 interferon beta 1 Homo sapiens 56-64 29066027-7 2018 ADA positive patients showed higher T cell responses to IFN-beta protein than ADA negative patients and untreated controls. N-(2-acetamido)iminodiacetic acid 78-81 interferon beta 1 Homo sapiens 56-64 29139001-12 2018 The real-world assessment further demonstrated that IFN-beta-1a-IM users had a statistically higher risk of treatment failure, defined as treatment switching or relapse treatment or death, with the assessment showing that IFN-beta-1a-IM was inferior to the other IFN-betas and to glatiramer acetate in both direct and indirect analysis. Glatiramer Acetate 280-298 interferon beta 1 Homo sapiens 52-60 29431732-5 2018 Specifically, blocking AhR redirected IFN-beta signaling to STAT3 phosphorylation through both tyrosine and serine sites, which subsequently facilitated STAT3 nuclear translocation and subsequent binding to the p53 promoter in the nucleus. Tyrosine 95-103 interferon beta 1 Homo sapiens 38-46 29431732-5 2018 Specifically, blocking AhR redirected IFN-beta signaling to STAT3 phosphorylation through both tyrosine and serine sites, which subsequently facilitated STAT3 nuclear translocation and subsequent binding to the p53 promoter in the nucleus. Serine 108-114 interferon beta 1 Homo sapiens 38-46 29345344-6 2018 Pam2Cys challenge, compared to Pam3Cys, induced PTB and promoted significantly higher expression of inflammatory cytokines, specifically IL-6 and IFN-beta, both in vivo and in vitro. S-(2,3-bis(palmitoyloxy)propyl)cysteine 0-7 interferon beta 1 Homo sapiens 146-154 29497558-8 2018 Conclusions: Low baseline ALC and treatment history with any interferon-beta were risk factors for fingolimod-induced lymphopenia, possibly predicted from ALC on day 2. Fingolimod Hydrochloride 99-109 interferon beta 1 Homo sapiens 61-76 29581840-5 2018 Induction of apoptosis by IFNbeta was measured by flow cytometric analysis of subG1-DNA-content, Hoechst 33258 staining and activation of caspase-3. Bisbenzimidazole 97-110 interferon beta 1 Homo sapiens 26-33 29402958-4 2018 Poly(I:C) activates both IRF3 and NF-kappaB, a requirement for induction of IFNbeta expression. Poly I-C 0-8 interferon beta 1 Homo sapiens 76-83 28497489-0 2018 Efficacy and safety of telaprevir with natural human interferon-beta and ribavirin in Japanese chronic hepatitis C patients with depression. telaprevir 23-33 interferon beta 1 Homo sapiens 53-68 29243005-1 2018 BACKGROUND: Low serum levels of 25-hydroxyvitamin D have been associated with worse outcomes in multiple sclerosis (MS) patients treated with interferon-beta. 25-hydroxyvitamin D 32-51 interferon beta 1 Homo sapiens 142-157 28752785-1 2018 We report the case of a 42-year-old female patient who developed peculiar skin lesions due to subcutaneous polyethylene glycol (PEG) interferon beta-1a. Polyethylene Glycols 107-126 interferon beta 1 Homo sapiens 133-148 28752785-1 2018 We report the case of a 42-year-old female patient who developed peculiar skin lesions due to subcutaneous polyethylene glycol (PEG) interferon beta-1a. Polyethylene Glycols 128-131 interferon beta 1 Homo sapiens 133-148 29202279-6 2018 Upon MTT assay, proliferation of choriocarcinoma (JEG-3) cells decreased when co-cultured with hNSCs expressing CD and IFN-beta genes. monooxyethylene trimethylolpropane tristearate 5-8 interferon beta 1 Homo sapiens 119-127 29294448-5 2018 Overexpression of 8b and 8ab resulted in the reduction of poly (I:C)-induced IRF3 dimerization and inhibition of the IFN-beta signaling pathway. Poly I-C 58-68 interferon beta 1 Homo sapiens 117-125 29410667-0 2018 Double-Stranded RNA Derived from Lactic Acid Bacteria Augments Th1 Immunity via Interferon-beta from Human Dendritic Cells. Lactic Acid 33-44 interferon beta 1 Homo sapiens 80-95 28987803-13 2018 Formoterol suppressed CpG-induced translocation of H3K4 specific methyltransferase WDR5 and suppressed H3K4 trimethylation in the IFNA and IFNB gene promoter region. Formoterol Fumarate 0-10 interferon beta 1 Homo sapiens 139-143 29412429-1 2018 OBJECTIVE: To evaluate the association between fraction of exhaled nitric oxide (FeNO) values and forced expiratory volume in the first second (FEV1) and the level of asthma control, as proposed by the Global Initiative for Asthma (GINA), in asthmatic children and adolescents attended at the National Institute of Women, Children and Adolescents Health Fernandes Figueira of Fundacao Oswaldo Cruz (IFF/FIOCRUZ). feno 81-85 interferon beta 1 Homo sapiens 399-402 29138248-6 2017 Furthermore, we found that ML323, a specific USP1-UAF1 inhibitor, attenuated IFN-beta expression and enhanced viral replication both in vitro and in vivo. ML323 27-32 interferon beta 1 Homo sapiens 77-85 29311663-4 2018 Receptor mutagenesis and cell signaling studies establish that the IFNAR1 mutation corresponding to a proline deletion in the hinge region of the membrane-proximal domain of IFNAR1 decreases the binding affinity of IFNAR1 to IFN-beta, impeding type I IFN signaling. Proline 102-109 interferon beta 1 Homo sapiens 225-233 29484976-8 2018 Less frequent dosing and improved pharmacological properties have been achieved by reaction of interferon beta with chemically activated polyethylene glycol. Polyethylene Glycols 137-156 interferon beta 1 Homo sapiens 95-110 29202299-0 2018 Repression of interferon beta-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages. ruxolitinib 74-85 interferon beta 1 Homo sapiens 14-29 29202299-8 2018 Most of cytokines targeted by ruxolitinib were shown to be regulated by IFNbeta in a JAK-sensitive manner. ruxolitinib 30-41 interferon beta 1 Homo sapiens 72-79 29202299-10 2018 Overall, these data provide evidence for ruxolitinib-mediated repression of inflammatory cytokines in human macrophages through inhibition of the LPS/IFNbeta/JAK/STAT signalling pathway, which probably contributes to the anti-inflammatory effects of the JAK inhibitor. ruxolitinib 41-52 interferon beta 1 Homo sapiens 150-157 28944501-5 2018 In our case, local injection of interferon (IFN)-beta with dacarbazine-nimustine-vincristine therapy provided antitumor effects on an invasive tumor on the upper gingiva. Dacarbazine 59-70 interferon beta 1 Homo sapiens 32-53 28944501-5 2018 In our case, local injection of interferon (IFN)-beta with dacarbazine-nimustine-vincristine therapy provided antitumor effects on an invasive tumor on the upper gingiva. Nimustine 71-80 interferon beta 1 Homo sapiens 32-53 28944501-5 2018 In our case, local injection of interferon (IFN)-beta with dacarbazine-nimustine-vincristine therapy provided antitumor effects on an invasive tumor on the upper gingiva. Vincristine 81-92 interferon beta 1 Homo sapiens 32-53 29128737-9 2018 The rate of SP conversion was higher for Interferon-beta1b 250mcg (HR = 2.054; p = 0.042), and not-significantly higher for Interferon-beta1a 30mcg (HR = 1.884; p = 0.081), when compared with Interferon-beta1a 44mcg. sp 12-14 interferon beta 1 Homo sapiens 41-57 29255467-5 2017 Here, we demonstrate that TLR-induced PGD2 production by macrophages was significantly potentiated by signaling common to IFN-beta and IFN-gamma in a signal transducer and activators of transcription (STAT)1-dependent mechanism. Prostaglandin D2 38-42 interferon beta 1 Homo sapiens 122-130 29155646-8 2018 DISCUSSION: These results indicate that both DHA and ATRA might help control disease progression in IFN-beta treated RRMS patients with the strongest effects produced by a combination of the two compounds. Docosahexaenoic Acids 45-48 interferon beta 1 Homo sapiens 100-108 29155646-8 2018 DISCUSSION: These results indicate that both DHA and ATRA might help control disease progression in IFN-beta treated RRMS patients with the strongest effects produced by a combination of the two compounds. Tretinoin 53-57 interferon beta 1 Homo sapiens 100-108 29276624-7 2017 Conclusion: In RRMS, IFN beta-1a significantly decreased the proportion of new T1 Gd+ lesions evolving into CBH and the risk of developing a CBH. S-(D-CARBOXYBUTYL)-L-HOMOCYSTEINE 108-111 interferon beta 1 Homo sapiens 21-29 29276624-7 2017 Conclusion: In RRMS, IFN beta-1a significantly decreased the proportion of new T1 Gd+ lesions evolving into CBH and the risk of developing a CBH. S-(D-CARBOXYBUTYL)-L-HOMOCYSTEINE 141-144 interferon beta 1 Homo sapiens 21-29 28906152-11 2017 Among treatment-naive patients, those receiving DMF had 2.4-times the risk (HR = 2.439, 95% CI = 1.007-5.917, p = .0483) of experiencing a discontinuation than patients receiving sc IFN beta-1a. Dimethyl Fumarate 48-51 interferon beta 1 Homo sapiens 182-190 28906152-12 2017 Non-persistent patients receiving DMF had 2.3-times the risk (HR = 2.311, 95% CI = 1.350-3.958, p = .0023) of experiencing an adverse event at a given time point than patients prescribed sc IFN beta-1a. Dimethyl Fumarate 34-37 interferon beta 1 Homo sapiens 190-198 28965604-3 2017 Previous work had indicated a Zn2+-dependent upregulation of STAT1 mRNA in response to LPS and IFN-beta, potentially affecting STAT1-dependent downstream signaling upon pre-incubation with these agents. Zinc 30-34 interferon beta 1 Homo sapiens 95-103 28965604-5 2017 The LPS- and IFN-beta-mediated increase of STAT1 mRNA and protein levels was abrogated by chelation of Zn2+ with the membrane permeable chelator N,N,N",N"-Tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) in RAW 264.7 macrophages. Zinc 103-107 interferon beta 1 Homo sapiens 13-21 28965604-5 2017 The LPS- and IFN-beta-mediated increase of STAT1 mRNA and protein levels was abrogated by chelation of Zn2+ with the membrane permeable chelator N,N,N",N"-Tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) in RAW 264.7 macrophages. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine 145-195 interferon beta 1 Homo sapiens 13-21 28965604-5 2017 The LPS- and IFN-beta-mediated increase of STAT1 mRNA and protein levels was abrogated by chelation of Zn2+ with the membrane permeable chelator N,N,N",N"-Tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) in RAW 264.7 macrophages. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine 197-201 interferon beta 1 Homo sapiens 13-21 28965604-6 2017 After 48h pre-incubation together with IFN-beta, TPEN also led to reduced nitric monoxide formation in response to a second stimulation with LPS. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine 49-53 interferon beta 1 Homo sapiens 39-47 28965604-6 2017 After 48h pre-incubation together with IFN-beta, TPEN also led to reduced nitric monoxide formation in response to a second stimulation with LPS. nitric monoxide 74-89 interferon beta 1 Homo sapiens 39-47 28859978-3 2017 Previous study showed that carbonyl cyanide 3-chlorophenylhydrazone (CCCP), the protonophore, inhibited STING-mediated IFN-beta production via disrupting mitochondrial membrane potential (MMP). carbonyl 3-chlorophenylhydrazone 27-67 interferon beta 1 Homo sapiens 119-127 28859978-3 2017 Previous study showed that carbonyl cyanide 3-chlorophenylhydrazone (CCCP), the protonophore, inhibited STING-mediated IFN-beta production via disrupting mitochondrial membrane potential (MMP). carbonyl 3-chlorophenylhydrazone 69-73 interferon beta 1 Homo sapiens 119-127 28684273-6 2017 In poly(dA:dT) stimulation assays, the immune molecules involved in the DDX41-mediated IFN-beta pathway in human cells were universally upregulated in chicken cells. poly 3-7 interferon beta 1 Homo sapiens 87-95 28321835-5 2017 Seventy-six percentages of patients shifted to teriflunomide from treatment with interferon-beta. teriflunomide 47-60 interferon beta 1 Homo sapiens 81-96 28666650-6 2017 Expression of duLSm14A induced IFN-beta through the activation of interferon regulatory factor-1 and nuclear factor-kappaB in DEFs. dulsm14a 14-22 interferon beta 1 Homo sapiens 31-39 28684273-6 2017 In poly(dA:dT) stimulation assays, the immune molecules involved in the DDX41-mediated IFN-beta pathway in human cells were universally upregulated in chicken cells. amsonic acid 8-10 interferon beta 1 Homo sapiens 87-95 28684273-6 2017 In poly(dA:dT) stimulation assays, the immune molecules involved in the DDX41-mediated IFN-beta pathway in human cells were universally upregulated in chicken cells. Thymidine 11-13 interferon beta 1 Homo sapiens 87-95 28689102-10 2017 CONCLUSION: The addition of monthly pulsed methylprednisolone to subcutaneous interferon beta or glatiramer acetate therapy significantly reduced the relapse rate and may also be beneficial in terms of disease progression. Methylprednisolone 43-61 interferon beta 1 Homo sapiens 78-93 28150518-0 2017 Chloroquine attenuates TLR3/IFN-beta signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis. Chloroquine 0-11 interferon beta 1 Homo sapiens 28-36 28150518-3 2017 METHODS: We examined chloroquine effect on the representative TLR3/IFN-beta-signaling axis, TLR3/IFN-beta/retinoic acid-inducible gene-I (RIG-I)/CCL5 in MCs treated with polyinosinic-polycytidylic acid (poly IC), a synthetic viral dsRNA analog and analyzed the expression of these molecules using reverse transcriptase-polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA). Chloroquine 21-32 interferon beta 1 Homo sapiens 67-75 28150518-5 2017 RESULTS: Pretreatment of cells with chloroquine attenuated IFN-beta, RIG-I and CCL5 expression and phosphorylation of STAT1 induced by poly IC, but not IFN-beta-induced phosphorylation of STAT1 and RIG-I expression induced by IFN-beta. Chloroquine 36-47 interferon beta 1 Homo sapiens 59-67 28150518-6 2017 Knockdown of p65 inhibited the poly IC-induced IFN-beta expression, and chloroquine pretreatment decreased the nuclear poly IC-induced translocation of NF-kappaB p65 in MCs. Poly I-C 31-38 interferon beta 1 Homo sapiens 47-55 28623559-0 2017 IFN-beta-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Reactive Oxygen Species 17-40 interferon beta 1 Homo sapiens 0-8 28623559-4 2017 Moreover, IFN-beta induced ROS production in human myotubes was found to contribute to mitochondrial malfunctions. Reactive Oxygen Species 27-30 interferon beta 1 Homo sapiens 10-18 28623559-7 2017 Mitochondrial dysfunctions, mediated by IFN-beta induced-ROS, contribute to poor exercise capacity. Reactive Oxygen Species 57-60 interferon beta 1 Homo sapiens 40-48 28955326-5 2017 In addition, PA inhibited IFN-beta induction by RIG-I, melanoma differentiation-associated gene 5, mitochondria antiviral signaling protein, TANK-binding kinase 1, inhibitor of nuclear factor kappa-B kinase-epsilon (IKKepsilon), and IRF3 overexpression. Protactinium 13-15 interferon beta 1 Homo sapiens 26-34 28205143-1 2017 A multifunctional platform to deliver three diverse proteins of insulin, interferon beta (INF-beta) and erythropoietin (EPO), using a novel copolymeric microparticulate system of TMC-PEGDMA-MAA, was synthesised as an intelligent pH-responsive 2-fold gastric and intestinal absorptive system. tmc-pegdma-maa 179-193 interferon beta 1 Homo sapiens 73-98 28955326-7 2017 The N-terminal endonuclease activity of PA was responsible for its interaction with IRF3 and inhibition of the IFN-beta signaling pathway. Protactinium 40-42 interferon beta 1 Homo sapiens 111-119 28716230-6 2017 CONCLUSIONS: IFN beta-1a SC tiw was associated with significantly higher rate of NEDA status compared with IFN beta-1a IM qw. neda 81-85 interferon beta 1 Homo sapiens 13-21 28511947-13 2017 Both DAA surgical technique variations are felt to be equivalent regarding the risk for IFF during DAA cementless total hip arthroplasty. daa 5-8 interferon beta 1 Homo sapiens 88-91 28686675-0 2017 Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study. Cetirizine 37-47 interferon beta 1 Homo sapiens 124-139 28686675-4 2017 We hypothesized that cetirizine, a second-generation histamine H1 receptor antagonist able to reduce the levels of IL-6, might improve IFNbeta-induced FLS. Cetirizine 21-31 interferon beta 1 Homo sapiens 135-142 28729851-3 2017 Screening assay: ADA in serum samples form complexes with immobilized IFN-beta and biotinylated IFN-beta, which are then detected using HRP labeled Streptavidin and TMB substrate. N-(2-acetamido)iminodiacetic acid 17-20 interferon beta 1 Homo sapiens 70-78 28729851-3 2017 Screening assay: ADA in serum samples form complexes with immobilized IFN-beta and biotinylated IFN-beta, which are then detected using HRP labeled Streptavidin and TMB substrate. N-(2-acetamido)iminodiacetic acid 17-20 interferon beta 1 Homo sapiens 96-104 28686675-5 2017 METHODS: We conducted a pilot, cross-over, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine 10 mg added after each IFNbeta injection to the standard of care for FLS (acetaminophen or nonsteroidal anti-inflammatory drugs) on FLS in patients with RRMS treated with IFNbeta. Cetirizine 122-132 interferon beta 1 Homo sapiens 156-163 28729851-3 2017 Screening assay: ADA in serum samples form complexes with immobilized IFN-beta and biotinylated IFN-beta, which are then detected using HRP labeled Streptavidin and TMB substrate. 3,3',5,5'-tetramethylbenzidine 165-168 interferon beta 1 Homo sapiens 70-78 28729851-3 2017 Screening assay: ADA in serum samples form complexes with immobilized IFN-beta and biotinylated IFN-beta, which are then detected using HRP labeled Streptavidin and TMB substrate. 3,3',5,5'-tetramethylbenzidine 165-168 interferon beta 1 Homo sapiens 96-104 28418769-6 2017 Persistency of neutralizing ADA was predicted by their titers at month 24 and month 36 of treatment and by an increase of antibody affinity within the second year of IFN-beta treatment. N-(2-acetamido)iminodiacetic acid 28-31 interferon beta 1 Homo sapiens 166-174 28426911-6 2017 RESULTS: Treatment of PBMCs with BX795 inhibited the phosphorylation of IFN regulatory factor 3 and IFNbeta promoter activity induced in HEK 293T cells by cyclic GMP-AMP or by genetic activation of STING. cyclic guanosine monophosphate-adenosine monophosphate 155-169 interferon beta 1 Homo sapiens 100-107 28418769-7 2017 The humoral immune response to IFN-beta observed in MS patients as a result of IFN-beta therapy is a multifactorial process that is influenced by ADA titers, affinity maturation, and IgG subclass switching. N-(2-acetamido)iminodiacetic acid 146-149 interferon beta 1 Homo sapiens 31-39 28418769-7 2017 The humoral immune response to IFN-beta observed in MS patients as a result of IFN-beta therapy is a multifactorial process that is influenced by ADA titers, affinity maturation, and IgG subclass switching. N-(2-acetamido)iminodiacetic acid 146-149 interferon beta 1 Homo sapiens 79-87 28340358-5 2017 CXCL10 production was preceded by lysosomal rupture as shown by time-dependent co-localization of galectin-3 and chitosan and slowed autophagy flux, and specifically depended on IFN-beta paracrine activity and STAT-2 activation that could be suppressed by PGE2. Dinoprostone 256-260 interferon beta 1 Homo sapiens 178-186 28283756-12 2017 Treatment of MS patients with interferon beta (IFN-beta) increases D1-like DRs and decreases D2-like DRs in Teffs, decreases D1-like DRs in Tregs, and most important: restores responsiveness of patient"s Teffs to dopamine. Dopamine 213-221 interferon beta 1 Homo sapiens 30-45 28751099-2 2017 Post hoc analyses of integrated data from DEFINE/CONFIRM were conducted to evaluate the effect of DMF in patients previously treated with interferon (IFN) beta. Dimethyl Fumarate 98-101 interferon beta 1 Homo sapiens 138-159 28283756-12 2017 Treatment of MS patients with interferon beta (IFN-beta) increases D1-like DRs and decreases D2-like DRs in Teffs, decreases D1-like DRs in Tregs, and most important: restores responsiveness of patient"s Teffs to dopamine. Dopamine 213-221 interferon beta 1 Homo sapiens 47-55 28039317-8 2017 At month 60, mean cumulative numbers of new T2, gadolinium-enhancing and T1 hypointense lesions were lower with sc IFN beta-1a qw (nominal p<0.05) and tiw versus DT (nominal p<0.001); T2 and T1 hypointense lesion volume change was lower for sc IFN beta-1a tiw versus DT (nominal p<0.01). Gadolinium 48-58 interferon beta 1 Homo sapiens 115-123 28229303-3 2017 Several disease-modifying agents (DMA) including beta-interferons (IFNbeta) are being used in MS patients in order to stop the disease at the early inflammatory stage, postpone disease progression and diminish future disability. dma 34-37 interferon beta 1 Homo sapiens 49-75 28129467-3 2017 In the present study, we report on the development of a novel, engineered form of human and murine IFN-beta, each conjugated with a polyethylene glycol molecule (PEG-hIFN-beta and PEG-mIFN-beta, respectively). Polyethylene Glycols 132-151 interferon beta 1 Homo sapiens 166-175 28387596-5 2017 These effects are more obvious when combining IFN-beta with classical antitumor therapies such as temozolamide, an oral chemotherapeutic, for both newly diagnosed and recurrent gliomas. Temozolomide 98-110 interferon beta 1 Homo sapiens 46-54 28211024-7 2017 Compared with DMF, the adjusted IRR (95% CI) for relapse in the year after initiating therapy was 1.27 (1.10-1.46) for IFNbeta, 1.34 (1.17-1.53) for GA, 1.23 (1.05-1.45) for teriflunomide, and 1.03 (0.88-1.21) for fingolimod. Dimethyl Fumarate 14-17 interferon beta 1 Homo sapiens 119-126 28473813-6 2017 The activity of asunaprevir-regulated innate immunity signal pathway was assessed with IFN-beta promoter or IFN-stimulated responsive element (ISRE) reporter assays and immunoblotting of key signal proteins. asunaprevir 16-27 interferon beta 1 Homo sapiens 87-95 28473813-8 2017 Asunaprevir treatment activated ISRE and IFN-beta promoter-luciferase activities and signaling proteins in the JAK-STAT, MAVS, and TRIF pathways in Huh 7.5.1 cells. asunaprevir 0-11 interferon beta 1 Homo sapiens 41-49 28039317-10 2017 CONCLUSIONS: Over 5 years in patients presenting with an FCDE, early sc IFN beta-1a tiw administration versus DT prolonged time to CDMS and McDonald MS, and reduced overall MRI activity. fcde 57-61 interferon beta 1 Homo sapiens 72-80 30050377-6 2017 Pegylation, the process by which molecules of polyethylene glycol are covalently linked to a compound, has been utilized to increase the half-life of IFNbeta and decrease the frequency of administration required. Polyethylene Glycols 46-65 interferon beta 1 Homo sapiens 150-157 28262817-5 2017 Here we show that OM-85 induced interferon-beta through the Toll-like receptor adaptors Trif and MyD88 in bone marrow-derived dendritic cells. om-85 18-23 interferon beta 1 Homo sapiens 32-47 28330867-6 2017 TIV-09 stimulated the secretion of type I interferons (IFNs) IFN-alpha and IFN-beta and type III IFN interleukin-29 (IL-29) by moDC and cDC subsets. tiv-09 0-6 interferon beta 1 Homo sapiens 75-83 27838463-0 2017 TiAl6V4 particles promote osteoclast formation via autophagy-mediated downregulation of interferon-beta in osteocytes. tial6v4 0-7 interferon beta 1 Homo sapiens 88-103 28109979-0 2017 Interferon (IFN)-induced protein 35 (IFI35) negatively regulates IFN-beta-phosphorylated STAT1-RIG-I-CXCL10/CCL5 axis in U373MG astrocytoma cells treated with polyinosinic-polycytidylic acid. Poly I-C 159-190 interferon beta 1 Homo sapiens 65-73 28338177-12 2017 The clinical efficacy of 5-ALA-PDT against CA may be related to the increased IFN-alpha and IFN-beta after treatment. Aminolevulinic Acid 25-30 interferon beta 1 Homo sapiens 92-100 27677346-8 2017 In addition, curcumin and IFN-beta/RA combination inhibited the expression of COX-2 and up-regulated GADD153. Tretinoin 35-37 interferon beta 1 Homo sapiens 26-34 27677346-9 2017 CONCLUSION: Curcumin synergistically increases the effects of IFN-beta/RA on breast cancer cells. Curcumin 12-20 interferon beta 1 Homo sapiens 62-70 28293479-1 2017 BACKGROUND: Multiple sclerosis (MS) patients treated with interferon beta (IFNbeta) are at risk of a declining response to treatment because of the production of IFNbeta-neutralizing antibodies (NAbs). nabs 195-199 interferon beta 1 Homo sapiens 58-73 28293479-1 2017 BACKGROUND: Multiple sclerosis (MS) patients treated with interferon beta (IFNbeta) are at risk of a declining response to treatment because of the production of IFNbeta-neutralizing antibodies (NAbs). nabs 195-199 interferon beta 1 Homo sapiens 75-82 28293479-1 2017 BACKGROUND: Multiple sclerosis (MS) patients treated with interferon beta (IFNbeta) are at risk of a declining response to treatment because of the production of IFNbeta-neutralizing antibodies (NAbs). nabs 195-199 interferon beta 1 Homo sapiens 162-169 27709605-4 2017 The fungal surrogate zymosan produced the phosphorylation of Y705-STAT3 and the expression of Ifnb1 and Socs3, but did not induce the interferon (IFN)-signature cytokines Cxcl9 and Cxcl10 in bone marrow-derived dendritic cells. Zymosan 21-28 interferon beta 1 Homo sapiens 94-99 28008721-2 2017 This study aimed to examine therapeutic effect of iPS-ML producing interferon-beta (iPS-ML/IFN-beta) towards primary and metastatic liver cancer and investigate the mechanism of that effect. IPS 50-53 interferon beta 1 Homo sapiens 67-82 28008721-2 2017 This study aimed to examine therapeutic effect of iPS-ML producing interferon-beta (iPS-ML/IFN-beta) towards primary and metastatic liver cancer and investigate the mechanism of that effect. IPS 50-53 interferon beta 1 Homo sapiens 91-99 28008721-2 2017 This study aimed to examine therapeutic effect of iPS-ML producing interferon-beta (iPS-ML/IFN-beta) towards primary and metastatic liver cancer and investigate the mechanism of that effect. IPS 84-87 interferon beta 1 Homo sapiens 67-82 28008721-10 2017 CONCLUSIONS: This study demonstrates the therapeutic potential of the iPS-ML/IFN-beta in patients with liver cancer. IPS 70-73 interferon beta 1 Homo sapiens 77-85 27923871-1 2017 The purpose of this work was to determine whether changes in cholesterol profiles after interferon-beta (IFN-beta)1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. Cholesterol 61-72 interferon beta 1 Homo sapiens 88-103 27188205-3 2017 MATERIALS AND METHODS: CD can convert a prodrug, 5-fluorocytosine (5-FC), to active 5-fluorouracil, which inhibits tumor growth through the inhibition of DNA synthesis,while IFN-beta also strongly inhibits tumor growth by inducing the apoptotic process. Flucytosine 49-65 interferon beta 1 Homo sapiens 174-182 27677689-0 2017 Bortezomib Enhances the Antitumor Effects of Interferon-beta Gene Transfer on Melanoma Cells. Bortezomib 0-10 interferon beta 1 Homo sapiens 45-60 27677689-7 2017 BTZ sub-pharmacological concentrations (5 nM) enhanced the cytotoxic effects of IFNbeta transgene expression on melanoma cells monolayers and spheroids. Bortezomib 0-3 interferon beta 1 Homo sapiens 80-87 27677689-10 2017 Furthermore, BTZ significantly increased the intracellular ROS generation induced by IFNbeta gene transfer in melanoma cells, an effect that was reversed by the addition of the ROS inhibitor N-acetyl-L-cystein. Bortezomib 13-16 interferon beta 1 Homo sapiens 85-92 27677689-10 2017 Furthermore, BTZ significantly increased the intracellular ROS generation induced by IFNbeta gene transfer in melanoma cells, an effect that was reversed by the addition of the ROS inhibitor N-acetyl-L-cystein. Reactive Oxygen Species 59-62 interferon beta 1 Homo sapiens 85-92 27677689-10 2017 Furthermore, BTZ significantly increased the intracellular ROS generation induced by IFNbeta gene transfer in melanoma cells, an effect that was reversed by the addition of the ROS inhibitor N-acetyl-L-cystein. Reactive Oxygen Species 177-180 interferon beta 1 Homo sapiens 85-92 27677689-10 2017 Furthermore, BTZ significantly increased the intracellular ROS generation induced by IFNbeta gene transfer in melanoma cells, an effect that was reversed by the addition of the ROS inhibitor N-acetyl-L-cystein. N-Acetyl-L-cysteine 191-209 interferon beta 1 Homo sapiens 85-92 27188205-3 2017 MATERIALS AND METHODS: CD can convert a prodrug, 5-fluorocytosine (5-FC), to active 5-fluorouracil, which inhibits tumor growth through the inhibition of DNA synthesis,while IFN-beta also strongly inhibits tumor growth by inducing the apoptotic process. Fluorouracil 84-98 interferon beta 1 Homo sapiens 174-182 28079476-7 2017 Our hypothesis based on preliminary data and published articles is that IFN-beta preferentially upregulates IRG1 in human macrophagic cells, which in turn produces itaconic acid. itaconic acid 164-177 interferon beta 1 Homo sapiens 72-80 27872213-3 2017 A recent study demonstrated that bacterial and fungal beta-glucans stimulate IFN-beta production by dendritic cells (DCs) following detection by the Dectin-1 receptor, but the effects of beta-glucan-induced type I IFNs have not been defined. beta-Glucans 54-66 interferon beta 1 Homo sapiens 77-85 27872213-3 2017 A recent study demonstrated that bacterial and fungal beta-glucans stimulate IFN-beta production by dendritic cells (DCs) following detection by the Dectin-1 receptor, but the effects of beta-glucan-induced type I IFNs have not been defined. beta-Glucans 54-65 interferon beta 1 Homo sapiens 77-85 29181127-6 2017 These results demonstrate that melatonin ameliorates OS in MS patients supporting the view that combined administration of interferon beta-1b and melatonin can be more effective in reducing OS in MS patients than interferon beta-1b alone. Melatonin 31-40 interferon beta 1 Homo sapiens 123-138 29181127-6 2017 These results demonstrate that melatonin ameliorates OS in MS patients supporting the view that combined administration of interferon beta-1b and melatonin can be more effective in reducing OS in MS patients than interferon beta-1b alone. Melatonin 31-40 interferon beta 1 Homo sapiens 213-228 29181127-6 2017 These results demonstrate that melatonin ameliorates OS in MS patients supporting the view that combined administration of interferon beta-1b and melatonin can be more effective in reducing OS in MS patients than interferon beta-1b alone. Melatonin 146-155 interferon beta 1 Homo sapiens 213-228 27426928-4 2016 Interestingly, difference from the human ELF4 (huELF4), poELF4 mutants lacking the serine/threonine rich domain, which has been demonstrated to be responsible for the phosphorylation of huELF4, were still capable of activating IFN-beta promoter. Serine 83-89 interferon beta 1 Homo sapiens 227-235 27923923-8 2016 Strikingly, we also observed abundant stretches of double-membrane sheets (a proposed intermediate of DMV formation) in IFN-beta-treated samples, suggesting the disruption of DMV biogenesis. (2R,3R)-2,3-dihydroxy-3-methylpentanoic acid 102-105 interferon beta 1 Homo sapiens 120-128 27923923-8 2016 Strikingly, we also observed abundant stretches of double-membrane sheets (a proposed intermediate of DMV formation) in IFN-beta-treated samples, suggesting the disruption of DMV biogenesis. (2R,3R)-2,3-dihydroxy-3-methylpentanoic acid 175-178 interferon beta 1 Homo sapiens 120-128 27979804-0 2016 Correction: IFN-beta Down-Regulates the Expression of DNA Repair Gene MGMT and Sensitizes Resistant Glioma Cells to Temozolomide. Temozolomide 116-128 interferon beta 1 Homo sapiens 12-20 27265253-0 2016 Interferon-beta therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. ammonium ferrous sulfate 116-119 interferon beta 1 Homo sapiens 0-15 27705941-3 2016 Overexpression of miR-22 in the cultured cells resulted in decreased activity of interferon regulatory factor-3 and nuclear factor-kappa B, which in turn led to reduced expression of interferon-beta and inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and chemokine (C-C motif) ligand 5, upon stimulation with poly(I:C), whereas knockdown of miR-22 had the opposite effect. poly 358-362 interferon beta 1 Homo sapiens 183-198 27452720-7 2016 The results showed that our recombinant sIFNAR2 protein potentiates the immunomodulatory effects of exogenous IFNbeta in CP-EAE by increasing the reduction of the induced inflammation and the tissue damage. cp-eae 121-127 interferon beta 1 Homo sapiens 110-117 27474091-10 2016 IFN-beta inhibited JNK activation and up-regulated CCh-induced ERK1/2 signalling. Carbachol 51-54 interferon beta 1 Homo sapiens 0-8 27474091-11 2016 In hippocampal neurons, Oxo-M reduced IFN-beta-induced apoptosis; this effect was antagonized by blockade of M1 /M3 receptors and ERK1/2. oxo- 24-28 interferon beta 1 Homo sapiens 38-46 27857690-0 2016 Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab. Ceramides 33-42 interferon beta 1 Homo sapiens 0-15 27857690-0 2016 Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab. Fingolimod Hydrochloride 107-117 interferon beta 1 Homo sapiens 0-15 27806057-5 2016 In multivariate Cox regression, IFNbeta-1a subcutaneous and IFNbeta-1b subcutaneous treated patients were at higher risk of ADA occurrence compared to IFNbeta-1a intramuscular-treated patients (pooled HR = 6.4, 95% CI 4.9-8.4 and pooled HR = 8.7, 95% CI 6.6-11.4 respectively). N-(2-acetamido)iminodiacetic acid 124-127 interferon beta 1 Homo sapiens 32-39 27806057-5 2016 In multivariate Cox regression, IFNbeta-1a subcutaneous and IFNbeta-1b subcutaneous treated patients were at higher risk of ADA occurrence compared to IFNbeta-1a intramuscular-treated patients (pooled HR = 6.4, 95% CI 4.9-8.4 and pooled HR = 8.7, 95% CI 6.6-11.4 respectively). N-(2-acetamido)iminodiacetic acid 124-127 interferon beta 1 Homo sapiens 60-67 27806057-5 2016 In multivariate Cox regression, IFNbeta-1a subcutaneous and IFNbeta-1b subcutaneous treated patients were at higher risk of ADA occurrence compared to IFNbeta-1a intramuscular-treated patients (pooled HR = 6.4, 95% CI 4.9-8.4 and pooled HR = 8.7, 95% CI 6.6-11.4 respectively). N-(2-acetamido)iminodiacetic acid 124-127 interferon beta 1 Homo sapiens 60-67 27806057-8 2016 Interestingly we observed that in Sweden and Germany, patients who started IFNbeta in April were at higher risk of developing ADA (HR = 1.6, 95% CI 1.1-2.4 and HR = 2.4, 95% CI 1.5-3.9 respectively). N-(2-acetamido)iminodiacetic acid 126-129 interferon beta 1 Homo sapiens 75-82 27914464-4 2016 Cell lines sensitive to IFN-beta activity also quantifying NAb level are applied because direct measurement of IFN-beta antiviral activity is complicated. nab 59-62 interferon beta 1 Homo sapiens 111-119 27914464-5 2016 This study was aimed at standardization and validation of a reporter cell system for measuring anti-human IFN-beta NAb titers, and evaluation data were obtained with samples from 33 patients with multiple sclerosis. nab 115-118 interferon beta 1 Homo sapiens 106-114 27800024-1 2016 Peginterferon beta1a is a modified form of interferon beta1a with a polyethylene glycol (PEG) group attached to the alpha-amino group of the N terminus of the interferon molecule. Polyethylene Glycols 68-87 interferon beta 1 Homo sapiens 3-19 27800024-1 2016 Peginterferon beta1a is a modified form of interferon beta1a with a polyethylene glycol (PEG) group attached to the alpha-amino group of the N terminus of the interferon molecule. Polyethylene Glycols 89-92 interferon beta 1 Homo sapiens 3-19 27852393-5 2016 Results: The mRNA levels of Acanthamoeba-induced TLR4, MyD88, NF-kappaB, TNF-alpha, IFN-beta and IL-8 in THCEs under hypoxia was down-regulated by 47%, 41%, 45%, 53%, 36% and 50% respectively, compared to control group. thces 105-110 interferon beta 1 Homo sapiens 84-92 27379765-12 2016 They also exhibited increased IFN-beta and -gamma-induced STAT1 phosphorylation that was reversed upon treatment with the JAK kinase inhibitor ruxolitinib. ruxolitinib 143-154 interferon beta 1 Homo sapiens 30-38 27586271-6 2016 Modified mRNAs (mmRNAs) containing pseudouridine and 5-methycytosine reduced TLR stimulation, cytotoxicity and IFN-beta expression in fibroblasts. Pseudouridine 35-48 interferon beta 1 Homo sapiens 111-119 27586271-6 2016 Modified mRNAs (mmRNAs) containing pseudouridine and 5-methycytosine reduced TLR stimulation, cytotoxicity and IFN-beta expression in fibroblasts. 5-methycytosine 53-68 interferon beta 1 Homo sapiens 111-119 27645024-4 2016 The complete understanding of transcriptional regulation of FAM26F is in its infancy however it is up regulated by various stimulants such as polyI:C, LPS, INF gamma and TNF alpha, and via various proposed pathways including TLR3, TLR4 IFN-beta and Dectin-1. Poly I-C 142-149 interferon beta 1 Homo sapiens 236-244 27609294-2 2016 We propose that TLR7 and TLR9 stimulation with loxorubin (LOX) and CpG, in combination with exogenous IFN-beta may effectively reconstitute endogenous IFN-beta production deficit and induce the secretion of immunoregulatory cytokines by B cells. loxorubin 47-56 interferon beta 1 Homo sapiens 151-159 27609294-2 2016 We propose that TLR7 and TLR9 stimulation with loxorubin (LOX) and CpG, in combination with exogenous IFN-beta may effectively reconstitute endogenous IFN-beta production deficit and induce the secretion of immunoregulatory cytokines by B cells. lox 58-61 interferon beta 1 Homo sapiens 151-159 27252601-0 2016 Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. Dimethyl Fumarate 43-60 interferon beta 1 Homo sapiens 79-94 27474091-3 2016 EXPERIMENTAL APPROACH: The effects of the ACh receptor agonist carbachol (CCh) on IFN-beta-induced apoptosis of human SH-SY5Y neuroblastoma cells were examined by using western blots, immunofluorescence and cytofluorimetry. Carbachol 63-72 interferon beta 1 Homo sapiens 82-90 27474091-3 2016 EXPERIMENTAL APPROACH: The effects of the ACh receptor agonist carbachol (CCh) on IFN-beta-induced apoptosis of human SH-SY5Y neuroblastoma cells were examined by using western blots, immunofluorescence and cytofluorimetry. Carbachol 74-77 interferon beta 1 Homo sapiens 82-90 27474091-7 2016 KEY RESULTS: In SH-SY5Y cells, CCh inhibited IFN-beta-induced mitochondrial cytochrome c release, activation of caspases 9, 7 and 3, PARP cleavage and DNA fragmentation. Carbachol 31-34 interferon beta 1 Homo sapiens 45-53 27468646-4 2016 CAM treatment led to a significant reduction in poly I:C- and RSV-mediated IL-8, CCL5, IFN-beta and -lambda production. Clarithromycin 0-3 interferon beta 1 Homo sapiens 87-95 27468646-4 2016 CAM treatment led to a significant reduction in poly I:C- and RSV-mediated IL-8, CCL5, IFN-beta and -lambda production. Poly I 48-54 interferon beta 1 Homo sapiens 87-95 27468646-4 2016 CAM treatment led to a significant reduction in poly I:C- and RSV-mediated IL-8, CCL5, IFN-beta and -lambda production. Carbon 0-1 interferon beta 1 Homo sapiens 87-95 27468646-5 2016 Furthermore, IFN-beta promoter activity (activated by poly I:C and RSV infection) was significantly reduced after treatment with CAM. Clarithromycin 129-132 interferon beta 1 Homo sapiens 13-21 27343364-6 2016 It was shown that only d-amino acid forms of amphipathic CPPs, penetratin and PenetraMax significantly enhanced the nasal absorption of IFN-beta. d-amino acid 23-35 interferon beta 1 Homo sapiens 136-144 27470347-0 2016 Interferon beta improves the efficacy of low dose cisplatin by inhibiting NF-kappaB/p-Akt signaling on HeLa cells. Cisplatin 50-59 interferon beta 1 Homo sapiens 0-15 27226571-8 2016 The phosphorylation of TLR3 on tyrosine 759 was shown to increase in parallel to IFN-beta production in an iNOS- and Src-dependent manner, and Src was found to directly interact with TLR3 in the endosomal compartment of poly(I:C)-treated cells. Tyrosine 31-39 interferon beta 1 Homo sapiens 81-89 27226571-8 2016 The phosphorylation of TLR3 on tyrosine 759 was shown to increase in parallel to IFN-beta production in an iNOS- and Src-dependent manner, and Src was found to directly interact with TLR3 in the endosomal compartment of poly(I:C)-treated cells. poly 220-224 interferon beta 1 Homo sapiens 81-89 27333035-5 2016 The subsequent molecular biological experiments confirmed the observed dynamics of the CTT and identified essential residues for the activation of the IFN-beta promoter, leading us to propose a new mechanism of STING activation. CTTHWGFTLC peptide 87-90 interferon beta 1 Homo sapiens 151-159 27363269-7 2016 The expressions of p-JAK2 and p-STAT3 were down-regulated while the expressions of GRIM-19 and Bax were up-regulated after treated with IFN-beta or ATRA on HepG2 cells, especially the combination of IFN-beta and ATRA. Tretinoin 148-152 interferon beta 1 Homo sapiens 199-207 27264175-4 2016 However, the STING agonist, DMXAA, induces expression of IFN-beta and other inflammatory cytokines, promotes dendritic cell (DC) maturation, and results in the striking expansion of leukemia-specific T cells. vadimezan 28-33 interferon beta 1 Homo sapiens 57-65 26635116-5 2016 Stimulation of the secretion by poly(I:C) was abolished by SB304680 (p38 inhibitor), LY294002 (PI3K inhibitor), Janus kinase (JAK) inhibitor I, RNA-activated protein kinase (PKR) inhibitor, and Bay 11-7082 (NF-kappaB inhibitor), while stimulation by IFN-beta was inhibited by all except Bay 11-7082. poly 32-36 interferon beta 1 Homo sapiens 250-258 27645339-9 2016 The risk of disability progression (3-month) was reduced by 19-28% with interferon-beta products, glatiramer acetate, fingolimod and teriflunomide, by 38-45% for pegylated interferon-beta, dimethyl fumarate and natalizumab and by 68% with alemtuzumab. Dimethyl Fumarate 189-206 interferon beta 1 Homo sapiens 72-87 26991559-9 2016 The proportion of patients with gadolinium-enhancing lesions reduced significantly during IFN beta. Gadolinium 32-42 interferon beta 1 Homo sapiens 90-98 27366230-1 2016 BACKGROUND: Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). nabs 141-145 interferon beta 1 Homo sapiens 24-39 27350308-6 2016 Azithromycin transiently increased expression of IFNbeta and IFNlambda1 and RIG-I like helicases in un-infected COPD cells. Azithromycin 0-12 interferon beta 1 Homo sapiens 49-71 27252601-2 2016 The objective of this study was to explore the safety and tolerability of DMF when administered with interferon beta (IFNbeta) or glatiramer acetate (GA). Dimethyl Fumarate 74-77 interferon beta 1 Homo sapiens 101-116 26615566-8 2016 It could be concluded that the substitution of Phe in the codon 101 position, which may increase the binding activity of IFNbeta with its receptors and introduction of an additional N glycosylation site (Asn-X-Thr) in the position 27 of IFNbeta protein may cause such an effect. asn-x-thr 204-213 interferon beta 1 Homo sapiens 237-244 26037530-0 2016 WT1 and interferon-beta-vitamin D association in MS: a longitudinal study. Vitamin D 24-33 interferon beta 1 Homo sapiens 8-23 26037530-1 2016 BACKGROUND: It has been suggested that polymorphisms in the WT1 gene modulate the effect of IFN-beta treatment in multiple sclerosis (MS) through regulation of the relationship between IFN-beta and vitamin D. Vitamin D 198-207 interferon beta 1 Homo sapiens 92-100 26037530-1 2016 BACKGROUND: It has been suggested that polymorphisms in the WT1 gene modulate the effect of IFN-beta treatment in multiple sclerosis (MS) through regulation of the relationship between IFN-beta and vitamin D. Vitamin D 198-207 interferon beta 1 Homo sapiens 185-193 26037530-5 2016 RESULTS: The mean concentrations of seasonally adjusted 25-hydroxyvitamin increased slightly (3.1 +- 1.2 nmol/l, P = 0.008) after initiation of IFN-beta. 25-hydroxyvitamin 56-73 interferon beta 1 Homo sapiens 144-152 26037530-6 2016 The association between IFN-beta treatment and 25-hydroxyvitamin D was similar in patients carrying any of the two alleles in the WT1 SNPs (rs10767935 and rs5030244) recently reported to modulate this relationship. 25-hydroxyvitamin D 47-66 interferon beta 1 Homo sapiens 24-32 26880763-5 2016 In this work, we have in vivo visualized the IFN-beta required for the antitumor immune response elicited in a therapeutic model of poly A:U administration. Poly A 132-138 interferon beta 1 Homo sapiens 45-53 26880763-7 2016 One single peritumoral dose of poly A:U was sufficient to induce IFN-beta, readily visualized in vivo. Poly A 31-37 interferon beta 1 Homo sapiens 65-73 26586642-7 2016 In addition, poly(I:C)- or Sendai virus (SeV)-induced IFN-beta expression in DEFs were significantly decreased by knock-down of duMAVS with siRNA. Poly I-C 13-21 interferon beta 1 Homo sapiens 54-62 26848042-9 2016 IFN-beta knockdown decreased the poly (I:C)-induced production of ROS and DNA damage, restored Psim and cytochrome c release, and suppressed caspase-9 and -3 activation, thereby suppressing poly (I:C)-mediated apoptosis in the HeLa cells. Poly I-C 33-43 interferon beta 1 Homo sapiens 0-8 26848042-9 2016 IFN-beta knockdown decreased the poly (I:C)-induced production of ROS and DNA damage, restored Psim and cytochrome c release, and suppressed caspase-9 and -3 activation, thereby suppressing poly (I:C)-mediated apoptosis in the HeLa cells. Reactive Oxygen Species 66-69 interferon beta 1 Homo sapiens 0-8 26848042-9 2016 IFN-beta knockdown decreased the poly (I:C)-induced production of ROS and DNA damage, restored Psim and cytochrome c release, and suppressed caspase-9 and -3 activation, thereby suppressing poly (I:C)-mediated apoptosis in the HeLa cells. Poly I-C 191-201 interferon beta 1 Homo sapiens 0-8 26848042-10 2016 Together, the results of the present study demonstrated that poly (I:C) transfection induced IFN-beta, contributing to ROS production, DNA damage, and caspase-9 and -3 activation in the HeLa cervical cancer cell line, leading to mitochondrial-mediated apoptosis. Reactive Oxygen Species 119-122 interferon beta 1 Homo sapiens 93-101 27006698-0 2016 Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease. fludarabine 0-11 interferon beta 1 Homo sapiens 30-45 26931196-16 2016 Treatment response to interferon-beta, expressed in relapse rate was independently influenced by gender and the presence of NAbs, but it seems that the presence of NAbs does not affect the treatment effect differently in women and men. nabs 124-128 interferon beta 1 Homo sapiens 22-37 26779831-1 2016 Neutralizing anti-drug antibodies (NAbs) against therapeutic interferon beta (IFNbeta) in people with multiple sclerosis (MS) are measured with cell-based bioassays. nabs 35-39 interferon beta 1 Homo sapiens 61-76 27063624-2 2016 Aim of this work was to quantitatively summarize by a meta-analysis the long-term impact of immunomodulatory drugs (Interferon-Beta (IFN-beta) or Glatiramer Acetate (GA)) in relapsing-remitting (RR) MS patients. Glatiramer Acetate 166-168 interferon beta 1 Homo sapiens 116-131 26615566-8 2016 It could be concluded that the substitution of Phe in the codon 101 position, which may increase the binding activity of IFNbeta with its receptors and introduction of an additional N glycosylation site (Asn-X-Thr) in the position 27 of IFNbeta protein may cause such an effect. Phenylalanine 47-50 interferon beta 1 Homo sapiens 121-128 26615566-8 2016 It could be concluded that the substitution of Phe in the codon 101 position, which may increase the binding activity of IFNbeta with its receptors and introduction of an additional N glycosylation site (Asn-X-Thr) in the position 27 of IFNbeta protein may cause such an effect. Phenylalanine 47-50 interferon beta 1 Homo sapiens 237-244 26485167-5 2016 In particular, the amount of IFN-beta released by LH hydrogels was significantly increased by 2.5-fold compared to that released by conventional cationic liposomes, such as Lipofectamine. Lipofectamine 173-186 interferon beta 1 Homo sapiens 29-37 26485167-4 2016 LH gels incorporating cGAMP (LH/cGAMP gels) elicited excellent induction of the cytokines interferon-beta (IFN-beta) and interleukin-6 (IL-6). cyclic guanosine monophosphate-adenosine monophosphate 22-27 interferon beta 1 Homo sapiens 90-105 26485167-4 2016 LH gels incorporating cGAMP (LH/cGAMP gels) elicited excellent induction of the cytokines interferon-beta (IFN-beta) and interleukin-6 (IL-6). cyclic guanosine monophosphate-adenosine monophosphate 22-27 interferon beta 1 Homo sapiens 107-115 26485167-4 2016 LH gels incorporating cGAMP (LH/cGAMP gels) elicited excellent induction of the cytokines interferon-beta (IFN-beta) and interleukin-6 (IL-6). Luteinizing Hormone 0-2 interferon beta 1 Homo sapiens 90-105 26485167-4 2016 LH gels incorporating cGAMP (LH/cGAMP gels) elicited excellent induction of the cytokines interferon-beta (IFN-beta) and interleukin-6 (IL-6). Luteinizing Hormone 0-2 interferon beta 1 Homo sapiens 107-115 26485167-4 2016 LH gels incorporating cGAMP (LH/cGAMP gels) elicited excellent induction of the cytokines interferon-beta (IFN-beta) and interleukin-6 (IL-6). cyclic guanosine monophosphate-adenosine monophosphate 32-37 interferon beta 1 Homo sapiens 90-105 26485167-4 2016 LH gels incorporating cGAMP (LH/cGAMP gels) elicited excellent induction of the cytokines interferon-beta (IFN-beta) and interleukin-6 (IL-6). cyclic guanosine monophosphate-adenosine monophosphate 32-37 interferon beta 1 Homo sapiens 107-115 27753028-1 2016 Oligodeoxynucleotide (ODN) analogues of cell-surface-bound circulating DNA inhibit the dsRNA-induced production of pro-inflammatory interleukin 6, interferon beta and antibacterial peptide beta-defensin 2 not only in human gingival fibroblasts, but also in human primary endothelial and transformed cells (Hela and A431). Oligodeoxyribonucleotides 0-20 interferon beta 1 Homo sapiens 147-162 27753028-1 2016 Oligodeoxynucleotide (ODN) analogues of cell-surface-bound circulating DNA inhibit the dsRNA-induced production of pro-inflammatory interleukin 6, interferon beta and antibacterial peptide beta-defensin 2 not only in human gingival fibroblasts, but also in human primary endothelial and transformed cells (Hela and A431). Oligodeoxyribonucleotides 22-25 interferon beta 1 Homo sapiens 147-162 26867030-0 2016 The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies. Methylprednisolone 14-32 interferon beta 1 Homo sapiens 102-117 26867030-1 2016 BACKGROUND/AIMS: We assessed the, hitherto unknown, impact of intravenous methylprednisolone (ivMP) pulses during relapses of multiple sclerosis (MS) on the kinetics of anti-interferon-beta neutralizing antibodies (Nabs) and binding antibodies (Babs). Methylprednisolone 74-92 interferon beta 1 Homo sapiens 174-189 26867030-1 2016 BACKGROUND/AIMS: We assessed the, hitherto unknown, impact of intravenous methylprednisolone (ivMP) pulses during relapses of multiple sclerosis (MS) on the kinetics of anti-interferon-beta neutralizing antibodies (Nabs) and binding antibodies (Babs). ivmp 94-98 interferon beta 1 Homo sapiens 174-189 26584874-1 2016 Key teaching points SAVI is a recently described interferonopathy resulting from constitutive action of STING and up-regulation of IFN-beta signaling. savi 22-26 interferon beta 1 Homo sapiens 133-141 26475277-1 2015 OBJECTIVE: The Escala Study evidenced that the administration of glatiramer acetate for relapsing-remitting multiple sclerosis improved the spasticity of patients previously treated with interferon-beta. Glatiramer Acetate 65-83 interferon beta 1 Homo sapiens 187-202 26653542-6 2015 Pretreatment with LPS for more than 2h shows inhibitory effect on IFN-beta-induced STAT1 phosphorylation but simultaneous treatment or post-treatment of LPS with IFN-beta did not show the inhibitory effect. Deuterium 36-38 interferon beta 1 Homo sapiens 66-74 26476109-8 2015 EtTollip significantly inhibited the activities of NF-kappaB and IFN-beta luciferase reporter when transfected into grouper spleen (GS) cells. ettollip 0-8 interferon beta 1 Homo sapiens 65-73 26476109-10 2015 When transfected EtTollip with EcMyd88, the activity of NF-kappaB was increased, while transfected EtTollip with EcIRF3, the activity of IFN-beta was significantly increased. ettollip 17-25 interferon beta 1 Homo sapiens 137-145 26246404-0 2015 Sphingosine-1-phosphate inhibits IL-1-induced expression of C-C motif ligand 5 via c-Fos-dependent suppression of IFN-beta amplification loop. sphingosine 1-phosphate 0-23 interferon beta 1 Homo sapiens 114-122 26475277-10 2015 The ratio of the costs during interferon-beta was 1.5 times the costs during glatiramer acetate; thus, a fixed budget of 5,000,000$ would enable 1,070 patients to be treated with glatiramer acetate and only 706 patients with interferon-beta. Glatiramer Acetate 179-197 interferon beta 1 Homo sapiens 30-45 26439457-0 2015 Cysteine as a Monothiol Reducing Agent to Prevent Copper-Mediated Oxidation of Interferon Beta During PEGylation by CuAAC. Cysteine 0-8 interferon beta 1 Homo sapiens 79-94 26277401-4 2015 We found that treatment of murine bone marrow-derived cells (BMCs) and human peripheral blood mononuclear cells with BPA induced the expression of ERalpha and IFN-beta, activated the IFN-signaling, and stimulated the expression of the p202 and IFI16 proteins. bisphenol A 117-120 interferon beta 1 Homo sapiens 159-167 26440888-1 2015 Upon DNA stimulation, cyclic GMP-AMP synthase (cGAS) synthesizes the second messenger cyclic GMP-AMP (cGAMP) that binds to the STING, triggering antiviral interferon-beta (IFN-beta) production. cyclic guanosine monophosphate-adenosine monophosphate 22-36 interferon beta 1 Homo sapiens 155-170 26440888-1 2015 Upon DNA stimulation, cyclic GMP-AMP synthase (cGAS) synthesizes the second messenger cyclic GMP-AMP (cGAMP) that binds to the STING, triggering antiviral interferon-beta (IFN-beta) production. cyclic guanosine monophosphate-adenosine monophosphate 22-36 interferon beta 1 Homo sapiens 172-180 26440888-1 2015 Upon DNA stimulation, cyclic GMP-AMP synthase (cGAS) synthesizes the second messenger cyclic GMP-AMP (cGAMP) that binds to the STING, triggering antiviral interferon-beta (IFN-beta) production. cyclic guanosine monophosphate-adenosine monophosphate 102-107 interferon beta 1 Homo sapiens 155-170 26440888-1 2015 Upon DNA stimulation, cyclic GMP-AMP synthase (cGAS) synthesizes the second messenger cyclic GMP-AMP (cGAMP) that binds to the STING, triggering antiviral interferon-beta (IFN-beta) production. cyclic guanosine monophosphate-adenosine monophosphate 102-107 interferon beta 1 Homo sapiens 172-180 26374509-3 2015 Approximately 30% of patients treated with first-line immunomodulators (interferon-beta or glatiramer acetate) show a suboptimal response during the first 1-2 years and require a switch to an alternative therapy. Glatiramer Acetate 91-109 interferon beta 1 Homo sapiens 72-87 26439457-0 2015 Cysteine as a Monothiol Reducing Agent to Prevent Copper-Mediated Oxidation of Interferon Beta During PEGylation by CuAAC. monothiol 14-23 interferon beta 1 Homo sapiens 79-94 26439457-0 2015 Cysteine as a Monothiol Reducing Agent to Prevent Copper-Mediated Oxidation of Interferon Beta During PEGylation by CuAAC. Copper 50-56 interferon beta 1 Homo sapiens 79-94 26439457-3 2015 We investigated whether PEGylation by CuAAC caused any modifications to the therapeutic protein interferon beta-1b, which was produced via global amino acid substitution with azidohomo-alanine at the N-terminus and contains no methionine residues. azidohomoalanine 175-192 interferon beta 1 Homo sapiens 96-111 26283481-0 2015 Stimulation of the RIG-I/MAVS Pathway by Polyinosinic:Polycytidylic Acid Upregulates IFN-beta in Airway Epithelial Cells with Minimal Costimulation of IL-8. Poly C 54-72 interferon beta 1 Homo sapiens 85-93 26283481-2 2015 Polyinosinic-polycytidylic acid [poly(I:C)] is a known inducer of IFN-beta but also costimulates an inflammatory response. Poly I-C 0-31 interferon beta 1 Homo sapiens 66-74 26283481-2 2015 Polyinosinic-polycytidylic acid [poly(I:C)] is a known inducer of IFN-beta but also costimulates an inflammatory response. Poly I-C 33-42 interferon beta 1 Homo sapiens 66-74 26283481-6 2015 Using cell lines and primary airway epithelial cells (both submerged and well-differentiated), we observed that pure poly(I:C) stimulated IFN-beta mainly through the TLR3/TRIF pathway and IL-8 through an unidentified pathway. poly 117-121 interferon beta 1 Homo sapiens 138-146 26283481-9 2015 In contrast, we show that stimulation of the RIG-I/MAVS pathway, such as when poly(I:C) is delivered intracellularly in a complex with liposomes or via nucleofection, selectively stimulates IFN-beta with low IL-8 costimulation. Poly I-C 78-87 interferon beta 1 Homo sapiens 190-198 26283481-11 2015 In conclusion, it is feasible to augment IFN-beta production in airway epithelial cells without excessive costimulation of IL-8 if the RIG-I/MAVS pathway is stimulated, such as via liposomal delivery of poly(I:C). poly 203-207 interferon beta 1 Homo sapiens 41-49 25480861-3 2015 METHODS: Intracellular adenosine triphosphate (iATP) in phytohemagglutinin (PHA)-stimulated CD4(+) cells of multiple sclerosis (MS) patients treated with IFN-beta and controls were analyzed in a luciferase-based assay. Adenosine Triphosphate 23-45 interferon beta 1 Homo sapiens 154-162 25480861-3 2015 METHODS: Intracellular adenosine triphosphate (iATP) in phytohemagglutinin (PHA)-stimulated CD4(+) cells of multiple sclerosis (MS) patients treated with IFN-beta and controls were analyzed in a luciferase-based assay. iatp 47-51 interferon beta 1 Homo sapiens 154-162 25480861-6 2015 RESULTS: IFN-beta-treated MS patients exhibited a dose-dependent reduction of iATP levels in CD4(+) T cells compared to controls (p < 0.001). iatp 78-82 interferon beta 1 Homo sapiens 9-17 25480861-9 2015 iATP levels in IFN-beta-responders were reduced compared to non-responders (p < 0.05), and the major T allele of the SNP rs7665116 of PGC-1alpha correlated with iATP-levels. iatp 0-4 interferon beta 1 Homo sapiens 15-23 25480861-9 2015 iATP levels in IFN-beta-responders were reduced compared to non-responders (p < 0.05), and the major T allele of the SNP rs7665116 of PGC-1alpha correlated with iATP-levels. iatp 164-168 interferon beta 1 Homo sapiens 15-23 26001632-11 2015 Finally, we observed that expression of interferon beta (IFN-beta) was increased in Bortezomib treated cells which indicated that the cellular antiviral mechanism was revived as a result of treatment and may contribute to control of viral multiplication. Bortezomib 84-94 interferon beta 1 Homo sapiens 40-55 26243192-3 2015 We showed that the mitogen-activated protein kinase (MAPK) kinase kinase (MAPKKK) apoptosis signal-regulating kinase 1 (ASK1) was activated in cells by the synthetic double-stranded RNA analog polyinosinic:polycytidylic acid [poly(I:C)] and by RNA viruses, and that ASK1 played an essential role in both the induction of the gene encoding IFN-beta (IFNB) and apoptotic cell death. Poly C 206-224 interferon beta 1 Homo sapiens 339-347 26243192-3 2015 We showed that the mitogen-activated protein kinase (MAPK) kinase kinase (MAPKKK) apoptosis signal-regulating kinase 1 (ASK1) was activated in cells by the synthetic double-stranded RNA analog polyinosinic:polycytidylic acid [poly(I:C)] and by RNA viruses, and that ASK1 played an essential role in both the induction of the gene encoding IFN-beta (IFNB) and apoptotic cell death. Poly C 206-224 interferon beta 1 Homo sapiens 349-353 26001632-11 2015 Finally, we observed that expression of interferon beta (IFN-beta) was increased in Bortezomib treated cells which indicated that the cellular antiviral mechanism was revived as a result of treatment and may contribute to control of viral multiplication. Bortezomib 84-94 interferon beta 1 Homo sapiens 57-65 25850711-6 2015 We also demonstrated that dynasore-induced activation of JNK occurs downstream of MAVS and is required for activation of NF-kappaB and IFN-beta. N'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide 26-34 interferon beta 1 Homo sapiens 135-143 25822580-4 2015 Co-stimulation with IFN-gamma and the TLR3 ligand poly (I:C) synergistically increased the expression of IFN-beta, IL-6, IL-8, and human beta-defensin-2 in NHEKs compared with poly (I:C) or IFN-gamma alone. poly 50-54 interferon beta 1 Homo sapiens 105-113 25822580-4 2015 Co-stimulation with IFN-gamma and the TLR3 ligand poly (I:C) synergistically increased the expression of IFN-beta, IL-6, IL-8, and human beta-defensin-2 in NHEKs compared with poly (I:C) or IFN-gamma alone. Iodine 20-21 interferon beta 1 Homo sapiens 105-113 25822580-4 2015 Co-stimulation with IFN-gamma and the TLR3 ligand poly (I:C) synergistically increased the expression of IFN-beta, IL-6, IL-8, and human beta-defensin-2 in NHEKs compared with poly (I:C) or IFN-gamma alone. Carbon 0-1 interferon beta 1 Homo sapiens 105-113 26193267-9 2015 Our data reveals that interferon-beta therapy improves the immunoregulation of autoaggressive T effector cells in MS patients by changing the IL-6 signal transduction pathway, thus restoring their sensitivity to Treg-mediated suppression. treg 212-216 interferon beta 1 Homo sapiens 22-37 25662354-0 2015 Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study. Vitamin K 0-9 interferon beta 1 Homo sapiens 138-153 26339361-7 2015 Finally, MTT assays demonstrated that DU145 cells growth slowed down, flow cytometry demonstrated that IFN-beta induced apoptosis increased from 0.0343 +- 0.0039 to 0.0612 + 0.0025 in DU145 prostate cancer cells. monooxyethylene trimethylolpropane tristearate 9-12 interferon beta 1 Homo sapiens 103-111 25869642-5 2015 Using IFN-beta reporter mice, we showed that direct administration of polyinosinic-polycytidylic acid (poly I:C), a potent inducer of IFN-beta, into the cerebrospinal fluid induced increased leukocyte numbers and transient upregulation of IFN-beta in CD45/CD11b-positive cells located in the meninges and choroid plexus, as well as enhanced IFN-beta expression by parenchymal microglial cells. Poly I-C 70-101 interferon beta 1 Homo sapiens 134-142 25869642-5 2015 Using IFN-beta reporter mice, we showed that direct administration of polyinosinic-polycytidylic acid (poly I:C), a potent inducer of IFN-beta, into the cerebrospinal fluid induced increased leukocyte numbers and transient upregulation of IFN-beta in CD45/CD11b-positive cells located in the meninges and choroid plexus, as well as enhanced IFN-beta expression by parenchymal microglial cells. Poly I-C 103-111 interferon beta 1 Homo sapiens 134-142 26054674-9 2015 The lower cytoplasmatic levels of reactive oxygen species detected after intracellular IFNbeta expression could be related to the resistance displayed by one human melanoma cell line. Reactive Oxygen Species 34-57 interferon beta 1 Homo sapiens 87-94 26171205-0 2015 Interferon-beta and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas. Temozolomide 57-69 interferon beta 1 Homo sapiens 0-15 26083387-4 2015 Kdm5b-specific siRNA inhibition in BMDC led to a 10-fold increase in IFN-beta as well as increases in IL-6 and TNF-alpha compared to control-transfected cells. bmdc 35-39 interferon beta 1 Homo sapiens 69-77 26056458-4 2015 The use of subcutaneous polyethylene glycol (PEG)ylated interferon beta-1a (PEG-IFN) has been proposed to offer a better combination of pharmacokinetic and pharmacodynamic profiles and therapy-related side effects. Polyethylene Glycols 24-43 interferon beta 1 Homo sapiens 56-71 26056458-4 2015 The use of subcutaneous polyethylene glycol (PEG)ylated interferon beta-1a (PEG-IFN) has been proposed to offer a better combination of pharmacokinetic and pharmacodynamic profiles and therapy-related side effects. peg-ifn 76-83 interferon beta 1 Homo sapiens 56-71 25963746-12 2015 5-FU increased the IFN-beta/receptor 2 (IFNAR2) and BXA levels, indicating that 5-FU increased sensitivity of endometrial cancer cells to IFN-beta, leading to apoptosis of cancer cells. Fluorouracil 0-4 interferon beta 1 Homo sapiens 19-27 25963746-12 2015 5-FU increased the IFN-beta/receptor 2 (IFNAR2) and BXA levels, indicating that 5-FU increased sensitivity of endometrial cancer cells to IFN-beta, leading to apoptosis of cancer cells. Fluorouracil 80-84 interferon beta 1 Homo sapiens 19-27 25891802-1 2015 PLK (Polo-like kinase) inhibitors, such as BI-2536, have been reported to suppress IFNB (encoding IFNbeta, interferon beta) gene transcription induced by ligands that activate TLR3 (Toll-like receptor 3) and TLR4. BI 2536 43-50 interferon beta 1 Homo sapiens 83-87 25891802-1 2015 PLK (Polo-like kinase) inhibitors, such as BI-2536, have been reported to suppress IFNB (encoding IFNbeta, interferon beta) gene transcription induced by ligands that activate TLR3 (Toll-like receptor 3) and TLR4. BI 2536 43-50 interferon beta 1 Homo sapiens 98-122 25891802-4 2015 We found that BET inhibitors that do not inhibit PLKs phenocopied the effect of BI-2536 on IFNB gene transcription. BI 2536 80-87 interferon beta 1 Homo sapiens 91-95 25803620-5 2015 Both intracellular and extracellular poly(I:C) induced the expression of IFNB, TNF, IL6, and IL8. Poly I-C 37-45 interferon beta 1 Homo sapiens 73-77 26023670-11 2015 CONCLUSION: Long (27-nucleotides) siRNAs targeting E6-E7 mRNAs effectively reduce the viability of HPV18-positive cervical cancer cells and show the synergistic effect in combination with IFN-b and thimerosal. 27-nucleotides 18-32 interferon beta 1 Homo sapiens 188-193 25824620-8 2015 The authors show that ELAVL1/HuR is required for the stabilization of IFN-beta mRNA, and suppression of ELAVL1/HuR by its inhibitor MS-444 leads to impaired expression of IFN-beta in response to viral dsRNA treatment. 5,8-dihydroxy-3-methyl-4-(9H)-naphtho(2,3-c)furanone 132-138 interferon beta 1 Homo sapiens 171-179 25817178-0 2015 Irbesartan attenuates production of high-mobility group box 1 in response to lipopolysaccharide via downregulation of interferon-beta production. Irbesartan 0-10 interferon beta 1 Homo sapiens 118-133 26023670-11 2015 CONCLUSION: Long (27-nucleotides) siRNAs targeting E6-E7 mRNAs effectively reduce the viability of HPV18-positive cervical cancer cells and show the synergistic effect in combination with IFN-b and thimerosal. Thimerosal 198-208 interferon beta 1 Homo sapiens 188-193 25312909-0 2015 Modulating effects of WT1 on interferon-beta-vitamin D association in MS. Vitamin D 45-54 interferon beta 1 Homo sapiens 29-44 25860871-9 2015 These findings suggest that PGG and PA may block or reduce the entry of the viruses into the cells to protect the cells from the virus destruction and abate virus replication, which may play an important role in interfering with expressions of rhinovirus receptors (intercellular adhesion molecule-1 and low-density lipoprotein receptor), inflammatory cytokines (interleukin (IL)-6, IL-8, tumor necrosis factor, interferon beta, and IL-1beta), and Toll-like receptor, which resulted in diminishing symptoms induced by HRV. pgg 28-31 interferon beta 1 Homo sapiens 412-427 25860871-9 2015 These findings suggest that PGG and PA may block or reduce the entry of the viruses into the cells to protect the cells from the virus destruction and abate virus replication, which may play an important role in interfering with expressions of rhinovirus receptors (intercellular adhesion molecule-1 and low-density lipoprotein receptor), inflammatory cytokines (interleukin (IL)-6, IL-8, tumor necrosis factor, interferon beta, and IL-1beta), and Toll-like receptor, which resulted in diminishing symptoms induced by HRV. paeonol 36-38 interferon beta 1 Homo sapiens 412-427 25680291-7 2015 Furthermore, IFN-beta was induced by polyI:C and VSV in both bat and mouse cells. Poly I-C 37-44 interferon beta 1 Homo sapiens 13-21 25312909-1 2015 OBJECTIVE: To investigate whether those genes involved in the vitamin D pathway modulate the relationship between 25-hydroxyvitamin D (25(OH)D) and IFN-beta, the relationship between IFN-beta and sun in predicting 25(OH)D, and the interaction between IFN-beta and 25(OH)D in modulating relapse risk in patients with MS. METHODS: Prospective cohort study of 169 participants with MS and genotype data followed 2002-2005. Vitamin D 62-71 interferon beta 1 Homo sapiens 148-156 25312909-1 2015 OBJECTIVE: To investigate whether those genes involved in the vitamin D pathway modulate the relationship between 25-hydroxyvitamin D (25(OH)D) and IFN-beta, the relationship between IFN-beta and sun in predicting 25(OH)D, and the interaction between IFN-beta and 25(OH)D in modulating relapse risk in patients with MS. METHODS: Prospective cohort study of 169 participants with MS and genotype data followed 2002-2005. 25-hydroxyvitamin D 114-133 interferon beta 1 Homo sapiens 148-156 25312909-10 2015 These findings indicate that WT1 variants may play a role in altering the effects of IFN-beta on vitamin D in MS. Vitamin D 97-106 interferon beta 1 Homo sapiens 85-93 25712217-4 2015 In this study, we demonstrate that productive HSV-2 infection suppresses Sendai virus (SeV) or polyinosinic-polycytidylic acid-induced IFN-beta production. Poly I-C 95-126 interferon beta 1 Homo sapiens 135-143 25515776-6 2015 Poly(dA:dT) induced the expression of pro-inflammatory cytokine genes including IFN-beta, TNF-alpha, IL-6 and IL-8 as well, whereas the pro-inflammatory cytokine production was suppressed by RIG-I siRNA, but not by AIM2 siRNA. poly 0-4 interferon beta 1 Homo sapiens 80-88 25515776-6 2015 Poly(dA:dT) induced the expression of pro-inflammatory cytokine genes including IFN-beta, TNF-alpha, IL-6 and IL-8 as well, whereas the pro-inflammatory cytokine production was suppressed by RIG-I siRNA, but not by AIM2 siRNA. amsonic acid 5-7 interferon beta 1 Homo sapiens 80-88 25515776-6 2015 Poly(dA:dT) induced the expression of pro-inflammatory cytokine genes including IFN-beta, TNF-alpha, IL-6 and IL-8 as well, whereas the pro-inflammatory cytokine production was suppressed by RIG-I siRNA, but not by AIM2 siRNA. Thymidine 8-10 interferon beta 1 Homo sapiens 80-88 25463536-7 2015 RESULTS: We show that macrocyclic NS3-4A RAVS with substitutions at residue D168 of the protease result in an increased capacity of NS3-4A to cleave MAVS and suppress IFN-beta induction compared with a comprehensive panel of RAVs and wild type HCV. d168 76-80 interferon beta 1 Homo sapiens 167-175 25609843-7 2015 Knockdown of the constitutively expressed DNA sensor DDX41 attenuates poly(dA:dT)-triggered IFN-beta production and cGAS induction. poly 70-74 interferon beta 1 Homo sapiens 92-100 25546031-1 2015 OBJECTIVE: In patients suffering multiple sclerosis activity despite treatment with interferon beta or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. Fingolimod Hydrochloride 180-190 interferon beta 1 Homo sapiens 84-99 25573804-0 2015 Heparan sulfate proteoglycans fine-tune macrophage inflammation via IFN-beta. Heparitin Sulfate 0-15 interferon beta 1 Homo sapiens 68-76 25646307-5 2015 IFN-beta treatment increases the absolute number of regulatory CD19(+)CD24(++)CD38(++) transitional B cells in peripheral blood relative to treatment-naive and Copaxone-treated patients. Glatiramer Acetate 160-168 interferon beta 1 Homo sapiens 0-8 25544388-3 2015 In the current work, human interferon beta (huIFN-beta) was used as a model to identify the potential positions for the addition of new N-glycosylation sites. Nitrogen 48-49 interferon beta 1 Homo sapiens 27-42 25609843-7 2015 Knockdown of the constitutively expressed DNA sensor DDX41 attenuates poly(dA:dT)-triggered IFN-beta production and cGAS induction. amsonic acid 75-77 interferon beta 1 Homo sapiens 92-100 25609843-7 2015 Knockdown of the constitutively expressed DNA sensor DDX41 attenuates poly(dA:dT)-triggered IFN-beta production and cGAS induction. Thymidine 78-80 interferon beta 1 Homo sapiens 92-100 25609843-8 2015 By analyzing the dynamic expression of poly(dA:dT)-induced IFN-beta and cGAS transcripts, we have found that induction of IFN-beta is earlier than cGAS. poly 39-43 interferon beta 1 Homo sapiens 59-67 25609843-8 2015 By analyzing the dynamic expression of poly(dA:dT)-induced IFN-beta and cGAS transcripts, we have found that induction of IFN-beta is earlier than cGAS. poly 39-43 interferon beta 1 Homo sapiens 122-130 25609843-8 2015 By analyzing the dynamic expression of poly(dA:dT)-induced IFN-beta and cGAS transcripts, we have found that induction of IFN-beta is earlier than cGAS. amsonic acid 44-46 interferon beta 1 Homo sapiens 59-67 25609843-8 2015 By analyzing the dynamic expression of poly(dA:dT)-induced IFN-beta and cGAS transcripts, we have found that induction of IFN-beta is earlier than cGAS. amsonic acid 44-46 interferon beta 1 Homo sapiens 122-130 25609843-8 2015 By analyzing the dynamic expression of poly(dA:dT)-induced IFN-beta and cGAS transcripts, we have found that induction of IFN-beta is earlier than cGAS. Thymidine 47-49 interferon beta 1 Homo sapiens 59-67 25609843-8 2015 By analyzing the dynamic expression of poly(dA:dT)-induced IFN-beta and cGAS transcripts, we have found that induction of IFN-beta is earlier than cGAS. Thymidine 47-49 interferon beta 1 Homo sapiens 122-130 25208455-6 2014 RESULTS: NAbs significantly abrogated the interferon-beta treatment efficacy in both genders. nabs 9-13 interferon beta 1 Homo sapiens 42-57 25666445-1 2015 Peginterferon beta-1a (Plegridy ), an interferon beta-1a conjugated to a methoxy polyethylene glycol (PEG) molecule, is available in the EU and the USA for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS). monomethoxypolyethylene glycol 73-100 interferon beta 1 Homo sapiens 3-18 25666445-1 2015 Peginterferon beta-1a (Plegridy ), an interferon beta-1a conjugated to a methoxy polyethylene glycol (PEG) molecule, is available in the EU and the USA for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS). Polyethylene Glycols 102-105 interferon beta 1 Homo sapiens 3-18 25158146-6 2015 Our results show that Sendai virus infection, which is recognized by RIG-I, led to IRF3 activation and IFN-beta expression and these responses were attenuated by the PI3K inhibitor (LY294002) and an Akt dominant-negative mutant in the macrophage cell line(RAW264.7). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 182-190 interferon beta 1 Homo sapiens 103-111 25158146-7 2015 IRF3 phosphorylation and dimerization as well as IFN-beta expression induced by a synthetic RIG-I agonist, short poly(I:C), were suppressed by LY294002 or siRNA-Akt in bone marrow-derived macrophages. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 143-151 interferon beta 1 Homo sapiens 49-57 25169051-0 2015 Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-beta: a longitudinal study in multiple sclerosis patients. Endocannabinoids 55-70 interferon beta 1 Homo sapiens 103-118 25461845-5 2015 In addition, retinoic acid inducible gene-I (RIG-I) and melanoma differentiation associated gene-5 (MDA5) play key roles in the detection of HTNV infection in HaCaT cells and in the up-regulation of interferon (IFN)-beta expression, which subsequently leads to the production of a large amount of antiviral interferon-stimulated genes (ISGs) and other chemokines used for immune cell recruitment. Tretinoin 13-26 interferon beta 1 Homo sapiens 199-220 26725862-4 2015 Therefore, we assumed that IFN-beta-nonresponsive patients with MS may have the similar B-cell abnormality and found an expansion of circulating PBs in these nonresponders. Lead 145-148 interferon beta 1 Homo sapiens 27-35 27118332-2 2015 We have recently shown that lactic acid bacteria (LAB), a major population of small intestinal microbiota and often found in fermented foods, contain a large amount of double-stranded RNA and capable of inducing interferon-beta (IFN-beta) production from dendritic cells (DCs) via the Toll-like receptor 3 (TLR3) pathway. Lactic Acid 28-39 interferon beta 1 Homo sapiens 212-227 27118332-2 2015 We have recently shown that lactic acid bacteria (LAB), a major population of small intestinal microbiota and often found in fermented foods, contain a large amount of double-stranded RNA and capable of inducing interferon-beta (IFN-beta) production from dendritic cells (DCs) via the Toll-like receptor 3 (TLR3) pathway. Lactic Acid 28-39 interferon beta 1 Homo sapiens 229-237 25117008-3 2015 The present study reports the enrichment of IFN-beta-1a glycoforms and their physicochemical and biological characterization by means of electrospray ionization-mass spectrometry, sialic acid content, thermal denaturation and various in vitro bioassays (antiproliferative, antiviral, immunomodulatory and reporter gene assay). N-Acetylneuraminic Acid 180-191 interferon beta 1 Homo sapiens 44-52 25802758-7 2015 At 48 months the mean standard deviation number of new CLs was significantly lower in patients treated with sc IFN beta-1a (1.4 +- 1.0, range 0-5) compared with im IFN beta-1a (2.3 +- 1.3, range 0-6, P = 0.004) and glatiramer acetate (2.2 +- 1.5, range 0-7, P = 0.03). calusterone 55-58 interferon beta 1 Homo sapiens 111-119 25375896-7 2014 Downregulation of c-Fos protein and induction of Ifnbeta mRNA in osteoclasts, both of which reportedly block osteoclastogenesis induced by 1,25(OH)2D3 in vitro, were both significantly higher following treatment with 1,25(OH)2D3 than with ED71. Calcitriol 217-228 interferon beta 1 Homo sapiens 49-56 25366113-0 2014 Multiple sclerosis: effects of IFN-beta treatment on vitamin D levels in multiple sclerosis are modified by genetic variants. Vitamin D 53-62 interferon beta 1 Homo sapiens 31-39 25158919-9 2014 Interferon beta (100-2500 IU/mL) and Cisplatin (0.01-100 muM) had an inhibitory effect on the proliferation of cancer cells in a dose-dependent manner, with the IC50 values at 1500 IU/mL and 20 muM for interferon beta and cisplatin, respectively. Cisplatin 37-46 interferon beta 1 Homo sapiens 202-217 25158919-9 2014 Interferon beta (100-2500 IU/mL) and Cisplatin (0.01-100 muM) had an inhibitory effect on the proliferation of cancer cells in a dose-dependent manner, with the IC50 values at 1500 IU/mL and 20 muM for interferon beta and cisplatin, respectively. Cisplatin 222-231 interferon beta 1 Homo sapiens 0-15 25158919-11 2014 More interestingly, synergistic, cytotoxic and genotoxic effects were observed after treatment with a combination of interferon beta with reduced dosage of cisplatin. Cisplatin 156-165 interferon beta 1 Homo sapiens 117-132 27200940-0 2014 Cost-Effectiveness of Subcutaneous Verse Intramuscular Interferon Beta-1A In Portugal Based on the Findings of Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis. verse 35-40 interferon beta 1 Homo sapiens 55-72 25143264-4 2014 Recent studies reveal that cytosolic DNA sensing via the STING/IFN-beta pathway induces indoleamine 2,3 dioxygenase (IDO), which catabolizes tryptophan to suppress effector and helper T-cell responses and activate Foxp3-lineage CD4(+) regulatory T (Treg) cells. Tryptophan 141-151 interferon beta 1 Homo sapiens 63-71 25375896-7 2014 Downregulation of c-Fos protein and induction of Ifnbeta mRNA in osteoclasts, both of which reportedly block osteoclastogenesis induced by 1,25(OH)2D3 in vitro, were both significantly higher following treatment with 1,25(OH)2D3 than with ED71. Calcitriol 139-150 interferon beta 1 Homo sapiens 49-56 25086905-3 2014 We show that in SH-SY5Y human neuroblastoma cells IFN-beta induced a delayed and sustained increase of p38 MAPK activity through a novel mechanism involving the sequential activation of Janus kinase-signal transducer and activator of transcription-1 signalling, enhanced expression of the NADPH oxidase catalytic subunit gp91(phox), increased reactive oxygen species production and stimulation of the MAPK kinase kinase transforming growth factor-beta-activated kinase 1. Reactive Oxygen Species 343-366 interferon beta 1 Homo sapiens 50-58 25478290-7 2014 RESULTS: We found that MUC18 over-expression promoted IL-8 production, while it inhibited IFN-beta expression following polyI:C stimulation or HRV infection. Poly I-C 120-127 interferon beta 1 Homo sapiens 90-98 25227113-0 2014 Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-beta-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system. Poly I-C 16-25 interferon beta 1 Homo sapiens 85-100 24388948-3 2014 Principal among these factors are Type I and Type II interferons (IFNs); the Type II IFN, IFN-gamma, stimulates the production of 1,25-dihydroxyvitamin D (1,25(OH)2D) from 25-hydroxyvitamin D (25OHD) by the granuloma-forming disease-activated macrophage, while the Type I IFNs, IFN-alpha and IFN-beta, block the hydroxylation reaction. 1,25-dihydroxyvitamin D 130-153 interferon beta 1 Homo sapiens 292-300 25227113-12 2014 CONCLUSIONS: These results suggest that poly(I:C) transfection induced two types of effects against RCC cells such as apoptosis, as a result of ROS-mediated DNA damage, and IFN-beta-mediated growth arrest, both of which were exerted via innate adjuvant receptors and the 2-5A system. Poly I-C 40-48 interferon beta 1 Homo sapiens 173-181 25182864-2 2014 Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) IFN beta-1a; IFN beta-1b SC; glatiramer acetate SC; oral dimethyl fumarate; oral teriflunomide; and intravenous alemtuzumab] indicated for first-line use in relapsing-remitting MS. Glatiramer Acetate 208-226 interferon beta 1 Homo sapiens 69-77 25182864-2 2014 Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) IFN beta-1a; IFN beta-1b SC; glatiramer acetate SC; oral dimethyl fumarate; oral teriflunomide; and intravenous alemtuzumab] indicated for first-line use in relapsing-remitting MS. Dimethyl Fumarate 236-253 interferon beta 1 Homo sapiens 69-77 25182864-2 2014 Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) IFN beta-1a; IFN beta-1b SC; glatiramer acetate SC; oral dimethyl fumarate; oral teriflunomide; and intravenous alemtuzumab] indicated for first-line use in relapsing-remitting MS. teriflunomide 260-273 interferon beta 1 Homo sapiens 69-77 24601852-9 2014 RESULTS: LL-37 and poly (I:C) synergistically induced the expression of IFN-beta in NHEKs. Poly I-C 19-28 interferon beta 1 Homo sapiens 72-80 25008936-4 2014 Subsequently, we showed that the inhibition of poly(I C)-induced IFN-beta production by PRRSV was dependent on the blocking of NF-kappaB signaling pathways. Poly I-C 47-56 interferon beta 1 Homo sapiens 65-73 25008936-14 2014 We found that nsp4 interfered with the NF-kappaB signaling pathway through the cleavage of NEMO (a key regulator of NF-kappaB signaling) at the E349-S350 site, leading to the downregulation of IFN-beta production induced by poly(I C). Poly I-C 224-232 interferon beta 1 Homo sapiens 193-201 24857619-0 2014 Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C. AIM: This study aims to evaluate the efficacy and safety of interferon-beta plus ribavirin therapy in older Japanese patients. Ribavirin 21-30 interferon beta 1 Homo sapiens 188-203 25170258-2 2014 Several clinical trials have shown consistent and sustained efficacy of glatiramer acetate 20 mg subcutaneously daily in reducing relapses and new demyelinating lesions on magnetic resonance imaging in patients with relapsing-remitting multiple sclerosis, as well as comparable efficacy to high-dose interferon beta. Glatiramer Acetate 72-90 interferon beta 1 Homo sapiens 300-315 25029335-10 2014 On stimulation with cGAMP, fibroblasts from the patients showed increased transcription of IFNB1 but not of the genes encoding interleukin-1 (IL1), interleukin-6 (IL6), or tumor necrosis factor (TNF). cyclic guanosine monophosphate-adenosine monophosphate 20-25 interferon beta 1 Homo sapiens 91-96 25132867-2 2014 She subsequently completed 72 weeks of natural IFN-beta plus ribavirin therapy without remarkable adverse effects and achieved a sustained viral response, suggesting differences in the pharmacological properties and biological effects of IFN-alpha and IFN-beta. Ribavirin 61-70 interferon beta 1 Homo sapiens 252-260 24857619-7 2014 CONCLUSION: Interferon-beta plus ribavirin therapy was safe in elderly patients, with lower proportions of patients with a dose reduction of interferon-beta or ribavirin and treatment discontinuation. Ribavirin 33-42 interferon beta 1 Homo sapiens 141-156 24857619-7 2014 CONCLUSION: Interferon-beta plus ribavirin therapy was safe in elderly patients, with lower proportions of patients with a dose reduction of interferon-beta or ribavirin and treatment discontinuation. Ribavirin 160-169 interferon beta 1 Homo sapiens 12-27 24850742-5 2014 Poly(I C) treatment induced a higher level of IFN-beta mRNA in HeLa cells stably expressing vp13 than in control cells. Poly I-C 0-10 interferon beta 1 Homo sapiens 48-56 24850742-11 2014 In HEV-infected hepatoma cells, wild-type HEV led to a higher level of RIG-I and more poly(I C)-induced IFN-beta expression than did ORF3-null mutants. Poly I-C 86-96 interferon beta 1 Homo sapiens 106-114 24857619-0 2014 Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C. AIM: This study aims to evaluate the efficacy and safety of interferon-beta plus ribavirin therapy in older Japanese patients. Ribavirin 209-218 interferon beta 1 Homo sapiens 0-15 23745758-3 2014 IFN-beta was administrated twice a day for 2 weeks followed by 24 or 48 weeks of PEG IFN/RBV. peg ifn 81-88 interferon beta 1 Homo sapiens 0-8 23745758-3 2014 IFN-beta was administrated twice a day for 2 weeks followed by 24 or 48 weeks of PEG IFN/RBV. Ribavirin 89-92 interferon beta 1 Homo sapiens 0-8 24444338-2 2014 The occurrence of neutralizing antidrug antibodies (NAbs) against IFNbeta may reduce treatment response. nabs 52-56 interferon beta 1 Homo sapiens 66-73 24444338-4 2014 We made a comparison between 2 bioassays; myxovirus resistance protein A (MxA) gene expression assay (MGA) and iLite anti-Human IFNbeta bioassay, to measure IFNbeta-specific NAb titers in 44 MS patients. nab 175-178 interferon beta 1 Homo sapiens 158-165 24668640-16 2014 If F-18 fluoro-deoxyglucose positron emission tomography is not available, this method may be used as a surrogate to conventional staging modalities. Deoxyglucose 14-27 interferon beta 1 Homo sapiens 0-4 24713431-0 2014 Fatty acid-binding protein E-FABP restricts tumor growth by promoting IFN-beta responses in tumor-associated macrophages. Fatty Acids 0-10 interferon beta 1 Homo sapiens 70-78 24708578-10 2014 NAb and BAb positivity significantly increased the likelihood of therapy change and reduced IFNbeta-associated adverse events. bab 8-11 interferon beta 1 Homo sapiens 92-99 24759080-4 2014 RECENT FINDINGS: Recent large placebo-controlled trials in relapsing-remitting multiple sclerosis have shown efficacy of new oral disease-modifying drugs, teriflunomide and dimethyl fumarate, with similar or better efficacy than the injectable disease-modifying drugs, IFN-beta and glatiramer acetate. teriflunomide 155-168 interferon beta 1 Homo sapiens 269-277 24759080-4 2014 RECENT FINDINGS: Recent large placebo-controlled trials in relapsing-remitting multiple sclerosis have shown efficacy of new oral disease-modifying drugs, teriflunomide and dimethyl fumarate, with similar or better efficacy than the injectable disease-modifying drugs, IFN-beta and glatiramer acetate. Dimethyl Fumarate 173-190 interferon beta 1 Homo sapiens 269-277 24748646-2 2014 Neutralising antibodies against IFNbeta (NAbs) promote a loss of IFNbeta bioactivity in a titre-dependent way and their development was associated with certain human leucocyte antigen (HLA) alleles. nabs 41-45 interferon beta 1 Homo sapiens 32-39 24748646-2 2014 Neutralising antibodies against IFNbeta (NAbs) promote a loss of IFNbeta bioactivity in a titre-dependent way and their development was associated with certain human leucocyte antigen (HLA) alleles. nabs 41-45 interferon beta 1 Homo sapiens 65-72 24909279-5 2014 After 24 hours, the expressions of pGL3-IFNB1 and pGE3-IFNB1 were tested in A549 cells. prostaglandin E3 50-54 interferon beta 1 Homo sapiens 55-60 24909279-8 2014 CONCLUSION: The recombinant vectors pGL3-IFNB1 and pGE3-IFNB1 containing IFN-beta promoter have been successfully constructed. prostaglandin E3 51-55 interferon beta 1 Homo sapiens 56-61 24909279-8 2014 CONCLUSION: The recombinant vectors pGL3-IFNB1 and pGE3-IFNB1 containing IFN-beta promoter have been successfully constructed. prostaglandin E3 51-55 interferon beta 1 Homo sapiens 73-81 24531619-6 2014 IFN-beta treatment also activated DAPK1 by decreasing its phosphorylation level at serine 308. Serine 83-89 interferon beta 1 Homo sapiens 0-8 25876471-4 2014 RESULTS: Both fingolimod doses significantly reduced annualized relapse rate in patients that received prior interferon-beta or glatiramer acetate, discontinued prior disease-modifying therapy owing to unsatisfactory therapeutic effect, were treatment-naive, or had prior disease-modifying therapy duration of >1-3 years (P<=0.0301 for all comparisons vs placebo). Fingolimod Hydrochloride 14-24 interferon beta 1 Homo sapiens 109-124 25876473-5 2014 RESULTS: Compared with interferon beta-1a intramuscular, fingolimod 0.5mg significantly reduced annualized relapse rate in patients who were treatment naive, received prior interferon-beta treatment, discontinued prior disease-modifying therapy for unsatisfactory therapeutic effect, or had prior disease-modifying therapy duration of >=1 year (P<=0.05, all comparisons). Fingolimod Hydrochloride 57-67 interferon beta 1 Homo sapiens 173-188 25876473-7 2014 Significant reductions were also seen with fingolimod 1.25mg for treatment-naive and prior interferon-beta-treated patients. Fingolimod Hydrochloride 43-53 interferon beta 1 Homo sapiens 91-106 24708578-14 2014 BAb titres can predict NAb positivity in patients on high-dose IFNbeta. bab 0-3 interferon beta 1 Homo sapiens 63-70 24009164-6 2014 RESULTS: We found that 22 of 164 (13.4%) patients developed NAbs during a median time of 23.8 months on IFN-b treatment. nabs 60-64 interferon beta 1 Homo sapiens 104-109 24526685-1 2014 Double-stranded RNA (dsRNA) induces phosphorylation of Toll-like receptor 3 (TLR3) at tyrosine 759 and subsequently triggers signaling pathways to promote interferon-beta (IFN-beta) production. Tyrosine 86-94 interferon beta 1 Homo sapiens 155-170 24526685-1 2014 Double-stranded RNA (dsRNA) induces phosphorylation of Toll-like receptor 3 (TLR3) at tyrosine 759 and subsequently triggers signaling pathways to promote interferon-beta (IFN-beta) production. Tyrosine 86-94 interferon beta 1 Homo sapiens 172-180 24547871-0 2014 BAb and MxA as functional biomarkers in routine clinical laboratories for the determination of anti-IFN-beta antibodies and their bioactivity levels in multiple sclerosis patients. butamben 0-3 interferon beta 1 Homo sapiens 100-108 24138091-8 2014 Moreover, it was found that paxilline substantially inhibited HS-induced activation of several different transcription factors in macrophages, including nuclear factor-kappaB, p38 and interferon regulatory factor-3, followed by decreased production of tumour necrosis factor-alpha and interferon-beta. paxilline 28-37 interferon beta 1 Homo sapiens 285-300 24396068-3 2014 IKK-epsilon was activated following TCR/CD28 stimulation of primary CD4(+) T cells; however, in T cells treated with poly(I C), TCR/CD28 costimulation blocked induction of IFN-beta transcription. Poly I-C 117-125 interferon beta 1 Homo sapiens 172-180 24586361-1 2014 BACKGROUND: Anti interferon-beta (IFN-beta) neutralizing antibodies (NAb) affect efficacy of treatment of multiple sclerosis patients, but exactly when the detrimental effects of NAbs offset therapeutic efficacy is debated. nabs 179-183 interferon beta 1 Homo sapiens 34-42 24390324-7 2014 Mutagenesis of the NY-1V GnT revealed that altering tyrosine 627 (Y627A/S/F) abolished GnT regulation of RIG-I/TBK1-directed IRF3 phosphorylation and transcriptional responses of ISRE, kappaB, and IFN-beta promoters. Tyrosine 52-60 interferon beta 1 Homo sapiens 197-205 24463573-4 2014 Here we show that oncolytic viruses and adjuvants such as poly(I:C) and CpG induce bystander death of cancer cells treated with SMCs that is mediated by interferon beta (IFN-beta), tumor necrosis factor alpha (TNF-alpha) and/or TNF-related apoptosis-inducing ligand (TRAIL). Poly I-C 58-67 interferon beta 1 Homo sapiens 153-168 24463573-4 2014 Here we show that oncolytic viruses and adjuvants such as poly(I:C) and CpG induce bystander death of cancer cells treated with SMCs that is mediated by interferon beta (IFN-beta), tumor necrosis factor alpha (TNF-alpha) and/or TNF-related apoptosis-inducing ligand (TRAIL). Poly I-C 58-67 interferon beta 1 Homo sapiens 170-178 24336144-5 2014 RESULTS: Patients with MRI evidence of poor response to IFN-beta treatment as defined by either >=2 new hyperintense T2 lesions or new gadolinium-enhancing lesions had significantly increased risk of both future relapses and progression as defined by the Expanded Disability Status Scale. Gadolinium 138-148 interferon beta 1 Homo sapiens 56-64 24399297-2 2014 Attachment of lysine 63 (Lys(63))-linked ubiquitin chains to the RNA sensor retinoic acid-inducible gene-I (RIG-I) by the ubiquitin E3 ligase tripartite motif protein 25 (TRIM25) leads to the activation of RIG-I and stimulates production of the antiviral cytokines interferon-alpha (IFN-alpha) and IFN-beta. Lysine 14-20 interferon beta 1 Homo sapiens 298-306 24399297-2 2014 Attachment of lysine 63 (Lys(63))-linked ubiquitin chains to the RNA sensor retinoic acid-inducible gene-I (RIG-I) by the ubiquitin E3 ligase tripartite motif protein 25 (TRIM25) leads to the activation of RIG-I and stimulates production of the antiviral cytokines interferon-alpha (IFN-alpha) and IFN-beta. Lysine 25-28 interferon beta 1 Homo sapiens 298-306 24227842-1 2014 Apolipoprotein B mRNA-editing catalytic polypeptide 3 (APOBEC3) proteins are interferon (IFN)-inducible antiviral factors that counteract various viruses such as hepatitis B virus (HBV) and human immunodeficiency virus type 1 (HIV-1) by inducing cytidine (C)-to-uracil (U) mutations in viral DNA and inhibiting reverse transcription. Cytidine 246-254 interferon beta 1 Homo sapiens 77-88 24227842-1 2014 Apolipoprotein B mRNA-editing catalytic polypeptide 3 (APOBEC3) proteins are interferon (IFN)-inducible antiviral factors that counteract various viruses such as hepatitis B virus (HBV) and human immunodeficiency virus type 1 (HIV-1) by inducing cytidine (C)-to-uracil (U) mutations in viral DNA and inhibiting reverse transcription. Uracil 262-268 interferon beta 1 Homo sapiens 77-88 24800175-3 2014 The intraperitoneal injection of iPS-MCs expressing interferon beta significantly inhibited the growth of human gastric and pancreatic cancers implanted in the peritoneal cavity of immunocompromised mice. ips-mcs 33-40 interferon beta 1 Homo sapiens 52-67 24141111-8 2014 The tumor inhibitory effect was greater with the HB1.F3.CD.IFN-beta cells, indicating an additional effect of IFN-beta to 5-FU. Fluorouracil 122-126 interferon beta 1 Homo sapiens 59-67 24321159-5 2013 RESULTS: The IFN-beta-treated group showed a highly significant reduction (hazard ratio [HR], 0.34, 95% confidence interval [CI] 0.19-0.61, p<0.001) in the risk of SP when compared with untreated patients. sp 167-169 interferon beta 1 Homo sapiens 13-21 24135008-5 2014 Interferon-beta1a also reduced the generation of the rotenone-induced inward current in striatal spiny neurons. Rotenone 53-61 interferon beta 1 Homo sapiens 0-16 23906644-6 2013 Using purified human monocytes we then show that phagocytosed live Bb, as well as equivalent amounts of borrelial RNA delivered into the phagosome by polyethylenimine (PEI), induces transcription of IFN-beta and secretion of TNF-alpha. Polyethyleneimine 168-171 interferon beta 1 Homo sapiens 199-207 23962003-3 2013 Covalent modification of IFN-beta with polyethylene glycol (PEG) improves the pharmacokinetic properties of the protein, but can adversely affect the protein"s in vitro bioactivity. Polyethylene Glycols 39-58 interferon beta 1 Homo sapiens 25-33 24339712-1 2013 Treatment with interferon beta (IFN-beta) induces the production of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in patients with multiple sclerosis (MS). babs 88-92 interferon beta 1 Homo sapiens 15-30 24339712-1 2013 Treatment with interferon beta (IFN-beta) induces the production of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in patients with multiple sclerosis (MS). babs 88-92 interferon beta 1 Homo sapiens 32-40 24204993-4 2013 In the absence of exogenous ligands, the R232H, R293Q and AQ SNPs had only modest effect on the stimulation of IFN-beta and NF-kappaB promoter activities in HEK293T cells, while HAQ had significantly lower intrinsic activity. aq 58-60 interferon beta 1 Homo sapiens 111-119 24339712-4 2013 The presence of BAbs was studied in serum samples from 124 MS patients using one of these IFN-beta medications by ELISA. babs 16-20 interferon beta 1 Homo sapiens 90-98 24339712-9 2013 NAbs were present in 25 (80.6%) of BAb-positive MS patients receiving IFN-beta. bab 35-38 interferon beta 1 Homo sapiens 70-78 23871888-10 2013 Treatment with CVB3 and polyinosinic:polycytidylic acid led to higher IFNbeta expression in PAR2ko than in wt fibroblasts and reduced virus replication in PAR2ko fibroblasts was abrogated by neutralizing IFNbeta antibody. polyinosinic 24-36 interferon beta 1 Homo sapiens 70-77 23871888-10 2013 Treatment with CVB3 and polyinosinic:polycytidylic acid led to higher IFNbeta expression in PAR2ko than in wt fibroblasts and reduced virus replication in PAR2ko fibroblasts was abrogated by neutralizing IFNbeta antibody. polyinosinic 24-36 interferon beta 1 Homo sapiens 204-211 23871888-10 2013 Treatment with CVB3 and polyinosinic:polycytidylic acid led to higher IFNbeta expression in PAR2ko than in wt fibroblasts and reduced virus replication in PAR2ko fibroblasts was abrogated by neutralizing IFNbeta antibody. Poly C 37-55 interferon beta 1 Homo sapiens 70-77 23871888-10 2013 Treatment with CVB3 and polyinosinic:polycytidylic acid led to higher IFNbeta expression in PAR2ko than in wt fibroblasts and reduced virus replication in PAR2ko fibroblasts was abrogated by neutralizing IFNbeta antibody. Poly C 37-55 interferon beta 1 Homo sapiens 204-211 24494633-5 2013 In patients who have not yet developed clinically definite MS (CDMS), but have had 1 attack of neurological symptoms consistent with MS (ie, clinically isolated syndrome [CIS]), the initiation of DMT (specifically, interferon beta, glatiramer acetate, and teriflunomide) following this attack has been shown to delay the conversion to CDMS. dmt 196-199 interferon beta 1 Homo sapiens 215-230 23911868-4 2013 Although short poly I:C ( 1-1.5 kb) induced greater amounts of TNF-alpha, IL-8, and IFN-beta and a stronger antiviral response in myeloid cells, it was a poor inducer in fibroblasts. Poly I-C 15-23 interferon beta 1 Homo sapiens 85-93 24204993-9 2013 Surprisingly, the AQ and HAQ variants maintained partial abilities to activate the IFN-beta signaling in the presence of ligands due primarily to the G230A substitution. aq 18-20 interferon beta 1 Homo sapiens 83-91 24139422-1 2013 BACKGROUND: Patients with multiple sclerosis (MS) whose disease activity is inadequately controlled with a platform therapy (interferon beta or glatiramer acetate [GA]) may switch to another platform therapy or escalate therapy to natalizumab or fingolimod, which were approved in the US in 2006 and 2010, respectively. Fingolimod Hydrochloride 246-256 interferon beta 1 Homo sapiens 125-140 23950974-5 2013 In line with this, expression of TLR7 protein was increased in pDCs of interferon-beta-treated, but not untreated or glatiramer acetate-treated patients with MS. Interferon-beta-induced upregulation of TLR7 in pDCs is of functional relevance since pre-treatment of PBMCs with interferon-beta resulted in a strongly increased production of interferon-alpha upon stimulation with the TLR7 agonist loxoribine. loxoribine 395-405 interferon beta 1 Homo sapiens 71-86 23962003-3 2013 Covalent modification of IFN-beta with polyethylene glycol (PEG) improves the pharmacokinetic properties of the protein, but can adversely affect the protein"s in vitro bioactivity. Polyethylene Glycols 60-63 interferon beta 1 Homo sapiens 25-33 23962003-4 2013 Random modification of lysine residues in IFN-beta with amine-reactive PEGs decreased the in vitro bioactivity of the protein 50-fold, presumably due to modification of lysine residues near critical receptor binding sites. Lysine 23-29 interferon beta 1 Homo sapiens 42-50 23962003-4 2013 Random modification of lysine residues in IFN-beta with amine-reactive PEGs decreased the in vitro bioactivity of the protein 50-fold, presumably due to modification of lysine residues near critical receptor binding sites. Polyethylene Glycols 71-75 interferon beta 1 Homo sapiens 42-50 23962003-4 2013 Random modification of lysine residues in IFN-beta with amine-reactive PEGs decreased the in vitro bioactivity of the protein 50-fold, presumably due to modification of lysine residues near critical receptor binding sites. Lysine 169-175 interferon beta 1 Homo sapiens 42-50 23962003-5 2013 PEGylated IFN-beta proteins that retained high in vitro bioactivity could be obtained by selective modification of the N-terminus of the protein with PEG. Polyethylene Glycols 0-3 interferon beta 1 Homo sapiens 10-18 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Cysteine 74-82 interferon beta 1 Homo sapiens 133-141 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Cysteine 74-82 interferon beta 1 Homo sapiens 224-232 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Polyethylene Glycols 26-29 interferon beta 1 Homo sapiens 133-141 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Polyethylene Glycols 26-29 interferon beta 1 Homo sapiens 224-232 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Cysteine 113-121 interferon beta 1 Homo sapiens 133-141 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Cysteine 113-121 interferon beta 1 Homo sapiens 224-232 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Polyethylene Glycols 92-95 interferon beta 1 Homo sapiens 133-141 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Polyethylene Glycols 92-95 interferon beta 1 Homo sapiens 224-232 23986532-6 2013 Moreover, systemic cyclic diguanylate monophosphate treatment to activate STING induced selective IFN-beta expression by CD11b(+) DCs and suppressed Th1 responses to immunization. cyclic diguanylate monophosphate 19-51 interferon beta 1 Homo sapiens 98-106 23831137-5 2013 This NAb assay utilizes an electrochemiluminescence detection platform and is based on the first step involved in all IFN-beta-induced biological activities, namely the binding of IFN-beta to its receptor, which is inhibited when NAbs are present. nab 5-8 interferon beta 1 Homo sapiens 118-126 23831137-5 2013 This NAb assay utilizes an electrochemiluminescence detection platform and is based on the first step involved in all IFN-beta-induced biological activities, namely the binding of IFN-beta to its receptor, which is inhibited when NAbs are present. nab 5-8 interferon beta 1 Homo sapiens 180-188 23831137-6 2013 Using this approach, NAb titers in clinical samples from multiple sclerosis patients treated with IFN-beta were determined and compared with those obtained using existing cell-based NAb assays. nab 21-24 interferon beta 1 Homo sapiens 98-106 23935197-3 2013 Treatment of macrophages with IFN-beta reduced cellular abundance of ifngr1 transcripts as rapidly and effectively as actinomycin D treatment. Dactinomycin 118-131 interferon beta 1 Homo sapiens 30-38 23956427-4 2013 In explanted skin and lung fibroblasts, the synthetic TLR3 ligand polyinosinic-polycytidylic acid (poly(I:C)), a dsRNA analog, caused dose- and time-dependent stimulation of IFN-beta production and generation of an IFN-response gene signature that was accompanied by substantial downregulation of collagen and alpha-smooth muscle actin gene expression. Poly I-C 66-97 interferon beta 1 Homo sapiens 174-182 23786783-12 2013 At 3 months, visual acuity improved a mean 0.31 logarithm of the minimal angle of resolution (range, -0.02 to -0.96, 15.6 letters on the Early Treatment Diabetic Retinopathy Study chart) in the IFN beta group versus a mean 0.09 logarithm of the minimal angle of resolution (range, 0.12 to -0.38, 4.7 letters) in the MTX arm (P = .0435, Mann-Whitney U test). Methotrexate 316-319 interferon beta 1 Homo sapiens 194-202 23990993-5 2013 We found that CsA treatment of HT-29 cells before, during, and after viral infection efficiently inhibited Wa strain RV replication and restored IFN-beta expression in a HT-29 cell line model. Cyclosporine 14-17 interferon beta 1 Homo sapiens 145-153 23977343-0 2013 Interferon-beta produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells. Cisplatin 73-82 interferon beta 1 Homo sapiens 0-15 23977343-0 2013 Interferon-beta produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells. Pemetrexed 86-96 interferon beta 1 Homo sapiens 0-15 23977343-8 2013 These data demonstrated firstly to our knowledge that IFN-beta produced synergistic anti-tumor effects with cisplatin or pemetrexed on mesothelioma through up-regulated p53 expression. Cisplatin 108-117 interferon beta 1 Homo sapiens 54-62 23977343-8 2013 These data demonstrated firstly to our knowledge that IFN-beta produced synergistic anti-tumor effects with cisplatin or pemetrexed on mesothelioma through up-regulated p53 expression. Pemetrexed 121-131 interferon beta 1 Homo sapiens 54-62 23950974-5 2013 In line with this, expression of TLR7 protein was increased in pDCs of interferon-beta-treated, but not untreated or glatiramer acetate-treated patients with MS. Interferon-beta-induced upregulation of TLR7 in pDCs is of functional relevance since pre-treatment of PBMCs with interferon-beta resulted in a strongly increased production of interferon-alpha upon stimulation with the TLR7 agonist loxoribine. loxoribine 395-405 interferon beta 1 Homo sapiens 162-177 23767916-0 2013 Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. Vitamin D 0-9 interferon beta 1 Homo sapiens 76-91 23863901-3 2013 This study investigates the role of Zn(2+) on Toll/IL-1R domain-containing adapter inducing IFN-beta (TRIF)-dependent signals, the other major intracellular pathway activated by TLR4. Zinc 36-38 interferon beta 1 Homo sapiens 92-100 23863901-4 2013 Chelation of Zn(2+) with the membrane-permeable chelator N,N,N",N"-Tetrakis(2-pyridylmethyl)ethylenediamine augmented TLR4-mediated production of IFN-beta and subsequent synthesis of inducible NO synthase and production of NO. Zinc 13-15 interferon beta 1 Homo sapiens 146-154 23863901-4 2013 Chelation of Zn(2+) with the membrane-permeable chelator N,N,N",N"-Tetrakis(2-pyridylmethyl)ethylenediamine augmented TLR4-mediated production of IFN-beta and subsequent synthesis of inducible NO synthase and production of NO. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine 57-107 interferon beta 1 Homo sapiens 146-154 23665342-2 2013 Both vitamin D and melatonin are essential mediators of the effect of sunlight in health, and as such are candidates to play a key role in MS. We hypothesized that vitamin D and melatonin may have related influences in patients with MS. METHODS: In a randomized, double blind study of 40 IFN-beta treated MS patients, 21 patients were assigned to 800 IU of vitamin D3 per day (low dose), while 19 patients received 4,370 IU vitamin D3 per day (high dose) for one year. Vitamin D 164-173 interferon beta 1 Homo sapiens 288-296 23665342-2 2013 Both vitamin D and melatonin are essential mediators of the effect of sunlight in health, and as such are candidates to play a key role in MS. We hypothesized that vitamin D and melatonin may have related influences in patients with MS. METHODS: In a randomized, double blind study of 40 IFN-beta treated MS patients, 21 patients were assigned to 800 IU of vitamin D3 per day (low dose), while 19 patients received 4,370 IU vitamin D3 per day (high dose) for one year. Melatonin 178-187 interferon beta 1 Homo sapiens 288-296 23665342-8 2013 CONCLUSIONS: Melatonin secretion is negatively correlated with alterations in serum 25-OH-D in IFN-beta treated patients with MS. Melatonin 13-22 interferon beta 1 Homo sapiens 95-103 23665342-8 2013 CONCLUSIONS: Melatonin secretion is negatively correlated with alterations in serum 25-OH-D in IFN-beta treated patients with MS. 25-oh-d 84-91 interferon beta 1 Homo sapiens 95-103 23770627-8 2013 ADA interaction with therapeutic IFNbeta results in immune complex formation and complement activation. N-(2-acetamido)iminodiacetic acid 0-3 interferon beta 1 Homo sapiens 33-40 23738920-8 2013 RESULTS: Diethylhexyl phthalate and butyl benzyl phthalate suppressed CpG-induced IFN-alpha/IFN-beta expression in pDCs, and the effect was reversed by aryl hydrocarbon receptor (AHR) antagonist. Diethylhexyl Phthalate 9-31 interferon beta 1 Homo sapiens 92-100 23738920-8 2013 RESULTS: Diethylhexyl phthalate and butyl benzyl phthalate suppressed CpG-induced IFN-alpha/IFN-beta expression in pDCs, and the effect was reversed by aryl hydrocarbon receptor (AHR) antagonist. butylbenzyl phthalate 36-58 interferon beta 1 Homo sapiens 92-100 23636788-4 2013 Human A549 lung and DU145 prostate carcinoma cells significantly responded to poly I:C stimulation, producing IFN-beta at levels that were capable of activating STAT1 and enhancing CXCL10, CD40, and CD86 expression on human monocyte-derived DCs. poly I:C 78-86 interferon beta 1 Homo sapiens 110-118 23636788-5 2013 IFN-beta produced by poly I:C-activated human cancer cells increased the capacity of monocyte-derived DCs to stimulate IFN-gamma production in an allogeneic stimulatory culture in vitro. Poly I 21-27 interferon beta 1 Homo sapiens 0-8 23747509-7 2013 In Adriamycin nephropathy, injections with either IFN-alpha or IFN-beta aggravated proteinuria, macrophage influx, and glomerulosclerosis. Doxorubicin 3-13 interferon beta 1 Homo sapiens 63-71 23767916-12 2013 CONCLUSION: Vitamin D supplementation to IFN-beta treated PwMS, at the doses used, seems safe and associated with dose-dependent changes in IL-17 serum levels, while not affecting IFN-beta related FLS. Vitamin D 12-21 interferon beta 1 Homo sapiens 41-49 23600838-7 2013 Further investigation of this observation revealed that cisplatin treatment during DC differentiation up-regulated significantly the interferon (IFN)-beta transcript. Cisplatin 56-65 interferon beta 1 Homo sapiens 133-154 23600838-9 2013 Blocking IFN-beta attenuated the cisplatin-enhanced T cell proliferation significantly. Cisplatin 33-42 interferon beta 1 Homo sapiens 9-17 23600838-10 2013 In conclusion, cisplatin treatment enhanced the immune stimulatory ability of human monocytes, a mechanism mediated mainly by the increased production of IFN-beta. Cisplatin 15-24 interferon beta 1 Homo sapiens 154-162 23738997-1 2013 Fingolimod 0.5 mg (Gilenya( ), Novartis Pharmaceuticals Corporation, FL, USA) is the first once-daily oral therapy approved for relapsing forms of multiple sclerosis (MS) in the USA and for rapidly evolving severe MS or highly active disease despite IFN-beta treatment in Europe. Fingolimod Hydrochloride 0-10 interferon beta 1 Homo sapiens 250-258 23329343-6 2013 Autophagy induced by IFN-beta was suppressed when p-ERK1/2 was impaired by treatment with U0126. U 0126 90-95 interferon beta 1 Homo sapiens 21-29 23507702-0 2013 Interferon-beta is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Hydrocortisone 57-65 interferon beta 1 Homo sapiens 0-15 23507702-0 2013 Interferon-beta is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Mitotane 141-149 interferon beta 1 Homo sapiens 0-15 23507702-14 2013 The increased sensitivity of ACC cells to mitotane induced by treatment with IFN-beta may open the opportunity for combined treatment regimens with lower mitotane doses. Mitotane 42-50 interferon beta 1 Homo sapiens 77-85 23507702-14 2013 The increased sensitivity of ACC cells to mitotane induced by treatment with IFN-beta may open the opportunity for combined treatment regimens with lower mitotane doses. Mitotane 154-162 interferon beta 1 Homo sapiens 77-85 23507702-15 2013 The inhibition of the expression of steroidogenic enzymes by IFN-beta is a novel mechanism that may explain its inhibitory effect on cortisol production. Hydrocortisone 133-141 interferon beta 1 Homo sapiens 61-69 23392170-7 2013 Expectedly, exogenous miR-145 decreased the expression level of SOCS7, and socs7-silencing enhanced IFN-beta induction by transfection with a TLR3 ligand, polyinosinic acid-polycytidylic acid (PIC). Poly I-C 155-191 interferon beta 1 Homo sapiens 100-108 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). Flucytosine 295-311 interferon beta 1 Homo sapiens 90-105 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). Flucytosine 295-311 interferon beta 1 Homo sapiens 107-115 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). -fc 314-317 interferon beta 1 Homo sapiens 90-105 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). -fc 314-317 interferon beta 1 Homo sapiens 107-115 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). Fluorouracil 343-357 interferon beta 1 Homo sapiens 90-105 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). Fluorouracil 343-357 interferon beta 1 Homo sapiens 107-115 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). Fluorouracil 359-363 interferon beta 1 Homo sapiens 90-105 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). Fluorouracil 359-363 interferon beta 1 Homo sapiens 107-115 23403306-6 2013 In particular, HB1.F3.CD.IFN-beta cells showed the synergistic cytotoxic activity of 5-FU and IFN-beta. Fluorouracil 85-89 interferon beta 1 Homo sapiens 25-33 23542035-2 2013 We show that sustained LPS or poly(I:C)-stimulated MCP-1 production requires an IFNbeta-mediated feedback loop. Poly I-C 30-39 interferon beta 1 Homo sapiens 80-87 23542035-4 2013 Blocking IFNbeta signaling with Ruxolitinib, a JAK inhibitor, inhibited MCP-1 transcription. ruxolitinib 32-43 interferon beta 1 Homo sapiens 9-16 22925919-1 2013 Resveratrol was suggested to inhibit Toll-like receptor (TLR)4-mediated activation of nuclear factor-kappaB (NF-kappaB) and Toll/interleukin-1 receptor domain-containing adaptor inducing interferon-beta (TRIF)-(TANK)-binding kinase 1, but the myeloid differentiation primary response gene 88-tumor necrosis factor receptor-associated factor 6 (TRAF6) pathway is not involved in this effect. Resveratrol 0-11 interferon beta 1 Homo sapiens 187-202 23658644-6 2013 Both dsRNA stimuli evoked early (3 h), concentration-dependent IFN-beta and IFN-lambda1 mRNA expression, which with dsRNA/LyoVec was much greater, and with dsRNA was much less, after 24 h. The effects were inhibited by dexamethasone. Dexamethasone 219-232 interferon beta 1 Homo sapiens 63-71 23983889-5 2013 In the 3-, 5-, and 10-year extension studies of 2 formulations of IFN-beta, the decreased conversion rate to CDMS remained meaningful when comparing early treatment of CIS to treatment delayed by a median of 2 to 3 years. cdms 109-113 interferon beta 1 Homo sapiens 66-74 23323765-5 2013 Analysis of a sample of recombinant human interferon-beta allowed the assignment of at least 18 glycoforms, plus a variety of deamidation, succinimide, and oxidation products, representing a considerable improvement over sheath-liquid CE-MS. succinimide 139-150 interferon beta 1 Homo sapiens 42-57 23258412-5 2013 cGAMP bound to STING, leading to the activation of IRF3 and induction of interferon-beta. cyclic guanosine monophosphate-adenosine monophosphate 0-5 interferon beta 1 Homo sapiens 73-88 23401273-3 2013 Human brain microvascular ECs expressed functional toll-like receptor 3 (TLR3) that could be activated by polyinosinic-polycytidylic acid (PolyI:C), resulting in the induction of endogenous interferon-beta (IFN-beta) and IFN-lambda. Poly I-C 106-137 interferon beta 1 Homo sapiens 190-205 23401273-3 2013 Human brain microvascular ECs expressed functional toll-like receptor 3 (TLR3) that could be activated by polyinosinic-polycytidylic acid (PolyI:C), resulting in the induction of endogenous interferon-beta (IFN-beta) and IFN-lambda. Poly I-C 106-137 interferon beta 1 Homo sapiens 207-215 23401273-3 2013 Human brain microvascular ECs expressed functional toll-like receptor 3 (TLR3) that could be activated by polyinosinic-polycytidylic acid (PolyI:C), resulting in the induction of endogenous interferon-beta (IFN-beta) and IFN-lambda. Poly I-C 139-146 interferon beta 1 Homo sapiens 190-205 23401273-3 2013 Human brain microvascular ECs expressed functional toll-like receptor 3 (TLR3) that could be activated by polyinosinic-polycytidylic acid (PolyI:C), resulting in the induction of endogenous interferon-beta (IFN-beta) and IFN-lambda. Poly I-C 139-146 interferon beta 1 Homo sapiens 207-215 23352460-9 2013 Poly(I:C) and CpG-oligonucleotide promoted the immunosuppressive potentiality of UC-MSCs, accompanied with the phosphorylation of interferon regulatory factor 3 (IRF3) and increased expression of indoleamine 2,3-dioxygenase and interferon beta, whereas activation of other TLR ligands (synthetic analog fibroblast-stimulating lipopeptide-1 and lipopolysaccharide) failed to affect the immunoregulatory activity of UC-MSCs. Poly I-C 0-8 interferon beta 1 Homo sapiens 228-243 23352460-9 2013 Poly(I:C) and CpG-oligonucleotide promoted the immunosuppressive potentiality of UC-MSCs, accompanied with the phosphorylation of interferon regulatory factor 3 (IRF3) and increased expression of indoleamine 2,3-dioxygenase and interferon beta, whereas activation of other TLR ligands (synthetic analog fibroblast-stimulating lipopeptide-1 and lipopolysaccharide) failed to affect the immunoregulatory activity of UC-MSCs. CPG-oligonucleotide 14-33 interferon beta 1 Homo sapiens 228-243 23449998-5 2013 The IFN-gamma-induced macrophage vitamin D-dependent antimicrobial peptide response was inhibited by IFN-beta and by IL-10, suggesting that the differential production of IFNs contributes to protection versus pathogenesis in some human bacterial infections. Vitamin D 33-42 interferon beta 1 Homo sapiens 101-109 23106696-6 2013 Furthermore, our analyses revealed that the inhibitory effect of ATO on iNOS expression was ascribed to the prevention of IRF3 phosphorylation, interferon (IFN)-beta expression, and STAT1 phosphorylation, but not the prevention of the MyD88-dependent pathway. Arsenic Trioxide 65-68 interferon beta 1 Homo sapiens 144-165 23106696-7 2013 Taken together, our results indicate that ATO prevents NO production by inhibiting the TIR-domain-containing adaptor protein inducing IFN-beta (TRIF)-dependent pathway, thus highlighting an anti-inflammatory property of ATO in innate immunity. Arsenic Trioxide 42-45 interferon beta 1 Homo sapiens 134-142 23106696-7 2013 Taken together, our results indicate that ATO prevents NO production by inhibiting the TIR-domain-containing adaptor protein inducing IFN-beta (TRIF)-dependent pathway, thus highlighting an anti-inflammatory property of ATO in innate immunity. Arsenic Trioxide 220-223 interferon beta 1 Homo sapiens 134-142 23015382-4 2013 Pretreatment of the cells with propolis inhibited poly I:C (synthetic dsRNA)-induced interferon (IFN)-beta expression. Poly I-C 50-58 interferon beta 1 Homo sapiens 85-106 22881993-12 2013 Instead, simvastatin inhibited dsRNA-induced IRF3 phosphorylation and generation of IFN-beta. Simvastatin 9-20 interferon beta 1 Homo sapiens 84-92 23378325-8 2013 In the IM IFNbeta-1a group, persistent disease activity predicted severe EDSS worsening: gadolinium-enhancing lesions (odds ratio [OR], 8.96; p < 0.001); relapses (OR, 4.44; p = 0.010); and new T2 lesions (OR, 2.90; p = 0.080). Gadolinium 89-99 interferon beta 1 Homo sapiens 10-17 23378325-11 2013 Particular attention should be paid to gadolinium-enhancing lesions on IFNbeta therapy, as their presence strongly correlates with severe disability 15 years later. Gadolinium 39-49 interferon beta 1 Homo sapiens 71-78 22881993-13 2013 CONCLUSIONS AND IMPLICATIONS: Independent of mevalonate and NF-kappaB, previously acknowledged anti-inflammatory mechanisms of pleiotropic statins, simvastatin selectively inhibited dsRNA-induced IRF3 activation and production of TSLP and IFN-beta in COPD epithelium. Simvastatin 148-159 interferon beta 1 Homo sapiens 239-247 23002173-9 2013 BAFF induction was blocked by addition of a neutralising anti-interferon-beta antibody or palivizumab. baff 0-4 interferon beta 1 Homo sapiens 62-77 23178692-11 2013 The caspase assay demonstrated that the overexpression of GRIM-19 enhanced the cellular sensitivity to interferon(IFN)-beta- and retinoic acid (RA)-induced death in HeLa cells. Tretinoin 144-146 interferon beta 1 Homo sapiens 103-123 23711618-6 2013 RESULTS: Three-year IFNbeta-1a or IFNbeta-1b monotherapy reduced serum nitrite levels by 77 and 71%, respectively, lowered multiple sclerosis relapse annual rate by 70 and 71%, respectively, and significantly and similarly lowered Expanded Disability Status Scale scores in both study groups (by 0.9 on average). Nitrites 71-78 interferon beta 1 Homo sapiens 20-27 23711618-6 2013 RESULTS: Three-year IFNbeta-1a or IFNbeta-1b monotherapy reduced serum nitrite levels by 77 and 71%, respectively, lowered multiple sclerosis relapse annual rate by 70 and 71%, respectively, and significantly and similarly lowered Expanded Disability Status Scale scores in both study groups (by 0.9 on average). Nitrites 71-78 interferon beta 1 Homo sapiens 34-41 23431360-11 2013 In vitro, interferon-beta treatment decreased oxidative stress (iNOS and ROS levels) and the release of pro-inflammatory cytokines after LPS stimulation, reducing axonal damage. Reactive Oxygen Species 73-76 interferon beta 1 Homo sapiens 10-25 23349882-5 2013 RESULTS: During interferon beta (IFNB) treatment, each 10 micromol/L increase in alpha-tocopherol reduced the odds (CI 95%) for simultaneous new T2 lesions by 36.8 (0.5-59.8) %, p = 0.048, and for combined unique activity by 35.4 (1.6-57.7) %, p = 0.042, in a hierarchical regression model. alpha-Tocopherol 81-97 interferon beta 1 Homo sapiens 16-31 23349882-5 2013 RESULTS: During interferon beta (IFNB) treatment, each 10 micromol/L increase in alpha-tocopherol reduced the odds (CI 95%) for simultaneous new T2 lesions by 36.8 (0.5-59.8) %, p = 0.048, and for combined unique activity by 35.4 (1.6-57.7) %, p = 0.042, in a hierarchical regression model. alpha-Tocopherol 81-97 interferon beta 1 Homo sapiens 33-37 23349882-8 2013 CONCLUSION: During treatment with IFNB, increasing serum concentrations of alpha-tocopherol were associated with reduced odds for simultaneous and subsequent MRI disease activity in RRMS patients. alpha-Tocopherol 75-91 interferon beta 1 Homo sapiens 34-38 23002173-10 2013 CONCLUSIONS: BAFF, produced through an interferon-beta-dependent process, is a consistent feature of airway infection, and suggests a role for the airway epithelia in supporting protective antibody and B cell responses in the lung. baff 13-17 interferon beta 1 Homo sapiens 39-54 23026532-6 2012 In interferon-beta1b treated MS patients, NO(2)+NO(3), 3-NT and RSNO plasma concentrations were significantly lower (p<0.05), while arginase activity, ADMA and SDMA levels were significantly increased (p<0.05) during the therapy, compared to the baseline levels in treated patients. Nitrogen Dioxide 42-47 interferon beta 1 Homo sapiens 3-19 23026532-6 2012 In interferon-beta1b treated MS patients, NO(2)+NO(3), 3-NT and RSNO plasma concentrations were significantly lower (p<0.05), while arginase activity, ADMA and SDMA levels were significantly increased (p<0.05) during the therapy, compared to the baseline levels in treated patients. 3-nitrotyrosine 55-59 interferon beta 1 Homo sapiens 3-19 23026532-6 2012 In interferon-beta1b treated MS patients, NO(2)+NO(3), 3-NT and RSNO plasma concentrations were significantly lower (p<0.05), while arginase activity, ADMA and SDMA levels were significantly increased (p<0.05) during the therapy, compared to the baseline levels in treated patients. rsno 64-68 interferon beta 1 Homo sapiens 3-19 22492130-6 2012 RESULTS: IM IFNbeta-1a significantly decreased the median number of gadolinium-enhanced lesions from 2.5 to 0.3 (p < 0.0001) compared with pre-treatment values. Gadolinium 68-78 interferon beta 1 Homo sapiens 12-19 23026532-6 2012 In interferon-beta1b treated MS patients, NO(2)+NO(3), 3-NT and RSNO plasma concentrations were significantly lower (p<0.05), while arginase activity, ADMA and SDMA levels were significantly increased (p<0.05) during the therapy, compared to the baseline levels in treated patients. symmetric dimethylarginine 163-167 interferon beta 1 Homo sapiens 3-19 22910063-12 2012 CONCLUSIONS: IFN-beta as add-on to azathioprine decreases relapse activity in active multiple sclerosis. Azathioprine 35-47 interferon beta 1 Homo sapiens 13-21 22910063-13 2012 In contrast, azathioprine add-on in patients with suboptimal response to IFN-beta does not improve the control over the disease activity. Azathioprine 13-25 interferon beta 1 Homo sapiens 73-81 23063848-0 2012 Analysis of interferon-beta mRNA stability control after poly(I:C) stimulation using RNA metabolic labeling by ethynyluridine. Poly I-C 57-66 interferon beta 1 Homo sapiens 12-27 23103873-5 2012 The induction of interferon-beta (IFN-beta) and/or IFN-lambda1 in response to stimulation by the dsRNA analogue polyinosinic:polycytidylic acid (poly(I:C)) was dependent on TLR3 and UNC-93B in all cells tested. Poly I-C 112-143 interferon beta 1 Homo sapiens 17-32 23103873-5 2012 The induction of interferon-beta (IFN-beta) and/or IFN-lambda1 in response to stimulation by the dsRNA analogue polyinosinic:polycytidylic acid (poly(I:C)) was dependent on TLR3 and UNC-93B in all cells tested. Poly I-C 112-143 interferon beta 1 Homo sapiens 34-42 23066157-3 2012 Small interfering RNA-mediated knockdown of Act1 in primary human skin fibroblasts specifically attenuates expression of IFN-beta and IFN-stimulated antiviral genes induced by a synthetic viral mimic, polyinosinic-polycytidylic acid. Poly I-C 201-232 interferon beta 1 Homo sapiens 121-129 23063848-0 2012 Analysis of interferon-beta mRNA stability control after poly(I:C) stimulation using RNA metabolic labeling by ethynyluridine. ethynyluridine 111-125 interferon beta 1 Homo sapiens 12-27 22915814-5 2012 Poly(I C) pretreatment upregulated beta interferon (IFN-beta), IFN-gamma, IL-1beta, and tumor necrosis factor (TNF) gene expression in the lungs. Poly I-C 0-8 interferon beta 1 Homo sapiens 35-60 23063848-2 2012 Treatment with polyinosinic:polycytidylic acid (poly(I:C)) induces transient accumulation of IFN-beta mRNA, which involves an increase and a decrease of IFN-beta mRNA. Poly I-C 15-46 interferon beta 1 Homo sapiens 93-101 23063848-2 2012 Treatment with polyinosinic:polycytidylic acid (poly(I:C)) induces transient accumulation of IFN-beta mRNA, which involves an increase and a decrease of IFN-beta mRNA. Poly I-C 15-46 interferon beta 1 Homo sapiens 153-161 23063848-2 2012 Treatment with polyinosinic:polycytidylic acid (poly(I:C)) induces transient accumulation of IFN-beta mRNA, which involves an increase and a decrease of IFN-beta mRNA. Poly I-C 48-57 interferon beta 1 Homo sapiens 93-101 23063848-2 2012 Treatment with polyinosinic:polycytidylic acid (poly(I:C)) induces transient accumulation of IFN-beta mRNA, which involves an increase and a decrease of IFN-beta mRNA. Poly I-C 48-57 interferon beta 1 Homo sapiens 153-161 22972931-5 2012 In contrast, 3-MA suppressed LPS-induced IFN-beta production and STAT signaling. 3-methyladenine 13-17 interferon beta 1 Homo sapiens 41-49 22948139-8 2012 Additionally, inhibition of translation by cycloheximide treatment rescued IFN-beta induction following PKR knockdown but not IPS-1 knockdown. Cycloheximide 43-56 interferon beta 1 Homo sapiens 75-83 22730064-6 2012 Stimulation with RSV or Poly(I:C) induced IFN-beta expression, which resulted in an increased expression of the viral receptors TLR3 and RIG-I, as well as an increased NOD2 expression. Poly I-C 24-32 interferon beta 1 Homo sapiens 42-50 22564111-9 2012 CONCLUSIONS: High correlation is demonstrated between the results obtained by the three methods, and we suggest the possibility of using ELISA measurements of BAbs to identify patients with high titres of anti-IFN-beta antibodies that block the biological response to IFN-beta. babs 159-163 interferon beta 1 Homo sapiens 210-218 22564111-9 2012 CONCLUSIONS: High correlation is demonstrated between the results obtained by the three methods, and we suggest the possibility of using ELISA measurements of BAbs to identify patients with high titres of anti-IFN-beta antibodies that block the biological response to IFN-beta. babs 159-163 interferon beta 1 Homo sapiens 268-276 22797253-0 2012 Temporally designed treatment of melanoma cells by ATRA and polyI: C results in enhanced chemokine and IFNbeta secretion controlled differently by TLR3 and MDA5. Poly I-C 60-68 interferon beta 1 Homo sapiens 103-110 22750230-0 2012 Mechanism of inhibition of lipopolysaccharide-induced interferon-beta production by 2-aminopurine. 2-Aminopurine 84-97 interferon beta 1 Homo sapiens 54-69 22750230-2 2012 Previously, we reported that 2-AP inhibits Toll-like receptor (TLR) ligand-induced nitric oxide production through the prevention of interferon (IFN)-beta production. 2-Aminopurine 29-33 interferon beta 1 Homo sapiens 133-154 22750230-3 2012 In this study, we investigated the mechanisms for 2-AP inhibition of lipopolysaccharide (LPS)-induced IFN-beta production. 2-Aminopurine 50-54 interferon beta 1 Homo sapiens 102-110 22750230-4 2012 A reporter gene assay showed that LPS-induced IFN-beta promoter, but not nuclear factor (NF)-kappaB, activation was significantly inhibited by 2-AP. 2-Aminopurine 143-147 interferon beta 1 Homo sapiens 46-54 22750230-5 2012 IFN-beta promoter activation induced by the overexpression of Toll/interleukin-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) was significantly inhibited by 2-AP in a dose-dependent manner, while TRIF- or myeloid differentiation primary response gene 88-dependent NF-kappaB activation was not inhibited. 2-Aminopurine 172-176 interferon beta 1 Homo sapiens 0-8 22750230-5 2012 IFN-beta promoter activation induced by the overexpression of Toll/interleukin-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) was significantly inhibited by 2-AP in a dose-dependent manner, while TRIF- or myeloid differentiation primary response gene 88-dependent NF-kappaB activation was not inhibited. 2-Aminopurine 172-176 interferon beta 1 Homo sapiens 125-133 22790964-6 2012 Treatment of Hep3B, human liver cancer cells, with the prodrug 5-fluorocytosine (5-FC) in the presence of HB1.F3.CD or HB1.F3.CD.IFN-beta cells resulted in the inhibition of Hep3B cell growth. Flucytosine 63-79 interferon beta 1 Homo sapiens 129-137 22249201-4 2012 We found that in response to poly I:C and LPS, monocytes, MDM and MDDC express a subtype pattern restricted primarily to IFN-beta and IFN-lambda1. Poly I-C 29-37 interferon beta 1 Homo sapiens 121-129 22972931-10 2012 These results not only shed new light on the action mechanisms of 3-MA to differentially regulate inflammatory outcomes derived from TLR4-mediated MyD88 and Toll/IL-1R domain-containing adapter inducing IFN-beta pathways, but also highlight the necessity to check autophagy status upon taking 3-MA as a general autophagy inhibitor. 3-methyladenine 66-70 interferon beta 1 Homo sapiens 203-211 22971466-0 2012 Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Phospholipids 5-17 interferon beta 1 Homo sapiens 61-77 22976494-7 2012 In total, 5.2% of IFN-beta-1a-treated patients (4/77) and 30.3% of IFN-beta-1b-treated patients (46/152) were positive for Nabs. nabs 123-127 interferon beta 1 Homo sapiens 67-75 23202910-8 2012 The HB1.F3.CE, HB.F3.CD, or HB1.F3.CD.IFN-beta cells significantly reduced the LNCaP cell viability in the presence of the prodrugs 5-FC or CPT-11. Irinotecan 140-146 interferon beta 1 Homo sapiens 38-46 22842821-6 2012 More importantly, ZD55-IFN-beta showed a synergistic effect on cancer cells when combined with doxorubicin. Doxorubicin 95-106 interferon beta 1 Homo sapiens 23-31 22487191-5 2012 By induction with IFN-beta, even in refractory cases, the high virus negative conversion rate in the early treatment phase and actions of pegylated IFN-alpha-2b and ribavirin in the maintenance treatment phase led to an additive effect. Ribavirin 165-174 interferon beta 1 Homo sapiens 18-26 22105341-0 2012 Evidence of vitamin D and interferon-beta cross-talk in human osteoblasts with 1alpha,25-dihydroxyvitamin D3 being dominant over interferon-beta in stimulating mineralization. Calcitriol 79-108 interferon beta 1 Homo sapiens 26-41 22912934-4 2012 Previous studies have shown that a variety of drugs such as interferon-beta (IFN-beta), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increased the sensitivity of TMZ through MGMT-dependent or MGMT-independent mechanisms. Valproic Acid 141-144 interferon beta 1 Homo sapiens 60-75 22912934-4 2012 Previous studies have shown that a variety of drugs such as interferon-beta (IFN-beta), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increased the sensitivity of TMZ through MGMT-dependent or MGMT-independent mechanisms. Valproic Acid 141-144 interferon beta 1 Homo sapiens 77-85 22912934-4 2012 Previous studies have shown that a variety of drugs such as interferon-beta (IFN-beta), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increased the sensitivity of TMZ through MGMT-dependent or MGMT-independent mechanisms. Temozolomide 175-178 interferon beta 1 Homo sapiens 60-75 22912934-4 2012 Previous studies have shown that a variety of drugs such as interferon-beta (IFN-beta), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increased the sensitivity of TMZ through MGMT-dependent or MGMT-independent mechanisms. Temozolomide 175-178 interferon beta 1 Homo sapiens 77-85 22745372-5 2012 Further study showed that NP1 blocked IFN-beta activation in response to SeV, poly(deoxyadenylic-thymidylic) acid, and IFN-beta pathway inducers, including retinoic acid-inducible protein I, mitochondrial antiviral signaling protein, inhibitor of kappaB kinase epsilon, and TANK-binding kinase 1. poly(deoxyadenylic-thymidylic) acid 78-113 interferon beta 1 Homo sapiens 38-46 23650472-5 2012 Additionally, RRMS patients with suboptimal response to interferon beta may benefit from reduced relapse rate after switching to GA, and those with clinically isolated syndrome may benefit from delayed conversion to CDMS. Glatiramer Acetate 129-131 interferon beta 1 Homo sapiens 56-71 22568929-5 2012 We also found that synthetic dsRNA-polyinosinic-polycytidilic acid, a Toll-like receptor 3 ligand, induced apoptosis of oral squamous carcinoma cells mainly via Toll-like receptor 3, through interferon-beta production and activation of caspases 3 and 9. polyinosinic-polycytidilic acid 35-66 interferon beta 1 Homo sapiens 191-206 22810896-4 2012 Unlike other TLRs, TLR3 requires phosphorylation of two specific tyrosine residues in its cytoplasmic domain to recruit the adaptor protein TRIF (Toll-interleukin-1 receptor domain-containing adaptor protein inducing interferon-beta) and initiate the antiviral response. Tyrosine 65-73 interferon beta 1 Homo sapiens 217-232 22700809-0 2012 Vitamin D and disease activity in multiple sclerosis before and during interferon-beta treatment. Vitamin D 0-9 interferon beta 1 Homo sapiens 71-86 22700809-4 2012 RESULTS: Prior to IFN-beta treatment, each 10 nmol/L increase in 25-hydroxyvitamin D was associated with 12.7% (p = 0.037) reduced odds for new T1 gadolinium-enhancing lesions, 11.7% (p = 0.044) for new T2 lesions, and 14.1% (p = 0.024) for combined unique activity. 25-hydroxyvitamin D 65-84 interferon beta 1 Homo sapiens 18-26 22700816-1 2012 OBJECTIVE: To determine whether interferon-beta (IFN-beta) medication use is associated with vitamin D levels and whether the two interact in exerting effects on relapse risk. Vitamin D 93-102 interferon beta 1 Homo sapiens 32-47 22700816-1 2012 OBJECTIVE: To determine whether interferon-beta (IFN-beta) medication use is associated with vitamin D levels and whether the two interact in exerting effects on relapse risk. Vitamin D 93-102 interferon beta 1 Homo sapiens 49-57 22700816-8 2012 CONCLUSION: In this study, we found that IFN-beta therapy is associated with greater production of vitamin D from sun exposure, suggesting part of the therapeutic effects of IFN-beta on relapse in MS may be through modulation of vitamin D metabolism. Vitamin D 99-108 interferon beta 1 Homo sapiens 41-49 22700816-8 2012 CONCLUSION: In this study, we found that IFN-beta therapy is associated with greater production of vitamin D from sun exposure, suggesting part of the therapeutic effects of IFN-beta on relapse in MS may be through modulation of vitamin D metabolism. Vitamin D 99-108 interferon beta 1 Homo sapiens 174-182 22700816-8 2012 CONCLUSION: In this study, we found that IFN-beta therapy is associated with greater production of vitamin D from sun exposure, suggesting part of the therapeutic effects of IFN-beta on relapse in MS may be through modulation of vitamin D metabolism. Vitamin D 229-238 interferon beta 1 Homo sapiens 41-49 22700816-8 2012 CONCLUSION: In this study, we found that IFN-beta therapy is associated with greater production of vitamin D from sun exposure, suggesting part of the therapeutic effects of IFN-beta on relapse in MS may be through modulation of vitamin D metabolism. Vitamin D 229-238 interferon beta 1 Homo sapiens 174-182 22700816-9 2012 These findings suggest persons being treated with IFN-beta should have vitamin D status monitored and maintained in the sufficiency range. Vitamin D 71-80 interferon beta 1 Homo sapiens 50-58 22595795-7 2012 In chemotherapy-sensitive EW7 monolayers, the combination of hIFNbeta gene and antineoplastic drugs displayed only additive or counteractive (methotrexate) effects, suggesting that cytotoxic mechanisms triggered by hIFNbeta gene lipofection could be saturating the signaling pathways. Methotrexate 142-154 interferon beta 1 Homo sapiens 61-69 22595795-8 2012 Conversely, in chemotherapy-resistant EW7 spheroids or M8 cells, the combination of hIFNbeta with drugs that mainly operate at the genotoxic level (doxorubicin, methotrexate and paclitaxel) presented only additive effects. Doxorubicin 148-159 interferon beta 1 Homo sapiens 84-92 22595795-8 2012 Conversely, in chemotherapy-resistant EW7 spheroids or M8 cells, the combination of hIFNbeta with drugs that mainly operate at the genotoxic level (doxorubicin, methotrexate and paclitaxel) presented only additive effects. Methotrexate 161-173 interferon beta 1 Homo sapiens 84-92 22595795-8 2012 Conversely, in chemotherapy-resistant EW7 spheroids or M8 cells, the combination of hIFNbeta with drugs that mainly operate at the genotoxic level (doxorubicin, methotrexate and paclitaxel) presented only additive effects. Paclitaxel 178-188 interferon beta 1 Homo sapiens 84-92 22595795-9 2012 However, drugs that also increase pro-oxidant species can complement the antitumor efficacy of the hIFNbeta gene and clearly caused potentiated effects (bleomycin, bortezomib, carboplatin, etoposide and vincristine). Bleomycin 153-162 interferon beta 1 Homo sapiens 99-107 22595795-9 2012 However, drugs that also increase pro-oxidant species can complement the antitumor efficacy of the hIFNbeta gene and clearly caused potentiated effects (bleomycin, bortezomib, carboplatin, etoposide and vincristine). Bortezomib 164-174 interferon beta 1 Homo sapiens 99-107 22595795-9 2012 However, drugs that also increase pro-oxidant species can complement the antitumor efficacy of the hIFNbeta gene and clearly caused potentiated effects (bleomycin, bortezomib, carboplatin, etoposide and vincristine). Carboplatin 176-187 interferon beta 1 Homo sapiens 99-107 22595795-9 2012 However, drugs that also increase pro-oxidant species can complement the antitumor efficacy of the hIFNbeta gene and clearly caused potentiated effects (bleomycin, bortezomib, carboplatin, etoposide and vincristine). Etoposide 189-198 interferon beta 1 Homo sapiens 99-107 22595795-9 2012 However, drugs that also increase pro-oxidant species can complement the antitumor efficacy of the hIFNbeta gene and clearly caused potentiated effects (bleomycin, bortezomib, carboplatin, etoposide and vincristine). Vincristine 203-214 interferon beta 1 Homo sapiens 99-107 22543056-0 2012 Capacity of capsazepinoids to relax human small airways and inhibit TLR3-induced TSLP and IFNbeta production in diseased bronchial epithelial cells. capsazepinoids 12-26 interferon beta 1 Homo sapiens 90-97 22543056-7 2012 TLR3-induced TSLP, TNFalpha, CXCL8, and IFNbeta mRNA and protein levels were dose-dependently and non-selectively inhibited by capsazepine, equally in cells from asthmatic and COPD donors. capsazepine 127-138 interferon beta 1 Homo sapiens 40-47 22543056-11 2012 We conclude that similar mechanisms may be involved in capsazepine-like inhibition of TLR3-induced epithelial TSLP and IFNbeta and that these are distinct from mechanisms involved in relaxation of small airways by these compounds. capsazepine 55-66 interferon beta 1 Homo sapiens 119-126 22533963-6 2012 In SH-SY5Y cells, blockade of either Janus kinase with pyridone 6 or signal transducer and activator of transcription (STAT) 1 with siRNA transfection attenuated IFN-beta-induced TrkB down-regulation. Pyridones 55-63 interferon beta 1 Homo sapiens 162-170 22703536-9 2012 CONCLUSIONS: There are considerable differences in the detection and quantification of IFNB-induced NAbs among laboratories offering NAb testing for clinical practice using different assay methods. nab 100-103 interferon beta 1 Homo sapiens 87-91 22698190-1 2012 BACKGROUND: Double-stranded RNA (dsRNA) and its mimic, polyinosinic acid: polycytidylic acid [Poly (I:C)], are recognized by toll-like receptor 3 (TLR3) and induce interferon (IFN)-beta in many cell types. Poly I 55-72 interferon beta 1 Homo sapiens 164-185 22698190-1 2012 BACKGROUND: Double-stranded RNA (dsRNA) and its mimic, polyinosinic acid: polycytidylic acid [Poly (I:C)], are recognized by toll-like receptor 3 (TLR3) and induce interferon (IFN)-beta in many cell types. Poly C 74-92 interferon beta 1 Homo sapiens 164-185 22698399-3 2012 Lenalidomide kills ABC DLBCL cells by augmenting interferon beta (IFNbeta) production, owing to the oncogenic MYD88 mutations in these lymphomas. Lenalidomide 0-12 interferon beta 1 Homo sapiens 49-64 22698399-3 2012 Lenalidomide kills ABC DLBCL cells by augmenting interferon beta (IFNbeta) production, owing to the oncogenic MYD88 mutations in these lymphomas. Lenalidomide 0-12 interferon beta 1 Homo sapiens 66-73 22698399-4 2012 In a cereblon-dependent fashion, lenalidomide downregulates IRF4 and SPIB, transcription factors that together prevent IFNbeta production by repressing IRF7 and amplify prosurvival NF-kappaB signaling by transactivating CARD11. Lenalidomide 33-45 interferon beta 1 Homo sapiens 119-126 22622860-5 2012 The number of gadolinium-enhancing T1 (T1-Gd) lesions was reduced in both teriflunomide groups, with relative risk reductions (RRRs) of 84.6% (p = 0.0005) and 82.8% (p < 0.0001) for 7 and 14 mg, respectively, compared with IFNbeta alone at 48 weeks. teriflunomide 74-87 interferon beta 1 Homo sapiens 226-233 22137446-4 2012 OBJECTIVE: To assess the influence of IFN-beta treatment on melatonin secretion, fatigue and sleep characteristics in patients with MS. METHODS: 13 MS patients and 12 healthy controls participated. Melatonin 60-69 interferon beta 1 Homo sapiens 38-46 21680782-2 2012 Two randomized, blinded phase I studies were conducted: a single-dose study (n = 60) comparing subcutaneous or intramuscular PEG-IFN beta-1a (63, 125, or 188 microg) with intramuscular unmodified IFN beta-1a 30 microg and a multiple-dose study (n = 69) comparing subcutaneous PEG-IFN beta-1a dosed once every 2 or 4 weeks with placebo. Polyethylene Glycols 125-128 interferon beta 1 Homo sapiens 129-137 21680782-5 2012 Increases in neopterin and 2",5"-OAS levels and changes in T helper cell pathway gene expression and lymphocyte subsets were greater and more sustained with PEG-IFN beta-1a than with unmodified IFN beta-1a. Neopterin 13-22 interferon beta 1 Homo sapiens 161-169 22623753-2 2012 Here, we demonstrate that signaling by IFNAR (the shared receptor for IFN-alpha and IFN-beta) on macrophages inhibits activation of Rac1 and the generation of reactive oxygen species (ROS) through suppressor of cytokine signaling 1 (SOCS1). Reactive Oxygen Species 159-182 interferon beta 1 Homo sapiens 84-92 22623753-2 2012 Here, we demonstrate that signaling by IFNAR (the shared receptor for IFN-alpha and IFN-beta) on macrophages inhibits activation of Rac1 and the generation of reactive oxygen species (ROS) through suppressor of cytokine signaling 1 (SOCS1). Reactive Oxygen Species 184-187 interferon beta 1 Homo sapiens 84-92 22450807-8 2012 In addition, LPS and IFN-beta-induced apoptosis was absent in cultured cells lacking STAT1, and, unlike in wild-type cells, a permissive effect of rapamycin was not observed. Sirolimus 147-156 interferon beta 1 Homo sapiens 21-29 22494956-11 2012 In patients who relapsed and had lesion activity despite treatment with interferon beta in the previous year, the ARR ratio for fingolimod 0 5 mg versus placebo was 0 38 (95% CI 0 21-0 68, p=0 0011), and for treatment-naive patients with rapidly evolving severe disease it was 0 33 (0 18-0 62, p=0 0006). Fingolimod Hydrochloride 128-138 interferon beta 1 Homo sapiens 72-87 22191463-6 2012 At approximately equimolar doses of IFNbetaFc (10 mug/kg) and IFNbeta-1a (3 mug/kg), the stimulation of neopterin over background levels was approximately equivalent, demonstrating that the longer half-life of IFNbetaFc compensated for the lower relative specific antiviral activity of IFNbetaFc measured in vitro. Neopterin 104-113 interferon beta 1 Homo sapiens 36-43 22191463-6 2012 At approximately equimolar doses of IFNbetaFc (10 mug/kg) and IFNbeta-1a (3 mug/kg), the stimulation of neopterin over background levels was approximately equivalent, demonstrating that the longer half-life of IFNbetaFc compensated for the lower relative specific antiviral activity of IFNbetaFc measured in vitro. ifnbetafc 210-219 interferon beta 1 Homo sapiens 36-43 22191463-6 2012 At approximately equimolar doses of IFNbetaFc (10 mug/kg) and IFNbeta-1a (3 mug/kg), the stimulation of neopterin over background levels was approximately equivalent, demonstrating that the longer half-life of IFNbetaFc compensated for the lower relative specific antiviral activity of IFNbetaFc measured in vitro. ifnbetafc 210-219 interferon beta 1 Homo sapiens 36-43 22404596-3 2012 The 166 residue polypeptide chain of interferon-beta was prepared by covalent condensation of two synthetic peptide segments and a glycosylated synthetic peptide bearing a complex-type glycan of biological origin. Polysaccharides 185-191 interferon beta 1 Homo sapiens 37-52 22404596-5 2012 Selective desulfurization followed by deprotection of the two Cys(Acm) residues gave the target full-length polypeptide chain of interferon-beta bearing either a complex-type sialyl biantennary oligosaccharide or its asialo form. Cysteine 62-65 interferon beta 1 Homo sapiens 129-144 22404596-5 2012 Selective desulfurization followed by deprotection of the two Cys(Acm) residues gave the target full-length polypeptide chain of interferon-beta bearing either a complex-type sialyl biantennary oligosaccharide or its asialo form. Oligosaccharides 194-209 interferon beta 1 Homo sapiens 129-144 22404596-6 2012 Subsequent folding with concomitant formation of the native disulfide bond afforded correctly folded homogeneous glycosyl-interferon-beta. Disulfides 60-69 interferon beta 1 Homo sapiens 122-137 22555508-8 2012 The great bystander effect of the hIFNbeta gene lipofection, involving the production of reactive oxygen species, would be among the main causes of its success. Reactive Oxygen Species 89-112 interferon beta 1 Homo sapiens 34-42 22013146-2 2012 Persistency depends on NAb titers, which differ between IFNbeta preparations. nab 23-26 interferon beta 1 Homo sapiens 56-63 22013146-3 2012 OBJECTIVE: This study evaluated IFNbeta preparation-specific NAb cut-off titers during early treatment for prediction of NAb persistency. nab 61-64 interferon beta 1 Homo sapiens 32-39 22013146-3 2012 OBJECTIVE: This study evaluated IFNbeta preparation-specific NAb cut-off titers during early treatment for prediction of NAb persistency. nab 121-124 interferon beta 1 Homo sapiens 32-39 22013146-8 2012 NAb frequency significantly decreased by 40.7% in the IFNbeta-1a and by 60% in the IFNbeta-1b group at follow-up after a mean time of 75.4 months on treatment, and median NAb titers decreased significantly in both groups. nab 0-3 interferon beta 1 Homo sapiens 54-61 22013146-9 2012 During baseline, NAb titers of >258 neutralizing units (NU) had a sensitivity of 81.3% and a specificity of 90.9% in the IFNbeta-1a group, whereas titers of >460 NU had a sensitivity of 100% and a specificity of 91.7% in the IFNbeta-1b group to predict persistency at follow-up. nab 17-20 interferon beta 1 Homo sapiens 124-131 22013146-11 2012 CONCLUSION: IFNbeta preparation-specific NAb cut-off titers for prediction of NAb persistency, which may be useful in individual treatment decision making, are provided. nab 41-44 interferon beta 1 Homo sapiens 12-19 22013146-11 2012 CONCLUSION: IFNbeta preparation-specific NAb cut-off titers for prediction of NAb persistency, which may be useful in individual treatment decision making, are provided. nab 78-81 interferon beta 1 Homo sapiens 12-19 22513956-19 2012 The mean number of new or enlarged gadolinium contrast-enhancing lesions was significantly decreased in the interferon beta and high-dose daclizumab group, compared with that in the interferon beta and placebo group. Gadolinium 35-45 interferon beta 1 Homo sapiens 108-123 22133480-1 2012 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate 73-91 interferon beta 1 Homo sapiens 167-182 22133480-1 2012 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate 73-91 interferon beta 1 Homo sapiens 184-192 22133480-1 2012 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate 93-95 interferon beta 1 Homo sapiens 167-182 22133480-1 2012 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate 93-95 interferon beta 1 Homo sapiens 184-192 22357660-6 2012 Such enhancement depended on autocrine IFN-beta being enhanced by RBV. Ribavirin 66-69 interferon beta 1 Homo sapiens 39-47 22357660-9 2012 CONCLUSIONS: Ribavirin augments the anti-HCV effects of IFN-alpha induced by ISGs through enhancing autocrine IFN-beta. Ribavirin 13-22 interferon beta 1 Homo sapiens 110-118 22285490-0 2012 LY294002 inhibits TLR3/4-mediated IFN-beta production via inhibition of IRF3 activation with a PI3K-independent mechanism. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 interferon beta 1 Homo sapiens 34-42 22285490-2 2012 In this report, we analyzed the effect of two known phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 and wortmannin on LPS- and poly(I:C)-induced IFN-beta production in peritoneal macrophages. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 100-108 interferon beta 1 Homo sapiens 154-162 22285490-2 2012 In this report, we analyzed the effect of two known phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 and wortmannin on LPS- and poly(I:C)-induced IFN-beta production in peritoneal macrophages. Wortmannin 113-123 interferon beta 1 Homo sapiens 154-162 22285490-3 2012 LY294002 inhibited LPS- and poly(I:C)-induced IFN-beta transcription and secretion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 interferon beta 1 Homo sapiens 46-54 22285490-5 2012 Furthermore, IRF3 transcriptional activation and binding to IFN-beta promoter were found to be inhibited by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 108-116 interferon beta 1 Homo sapiens 60-68 22285490-6 2012 Therefore, our findings demonstrate LY294002 negatively regulates LPS- and poly(I:C)-induced IFN-beta production through inhibition of IRF3 activation in a PI3K-independent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 interferon beta 1 Homo sapiens 93-101 22137446-8 2012 CONCLUSION: Our findings suggest dysregulation of Melatonin secretion in MS, which may be influenced by IFN-beta treatment. Melatonin 50-59 interferon beta 1 Homo sapiens 104-112 22024499-8 2012 Fibroblasts with the L412F variant showed decreased secretion of IFNlambda in response to stimulation with both polyinosine ploycytidylic acid (Poly I:C) and CMV and P2.1 cells transfected with the L412F variant showed reduced secretion of IFN-beta in comparison to cells transfected with the wild type receptor. ifnlambda 65-74 interferon beta 1 Homo sapiens 240-248 22036215-5 2012 IFN responses in PBMNC were assessed by in vitro IFN-beta-induced activation of phospho-tyrosine-STAT1 and phospho-serine-STAT1 transcription factors, and MxA proteins using Western blots. Tyrosine 88-96 interferon beta 1 Homo sapiens 49-57 21920559-6 2012 RESULTS: The adjusted PCBV from baseline to year 5 was -2.27% in GA, -2.62% in LD-IFNB, and -3.21% in the HD-IFNB groups (-2.27 vs -2.62, p=0.0036; -2.27 vs -3.21, p<0.0001; -2.62 vs -3.21, p<0.0001). pcbv 22-26 interferon beta 1 Homo sapiens 82-86 21871555-0 2012 The PPAR-gamma agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-beta treated pancreatic cancer cells. Troglitazone 23-35 interferon beta 1 Homo sapiens 99-114 21871555-2 2012 In addition, since IFN-mediated signalling components STATs are controlled by PPAR gamma we studied the pharmacological interaction between recombinant IFN-beta and the PPAR-gamma agonist troglitazone (TGZ). Troglitazone 202-205 interferon beta 1 Homo sapiens 152-160 21871555-2 2012 In addition, since IFN-mediated signalling components STATs are controlled by PPAR gamma we studied the pharmacological interaction between recombinant IFN-beta and the PPAR-gamma agonist troglitazone (TGZ). Troglitazone 188-200 interferon beta 1 Homo sapiens 152-160 21691053-8 2012 Endosomal TLR3 inhibition by chloroquine dose-dependently inhibited dsRNA-induced TSLP generation and reduced generation of CXCL8, TNF-alpha, and IFN-beta. Chloroquine 29-40 interferon beta 1 Homo sapiens 146-154 21918983-0 2012 Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. Metals 89-94 interferon beta 1 Homo sapiens 36-51 21918983-0 2012 Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. Polystyrenes 100-111 interferon beta 1 Homo sapiens 36-51 21918983-9 2012 Incubation with stainless steel considerably enhanced the immunogenicity of rhIFNbeta-1a in transgenic mice immune tolerant for human interferon beta. Stainless Steel 16-31 interferon beta 1 Homo sapiens 134-149 21716324-5 2011 Bafilomycin A1, which inhibits endosomal acidification to block the TLR3 pathway, blocked the dsRNA-induced expression of TSLP, IL-8, IFN-beta, and other molecules including the dsRNA sensors, whereas it did not inhibit diacyllipopeptide-induced expression of TSLP and IL-8. bafilomycin A1 0-14 interferon beta 1 Homo sapiens 134-142 23056170-3 2012 In our efforts to identify small molecules that selectively enhance PRR-mediated antiviral, but not the detrimental inflammatory response, we discovered a compound, RO 90-7501 ("2"-(4-Aminophenyl)-[2,5"-bi-1H-benzimidazol]-5-amine), that significantly promoted both TLR3 and RLR ligand-induced IFN-beta gene expression and antiviral response, most likely via selective activation of p38 mitogen-activated protein kinase (MAPK) pathway. ro 90-7501 ("2"-(4-aminophenyl)-[2,5"-bi-1h-benzimidazol]-5-amine 165-230 interferon beta 1 Homo sapiens 294-302 23028806-8 2012 The overexpression of MAVS enhanced interferon-beta (IFN-beta) expression in response to polyI:C, suggesting that the degradation of MAVS contributes to the suppression of the hyper-immune reaction in late-phase antiviral signaling. Poly I-C 89-96 interferon beta 1 Homo sapiens 36-51 23028806-8 2012 The overexpression of MAVS enhanced interferon-beta (IFN-beta) expression in response to polyI:C, suggesting that the degradation of MAVS contributes to the suppression of the hyper-immune reaction in late-phase antiviral signaling. Poly I-C 89-96 interferon beta 1 Homo sapiens 53-61 22879913-3 2012 Although it has been widely noted that interferon-beta (IFNbeta) downregulates both the basal and phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 expression at the transcriptional level, the molecular mechanism of this repression is poorly understood. Tetradecanoylphorbol Acetate 98-129 interferon beta 1 Homo sapiens 39-54 22879913-3 2012 Although it has been widely noted that interferon-beta (IFNbeta) downregulates both the basal and phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 expression at the transcriptional level, the molecular mechanism of this repression is poorly understood. Tetradecanoylphorbol Acetate 98-129 interferon beta 1 Homo sapiens 56-63 22879913-3 2012 Although it has been widely noted that interferon-beta (IFNbeta) downregulates both the basal and phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 expression at the transcriptional level, the molecular mechanism of this repression is poorly understood. Tetradecanoylphorbol Acetate 131-134 interferon beta 1 Homo sapiens 39-54 22879913-3 2012 Although it has been widely noted that interferon-beta (IFNbeta) downregulates both the basal and phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 expression at the transcriptional level, the molecular mechanism of this repression is poorly understood. Tetradecanoylphorbol Acetate 131-134 interferon beta 1 Homo sapiens 56-63 22844514-4 2012 A tyrosine-scanning mutational analysis revealed that MAVS tyrosine-9 (Y9) is a phosphorylation site that is required for IFN-beta signaling. Tyrosine 2-10 interferon beta 1 Homo sapiens 122-130 22844514-4 2012 A tyrosine-scanning mutational analysis revealed that MAVS tyrosine-9 (Y9) is a phosphorylation site that is required for IFN-beta signaling. Tyrosine 59-67 interferon beta 1 Homo sapiens 122-130 22629344-3 2012 In addition, IL-15, IL-18, and IFN-beta secreted by poly I:C-treated macrophages are also involved in NKG2D expression and NK cell activation. Poly I-C 52-60 interferon beta 1 Homo sapiens 31-39 22479513-7 2012 Further studies revealed that mutating Y393 to phenylalanine inhibits the ability of TRIM21 to interact with its substrate, IRF3, thus providing a molecular explanation for the lack of activity of Y393 on the IFN-beta promoter. Phenylalanine 47-60 interferon beta 1 Homo sapiens 209-217 22396773-3 2012 In the current studies, we demonstrate that topotecan (TPT), a topoisomerase I-targeting drug with a well-defined mechanism of action, stimulates major histocompatibility complex class I (MHC I) expression in breast cancer cells through elevated expression/secretion of interferon-beta (IFN-beta) and activation of type I IFN signaling. Topotecan 44-53 interferon beta 1 Homo sapiens 270-285 22396773-3 2012 In the current studies, we demonstrate that topotecan (TPT), a topoisomerase I-targeting drug with a well-defined mechanism of action, stimulates major histocompatibility complex class I (MHC I) expression in breast cancer cells through elevated expression/secretion of interferon-beta (IFN-beta) and activation of type I IFN signaling. Topotecan 44-53 interferon beta 1 Homo sapiens 287-295 22396773-3 2012 In the current studies, we demonstrate that topotecan (TPT), a topoisomerase I-targeting drug with a well-defined mechanism of action, stimulates major histocompatibility complex class I (MHC I) expression in breast cancer cells through elevated expression/secretion of interferon-beta (IFN-beta) and activation of type I IFN signaling. Topotecan 55-58 interferon beta 1 Homo sapiens 270-285 22396773-3 2012 In the current studies, we demonstrate that topotecan (TPT), a topoisomerase I-targeting drug with a well-defined mechanism of action, stimulates major histocompatibility complex class I (MHC I) expression in breast cancer cells through elevated expression/secretion of interferon-beta (IFN-beta) and activation of type I IFN signaling. Topotecan 55-58 interferon beta 1 Homo sapiens 287-295 22396773-6 2012 Consistently, TPT-treated cells exhibit elevated expression of multiple cytokines such as IFN-beta, TNF-alpha, IL-6 and IL-8. Topotecan 14-17 interferon beta 1 Homo sapiens 90-98 22396773-7 2012 Third, either knocking down the type I interferon receptor subunit 1 (IFNAR1) or addition of neutralizing antibody against IFN-beta results in reduced MHC I expression in TPT-treated cells. Topotecan 171-174 interferon beta 1 Homo sapiens 123-131 22396773-8 2012 Together, these results suggest that TPT induces increased IFN-beta autocrine/paracrine signaling through type I IFN receptor, resulting in the elevated MHC I expression in tumor cells. Topotecan 37-40 interferon beta 1 Homo sapiens 59-67 22396773-9 2012 Studies have also demonstrated that other chemotherapeutic agents (e.g. etoposide, cisplatin, paclitaxel and vinblastine) similarly induce increased IFN-beta secretion and elevated MHC I expression. Etoposide 72-81 interferon beta 1 Homo sapiens 149-157 22396773-9 2012 Studies have also demonstrated that other chemotherapeutic agents (e.g. etoposide, cisplatin, paclitaxel and vinblastine) similarly induce increased IFN-beta secretion and elevated MHC I expression. Cisplatin 83-92 interferon beta 1 Homo sapiens 149-157 22396773-9 2012 Studies have also demonstrated that other chemotherapeutic agents (e.g. etoposide, cisplatin, paclitaxel and vinblastine) similarly induce increased IFN-beta secretion and elevated MHC I expression. Paclitaxel 94-104 interferon beta 1 Homo sapiens 149-157 22396773-9 2012 Studies have also demonstrated that other chemotherapeutic agents (e.g. etoposide, cisplatin, paclitaxel and vinblastine) similarly induce increased IFN-beta secretion and elevated MHC I expression. Vinblastine 109-120 interferon beta 1 Homo sapiens 149-157 21964048-5 2011 The treatment of EPCs with TLR3 agonist Poly I:C up-regulated the expression of cytokines IL-1beta, IL-6, IL-8, TNF-alpha, IFN-alpha, and IFN-beta, indicating that EPCs expressed functional TLR3. Poly I 40-46 interferon beta 1 Homo sapiens 138-146 21964048-5 2011 The treatment of EPCs with TLR3 agonist Poly I:C up-regulated the expression of cytokines IL-1beta, IL-6, IL-8, TNF-alpha, IFN-alpha, and IFN-beta, indicating that EPCs expressed functional TLR3. Carbon 19-20 interferon beta 1 Homo sapiens 138-146 22136495-11 2011 In addition, megakaryocytes increased IFN-I transcript levels and produced IFN-beta upon stimulation with PolyI:C, a synthetic dsRNA that mimics viral infection. Poly I-C 106-113 interferon beta 1 Homo sapiens 75-83 22065573-7 2011 We demonstrate that the TLR3 ligand polyriboinosinic:polyribocytidylic acid (poly(I:C)) induces expression and nuclear translocation of YinYang1 where it interacts with the IFN-beta promoter and inhibits the binding of IRF7 to the latter. polyriboinosinic 36-52 interferon beta 1 Homo sapiens 173-181 22065573-7 2011 We demonstrate that the TLR3 ligand polyriboinosinic:polyribocytidylic acid (poly(I:C)) induces expression and nuclear translocation of YinYang1 where it interacts with the IFN-beta promoter and inhibits the binding of IRF7 to the latter. Poly C 53-75 interferon beta 1 Homo sapiens 173-181 22065573-7 2011 We demonstrate that the TLR3 ligand polyriboinosinic:polyribocytidylic acid (poly(I:C)) induces expression and nuclear translocation of YinYang1 where it interacts with the IFN-beta promoter and inhibits the binding of IRF7 to the latter. poly 36-40 interferon beta 1 Homo sapiens 173-181 21877251-8 2011 Using oligonucleotide microarray, we demonstrated a dramatic increase in proinflammatory cytokine and chemokine transcripts (CXCL10, CXCL11, TNFSF10, CCL5, CCL4, CCL2, IFNB1, CCL20, IL-8, and CCL11). Oligonucleotides 6-21 interferon beta 1 Homo sapiens 168-173 21952237-8 2011 Poly(I:C) was also shown to induce interferon (IFN)-beta mRNA expression in trophoblasts. poly 0-4 interferon beta 1 Homo sapiens 35-56 21952237-8 2011 Poly(I:C) was also shown to induce interferon (IFN)-beta mRNA expression in trophoblasts. Carbon 7-8 interferon beta 1 Homo sapiens 35-56 21952237-10 2011 Pretreating with neutralizing antibody against IFN-beta significantly suppressed IDO induction by poly(I:C). poly 98-102 interferon beta 1 Homo sapiens 47-55 22277391-5 2011 Previously, we demonstrated that Interferon-beta (IFN-beta) markedly enhanced chemosensitivity to TMZ in an in vitro study of human glioma cells; this finding suggested that one of the major mechanisms by which IFN-beta enhances chemosensitivity is the downregulation of MGMT transcription via p53 induction. Temozolomide 98-101 interferon beta 1 Homo sapiens 33-48 22277391-5 2011 Previously, we demonstrated that Interferon-beta (IFN-beta) markedly enhanced chemosensitivity to TMZ in an in vitro study of human glioma cells; this finding suggested that one of the major mechanisms by which IFN-beta enhances chemosensitivity is the downregulation of MGMT transcription via p53 induction. Temozolomide 98-101 interferon beta 1 Homo sapiens 50-58 22277391-5 2011 Previously, we demonstrated that Interferon-beta (IFN-beta) markedly enhanced chemosensitivity to TMZ in an in vitro study of human glioma cells; this finding suggested that one of the major mechanisms by which IFN-beta enhances chemosensitivity is the downregulation of MGMT transcription via p53 induction. Temozolomide 98-101 interferon beta 1 Homo sapiens 211-219 21769425-5 2011 Treatment of a human non-small cell lung carcinoma cell line (A549, a lung carcinoma derived from human lung epithelial cells) with the pro-drug 5-fluorocytosine (5-FC) in the presence of HB1.F3.CD or HB1.F3.CD.IFN-beta cells resulted in the inhibition of lung cancer cell growth. Flucytosine 145-161 interferon beta 1 Homo sapiens 211-219 21337319-8 2011 Stimulation with poly(I-C) induced the activation of IFN regulatory factor 3 (IRF-3), NF-kappaB, and activator protein 1 (AP-1) c-Jun as well as the subsequent production of IFNbeta, CXCL8, and MMP-3. Poly I-C 17-25 interferon beta 1 Homo sapiens 174-181 21868529-7 2011 In using a co-culture system and MTT assay, reduced viability of endometrial cancer cells was observed in the presence of HB1.F3.CD and HB1.F3.CD.IFN-beta cells with prodrug 5-FC. monooxyethylene trimethylolpropane tristearate 33-36 interferon beta 1 Homo sapiens 146-154 21700474-7 2011 Interestingly, the results indicated that beneficial effects of rosiglitazone on LPS-induced inflammation in VSMCs were mediated via interference of TLR4 and its downstream signaling components including Toll-interleukin-1 (IL-1) receptor domain-containing adaptor inducing interferon-beta (TRIF), interferon regulatory factor 3 (IRF3) and interferon-gamma inducible protein 10 (IP-10). Rosiglitazone 64-77 interferon beta 1 Homo sapiens 274-289 21478011-11 2011 For IFNbeta 100 IU/ml the SER was 1.72 for in MiaPaca-2 and 1.51 in Panc-1. Serine 26-29 interferon beta 1 Homo sapiens 4-11 21544609-2 2011 Secretion and activity of hIFN-beta with AmyE propeptide increased by more than four-fold compared to that without AmyE propeptide. amye propeptide 41-56 interferon beta 1 Homo sapiens 26-35 21544609-2 2011 Secretion and activity of hIFN-beta with AmyE propeptide increased by more than four-fold compared to that without AmyE propeptide. amye propeptide 115-130 interferon beta 1 Homo sapiens 26-35 21544609-3 2011 Moreover, under conditions of co-expressed PrsA, the secretion production and activity of hIFN-beta with AmyE propeptide increased by more than 1.5-fold. amye propeptide 105-120 interferon beta 1 Homo sapiens 90-99 21544609-4 2011 AmyE propeptide and co-expression of PrsA thus have an additive effect on enhancing the production of the hIFN-beta in B. subtilis. propeptide 5-15 interferon beta 1 Homo sapiens 106-115 21805051-3 2011 Recently, a synergistic antitumor effect between TMZ and interferon-beta (IFN-beta) was reported in malignant glioma cells. Temozolomide 49-52 interferon beta 1 Homo sapiens 74-82 21805051-8 2011 We present a list of the most highly upregulated and downregulated genes which may be involved in conferring a response to IFN-beta and synergistic effect between IFN-beta and TMZ in malignant gliomas. Temozolomide 176-179 interferon beta 1 Homo sapiens 123-131 21327711-1 2011 Our previous study demonstrated that interferon-beta markedly enhanced chemosensitivity to temozolomide; one of the major mechanisms is downregulation of O(6)-methylguanine DNA-methyltransferase transcription via p53 induction. Temozolomide 91-103 interferon beta 1 Homo sapiens 37-52 21690216-2 2011 A 20-kDa polyethylene glycol (PEG)-conjugated IFN beta-1a (PEG-IFN beta-1a) is being developed to decrease the frequency of administration and improve patient convenience and compliance. Polyethylene Glycols 9-28 interferon beta 1 Homo sapiens 46-54 21690216-2 2011 A 20-kDa polyethylene glycol (PEG)-conjugated IFN beta-1a (PEG-IFN beta-1a) is being developed to decrease the frequency of administration and improve patient convenience and compliance. Polyethylene Glycols 9-28 interferon beta 1 Homo sapiens 63-71 21690216-2 2011 A 20-kDa polyethylene glycol (PEG)-conjugated IFN beta-1a (PEG-IFN beta-1a) is being developed to decrease the frequency of administration and improve patient convenience and compliance. Polyethylene Glycols 30-33 interferon beta 1 Homo sapiens 46-54 21690216-2 2011 A 20-kDa polyethylene glycol (PEG)-conjugated IFN beta-1a (PEG-IFN beta-1a) is being developed to decrease the frequency of administration and improve patient convenience and compliance. Polyethylene Glycols 30-33 interferon beta 1 Homo sapiens 63-71 21690216-7 2011 Consistent with the pharmacology of type I IFNs, PEG-IFN beta-1a resulted in the elevation of neopterin concentration, a transient body temperature increase, and a reversible lymphocyte count decrease. Neopterin 94-103 interferon beta 1 Homo sapiens 53-61 21690216-8 2011 As expected, neutralizing antibodies to PEG-IFN beta-1a formed in almost all monkeys after 5 weeks of treatment, which resulted in significantly reduced drug exposure and abrogation of neopterin induction. Neopterin 185-194 interferon beta 1 Homo sapiens 44-52 21330073-0 2011 Levocetrizine has anti-inflammatory effects against Toll-like receptor (TLR)3 through the inhibition of Toll-IL-1 receptor (TIR)-domain-containing adapter inducing IFN-beta (TRIF) and receptor-interacting protein (RIP). levocetirizine 0-13 interferon beta 1 Homo sapiens 164-172 21420486-3 2011 We have found that IFN-beta suppressed IL-23 and IL-1beta production and increased IL-10 production by human dendritic cells (DC) activated with the TLR2 and dectin-1 agonist zymosan. Zymosan 175-182 interferon beta 1 Homo sapiens 19-27 21420486-5 2011 IFN-beta induced IL-27 expression by DC, and neutralisation of IL-27 abrogated the suppressive effects of IFN-beta on zymosan-induced IL-1 and IL-23 production and the generation of Th17 cells in vitro. Zymosan 118-125 interferon beta 1 Homo sapiens 0-8 21420486-5 2011 IFN-beta induced IL-27 expression by DC, and neutralisation of IL-27 abrogated the suppressive effects of IFN-beta on zymosan-induced IL-1 and IL-23 production and the generation of Th17 cells in vitro. Zymosan 118-125 interferon beta 1 Homo sapiens 106-114 21751747-4 2011 In a 12-month, comparative, double-blind, randomised trial including 1292 patients daily treatment with oral fingolimod (0.5 mg or 1.25 mg) modestly prolonged the interval between exacerbations compared to weekly intramuscular injections of interferon beta-1a: about one exacerbation prevented every 6 years. Fingolimod Hydrochloride 109-119 interferon beta 1 Homo sapiens 241-256 21386060-3 2011 IFN-beta suppressed insulin-induced tyrosine phosphorylation of IRS-1 without affecting its expression, whereas IFN-gamma reduced both the protein level and tyrosine phosphorylation. Tyrosine 36-44 interferon beta 1 Homo sapiens 0-8 21631512-6 2011 In contrast, resveratrol, EGCG, luteolin, and structural analogs of luteolin specifically inhibit TLR3 and TLR4 signaling by targeting TANK binding kinase 1 (TBK1) and receptor interacting protein 1 (RIP1) in Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) complex. Resveratrol 13-24 interferon beta 1 Homo sapiens 263-271 21386060-7 2011 Notably, IFN-beta-induced SOCS1 expression and suppression of insulin-induced tyrosine phosphorylation of IRS-1 were attenuated by siRNA-mediated knockdown of STAT1. Tyrosine 78-86 interferon beta 1 Homo sapiens 9-17 21761953-1 2011 Disease-modifying treatments (DMTs), which are the foundation of multiple sclerosis (MS) care, reduce clinical exacerbations (relapses) and slow disease progression; however, improving quality of life (QOL) is an unmet need for many individuals with MS. DMTs, including interferon-beta, glatiramer acetate, natalizumab, mitoxantrone, and fingolimod, reduce the rate and severity of relapses, the accumulation of brain and spinal cord lesions as shown on magnetic resonance imaging (MRI), and disability progression. Dimethyl trisulfide 30-34 interferon beta 1 Homo sapiens 270-285 21304408-5 2011 Increased IFN-beta expression induced by Poly(I:C) transfection was accompanied by enhanced production of IL-10 and IL-12p70 in the FCs. Poly I-C 41-50 interferon beta 1 Homo sapiens 10-18 21899047-6 2011 Obtained preparation of interferon-beta was pure by gel-electrophoresis and by HPLC analysis, and had practically indentical level of antiproliferative activity with well-known preparation of Betaferone. betaferone 192-202 interferon beta 1 Homo sapiens 24-39 21658324-9 2011 On the basis of in vitro reactivity with known, well-characterized monoclonal and polyclonal antibody preparations, Blastoferon shares immunological determinants with other human interferon- beta products, especially IFN- beta 1a. blastoferon 116-127 interferon beta 1 Homo sapiens 180-196 21658324-9 2011 On the basis of in vitro reactivity with known, well-characterized monoclonal and polyclonal antibody preparations, Blastoferon shares immunological determinants with other human interferon- beta products, especially IFN- beta 1a. blastoferon 116-127 interferon beta 1 Homo sapiens 218-227 21177756-0 2011 Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. baff 35-39 interferon beta 1 Homo sapiens 0-15 21177756-6 2011 IFN-beta therapy caused an increase in plasma BAFF levels after both 3 and 6 months of therapy (p<0.002). baff 46-50 interferon beta 1 Homo sapiens 0-8 21177756-9 2011 Despite its known beneficial effects, IFN-beta therapy causes a sustained increase in plasma BAFF levels, which does not translate into increased levels of anti-MBP autoantibodies. baff 93-97 interferon beta 1 Homo sapiens 38-46 21472719-6 2011 The median survival time (MST) of the patients who received the combination of IFN-beta and TMZ was significantly greater with 19.9 months as compared to the TMZ alone group (12.7 months). Temozolomide 158-161 interferon beta 1 Homo sapiens 79-87 21472719-7 2011 Notably, in even patients whose tumors had unmethylated MGMT promoter, the MST prolonged to 17.2 months when receiving TMZ with IFN-beta, compared to 12.5 months in those receiving TMZ without IFN-beta. Temozolomide 119-122 interferon beta 1 Homo sapiens 128-136 21149803-9 2011 Second-line DMT use was restricted to interferon beta and glatiramer acetate in 203 children (78.7%), whereas other treatments such as broad-spectrum chemotherapies (cyclophosphamide, mitoxantrone hydrochloride), natalizumab, corticosteroids (monthly), and daclizumab were used at some point during the observation period for disease management in 55 children (21.3%). dmt 12-15 interferon beta 1 Homo sapiens 38-53 21480323-11 2011 The sustained efficacy of IFN-beta and IFN-lambda could be an important advantage for the treatment patients who are nonresponders to pegIFN-alpha, through a preactivated endogenous IFN system. pegifn-alpha 134-146 interferon beta 1 Homo sapiens 26-34 20532646-0 2011 n-Dodecyl-beta-D-maltoside inhibits aggregation of human interferon-beta-1b and reduces its immunogenicity. dodecyl maltoside 0-26 interferon beta 1 Homo sapiens 57-72 20532646-3 2011 We tested the ability of dodecylmaltoside, a nontoxic alkylsaccharide surfactant, to reduce aggregation of interferon-beta in vitro and to reduce its immunogenicity in vivo. dodecyl maltoside 25-41 interferon beta 1 Homo sapiens 107-122 20532646-6 2011 Dodecylmaltoside reduces the aggregation of interferon-beta in vitro and its immunogenicity in vivo. dodecyl maltoside 0-16 interferon beta 1 Homo sapiens 44-59 21408089-8 2011 Moreover, we show that infection of primary macrophages containing a genetic knockout of the major type I interferon, IFNbeta, leads to only a partial suppression of the sterol pathway, while genetic knockout of the receptor for all type I interferon family members, ifnar1, or associated signaling component, tyk2, completely abolishes the reduction of the sterol biosynthetic activity upon infection. Sterols 170-176 interferon beta 1 Homo sapiens 99-125 21408089-8 2011 Moreover, we show that infection of primary macrophages containing a genetic knockout of the major type I interferon, IFNbeta, leads to only a partial suppression of the sterol pathway, while genetic knockout of the receptor for all type I interferon family members, ifnar1, or associated signaling component, tyk2, completely abolishes the reduction of the sterol biosynthetic activity upon infection. Sterols 358-364 interferon beta 1 Homo sapiens 99-125 21485162-6 2011 Clinical trials demonstrated that early treatment of CIS patients with the standard dose of interferon beta (IFNbeta) significantly reduced the risk of progression to CDMS by 44 to 50%. cdms 167-171 interferon beta 1 Homo sapiens 92-107 21485162-6 2011 Clinical trials demonstrated that early treatment of CIS patients with the standard dose of interferon beta (IFNbeta) significantly reduced the risk of progression to CDMS by 44 to 50%. cdms 167-171 interferon beta 1 Homo sapiens 109-116 21485162-7 2011 After 5 years of followup, the results of the IFNbeta treatment extension studies confirmed that the risk of conversion to CDMS was significantly reduced by 35 to 37% in patients receiving early treatment compared to that in those receiving delayed treatment. cdms 123-127 interferon beta 1 Homo sapiens 46-53 21106742-9 2011 PUUV-Pa caused stronger induction of IFN-beta, ISG56, and MxA than PUUV-La and PUUV-Sm, while PUUV-Sm caused stronger MxA and ISG56 induction than PUUV-La. puuv-pa 0-7 interferon beta 1 Homo sapiens 37-45 21978158-6 2011 In particular, Lyn kinase oligonucleotides resulted in decreased expression of TLR-9-induced tumor necrosis factor alpha (TNF-alpha) but strongly upregulated canonical TLR-3-induced interferon beta (IFN-beta) and non-canonical TLR-3-induced NF-kappaB-dependent p35 (35kDa) subunit of interleukin 12 (IL-12p35) gene transcription. Oligonucleotides 26-42 interferon beta 1 Homo sapiens 182-197 21978158-6 2011 In particular, Lyn kinase oligonucleotides resulted in decreased expression of TLR-9-induced tumor necrosis factor alpha (TNF-alpha) but strongly upregulated canonical TLR-3-induced interferon beta (IFN-beta) and non-canonical TLR-3-induced NF-kappaB-dependent p35 (35kDa) subunit of interleukin 12 (IL-12p35) gene transcription. Oligonucleotides 26-42 interferon beta 1 Homo sapiens 199-207 21832855-13 2011 TLR3, IRF3 and de novo synthesized IFN-beta may mediate the poly (I:C)-induced expression of ISG20, and RIG-I may mediate ISG20 expression induced by poly (I:C)/cationic lipid complex. Poly I-C 60-70 interferon beta 1 Homo sapiens 35-43 21485162-8 2011 However, not every patient with CIS will progress to CDMS; the IFNbeta treatment is appropriately indicated for CIS patients who are diagnosed with MS by McDonald diagnostic criteria based on MRI findings of dissemination in space and time and are at high risk for conversion to CDMS. cdms 53-57 interferon beta 1 Homo sapiens 63-70 21485162-8 2011 However, not every patient with CIS will progress to CDMS; the IFNbeta treatment is appropriately indicated for CIS patients who are diagnosed with MS by McDonald diagnostic criteria based on MRI findings of dissemination in space and time and are at high risk for conversion to CDMS. cdms 279-283 interferon beta 1 Homo sapiens 63-70 21677781-7 2011 Remarkably, ongoing protein synthesis and viral replication are required to maintain repression of the IFNbeta gene in persistently infected cells, as the gene can be activated by the protein synthesis inhibitor cycloheximide, or by the antiviral drug ribavirin. Cycloheximide 212-225 interferon beta 1 Homo sapiens 103-110 21677781-7 2011 Remarkably, ongoing protein synthesis and viral replication are required to maintain repression of the IFNbeta gene in persistently infected cells, as the gene can be activated by the protein synthesis inhibitor cycloheximide, or by the antiviral drug ribavirin. Ribavirin 252-261 interferon beta 1 Homo sapiens 103-110 21170271-0 2010 Cellular reactive oxygen species inhibit MPYS induction of IFNbeta. Reactive Oxygen Species 9-32 interferon beta 1 Homo sapiens 59-66 21170271-3 2010 STING, which was recently shown to mediate activation of IFNbeta expression during infection, is a ROS sensor. Reactive Oxygen Species 99-102 interferon beta 1 Homo sapiens 57-64 21170271-4 2010 ROS induce intermolecular disulfide bonds formation in MPYS homodimer and inhibit MPYS IFNbeta stimulatory activity. Reactive Oxygen Species 0-3 interferon beta 1 Homo sapiens 87-94 21170271-4 2010 ROS induce intermolecular disulfide bonds formation in MPYS homodimer and inhibit MPYS IFNbeta stimulatory activity. Disulfides 26-35 interferon beta 1 Homo sapiens 87-94 21170271-5 2010 Cys-64, -148, -292, -309 and the potential C88xxC91 redox motif in MPYS are indispensable for IFNbeta stimulation and IRF3 activation. Cysteine 0-3 interferon beta 1 Homo sapiens 94-101 21170271-6 2010 Thus, our results identify a novel mechanism for ROS regulation of IFNbeta stimulation. Reactive Oxygen Species 49-52 interferon beta 1 Homo sapiens 67-74 20640890-4 2010 GRIM-19 (gene associated with retinoid-interferon-induced-mortality-19), a subunit of mitochondrial complex-I was previously implicated in Interferon-beta and retionoic acid induced apoptosis in many tumor cells. Retinoids 30-38 interferon beta 1 Homo sapiens 139-154 20626428-7 2010 Moreover, we try to address the evident question whether usage of this combination routinely requires caution, since the number of IFN-beta-treated MS patients receiving statins for lowering of cholesterol is expected to grow. Cholesterol 194-205 interferon beta 1 Homo sapiens 131-139 21509198-4 2011 We addressed the question of intracellular pathways used by IFNbeta and GA to induce sIL-1Ra in human monocytes in two recent studies. sil-1ra 85-92 interferon beta 1 Homo sapiens 60-67 22156480-3 2011 DFPP was used in combination with IFN-beta/RBV with subsequent administration of PEG-IFN-alpha2a/RBV therapy (DFPP + IFN-beta/RBV then PEG-IFN/RBV). dfpp 0-4 interferon beta 1 Homo sapiens 117-125 22156480-3 2011 DFPP was used in combination with IFN-beta/RBV with subsequent administration of PEG-IFN-alpha2a/RBV therapy (DFPP + IFN-beta/RBV then PEG-IFN/RBV). Polyethylene Glycols 81-84 interferon beta 1 Homo sapiens 117-125 21040977-4 2011 We show that stimulation of moDCs with TLR7/8 ligand R848 together with TLR3 or TLR4 ligands, polyI:C or LPS, respectively, leads to a synergistic expression of IFN-beta and IFN-lambda1 mRNAs. Poly I-C 94-101 interferon beta 1 Homo sapiens 161-169 21076398-0 2011 Cardiac glycosides are potent inhibitors of interferon-beta gene expression. Glycosides 8-18 interferon beta 1 Homo sapiens 44-59 21076398-1 2011 Here we report that bufalin and other cardiac glycoside inhibitors of the sodium-potassium ATPase (sodium pump) potently inhibit the induction of the interferon-beta (IFNbeta) gene by virus, double-stranded RNA or double-stranded DNA. bufalin 20-27 interferon beta 1 Homo sapiens 150-165 21076398-1 2011 Here we report that bufalin and other cardiac glycoside inhibitors of the sodium-potassium ATPase (sodium pump) potently inhibit the induction of the interferon-beta (IFNbeta) gene by virus, double-stranded RNA or double-stranded DNA. bufalin 20-27 interferon beta 1 Homo sapiens 167-174 21076398-1 2011 Here we report that bufalin and other cardiac glycoside inhibitors of the sodium-potassium ATPase (sodium pump) potently inhibit the induction of the interferon-beta (IFNbeta) gene by virus, double-stranded RNA or double-stranded DNA. Glycosides 46-55 interferon beta 1 Homo sapiens 150-165 21076398-1 2011 Here we report that bufalin and other cardiac glycoside inhibitors of the sodium-potassium ATPase (sodium pump) potently inhibit the induction of the interferon-beta (IFNbeta) gene by virus, double-stranded RNA or double-stranded DNA. Glycosides 46-55 interferon beta 1 Homo sapiens 167-174 21076398-2 2011 Cardiac glycosides increase the intracellular sodium concentration, which appears to inhibit the ATPase activity of the RNA sensor RIG-I, an essential and early component in the IFNbeta activation pathway. Glycosides 8-18 interferon beta 1 Homo sapiens 178-185 21076398-2 2011 Cardiac glycosides increase the intracellular sodium concentration, which appears to inhibit the ATPase activity of the RNA sensor RIG-I, an essential and early component in the IFNbeta activation pathway. Sodium 46-52 interferon beta 1 Homo sapiens 178-185 21832855-9 2011 The poly (I:C)-induced expressions of IFN-beta and ISG20 were inhibited by dexamethasone. Dexamethasone 75-88 interferon beta 1 Homo sapiens 38-46 20850164-2 2010 We report that the PRRSV nonstructural protein 1alpha (Nsp1alpha) subunit of Nsp1 is a nuclear-cytoplasmic protein distributed to the nucleus and contains a strong suppressive activity for IFN-beta production that is mediated through the retinoic acid-inducible gene I (RIG-I) signaling pathway. Tretinoin 238-251 interferon beta 1 Homo sapiens 189-197 20837746-2 2010 IFN-beta, which is widely used to improve the course of relapsing, remitting multiple sclerosis, induces the production of sIL-1Ra in human monocytes through mechanisms that remain largely unknown. sil-1ra 123-130 interferon beta 1 Homo sapiens 0-8 21044071-7 2010 Moreover, long-term IFN-beta treatment led to down-regulation of phosphatidylinositol 3-kinase/Akt signaling and IFN-beta-induced apoptosis was attenuated in cells expressing constitutively active Akt. Phosphatidylinositols 65-85 interferon beta 1 Homo sapiens 20-28 20657019-1 2010 BACKGROUND: The authors previously reported that human ocular surface epithelium expressed TLR3 and that its ligand polyI:C stimulated the secretion of IL-6, IL-8 and IFN-beta. Poly I-C 116-123 interferon beta 1 Homo sapiens 167-175 20736039-0 2010 Loss-of-function mutations E6 27X and I923V of IFIH1 are associated with lower poly(I:C)-induced interferon-beta production in peripheral blood mononuclear cells of type 1 diabetes patients. poly 79-83 interferon beta 1 Homo sapiens 97-112 20957750-9 2010 Our findings offer a new mechanistic insight into TLR3/TRIF signalling through a hitherto unknown mechanism whereby Mal inhibits poly(I:C)-induced IRF7 activation and concomitant IFN-beta production. Poly I-C 129-138 interferon beta 1 Homo sapiens 179-187 20736039-4 2010 The carriage of the predisposing IFIH1 EI/EI haplogenotype was significantly associated with a 1.5- to 1.7-fold increase in the poly(I:C)-stimulated secretion of IFN-beta in PMBCs compared with the other IFIH1 variants. pmbcs 174-179 interferon beta 1 Homo sapiens 162-170 20817120-5 2010 We showed that loxoribine up-regulated the expression of TLR7, CD40, CD54, CD80, CD83 and CCR7 and stimulated the production of IL-12, IL-23, IL-27 and IL-10 by MoDCs, whereas the level of interferon (IFN)-beta was not modulated. loxoribine 15-25 interferon beta 1 Homo sapiens 189-210 20817120-8 2010 In conclusion, our results show that loxoribine stimulated differentiation, maturation, allostimulatory as well as Th1 and Th17 polarization capability of human MoDCs and suggests that these effects might be associated with up-regulation of TLR7 expression, but not increased IFN-beta production. loxoribine 37-47 interferon beta 1 Homo sapiens 276-284 20728939-2 2010 Here we show that TLR3 signaling can induce robust cytokine secretion including interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), IL-12p70 and interferon beta (IFN-beta), and our data reveal for the first time that inhibiting mTOR with rapamycin, suppresses these TLR3 induced responses but actually enhances bioactive IL-12p70 production in human oral keratinocytes. Sirolimus 257-266 interferon beta 1 Homo sapiens 181-189 20728939-5 2010 Furthermore, we provide evidence that Poly I:C induced expression of IL-1beta, TNFalpha, IL-12p70 and IFN-beta was blocked by JNK inhibitor SP600125. Poly I-C 38-46 interferon beta 1 Homo sapiens 102-110 20728939-5 2010 Furthermore, we provide evidence that Poly I:C induced expression of IL-1beta, TNFalpha, IL-12p70 and IFN-beta was blocked by JNK inhibitor SP600125. pyrazolanthrone 140-148 interferon beta 1 Homo sapiens 102-110 20877565-10 2010 EGCG also inhibited IL6 secretion and IFN- beta mRNA synthesis in BEAS-2B cells, which harbors intact endogenous RIG-I signaling pathway. epigallocatechin gallate 0-4 interferon beta 1 Homo sapiens 38-47 20524007-9 2010 These results suggest that apoE-containing lipoprotein metabolism and, possibly, tobacco smoking may be associated with risk of NAb production in female MS patients treated with IFN-beta. nab 128-131 interferon beta 1 Homo sapiens 178-186 20125114-8 2010 PDTC inhibited the production of IL-8 and TNF-alpha whereas U0126 inhibited the synthesis of IFN-beta. U 0126 60-65 interferon beta 1 Homo sapiens 93-101 20230221-9 2010 Treatment with the anti-inflammatory agent CDDO-Me before and after MSC-IFN-beta injections resulted in reduction of MSC in the tumors and reversed the positive effect of tumor inhibition by MSC-IFN-beta alone (P=0.041). bardoxolone methyl 43-50 interferon beta 1 Homo sapiens 72-80 20230221-9 2010 Treatment with the anti-inflammatory agent CDDO-Me before and after MSC-IFN-beta injections resulted in reduction of MSC in the tumors and reversed the positive effect of tumor inhibition by MSC-IFN-beta alone (P=0.041). bardoxolone methyl 43-50 interferon beta 1 Homo sapiens 195-203 20519457-4 2010 In line with this hypothesis, expression of E3 ablated both IFN-beta expression and NF-kappaB activity in response to the dsDNA, poly(dA-dT). poly 129-133 interferon beta 1 Homo sapiens 60-68 20519457-4 2010 In line with this hypothesis, expression of E3 ablated both IFN-beta expression and NF-kappaB activity in response to the dsDNA, poly(dA-dT). da-dt 134-139 interferon beta 1 Homo sapiens 60-68 20519457-8 2010 Consistent with this, RNA from poly(dA-dT) transfected cells induced IFN-beta and expression of the E3 dsRNA-binding domain was sufficient to ablate this response. poly 31-35 interferon beta 1 Homo sapiens 69-77 20519457-8 2010 Consistent with this, RNA from poly(dA-dT) transfected cells induced IFN-beta and expression of the E3 dsRNA-binding domain was sufficient to ablate this response. da-dt 36-41 interferon beta 1 Homo sapiens 69-77 20639271-3 2010 OBJECTIVE: To assess the utility of measuring urinary neopterin and nitric oxide metabolite excretion for monitoring interferon beta-1a (IFNbeta-1a) treatment in patients with primary progressive multiple sclerosis. Neopterin 54-63 interferon beta 1 Homo sapiens 117-132 20526818-8 2010 IFN-beta causes up-regulated and lovastatin down-regulated expression of CD86, which results in a biased Th-cell responses in MS. Lovastatin 33-43 interferon beta 1 Homo sapiens 0-8 20561966-4 2010 The abolishment of miR-122 by AMO-122 inhibited endogenous IFN induction by IFN-beta. amo-122 30-37 interferon beta 1 Homo sapiens 76-84 20478305-1 2010 Gene associated with retinoid-IFN-induced mortality 19 (GRIM-19), as a novel IFN-beta/RA-inducible gene product, was identified as a potential tumor suppressor associated with growth inhibition and cell apoptosis. Retinoids 21-29 interferon beta 1 Homo sapiens 77-85 20560107-6 2010 The expression levels of interferon-beta protein and mRNA, which is a key molecule in MyD88-independent pathway, were significantly inhibited by metformin. Metformin 145-154 interferon beta 1 Homo sapiens 25-40 20560107-8 2010 Metformin was suggested to inhibit lipopolysaccharide-induced nitric oxide production via inhibition of interferon-beta production in MyD88-independent pathway. Metformin 0-9 interferon beta 1 Homo sapiens 104-119 20560107-8 2010 Metformin was suggested to inhibit lipopolysaccharide-induced nitric oxide production via inhibition of interferon-beta production in MyD88-independent pathway. Nitric Oxide 62-74 interferon beta 1 Homo sapiens 104-119 20717508-13 2010 The MTT assay showed that the sense-transfection cells were more sensitive to the combination of interferon-beta and retinoic acid than U343MG-A cells or antisense-transfection cells; the anti-proliferative activity was related to apoptosis. monooxyethylene trimethylolpropane tristearate 4-7 interferon beta 1 Homo sapiens 97-112 20610349-3 2010 In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium, a European-based project of the 6th Framework Programme of the European Commission, to review and discuss data on NAbs and their practical consequences for the treatment of patients with MS on interferon beta. nabs 44-48 interferon beta 1 Homo sapiens 52-67 20488825-0 2010 Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Simvastatin 0-11 interferon beta 1 Homo sapiens 88-103 20488825-15 2010 This interventional study provides Class I evidence stating that adding simvastatin 40 mg/day to IFNb 1a 30 microg a week in patients with relapsing-remitting multiple sclerosis may reduce the relapse rate (moderate effect size r = 0.29) (p = 0.01) compared with treatment with IFNb 1a alone. Simvastatin 72-83 interferon beta 1 Homo sapiens 97-103 20488825-15 2010 This interventional study provides Class I evidence stating that adding simvastatin 40 mg/day to IFNb 1a 30 microg a week in patients with relapsing-remitting multiple sclerosis may reduce the relapse rate (moderate effect size r = 0.29) (p = 0.01) compared with treatment with IFNb 1a alone. Simvastatin 72-83 interferon beta 1 Homo sapiens 97-101 20406818-0 2010 Negative role of RIG-I serine 8 phosphorylation in the regulation of interferon-beta production. Serine 23-29 interferon beta 1 Homo sapiens 69-84 21179613-8 2010 Cyclophosphamide and natalizumab could be offered as second-line treatment in patients with a poor response to IFNB or GA. Cyclophosphamide 0-16 interferon beta 1 Homo sapiens 111-115 20406818-2 2010 Upon recognition of viral RNA, TRIM25 E3 ligase binds the first caspase recruitment domain (CARD) of RIG-I and subsequently induces lysine 172 ubiquitination of the second CARD of RIG-I, which is essential for the interaction with downstream MAVS/IPS-1/CARDIF/VISA and, thereby, IFN-beta mRNA production. Lysine 132-138 interferon beta 1 Homo sapiens 279-287 20406818-4 2010 Here, we report the identification of serine 8 phosphorylation at the first CARD of RIG-I as a negative regulatory mechanism of RIG-I-mediated IFN-beta production. Serine 38-44 interferon beta 1 Homo sapiens 143-151 20532218-6 2010 Here, we found that NOX2 and ROS are required for the host cell to trigger an efficient RIG-I-mediated IRF-3 activation and downstream antiviral IFNbeta and IFIT1 gene expression. Reactive Oxygen Species 29-32 interferon beta 1 Homo sapiens 145-152 21161001-10 2010 CONCLUSION: These results suggest the possibilities of shortening the duration of Peg-IFN plus RBV combination therapy by actively reducing HCV-RNA levels using the IFN-beta induction regimen. Ribavirin 95-98 interferon beta 1 Homo sapiens 165-173 20637960-19 2010 Furthermore, the results suggest that GA may reduce spasticity in patients previously treated with IFN-beta. Glatiramer Acetate 38-40 interferon beta 1 Homo sapiens 99-107 20428788-7 2010 It was found that IFN beta and/or RBV suppressed miR-122 expression marginally, with a synergetic anti-HCV effect between IFN beta and RBV. Ribavirin 34-37 interferon beta 1 Homo sapiens 122-130 20008294-5 2010 We found that vitamin D induces IkappaBalpha, an NF-kappaB inhibitor, in airway epithelium and decreases RSV induction of NF-kappaB-driven genes such as IFN-beta and CXCL10. Vitamin D 14-23 interferon beta 1 Homo sapiens 153-161 20200155-5 2010 Overexpression of TRIS activates NF-kappaB, interferon-stimulated response element (ISRE), and the interferon-beta promoter, whereas knockdown of TRIS inhibited TLR3-mediated signaling, suggesting that TRIS is involved in TLR3-mediated signaling. Tromethamine 18-22 interferon beta 1 Homo sapiens 99-114 20190134-6 2010 In vivo treatment with IFN-beta results in lower numbers of DCs migrating to the draining lymph node following exposure to FITC and in reduced expression of CCR7 and MMP-9 in splenic CD11c(+) DCs following LPS administration. Fluorescein-5-isothiocyanate 123-127 interferon beta 1 Homo sapiens 23-31 19936821-5 2010 DMT was reported for 32 paternities of 46 children; 30 under IFN beta, 12 under glatiramer acetate, 2 under natalizumab, 1 under methotrexate and 1 under combined azathioprine- and IFN beta-1b-treatment. dmt 0-3 interferon beta 1 Homo sapiens 61-69 19936821-5 2010 DMT was reported for 32 paternities of 46 children; 30 under IFN beta, 12 under glatiramer acetate, 2 under natalizumab, 1 under methotrexate and 1 under combined azathioprine- and IFN beta-1b-treatment. dmt 0-3 interferon beta 1 Homo sapiens 181-189 20507321-7 2010 Moreover, treating gastric cancer cells with DAC enhanced the suppressive effects of interferon-alpha, interferon-beta, and interferon-gamma on cell growth. Decitabine 45-48 interferon beta 1 Homo sapiens 103-118 20445436-11 2010 A randomized controlled trial for patients with active disease despite IFNB therapy showed that baseline NAb titers were reduced by subsequent intravenous methylprednisolone treatment, but the incidence of NAbs was too small to assess clinical relevance. nab 105-108 interferon beta 1 Homo sapiens 71-75 20445436-11 2010 A randomized controlled trial for patients with active disease despite IFNB therapy showed that baseline NAb titers were reduced by subsequent intravenous methylprednisolone treatment, but the incidence of NAbs was too small to assess clinical relevance. Methylprednisolone 155-173 interferon beta 1 Homo sapiens 71-75 20445436-13 2010 CONCLUSIONS: Pulse methylprednisolone therapy may reduce the risk of developing NAbs (but possibly not high-titer NAbs of clinical importance) when coadministered with newly initiated IFNB therapy. Methylprednisolone 19-37 interferon beta 1 Homo sapiens 184-188 20070395-0 2010 Advantage of IFN-beta/alpha2b same-day administration for ribavirin-intolerant patients with chronic hepatitis C. AIM: Although interferon (IFN)/ribavirin is the mainstream combination treatment for chronic hepatitis C in patients with a high viral load, ribavirin is problematic for women of childbearing age and patients with anemia. Ribavirin 58-67 interferon beta 1 Homo sapiens 13-21 20456216-2 2010 Prior to the United States Food and Drug Administration approval of the immunomodulatory agent, interferon-beta1b in 1993, no other drug had been shown to alter the course of the disease in a controlled study of MS. At present, there are five licenced disease-modifying agents in MS - interferon-beta1b, interferon-beta1a, glatiramer acetate, natalizumab and mitoxantrone. Glatiramer Acetate 323-341 interferon beta 1 Homo sapiens 96-112 20456216-2 2010 Prior to the United States Food and Drug Administration approval of the immunomodulatory agent, interferon-beta1b in 1993, no other drug had been shown to alter the course of the disease in a controlled study of MS. At present, there are five licenced disease-modifying agents in MS - interferon-beta1b, interferon-beta1a, glatiramer acetate, natalizumab and mitoxantrone. Mitoxantrone 359-371 interferon beta 1 Homo sapiens 96-112 20511708-7 2010 Especially, the results suggested that beneficial effects of fenofibrate on LPS-stimulated inflammatory responses in VSMCs were mediated through interference of TLR4 and its downstream signaling components such as Toll-interleckin-1(IL-1) receptor domain- containing adaptor inducing interferon-beta (TRIF), interferon regulatory factor 3 (IRF3) and interferon-gamma inducible protein 10 (IP-10). Fenofibrate 61-72 interferon beta 1 Homo sapiens 284-299 19457609-3 2009 In this study, we showed that via STAT3 signaling, IFN-beta suppressed the proliferation, self-renewal, and tumorigenesis of GICs, induced their terminal differentiation to mature oligodendroglia-like cells, and exhibited synergistic cytotoxicity with temozolomide. Temozolomide 252-264 interferon beta 1 Homo sapiens 51-59 19782108-7 2009 Taken together, these results indicated that N-glycan of CSFV E(rns) is essential for E(rns) blocking of IFN-beta induction. n-glycan 45-53 interferon beta 1 Homo sapiens 105-113 19782108-7 2009 Taken together, these results indicated that N-glycan of CSFV E(rns) is essential for E(rns) blocking of IFN-beta induction. Radon 64-67 interferon beta 1 Homo sapiens 105-113 19884577-5 2009 RESULTS: Treatment with IM IFNbeta-1a was associated with a lower rate of NAb formation among 718 patients screened (p < 0.0001 vs SC IFNbeta-1a 22 microg, 44 microg, and IFNbeta-1b). nab 74-77 interferon beta 1 Homo sapiens 27-34 19810673-2 2009 This study finds that the innate immune response (as measured by interferon-beta levels) to densely functionalized, oligonucleotide-modified nanoparticles is significantly less (up to a 25-fold decrease) when compared to a lipoplex carrying the same DNA sequence. Oligonucleotides 116-131 interferon beta 1 Homo sapiens 65-80 20663416-7 2010 Cyclophosphamide is used in relapsing or actively progressive MS as second-line therapy in patients unresponsive to interferon beta or glatiramer acetate who are not candidates for natalizumab. Cyclophosphamide 0-16 interferon beta 1 Homo sapiens 116-131 19864388-7 2010 Our results also show that part of the A9 permissiveness to MVMp relies on the inability to produce type I IFNs upon parvovirus infection, a feature related either to an A9 intrinsic deficiency of this process or to an MVMp-triggered inhibitory mechanism, since stimulation of these cells by exogenous IFN-beta strongly inhibits the parvovirus life cycle. mvmp 219-223 interferon beta 1 Homo sapiens 302-310 19913487-7 2009 Mutagenesis of these phenylalanines abolishes the effects of DDX3 on interferon-beta promoter induction. Phenylalanine 21-35 interferon beta 1 Homo sapiens 69-84 19667211-9 2009 RESULTS: CCL1, CCL2, CCL7, CXCL10, CXCL11, and CCR1 gene expression was strongly upregulated in interferon beta-treated, NAB-negative MS patients. nab 121-124 interferon beta 1 Homo sapiens 96-111 19667211-12 2009 Accordingly, serum chemokine protein levels of interferon beta-treated, NAB-negative MS patients were significantly higher than in untreated or interferon beta-treated, NAB-positive MS patients. nab 72-75 interferon beta 1 Homo sapiens 47-62 19667211-12 2009 Accordingly, serum chemokine protein levels of interferon beta-treated, NAB-negative MS patients were significantly higher than in untreated or interferon beta-treated, NAB-positive MS patients. nab 169-172 interferon beta 1 Homo sapiens 144-159 19728309-0 2009 PolyI:C plus IL-2 or IL-12 induce IFN-gamma production by human NK cells via autocrine IFN-beta. Poly I-C 0-7 interferon beta 1 Homo sapiens 87-95 19728309-3 2009 PolyI:C plus IL-2/IL-12 induced IFN-beta (but not IFN-alpha) mRNA expression and protein production by highly pure human NK cells and by the human NK cell line NK92. Poly I-C 0-7 interferon beta 1 Homo sapiens 32-40 19728309-4 2009 Neutralizing anti-IFNAR1 or anti-IFN-beta Ab prevented the production of IFN-gamma induced by polyI:C plus IL-2/IL-12. Poly I-C 94-101 interferon beta 1 Homo sapiens 33-41 19728309-7 2009 Collectively, these data demonstrate that NK cells, in response to polyI:C plus IL-2/IL-12, produce IFN-beta that induce, in an autocrine manner, the production of IFN-gamma and thereby highlight that NK cells may control the outcome of protective or injurious immune responses through type I IFN secretion. Poly I-C 67-74 interferon beta 1 Homo sapiens 100-108 19921551-0 2009 [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis]. Glatiramer Acetate 1-19 interferon beta 1 Homo sapiens 23-38 19882369-7 2009 As second-line therapy, Cy can be used in non-responders to IFN-beta or glatiramer acetate. Cyclophosphamide 24-26 interferon beta 1 Homo sapiens 60-68 19740351-7 2009 However, in the presence of actinomycin D, a DNA-damaging agent, addition of IFN-beta enhanced the susceptibility of PBMC to apoptosis. Dactinomycin 28-41 interferon beta 1 Homo sapiens 77-85 19054274-6 2009 RESULTS: A single subcutaneous injection of 12 x 10(6) IU of hIFN beta 1a resulted in a median AUC((0-48)) (area under the curve) of 14.82 ng/ml, a C(max) (maximum plasma concentrations) of 1.51 ng/ml and a T(max) (time to achieve maximum plasma concentrations) of 3 h. IFN beta was biologically active as demonstrated by an increase in neopterin levels. Neopterin 337-346 interferon beta 1 Homo sapiens 61-70 19465447-13 2009 NAB titers decreased significantly and transiently after infusion of 16 MIU IFNbeta-1b but not after both forms of 8 MIU applications. nab 0-3 interferon beta 1 Homo sapiens 76-83 19513561-0 2009 Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Temozolomide 51-63 interferon beta 1 Homo sapiens 10-18 19513561-10 2009 Furthermore, significant amounts of endogenous IFN-beta protein were detected in TMZ-treated T98G cells by ELISA. Temozolomide 81-84 interferon beta 1 Homo sapiens 47-55 19513561-11 2009 These results suggest that the clinical therapeutic efficacy of TMZ might be improved by a combination with IFN-beta in malignant gliomas unmethylated at the MGMT gene. Temozolomide 64-67 interferon beta 1 Homo sapiens 108-116 19428330-6 2009 Another mechanism pertinent to the anti-resorptive effect of IFN-beta is the induction of nitric oxide which has been shown to inhibit osteoclast formation. Nitric Oxide 90-102 interferon beta 1 Homo sapiens 61-69 19054274-6 2009 RESULTS: A single subcutaneous injection of 12 x 10(6) IU of hIFN beta 1a resulted in a median AUC((0-48)) (area under the curve) of 14.82 ng/ml, a C(max) (maximum plasma concentrations) of 1.51 ng/ml and a T(max) (time to achieve maximum plasma concentrations) of 3 h. IFN beta was biologically active as demonstrated by an increase in neopterin levels. Neopterin 337-346 interferon beta 1 Homo sapiens 62-70 19409854-14 2009 INTERPRETATION: Oral methylprednisolone given in pulses every 4 weeks as an add-on therapy to subcutaneous interferon beta-1a in patients with relapsing-remitting multiple sclerosis leads to a significant reduction in relapse rate. Methylprednisolone 21-39 interferon beta 1 Homo sapiens 107-122 19484123-8 2009 The Lys 154, 164, and 172 residues of the RIG-I CARD domain were critical for efficient REUL-mediated ubiquitination, as well as the ability of RIG-I to induce activation of IFN-beta promoter. Lysine 4-7 interferon beta 1 Homo sapiens 174-182 19452017-9 2009 RESULTS: The expressions of MIP1-alpha, MIP1-beta, IL-6, IL-8, RANTES, IFN-beta, and TLR3 were up-regulated in HCECs exposed to poly(I:C). poly 128-132 interferon beta 1 Homo sapiens 71-79 19452017-10 2009 The poly(I:C)-induced expressions of IL-6 and IL-8 were down-regulated by both DEX and CsA, while the expressions of IFN-beta and TLR3 were suppressed by DEX alone. Poly I-C 4-12 interferon beta 1 Homo sapiens 117-125 19452017-10 2009 The poly(I:C)-induced expressions of IL-6 and IL-8 were down-regulated by both DEX and CsA, while the expressions of IFN-beta and TLR3 were suppressed by DEX alone. Dexamethasone 154-157 interferon beta 1 Homo sapiens 117-125 19452017-12 2009 When HCECs were inoculated with HSV-1, DEX led to a decrease in the expression of IL6, IFN-beta, and TLR3, and an extension of plaque formation. Dexamethasone 39-42 interferon beta 1 Homo sapiens 87-95 19097723-6 2009 We show the rapid (4h) induction of the type I IFN-inducible 6-16 mRNA in A549 lung carcinoma cells is sensitively and reproducibly concentration-dependent for both IFNbeta and IFNalpha2a stimulation, is quantifiable by either approach, and is readily adaptable for the detection and measurement of NAbs against type I IFNs. 4h 19-21 interferon beta 1 Homo sapiens 165-172 19353519-8 2009 PKR and IFN-beta play a central, previously unidentified role in orchestrating the production of immunosuppressive kynurenines by MSC. Kynurenine 115-126 interferon beta 1 Homo sapiens 8-16 19351494-10 2009 The secretory volume of IFN-beta in pEF-BOS-FLAG/DeltaIPS-1 class was much lower compared with that in pEF-BOS-FLAG/IPS-1 class. deltaips 49-57 interferon beta 1 Homo sapiens 24-32 19028832-2 2009 OBJECTIVE: We wanted to test whether immunosuppression with cyclic methylprednisolone (MP) in combination with azathioprine (AZA) for 6 months accelerates recovery of IFN-beta bioactivity in patients with multiple sclerosis (MS) with abolished in-vivo myxovirus resistance protein A (MxA) mRNA response to IFN-beta. cyclic methylprednisolone 60-85 interferon beta 1 Homo sapiens 167-175 19028832-2 2009 OBJECTIVE: We wanted to test whether immunosuppression with cyclic methylprednisolone (MP) in combination with azathioprine (AZA) for 6 months accelerates recovery of IFN-beta bioactivity in patients with multiple sclerosis (MS) with abolished in-vivo myxovirus resistance protein A (MxA) mRNA response to IFN-beta. cyclic methylprednisolone 60-85 interferon beta 1 Homo sapiens 306-314 19028832-2 2009 OBJECTIVE: We wanted to test whether immunosuppression with cyclic methylprednisolone (MP) in combination with azathioprine (AZA) for 6 months accelerates recovery of IFN-beta bioactivity in patients with multiple sclerosis (MS) with abolished in-vivo myxovirus resistance protein A (MxA) mRNA response to IFN-beta. Methylprednisolone 87-89 interferon beta 1 Homo sapiens 167-175 19028832-2 2009 OBJECTIVE: We wanted to test whether immunosuppression with cyclic methylprednisolone (MP) in combination with azathioprine (AZA) for 6 months accelerates recovery of IFN-beta bioactivity in patients with multiple sclerosis (MS) with abolished in-vivo myxovirus resistance protein A (MxA) mRNA response to IFN-beta. Methylprednisolone 87-89 interferon beta 1 Homo sapiens 306-314 19028832-2 2009 OBJECTIVE: We wanted to test whether immunosuppression with cyclic methylprednisolone (MP) in combination with azathioprine (AZA) for 6 months accelerates recovery of IFN-beta bioactivity in patients with multiple sclerosis (MS) with abolished in-vivo myxovirus resistance protein A (MxA) mRNA response to IFN-beta. Azathioprine 111-123 interferon beta 1 Homo sapiens 167-175 19028832-2 2009 OBJECTIVE: We wanted to test whether immunosuppression with cyclic methylprednisolone (MP) in combination with azathioprine (AZA) for 6 months accelerates recovery of IFN-beta bioactivity in patients with multiple sclerosis (MS) with abolished in-vivo myxovirus resistance protein A (MxA) mRNA response to IFN-beta. Azathioprine 125-128 interferon beta 1 Homo sapiens 167-175 19304544-6 2009 The mRNA level of TLR3, TRIF, and IFN-beta were also increased following Poly I:C treatment in comparison with the control group. Poly I-C 73-81 interferon beta 1 Homo sapiens 34-42 19304544-7 2009 CONCLUSION: Poly I:C can induce significant growth inhibition and apoptosis of SMMC-7721 cells in a dose- and time-dependent manner possibly by causing cell cycle arrest and TLR3 signaling pathway activation that leads to IFN-beta production and cell apoptosis. Poly I-C 12-20 interferon beta 1 Homo sapiens 222-230 19174562-8 2009 Using USDDS, we then demonstrate that STAT1 phosphorylation at Y701 induced by interferon-beta treatment inhibits SUMOylation of K703 in vivo. amosulalol hydrochloride 129-133 interferon beta 1 Homo sapiens 79-94 19363997-8 2009 Regarding the treatment of NMO, there are refractory patients which can be treated with interferon beta, so immunosuppressive agents such as low-dose oral prednisolone and/or azathioprine reduce the rate of relapse, while, unlike in MS, the therapeutic efficacy of interferon beta is unclear in NMO. Prednisolone 155-167 interferon beta 1 Homo sapiens 88-103 19363997-8 2009 Regarding the treatment of NMO, there are refractory patients which can be treated with interferon beta, so immunosuppressive agents such as low-dose oral prednisolone and/or azathioprine reduce the rate of relapse, while, unlike in MS, the therapeutic efficacy of interferon beta is unclear in NMO. Prednisolone 155-167 interferon beta 1 Homo sapiens 265-280 19363997-8 2009 Regarding the treatment of NMO, there are refractory patients which can be treated with interferon beta, so immunosuppressive agents such as low-dose oral prednisolone and/or azathioprine reduce the rate of relapse, while, unlike in MS, the therapeutic efficacy of interferon beta is unclear in NMO. Azathioprine 175-187 interferon beta 1 Homo sapiens 88-103 19363997-8 2009 Regarding the treatment of NMO, there are refractory patients which can be treated with interferon beta, so immunosuppressive agents such as low-dose oral prednisolone and/or azathioprine reduce the rate of relapse, while, unlike in MS, the therapeutic efficacy of interferon beta is unclear in NMO. Azathioprine 175-187 interferon beta 1 Homo sapiens 265-280 19514518-6 2009 Interferon beta (IFN-beta), which is an immunomodulatory drug, is the only drug approved in Japan for treating MS; however, it is only partially effective or rather ineffective for treating patients with rapidly worsening or fulminant MS. Our pilot studies confirmed the benefits of mitoxantrone in Japanese patients with MS, and in this study, we review its potential appliciation for the treatment of MS by Japanese neurologists. Mitoxantrone 283-295 interferon beta 1 Homo sapiens 0-15 19514518-6 2009 Interferon beta (IFN-beta), which is an immunomodulatory drug, is the only drug approved in Japan for treating MS; however, it is only partially effective or rather ineffective for treating patients with rapidly worsening or fulminant MS. Our pilot studies confirmed the benefits of mitoxantrone in Japanese patients with MS, and in this study, we review its potential appliciation for the treatment of MS by Japanese neurologists. Mitoxantrone 283-295 interferon beta 1 Homo sapiens 17-25 19380831-5 2009 In the present study, we investigated MspTL-mediated activation of signaling pathways stimulating up-regulation of IFN-beta and IFN-stimulated genes in a human monocytic cell line, THP-1 cells, and primary cultured human gingival fibroblasts. msptl 38-43 interferon beta 1 Homo sapiens 115-123 19380831-6 2009 MspTL treatment of the cells induced IFN-beta and the IFN-stimulated genes IFN-gamma-inducible protein-10 (IP-10) and RANTES. msptl 0-5 interferon beta 1 Homo sapiens 37-45 19380831-7 2009 A neutralizing anti-IFN-beta Ab significantly reduced the expression of IP-10 and RANTES, as well as STAT-1 activation, which was also induced by MspTL. msptl 146-151 interferon beta 1 Homo sapiens 20-28 19007809-4 2009 In mammals, poly I:C induces IFN-beta through the RIG-I/MDA5 or the TLR3 pathway, both of which are dependent on NF-kB. Poly I-C 12-20 interferon beta 1 Homo sapiens 29-37 19007809-6 2009 The presence of an NF-kappaB site in their promoters and their strong up-regulation by poly I:C, suggest that salmon IFNa1/IFNa2 are induced through similar pathways as IFN-beta. Poly I-C 87-95 interferon beta 1 Homo sapiens 169-177 19278300-10 2009 CONCLUSION: Use of an IFN-beta-1b dose higher than the currently approved 250-microg dose is associated with an increased probability of NAb disappearance. nab 137-140 interferon beta 1 Homo sapiens 22-30 19201909-0 2009 IFN-beta impairs superoxide-dependent parasite killing in human macrophages: evidence for a deleterious role of SOD1 in cutaneous leishmaniasis. Superoxides 17-27 interferon beta 1 Homo sapiens 0-8 19201909-4 2009 However, IFN-beta significantly reduced superoxide release in Leishmania-infected as well as uninfected human macrophages. Superoxides 40-50 interferon beta 1 Homo sapiens 9-17 19201909-5 2009 This decrease in superoxide production was paralleled by a significant IFN-beta-mediated increase in superoxide dismutase 1 (SOD1) protein levels. Superoxides 17-27 interferon beta 1 Homo sapiens 71-79 19200860-3 2009 This choice has been influenced by the perception that interferon-beta preparations have greater efficacy than glatiramer acetate, due to apparently more rapid and robust reduction of gadolinium-enhancing lesions seen on magnetic resonance imaging in the pivotal trials of these agents. Gadolinium 184-194 interferon beta 1 Homo sapiens 55-70 19200865-5 2009 There is some evidence that interferon-beta treatment may exacerbate depressive symptoms and a switch to glatiramer acetate can be envisaged in patients treated with an interferon-beta in whom depressive symptoms become an issue. Glatiramer Acetate 105-123 interferon beta 1 Homo sapiens 169-184 19052084-4 2009 Using reporter assays, we show that BGLF4 effectively suppresses the activities of the poly(I:C)-stimulated IFN-beta promoter and IRF3-responsive element. Poly I-C 87-96 interferon beta 1 Homo sapiens 108-116 18930547-0 2009 Cigarette smoke attenuation of poly I:C-induced innate antiviral responses in human PBMC is mainly due to inhibition of IFN-beta production. Poly I-C 31-39 interferon beta 1 Homo sapiens 120-128 19028691-6 2009 Double-stranded PRNAs 50 nucleotides long as well as polyinosinic-polycytidylic acid activated the RNA-dependent protein kinase (PKR) and induced significant levels of IFN-beta and apoptosis, whereas shorter PRNAs and chemically synthesized dsRNAs did not. Poly I-C 53-84 interferon beta 1 Homo sapiens 168-176 19028691-7 2009 Effector caspase activation and apoptosis following RNA transfection was enhanced by pretreatment with IFN, and removal of the 5"-phosphate from PRNAs decreased induction of both IFN-beta and apoptosis. 5"-phosphate 127-139 interferon beta 1 Homo sapiens 179-187 19000652-5 2009 Analysis of the expression of breast cancer related genes indicated that EGFR, HER2, bcl-2, and COX-2 were significantly downregulated, while IFN-beta and p21 were remarkably upregulated by berberine. Berberine 190-199 interferon beta 1 Homo sapiens 142-150 19480465-13 2009 Biferonex(R) is a pH neutral and human serum albumin-free IFNbeta-1a. biferonex 0-9 interferon beta 1 Homo sapiens 58-65 18824168-0 2008 Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Catecholamines 50-64 interferon beta 1 Homo sapiens 13-28 18727672-3 2009 METHODS: Data from IFNbeta-treated MS patients who had been tested for NAbs twice (n = 822) were analysed. nabs 71-75 interferon beta 1 Homo sapiens 19-26 19117201-1 2009 Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in a percentage of patients. babs 116-120 interferon beta 1 Homo sapiens 0-21 19378035-4 2009 We found that LPS induced TLR4 tyrosine phosphorylation and mutations of tyrosine residues in the Toll-IL-1R signaling domain markedly suppressed TLR4-mediated activation of JNK and p38 MAP kinases and transcription factors NF-kappaB, RANTES, and IFN-beta. Tyrosine 31-39 interferon beta 1 Homo sapiens 247-255 19449179-0 2009 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. Calcitriol 0-32 interferon beta 1 Homo sapiens 69-77 19378035-4 2009 We found that LPS induced TLR4 tyrosine phosphorylation and mutations of tyrosine residues in the Toll-IL-1R signaling domain markedly suppressed TLR4-mediated activation of JNK and p38 MAP kinases and transcription factors NF-kappaB, RANTES, and IFN-beta. Tyrosine 73-81 interferon beta 1 Homo sapiens 247-255 20017362-4 2009 Free human recombinant interferon-beta was obtained as a result of treatment of the chimeric protein DBD-IFN-beta immobilized on sephadex G-25 with human enteropeptidase. sephadex 129-142 interferon beta 1 Homo sapiens 23-38 20017362-4 2009 Free human recombinant interferon-beta was obtained as a result of treatment of the chimeric protein DBD-IFN-beta immobilized on sephadex G-25 with human enteropeptidase. sephadex 129-142 interferon beta 1 Homo sapiens 105-113 18948302-6 2009 Further studies showed that IFN-alpha, IFN-beta, and IFN-gamma significantly attenuate TCDD-induced increases in CYP1A1 mRNA levels to varying degrees, but concentrations as high as 1000 U/ml of type I IFNs did not reverse the effect of TCDD on the anti-sRBC IgM AFC response. Polychlorinated Dibenzodioxins 87-91 interferon beta 1 Homo sapiens 39-47 19134456-7 2009 Puerarin significantly enhanced the gene expressions in endometriotic stromal cells, including BAD, BAX, CASP8, CASP9, TNFRSF6, CDKN1B, CDKN2A, IFNA1 and IFNB1, and reduced the gene expressions of FOS, CHEK2, SRC, ITGB5, MMP9, PDGFA and NFKBIA. puerarin 0-8 interferon beta 1 Homo sapiens 154-159 18950872-7 2008 The expression of the pharmacodynamic mRNA markers of IFN-beta effect showed differences in time profiles for the Good Responder and Partial Responders to IFN-beta therapy and the Jak-STAT, TNFRSF10B, IL6, TGFbeta, retinoic acid and CDC42 pathways were differentially modulated. Tretinoin 215-228 interferon beta 1 Homo sapiens 54-62 18832709-8 2008 Furthermore, poly(I:C)-induced IFN-beta production is inhibited by pretreatment of cells with B- and C-type oligodeoxynucleotides (ODNs) but not with TLR7/8 ligands. Poly I-C 13-21 interferon beta 1 Homo sapiens 31-39 18594991-4 2008 Molecular examination demonstrated that type I interferons (interferon-alpha and interferon-beta) increased in the frontal lobe in response to chronic methamphetamine treatment, in correlation with the neuronal changes. Methamphetamine 151-166 interferon beta 1 Homo sapiens 81-96 19056675-0 2008 IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression. Temozolomide 63-75 interferon beta 1 Homo sapiens 0-8 19056675-2 2008 We hypothesized that IFN-beta could sensitize neuroblastoma cells to the cytotoxic effects of temozolomide through its ability to down-regulate MGMT expression. Temozolomide 94-106 interferon beta 1 Homo sapiens 21-29 19056675-6 2008 Temozolomide had little effect on in vitro proliferation of the neuroblastoma cell lines with high MGMT expression, but pretreatment with IFN-beta significantly decreased MGMT expression and cell counts (NB-1691: 36 +/- 3% of control, P = 0.0008; SK-N-AS: 54 +/- 7% control, P = 0.003). sk-n-as 247-254 interferon beta 1 Homo sapiens 138-146 19056675-8 2008 IFN-beta appears to sensitize neuroblastoma cells to the cytotoxic effects of temozolomide through attenuation of MGMT expression. Temozolomide 78-90 interferon beta 1 Homo sapiens 0-8 18726131-0 2008 Neural progenitor cell-mediated delivery of interferon beta improves neuroblastoma response to cyclophosphamide. Cyclophosphamide 95-111 interferon beta 1 Homo sapiens 44-59 18164542-7 2008 Due to its lower efficacy, glatiramer acetate should be used as a second choice in case of intolerable side effects or toxicity of interferon beta. Glatiramer Acetate 27-45 interferon beta 1 Homo sapiens 131-146 18678606-6 2008 These results suggest that TNF-alpha and PGE2 activate STAT-mediated components of human DC maturation by alternative pathways to the IFN-beta-mediated autocrine loop used by TLRs. Dinoprostone 41-45 interferon beta 1 Homo sapiens 134-142 19094453-1 2008 The development of neutralizing antibodies (NAbs) against interferon-beta(IFNbeta) reduces clinical efficacy and markers of bioactivity in patients with multiple sclerosis (MS), although it has also been shown that a poor response to IFNbeta coincided with unexpectedly low NAb levels. nab 44-47 interferon beta 1 Homo sapiens 58-82 19094453-1 2008 The development of neutralizing antibodies (NAbs) against interferon-beta(IFNbeta) reduces clinical efficacy and markers of bioactivity in patients with multiple sclerosis (MS), although it has also been shown that a poor response to IFNbeta coincided with unexpectedly low NAb levels. nab 44-47 interferon beta 1 Homo sapiens 74-81 19198124-9 2008 Thus, inhibitor for glutaminase and gap-junction may be other candidates to treat MS. Interferon-beta also effectively suppress glutamate production by these cells and subsequently suppress development of axonal degeneration. Glutamic Acid 128-137 interferon beta 1 Homo sapiens 86-101 19267105-0 2008 Disappearance of gadolinium enhancement in a chemoresistant astrocytoma of the tectum after high-dose interferon beta. Gadolinium 17-27 interferon beta 1 Homo sapiens 102-117 19267105-1 2008 Interferon beta 6 million units per week was administered to a patient with an aggressive astrocytoma in the tectum that was resistant to cisplatin, etoposide, vinblastine, and the oral alkylating agent temozolomide. Cisplatin 138-147 interferon beta 1 Homo sapiens 0-15 19267105-1 2008 Interferon beta 6 million units per week was administered to a patient with an aggressive astrocytoma in the tectum that was resistant to cisplatin, etoposide, vinblastine, and the oral alkylating agent temozolomide. Etoposide 149-158 interferon beta 1 Homo sapiens 0-15 19267105-1 2008 Interferon beta 6 million units per week was administered to a patient with an aggressive astrocytoma in the tectum that was resistant to cisplatin, etoposide, vinblastine, and the oral alkylating agent temozolomide. Vinblastine 160-171 interferon beta 1 Homo sapiens 0-15 19267105-1 2008 Interferon beta 6 million units per week was administered to a patient with an aggressive astrocytoma in the tectum that was resistant to cisplatin, etoposide, vinblastine, and the oral alkylating agent temozolomide. Temozolomide 203-215 interferon beta 1 Homo sapiens 0-15 19267105-3 2008 Interferon beta caused the disappearance of the gadolinium-enhanced lesion in the tectum. Gadolinium 48-58 interferon beta 1 Homo sapiens 0-15 19267105-5 2008 Administration of interferon beta might have a favorable effect on tectal gliomas that are immunopositive for MGMT and resistant to chemoradiotherapy including temozolomide. Temozolomide 160-172 interferon beta 1 Homo sapiens 18-33 18575814-2 2008 The recombinant human interferon-beta (huIFN-beta) 1b was expressed in the food-grade lactic acid bacterium, Lactococcus lactis, using a nisin-controlled gene expression system. Lactic Acid 86-97 interferon beta 1 Homo sapiens 22-37 18825744-0 2008 IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Adenosine 28-37 interferon beta 1 Homo sapiens 0-8 18825744-7 2008 Upregulation of ecto-5"-nucleotidase and a subsequent increase in adenosine production might contribute to the beneficial effects of IFN-beta on MS via enhancing the endothelial barrier function. Adenosine 66-75 interferon beta 1 Homo sapiens 133-141 18459156-0 2008 Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta. ME3738 96-102 interferon beta 1 Homo sapiens 122-137 18641315-7 2008 Ro52-mediated IRF3 degradation significantly inhibits IFN-beta promoter activity, an effect that is reversed in the presence of the proteasomal inhibitor MG132. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 154-159 interferon beta 1 Homo sapiens 54-62 18606968-1 2008 Disease-modifying agents (DMAs), including interferon beta (IFNbeta) and glatiramer acetate (GA), are the mainstays of long-term treatment of multiple sclerosis (MS). Dimethyl acetylsuccinate 26-30 interferon beta 1 Homo sapiens 43-58 18606968-1 2008 Disease-modifying agents (DMAs), including interferon beta (IFNbeta) and glatiramer acetate (GA), are the mainstays of long-term treatment of multiple sclerosis (MS). Dimethyl acetylsuccinate 26-30 interferon beta 1 Homo sapiens 60-67 18081914-2 2008 Two to forty per cent of IFN-beta-treated multiple sclerosis (MS) patients develop IFN-beta-neutralizing antibodies (NAb) with subsequent attenuation of MxA protein induction. nab 117-120 interferon beta 1 Homo sapiens 25-33 18081914-2 2008 Two to forty per cent of IFN-beta-treated multiple sclerosis (MS) patients develop IFN-beta-neutralizing antibodies (NAb) with subsequent attenuation of MxA protein induction. nab 117-120 interferon beta 1 Homo sapiens 83-91 18459156-0 2008 Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta. 22beta-methoxyolean-12-ene-3beta 46-78 interferon beta 1 Homo sapiens 122-137 18459156-0 2008 Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta. (4beta)-diol 82-94 interferon beta 1 Homo sapiens 122-137 18505772-1 2008 OBJECTIVE: To establish whether multiple sclerosis (MS) patients, who have lost the therapeutic effect of interferon-beta (IFN-beta) owing to neutralizing antibodies (NAbs) and subsequently revert from a NAb-positive to a NAb-negative state under continued IFN-beta-1b therapy, regain clinical effect after reversion. nab 167-170 interferon beta 1 Homo sapiens 123-131 18505772-3 2008 However, some patients, who become NAb-positive under treatment with IFN-beta-1b, may revert to a NAb-negative state under continuous treatment. nab 35-38 interferon beta 1 Homo sapiens 69-77 18505772-3 2008 However, some patients, who become NAb-positive under treatment with IFN-beta-1b, may revert to a NAb-negative state under continuous treatment. nab 98-101 interferon beta 1 Homo sapiens 69-77 18505772-14 2008 CONCLUSION: Under NAb-positive periods, the clinical effect of IFN-beta was abolished. nab 18-21 interferon beta 1 Homo sapiens 63-71 18505778-2 2008 In a previous study we have found a direct stabilization of barrier characteristics after treatment of bovine brain capillary endothelial cells (BCECs) with human recombinant interferon-beta-1a (IFN-beta-1a) in an in vitro BBB model. 1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE 223-226 interferon beta 1 Homo sapiens 175-190 18428149-8 2008 For the functional analyses, myeloid dendritic cells from the patients induced significantly less amounts of IFN-beta, TNF-alpha and IL-12p70 in response to polyinosine-polycytidylic acid or lipopolysaccharide. polyinosine-polycytidylic acid 157-187 interferon beta 1 Homo sapiens 109-117 18771559-3 2008 Here we show that Legionella pneumophila infection, and intracellular challenge with poly(dA-dT), but not with poly(dG-dC), induced expression of IFNbeta, full-length hZBP1 and a prominent splice variant lacking the first Zalpha domain (hZBP1DeltaZalpha) in human cells. poly 85-89 interferon beta 1 Homo sapiens 146-153 18771559-3 2008 Here we show that Legionella pneumophila infection, and intracellular challenge with poly(dA-dT), but not with poly(dG-dC), induced expression of IFNbeta, full-length hZBP1 and a prominent splice variant lacking the first Zalpha domain (hZBP1DeltaZalpha) in human cells. da-dt 90-95 interferon beta 1 Homo sapiens 146-153 18771559-4 2008 Overexpression of hZBP1 but not hZBP1DeltaZalpha slightly amplified poly(dA-dT)-stimulated IFNbeta reporter activation in HEK293 cells, but had no effect on IFNbeta and IL-8 production induced by bacteria or poly(dA-dT) in A549 cells. Poly dA-dT 68-79 interferon beta 1 Homo sapiens 91-98 18771559-4 2008 Overexpression of hZBP1 but not hZBP1DeltaZalpha slightly amplified poly(dA-dT)-stimulated IFNbeta reporter activation in HEK293 cells, but had no effect on IFNbeta and IL-8 production induced by bacteria or poly(dA-dT) in A549 cells. poly 68-72 interferon beta 1 Homo sapiens 91-98 18771559-4 2008 Overexpression of hZBP1 but not hZBP1DeltaZalpha slightly amplified poly(dA-dT)-stimulated IFNbeta reporter activation in HEK293 cells, but had no effect on IFNbeta and IL-8 production induced by bacteria or poly(dA-dT) in A549 cells. da-dt 73-78 interferon beta 1 Homo sapiens 91-98 18771559-5 2008 We found that mZBP1 siRNA impaired poly(dA-dT)-induced IFNbeta responses in mouse L929 fibroblasts at a later time point, while multiple hZBP1 siRNAs did not suppress IFNbeta or IL-8 expression induced by poly(dA-dT) or bacterial infection in human cells. Poly dA-dT 35-46 interferon beta 1 Homo sapiens 55-62 18771559-5 2008 We found that mZBP1 siRNA impaired poly(dA-dT)-induced IFNbeta responses in mouse L929 fibroblasts at a later time point, while multiple hZBP1 siRNAs did not suppress IFNbeta or IL-8 expression induced by poly(dA-dT) or bacterial infection in human cells. poly 35-39 interferon beta 1 Homo sapiens 55-62 18771559-5 2008 We found that mZBP1 siRNA impaired poly(dA-dT)-induced IFNbeta responses in mouse L929 fibroblasts at a later time point, while multiple hZBP1 siRNAs did not suppress IFNbeta or IL-8 expression induced by poly(dA-dT) or bacterial infection in human cells. da-dt 40-45 interferon beta 1 Homo sapiens 55-62 18771559-6 2008 In contrast, IRF3 siRNA strongly impaired the IFNbeta responses to poly(dA-dT) or bacterial infection. poly 67-71 interferon beta 1 Homo sapiens 46-53 18771559-6 2008 In contrast, IRF3 siRNA strongly impaired the IFNbeta responses to poly(dA-dT) or bacterial infection. da-dt 72-77 interferon beta 1 Homo sapiens 46-53 18771559-7 2008 In conclusion, intracellular bacteria and cytosolic poly(dA-dT) activate IFNbeta responses in different human cells without requiring human ZBP1. poly 52-56 interferon beta 1 Homo sapiens 73-80 18771559-7 2008 In conclusion, intracellular bacteria and cytosolic poly(dA-dT) activate IFNbeta responses in different human cells without requiring human ZBP1. da-dt 57-62 interferon beta 1 Homo sapiens 73-80 18611945-4 2008 We found that RSV initial attachment to cells blocked polyI:C-mediated IFN-beta induction, and this early IFN-beta-modulating event was abrogated by antibodies against envelope proteins of RSV, demonstrating the presence of a IFN-regulatory mode by early RSV attachment to host cells. Poly I-C 54-61 interferon beta 1 Homo sapiens 71-79 18713996-9 2008 Poly(I-C)-induced expression of IP-10, RANTES, and IFN-beta mRNA was decreased in MKK4- or MKK7-deficient FLS. Poly I-C 0-8 interferon beta 1 Homo sapiens 51-59 18715196-4 2008 We used microarray analysis and RT-PCR to measure gene expression in whole blood, 9-15 h postinjection, in patients with and without NAbs to IFN-beta. nabs 133-137 interferon beta 1 Homo sapiens 141-149 18690500-0 2008 Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. Glatiramer Acetate 0-18 interferon beta 1 Homo sapiens 71-86 18690500-2 2008 This is the first study that shows that switching patients from IFNbeta to glatiramer acetate (GA) in case of neutralising antibodies (NAb) positivity is effective in reducing relapse rate and in delaying the time to first relapse. Glatiramer Acetate 75-93 interferon beta 1 Homo sapiens 64-71 18690500-2 2008 This is the first study that shows that switching patients from IFNbeta to glatiramer acetate (GA) in case of neutralising antibodies (NAb) positivity is effective in reducing relapse rate and in delaying the time to first relapse. Glatiramer Acetate 95-97 interferon beta 1 Homo sapiens 64-71 18573823-4 2008 In contrast, when atorvastatin is added to interferon-beta, hs-CRP serum levels decrease to the normal range (P<0.05), indicating an anti-inflammatory action of atorvastatin in MS. Atorvastatin 164-176 interferon beta 1 Homo sapiens 43-58 19669308-8 2008 In contrast, transfection of HIBECs with polyI:C induced a marked increase in mRNAs encoding a variety of chemokines/cytokines, including IFN-beta, IL-6, and TNF-alpha. Poly I-C 41-48 interferon beta 1 Homo sapiens 138-146 19669308-9 2008 The induction of IFN-beta mRNA was efficiently inhibited by an siRNA against MAVS but not against TICAM-1, indicating that the main signaling pathway for IFN-beta induction following polyI:C transfection is via retinoic acid-inducible gene I (RIG-I)/melanoma differentiation-associated gene 5 (MDA5) in HIBECs. Poly I-C 183-190 interferon beta 1 Homo sapiens 17-25 19669308-9 2008 The induction of IFN-beta mRNA was efficiently inhibited by an siRNA against MAVS but not against TICAM-1, indicating that the main signaling pathway for IFN-beta induction following polyI:C transfection is via retinoic acid-inducible gene I (RIG-I)/melanoma differentiation-associated gene 5 (MDA5) in HIBECs. Poly I-C 183-190 interferon beta 1 Homo sapiens 154-162 17986500-9 2008 CONCLUSIONS: MRI activity and NAb occurrence during the first 6 months of interferon beta treatment were reliable predictors of long term clinical response, particularly when combined. nab 30-33 interferon beta 1 Homo sapiens 74-89 18459156-10 2008 Interferon-beta knockdown by small interfering RNA abrogated the anti-HCV effect of ME3738. ME3738 84-90 interferon beta 1 Homo sapiens 0-15 18459156-13 2008 The enhancement of autocrine IFN-beta suggests that ME3738 exerts antiviral action along the type I IFN pathway. ME3738 52-58 interferon beta 1 Homo sapiens 29-37 18389479-4 2008 DiC14-amidine liposomes also activated human DC, as shown by synthesis of IL-12p40 and TNF-alpha, accumulation of IL-6, IFN-beta and CXCL10 mRNA, and up-regulation of membrane expression of CD80 and CD86. N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine 0-13 interferon beta 1 Homo sapiens 120-128 18389479-6 2008 Finally, we demonstrated in mouse and human cells that diC14-amidine liposomes use Toll-like receptor 4 to elicit both MyD88-dependent and Toll/IL-1R-containing adaptor inducing interferon IFN-beta (TRIF)-dependent responses. Amidines 61-68 interferon beta 1 Homo sapiens 189-197 17669408-9 2008 Treatment of FTEC with TLR3 agonist poly(I:C) resulted in increased expression of interleukin-8, tumor-necrosis factor alpha, human beta-defensin 2, interferon beta, and interferon stimulated genes myxovirus resistance gene 1, 2",5"-oligoadenylate synthetase, and protein kinase R. Additionally, FTEC exposed to poly(I:C) also resulted in the induction of TLR2, TLR3, and TLR7. poly 36-40 interferon beta 1 Homo sapiens 149-164 17669408-9 2008 Treatment of FTEC with TLR3 agonist poly(I:C) resulted in increased expression of interleukin-8, tumor-necrosis factor alpha, human beta-defensin 2, interferon beta, and interferon stimulated genes myxovirus resistance gene 1, 2",5"-oligoadenylate synthetase, and protein kinase R. Additionally, FTEC exposed to poly(I:C) also resulted in the induction of TLR2, TLR3, and TLR7. Carbon 16-17 interferon beta 1 Homo sapiens 149-164 18252870-7 2008 poly(I:C), on the other hand, induced a strong and long-lasting (>12 h) IFN-beta mRNA and protein response, particularly when transfected, whereas only a protracted TNF response was observed when poly(I:C) was transfected. Poly I-C 0-8 interferon beta 1 Homo sapiens 75-83 18252870-7 2008 poly(I:C), on the other hand, induced a strong and long-lasting (>12 h) IFN-beta mRNA and protein response, particularly when transfected, whereas only a protracted TNF response was observed when poly(I:C) was transfected. Poly I 0-7 interferon beta 1 Homo sapiens 75-83 18426595-10 2008 In patients testing positive for NAbs (NAb+) to IFN beta-1a 44 mcg sc tiw, changes in BOD were smaller than in NAb negative (NAb-) patients, but similar to those receiving IFN beta-1a, 30 mcg im qw. nab 33-36 interferon beta 1 Homo sapiens 48-56 18426595-10 2008 In patients testing positive for NAbs (NAb+) to IFN beta-1a 44 mcg sc tiw, changes in BOD were smaller than in NAb negative (NAb-) patients, but similar to those receiving IFN beta-1a, 30 mcg im qw. nab 39-42 interferon beta 1 Homo sapiens 48-56 18426595-10 2008 In patients testing positive for NAbs (NAb+) to IFN beta-1a 44 mcg sc tiw, changes in BOD were smaller than in NAb negative (NAb-) patients, but similar to those receiving IFN beta-1a, 30 mcg im qw. nab 39-42 interferon beta 1 Homo sapiens 48-56 18425915-12 2008 The metanalyses showed that the proportion of patients converting to CDMS was significantly lower in IFN beta-treated than in placebo-treated patients both after one year (pooled OR 0.53; 95% CI, 0.40 to 0.71; p <0.0001) as well as after two years of follow-up (pooled OR 0.52; 95% CI, 0.38 to 0.70; p <0.0001). cdms 69-73 interferon beta 1 Homo sapiens 101-109 18425915-15 2008 AUTHORS" CONCLUSIONS: The efficacy of IFN beta treatment on preventing the conversion from CIS to CDMS was confirmed over two years of follow-up. cdms 98-102 interferon beta 1 Homo sapiens 38-46 18268020-4 2008 Viral RNA binding to RIG-I stimulates the velocity of ATP hydrolysis by 33-fold, which at the cellular level translates into a 43-fold increase of interferon-beta expression. Adenosine Triphosphate 54-57 interferon beta 1 Homo sapiens 147-162 18330707-6 2008 siRNA-mediated inhibition of ectopic ISG12a protein expression prevented the sensitization to etoposide-induced apoptosis and also decreased the ability of IFN-beta pretreatment to sensitize cells to etoposide, thereby demonstrating a role for ISG12a in this process. Etoposide 200-209 interferon beta 1 Homo sapiens 156-164 17564708-2 2008 In our previous experiments, we observed that IFN-beta sensitized TMZ-resistant glioma cells with the unmethylated MGMT promoter and that the mechanism of action was possibly due to attenuation of MGMT expression via induction of TP53. Temozolomide 66-69 interferon beta 1 Homo sapiens 46-54 17564708-9 2008 In this context, IFN-beta inactivates MGMT via p53 gene induction and enhances the therapeutic efficacy to TMZ. Temozolomide 107-110 interferon beta 1 Homo sapiens 17-25 18312403-14 2008 Mean serum UA levels significantly increased when determined during Interferon Beta or Glatiramer Acetate therapy (r: 0.84, P < 0.001). Uric Acid 11-13 interferon beta 1 Homo sapiens 68-83 18304744-9 2008 Our study suggests both IFN-beta and IFN-alpha, which share the same receptor, may be bound with relatively high affinity in these structures, possibly offering new insight into a neurovegetative syndrome induced by IFN-alpha therapy and suspected to involve altered dopamine neurotransmission in the basal ganglia. Dopamine 267-275 interferon beta 1 Homo sapiens 24-32 18322232-0 2008 STAT-1 signaling in human lung fibroblasts is induced by vanadium pentoxide through an IFN-beta autocrine loop. vanadium pentoxide 57-75 interferon beta 1 Homo sapiens 87-95 18322232-6 2008 In this study, we identified IFN-beta as the protein that mediates STAT-1 activation by V(2)O(5) in normal human lung fibroblasts and identified NADPH and xanthine oxidase systems as sources of H(2)O(2) that drive IFN-beta gene expression. h(2) 194-198 interferon beta 1 Homo sapiens 29-37 18322232-10 2008 Apocynin and allopurinol also decreased V(2)O(5)-induced IFN-beta mRNA levels and CXCL10 expression. Allopurinol 13-24 interferon beta 1 Homo sapiens 57-65 18322232-12 2008 Taken together, these data indicate that fibroblasts play a role in the innate immune response to vanadium-induced oxidative stress by synthesizing IFN-beta and activating STAT-1 to cause growth arrest and increase levels of CXCL10, a potent antifibrotic factor. Vanadium 98-106 interferon beta 1 Homo sapiens 148-156 18199340-9 2008 IFN-beta production was induced after poly I:C/CHX treatment and neutralization of IFN-beta slightly reduced poly I:C/CHX -induced apoptosis. poly 38-42 interferon beta 1 Homo sapiens 0-8 18279804-8 2008 Selenium also suppressed the expression of COX-2 and iNOS and the endogenous IFN beta mRNA induced by poly[I:C] or LPS. Selenium 0-8 interferon beta 1 Homo sapiens 77-85 17986510-2 2008 The frequency of Nabs varies depending on IFN-beta product and the Nab assay used. nab 17-20 interferon beta 1 Homo sapiens 42-50 18094073-7 2008 However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells. Sirolimus 67-76 interferon beta 1 Homo sapiens 128-135 18094073-7 2008 However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells. Sirolimus 78-87 interferon beta 1 Homo sapiens 128-135 18209079-0 2008 Sphingosine 1-phosphate 1 and TLR4 mediate IFN-beta expression in human gingival epithelial cells. sphingosine 1-phosphate 0-23 interferon beta 1 Homo sapiens 43-51 18098265-3 2008 Here we report the effects of the penultimate residue (the residue after the initiator Met) on the processing of two unnatural amino acids, L-azidohomoalanine (AHA) and L-homopropargylglycine (HPG), at the N terminus of recombinant human interferon-beta in E. coli. azidohomoalanine 140-158 interferon beta 1 Homo sapiens 238-253 18098265-3 2008 Here we report the effects of the penultimate residue (the residue after the initiator Met) on the processing of two unnatural amino acids, L-azidohomoalanine (AHA) and L-homopropargylglycine (HPG), at the N terminus of recombinant human interferon-beta in E. coli. L-homopropargylglycine 169-191 interferon beta 1 Homo sapiens 238-253 18098265-3 2008 Here we report the effects of the penultimate residue (the residue after the initiator Met) on the processing of two unnatural amino acids, L-azidohomoalanine (AHA) and L-homopropargylglycine (HPG), at the N terminus of recombinant human interferon-beta in E. coli. 4-HYDROXYPHENYL GLYOXAL 193-196 interferon beta 1 Homo sapiens 238-253 18199340-9 2008 IFN-beta production was induced after poly I:C/CHX treatment and neutralization of IFN-beta slightly reduced poly I:C/CHX -induced apoptosis. poly 109-113 interferon beta 1 Homo sapiens 83-91 18540482-1 2008 Blastoferon, in the following referred to as the test product, is a pharmaceutical product of interferon beta la (CAS 220581-49-7) currently marketed as a biosimilar to the innovator Interferon beta la product (referred to as the reference product). blastoferon 0-11 interferon beta 1 Homo sapiens 94-109 18540482-1 2008 Blastoferon, in the following referred to as the test product, is a pharmaceutical product of interferon beta la (CAS 220581-49-7) currently marketed as a biosimilar to the innovator Interferon beta la product (referred to as the reference product). blastoferon 0-11 interferon beta 1 Homo sapiens 183-198 17911184-5 2008 Patients with NAb titres of up to 150 TRU/ml (ten times reduction units per ml) still had retained IFNbeta bioactivity, whereas greatly reduced levels of IFNbeta bioactivity were found in patients with NAbs of 150-600 TRU/ml. nab 14-17 interferon beta 1 Homo sapiens 99-106 18981624-1 2008 OBJECTIVE: The aim of this pilot study was to determine the safety and efficacy of natural human interferon beta (nIFNbeta) plus ribavirin (RBV) in patients with chronic hepatitis C who did not respond to pegylated interferon alpha (PEG-IFN), with special emphasis on the incidence of mental disorders or refusal for fear of adverse effects. peg-ifn 233-240 interferon beta 1 Homo sapiens 97-112 17911184-8 2008 CONCLUSION: There is a stepwise loss of IFNbeta bioactivity with increasing NAb titres and it is possible to identify functionally critical NAb titre levels that are useful to support treatment decisions at the individual patient level. nab 76-79 interferon beta 1 Homo sapiens 40-47 17979888-0 2007 Curcumin modulation of IFN-beta and IL-12 signalling and cytokine induction in human T cells. Curcumin 0-8 interferon beta 1 Homo sapiens 23-31 17661372-4 2007 Stimulation with polyinosinic-polycytidylic acid [poly(I:C), a synthetic analog of viral dsRNA] induced the activation of transcription factors [nuclear factor (NF)-kappaB and interferon regulatory factor 3 (IRF3)] and the production of interferon-beta1 (IFN-beta1) and MxA as potent antiviral responses. Poly I-C 17-48 interferon beta 1 Homo sapiens 237-253 17661372-4 2007 Stimulation with polyinosinic-polycytidylic acid [poly(I:C), a synthetic analog of viral dsRNA] induced the activation of transcription factors [nuclear factor (NF)-kappaB and interferon regulatory factor 3 (IRF3)] and the production of interferon-beta1 (IFN-beta1) and MxA as potent antiviral responses. Poly I-C 17-48 interferon beta 1 Homo sapiens 255-264 17661372-4 2007 Stimulation with polyinosinic-polycytidylic acid [poly(I:C), a synthetic analog of viral dsRNA] induced the activation of transcription factors [nuclear factor (NF)-kappaB and interferon regulatory factor 3 (IRF3)] and the production of interferon-beta1 (IFN-beta1) and MxA as potent antiviral responses. Poly I-C 50-58 interferon beta 1 Homo sapiens 237-253 17661372-4 2007 Stimulation with polyinosinic-polycytidylic acid [poly(I:C), a synthetic analog of viral dsRNA] induced the activation of transcription factors [nuclear factor (NF)-kappaB and interferon regulatory factor 3 (IRF3)] and the production of interferon-beta1 (IFN-beta1) and MxA as potent antiviral responses. Poly I-C 50-58 interferon beta 1 Homo sapiens 255-264 17889376-5 2007 We further identified a predictive relationship between positive BAbs levels and NAbs activity in patients treated with IFNbeta-1a products, but not those treated with IFNbeta-1b. babs 65-69 interferon beta 1 Homo sapiens 120-127 17911479-0 2007 Mechanism of action of IFN-beta in the treatment of multiple sclerosis: a special reference to CD73 and adenosine. Adenosine 104-113 interferon beta 1 Homo sapiens 23-31 17911479-8 2007 Adenosine, a known neuroprotective agent, might contribute to the beneficial effects of IFN-beta on MS. Adenosine 0-9 interferon beta 1 Homo sapiens 88-96 18209032-10 2008 Treatment with flagellin or RANKL stimulated STAT1 activation, and STAT1 deficiency or the JAK2 inhibitor AG490 dramatically prevented IFN-beta induction in response to flagellin or RANKL. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 106-111 interferon beta 1 Homo sapiens 135-143 17645749-2 2007 From an in vitro study, beta-interferon (IFN-beta) has been reported to enhance the antiproliferative effects of doxorubicin on HCC cell lines. Doxorubicin 113-124 interferon beta 1 Homo sapiens 41-49 17950468-1 2007 Many multiple sclerosis (MS) patients treated with interferon-beta (IFNbeta) develop anti-IFNbeta antibodies (BAbs), which can interfere with both in vitro and in vivo bioactivity of the injected cytokine. butamben 110-114 interferon beta 1 Homo sapiens 51-66 17950468-1 2007 Many multiple sclerosis (MS) patients treated with interferon-beta (IFNbeta) develop anti-IFNbeta antibodies (BAbs), which can interfere with both in vitro and in vivo bioactivity of the injected cytokine. butamben 110-114 interferon beta 1 Homo sapiens 68-75 17950468-1 2007 Many multiple sclerosis (MS) patients treated with interferon-beta (IFNbeta) develop anti-IFNbeta antibodies (BAbs), which can interfere with both in vitro and in vivo bioactivity of the injected cytokine. butamben 110-114 interferon beta 1 Homo sapiens 90-97 18080224-0 2007 Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial. Steroids 24-31 interferon beta 1 Homo sapiens 82-97 17905201-4 2007 IFN-beta suppressed the production of glutamate and superoxide by activated microglia to 70% and 75% of lipopolysaccharide stimulation, respectively, and prevented microglial-induced neuronal cell death. Glutamic Acid 38-47 interferon beta 1 Homo sapiens 0-8 17905201-4 2007 IFN-beta suppressed the production of glutamate and superoxide by activated microglia to 70% and 75% of lipopolysaccharide stimulation, respectively, and prevented microglial-induced neuronal cell death. Superoxides 52-62 interferon beta 1 Homo sapiens 0-8 17905201-5 2007 Although IFN-beta enhanced the production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and nitric oxide (NO) by activated microglia, these molecules did not directly induce neurotoxicity in cultured cortical neurons. Nitric Oxide 108-120 interferon beta 1 Homo sapiens 9-17 24299942-7 2007 In the patients treated with IFNbeta-1b there was a significant increase in the ratio of NAA/Cr in NAWM (p=0.028) at 24 months after the initiation of treatment. N-acetylaspartate 89-92 interferon beta 1 Homo sapiens 29-36 24299942-7 2007 In the patients treated with IFNbeta-1b there was a significant increase in the ratio of NAA/Cr in NAWM (p=0.028) at 24 months after the initiation of treatment. Creatine 93-95 interferon beta 1 Homo sapiens 29-36 24299942-7 2007 In the patients treated with IFNbeta-1b there was a significant increase in the ratio of NAA/Cr in NAWM (p=0.028) at 24 months after the initiation of treatment. nawm 99-103 interferon beta 1 Homo sapiens 29-36 17911629-5 2007 Polyinosinic-polycytidylic acid activated IFN regulatory factor 3 dimerization and phosphorylation, increased activity of the IFN-stimulated response element, induced a significant increase in IFN-beta mRNA transcripts and IFN-beta secretion, and up-regulated the expression of IFN-regulated genes in IECs. Poly I-C 0-31 interferon beta 1 Homo sapiens 193-201 17911629-5 2007 Polyinosinic-polycytidylic acid activated IFN regulatory factor 3 dimerization and phosphorylation, increased activity of the IFN-stimulated response element, induced a significant increase in IFN-beta mRNA transcripts and IFN-beta secretion, and up-regulated the expression of IFN-regulated genes in IECs. Poly I-C 0-31 interferon beta 1 Homo sapiens 223-231 17979888-8 2007 IFN-beta-induced STAT4 phosphorylation, IL-10 production and IFN receptor (IFNAR) subunits 1 and 2 expression were enhanced by curcumin. Curcumin 127-135 interferon beta 1 Homo sapiens 0-8 17683572-0 2007 Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma. Temozolomide 78-90 interferon beta 1 Homo sapiens 17-32 17892396-3 2007 We investigated the contribution of these kinases to IFN-beta expression in human macrophages treated with poly(I:C), lipopolysaccharide (LPS), Sendai virus, or vesicular stomatitis virus (VSV). Poly I-C 107-115 interferon beta 1 Homo sapiens 53-61 17619058-3 2007 Eleven percent of IFNbeta-treated patients showed a lack of MxA induction, with an inverse correlation between MxA mRNA and the presence of BAbs and NAbs. butamben 140-144 interferon beta 1 Homo sapiens 18-25 17619058-3 2007 Eleven percent of IFNbeta-treated patients showed a lack of MxA induction, with an inverse correlation between MxA mRNA and the presence of BAbs and NAbs. nabs 149-153 interferon beta 1 Homo sapiens 18-25 17626075-4 2007 PIC induction of IDO was mediated in part by IFN-beta but not IFN-gamma, and both NF-kappaB and interferon regulatory factor 3 (IRF3) were required. Poly I-C 0-3 interferon beta 1 Homo sapiens 45-53 17683572-5 2007 Here we report a patient with TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of interferon-beta and TMZ. Temozolomide 30-33 interferon beta 1 Homo sapiens 124-139 17683572-11 2007 CONCLUSION: It is considered that interferon-beta pre-administration increased the TMZ sensitivity of the glioma, which had been refractory to TMZ monotherapy. Temozolomide 83-86 interferon beta 1 Homo sapiens 34-49 17683572-11 2007 CONCLUSION: It is considered that interferon-beta pre-administration increased the TMZ sensitivity of the glioma, which had been refractory to TMZ monotherapy. Temozolomide 143-146 interferon beta 1 Homo sapiens 34-49 17662004-5 2007 It is concluded that NAb titres are important for the biological response to IFN-beta. nab 21-24 interferon beta 1 Homo sapiens 77-85 17468449-2 2007 Anti-IFN-beta NAb are a subset of anti-IFN-beta binding antibodies (BAb) and all patients with NAb generally have high levels of associated BAb. bab 68-71 interferon beta 1 Homo sapiens 5-13 17643724-0 2007 Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival. DAV protocol 121-124 interferon beta 1 Homo sapiens 19-34 17654600-7 2007 In the IFN beta-1a/ribavirin group, 73 of 127 patients (57.5%) achieved an SVR [P < 0.001 versus IFN beta-1a; the adjusted odds ratio was 4.54 (95% confidence interval: 2.53, 8.13)]. Ribavirin 19-28 interferon beta 1 Homo sapiens 7-15 17654600-7 2007 In the IFN beta-1a/ribavirin group, 73 of 127 patients (57.5%) achieved an SVR [P < 0.001 versus IFN beta-1a; the adjusted odds ratio was 4.54 (95% confidence interval: 2.53, 8.13)]. Ribavirin 19-28 interferon beta 1 Homo sapiens 100-108 17654600-10 2007 The addition of ribavirin to IFN beta-1a significantly increased the proportion of patients who achieved an SVR versus IFN beta-1a monotherapy. Ribavirin 16-25 interferon beta 1 Homo sapiens 119-127 17784815-5 2007 NAb titers obtained using IFN-beta1b averaged 3-5-fold lower than titers of the same sample assayed using either IFN-beta1a or human fibroblast-derived IFN-beta. nab 0-3 interferon beta 1 Homo sapiens 26-34 17522204-1 2007 Hantaviruses, causing hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS), are known to be sensitive to nitric oxide (NO) and to pretreatment with type I and II interferons (alpha interferon [IFN-alpha]/IFN-beta and IFN-gamma, respectively). Nitric Oxide 144-156 interferon beta 1 Homo sapiens 243-251 17468449-2 2007 Anti-IFN-beta NAb are a subset of anti-IFN-beta binding antibodies (BAb) and all patients with NAb generally have high levels of associated BAb. bab 68-71 interferon beta 1 Homo sapiens 39-47 17468449-2 2007 Anti-IFN-beta NAb are a subset of anti-IFN-beta binding antibodies (BAb) and all patients with NAb generally have high levels of associated BAb. bab 140-143 interferon beta 1 Homo sapiens 5-13 17468449-3 2007 The purpose of this research was to assess the association between autoreactive antibodies (ARAB) and the risk of developing anti-IFN-beta BAb in MS patients. bab 139-142 interferon beta 1 Homo sapiens 130-138 17177965-8 2007 In vitro studies evaluating the cell source of these cytokines revealed that polyriboinosinic polyribocytidylic acid (poly I:C) activated retinal vascular endothelial cells produce sE-selectin, sICAM-1 and IFN-beta. Poly I-C 77-116 interferon beta 1 Homo sapiens 206-214 17389300-4 2007 In addition, the rate of NAb production is probably less with IFNbeta-1a treatment than with IFNbeta-1b treatment, although the magnitude and persistence of this difference is difficult to determine (Level B). nab 25-28 interferon beta 1 Homo sapiens 62-69 17389300-4 2007 In addition, the rate of NAb production is probably less with IFNbeta-1a treatment than with IFNbeta-1b treatment, although the magnitude and persistence of this difference is difficult to determine (Level B). nab 25-28 interferon beta 1 Homo sapiens 93-100 17389300-8 2007 Although the finding of sustained high-titer NAbs (>100 to 200 NU/mL) is associated with a reduction in the therapeutic effects of IFNbeta on radiographic and clinical measures of MS disease activity, there is insufficient information on the utilization of NAb testing to provide specific recommendations regarding when to test, which test to use, how many tests are necessary, or which cutoff titer to apply (Level U). nab 45-48 interferon beta 1 Homo sapiens 134-141 17239348-4 2007 Here we showed that chemically synthesized TLR4-agonistic lipid A analogues but not antagonistic lipid A activate IFN-beta promoter in TLR4-expressing HEK293 cells. Lipid A 58-65 interferon beta 1 Homo sapiens 114-122 17439886-10 2007 In conclusion, NAbs to IFNbeta are common in a clinical setting and the IFNbeta preparations differ not only in NAb seroprevalence, but also in immunogenicity. nab 15-18 interferon beta 1 Homo sapiens 23-30 17439886-10 2007 In conclusion, NAbs to IFNbeta are common in a clinical setting and the IFNbeta preparations differ not only in NAb seroprevalence, but also in immunogenicity. nab 15-18 interferon beta 1 Homo sapiens 72-79 17277112-6 2007 In contrast, IL-10 is produced by HC-primed CD8 T cells if IFN-beta-producing NKT cells are coactivated by the same HC presenting a glycolipid (in the context of CD1d) and an antigenic peptide (in the context of K(b)). Glycolipids 132-142 interferon beta 1 Homo sapiens 59-67 17273997-3 2007 TLR-3 and TLR-4 induce IFN-beta by activating IRF-3; TLR-9 induces IFN-alpha and IFN-beta through IRF-7, at least when engaged by type A CpG oligonucleotides (CpG-A) in plasmacytoid DC (pDC). Oligonucleotides 141-157 interferon beta 1 Homo sapiens 81-89 17273997-4 2007 In this issue of the European Journal of Immunology, it is demonstrated that TLR-9 induces IFN-beta when engaged by type B CpG oligonucleotides (CpG-B) in myeloid DC and macrophages. Oligonucleotides 127-143 interferon beta 1 Homo sapiens 91-99 17457510-5 2007 NAb testing is a critical component of care for MS patients because it provides information on one of the most important factors determining clinical responsiveness to IFNbeta therapy. nab 0-3 interferon beta 1 Homo sapiens 168-175 17572015-8 2007 IFN-beta with 10 muM of 5-FU frequently induced synergistic antiproliferative effects. Fluorouracil 24-28 interferon beta 1 Homo sapiens 0-8 17548434-2 2007 It frequently induces the formation of neutralising anti-Interferon Beta Antibodies (Nabs) which may abrogate the clinical efficacy of the drug. nabs 85-89 interferon beta 1 Homo sapiens 57-72 17548440-2 2007 However, data from pivotal trials of IFN-beta in MS suggest that NAb-positive patients may have a reduced relapse rate during the first six to 12 months of therapy. nab 65-68 interferon beta 1 Homo sapiens 37-45 17548440-6 2007 This is in accordance with observations in randomised studies of the three different IFN-beta preparations, showing that patients who become NAb-positive have lower relapse rates during the first six or 12 months of therapy. nab 141-144 interferon beta 1 Homo sapiens 85-93 17548442-3 2007 After mitoxantrone therapy, some patients received DMT (interferon-beta or glatiramer acetate) while others did not. dmt 51-54 interferon beta 1 Homo sapiens 56-71 17296604-3 2007 Inhibition of conventional PKC (cPKC) activity in monocyte-derived dendritic cells or TLR3-expressing cells by an isoform-specific inhibitor, Go6976, selectively inhibited IFN-beta synthesis induced by double-stranded RNA polyinosine-polycytidylic acid. Go 6976 142-148 interferon beta 1 Homo sapiens 172-180 17296604-3 2007 Inhibition of conventional PKC (cPKC) activity in monocyte-derived dendritic cells or TLR3-expressing cells by an isoform-specific inhibitor, Go6976, selectively inhibited IFN-beta synthesis induced by double-stranded RNA polyinosine-polycytidylic acid. polyinosine-polycytidylic acid 222-252 interferon beta 1 Homo sapiens 172-180 16826196-3 2007 Here, we demonstrate that mitochondrial respiratory chain (MRC) plays an essential role in the IFN-beta/RA-induced cancer cell death. Tretinoin 104-106 interferon beta 1 Homo sapiens 95-103 16826196-5 2007 Mitochondrial-nuclear translocation of these subunits was not observed, but overproduction of reactive oxygen species (ROS), which causes loss of mitochondrial function, was detected upon IFN-beta/RA treatment. Reactive Oxygen Species 94-117 interferon beta 1 Homo sapiens 188-196 16826196-5 2007 Mitochondrial-nuclear translocation of these subunits was not observed, but overproduction of reactive oxygen species (ROS), which causes loss of mitochondrial function, was detected upon IFN-beta/RA treatment. Reactive Oxygen Species 119-122 interferon beta 1 Homo sapiens 188-196 16826196-8 2007 Our data suggest that the MRC regulates IFN-beta/RA-induced cell death by modulating ROS production and late gene expression. Reactive Oxygen Species 85-88 interferon beta 1 Homo sapiens 40-48 17177965-8 2007 In vitro studies evaluating the cell source of these cytokines revealed that polyriboinosinic polyribocytidylic acid (poly I:C) activated retinal vascular endothelial cells produce sE-selectin, sICAM-1 and IFN-beta. Poly C 118-126 interferon beta 1 Homo sapiens 206-214 16961130-1 2006 OBJECT: This Phase II study was performed to determine the safety, tolerability, and efficacy of combining nimustine (ACNU)-carboplatin-vincristine-Interferon-beta (IFNbeta) chemotherapy. Nimustine 107-116 interferon beta 1 Homo sapiens 165-172 17263000-7 2006 The proportion of NAb-positive patients within the BAb-positive group differed significantly among treatment groups, ranging between 12% (IFNbeta-1a im) and 51% (IFNbeta-1a sc). bab 51-54 interferon beta 1 Homo sapiens 138-145 17263000-7 2006 The proportion of NAb-positive patients within the BAb-positive group differed significantly among treatment groups, ranging between 12% (IFNbeta-1a im) and 51% (IFNbeta-1a sc). bab 51-54 interferon beta 1 Homo sapiens 162-169 17263000-10 2006 Except for conflicting data regarding IFNbeta-1a sc, the results are generally consistent with the literature and together with the differing proportion of NAb-positive patients within the BAb-positive group, provide further insight into the immunogenicity of the IFNbeta preparations. bab 189-192 interferon beta 1 Homo sapiens 264-271 16732315-1 2006 Gene associated with retinoid interferon-induced mortality (GRIM)-19, an inhibitor of transcription factor STAT3, was originally identified as a critical regulatory protein in a genetic screen that was designed to identify the gene products necessary for Interferon (IFN)-beta- and retinoic acid-induced cell death. Retinoids 21-29 interferon beta 1 Homo sapiens 255-276 17082634-10 2006 BAFF was also strongly induced by IFN-beta, a cytokine induced by dsRNA. baff 0-4 interferon beta 1 Homo sapiens 34-42 17082634-12 2006 These results suggest that BAFF is induced by dsRNA in airway epithelial cells and that the response results via an autocrine pathway involving IFN-beta. baff 27-31 interferon beta 1 Homo sapiens 144-152 17101906-0 2006 Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. We measured neutralizing antibodies (NABs) and the in vivo biologic response to interferon-beta on neopterin and beta(2)-microglobulin blood levels. Neopterin 199-208 interferon beta 1 Homo sapiens 180-195 16978784-0 2006 Suppressive effect of simvastatin on interferon-beta-induced expression of CC chemokine ligand 5 in microglia. Simvastatin 22-33 interferon beta 1 Homo sapiens 37-52 16978784-6 2006 The simvastatin treatment significantly diminished the microglial CCL5 expression induced by IFN-beta alone or by IFN-beta/TNF-alpha combination. Simvastatin 4-15 interferon beta 1 Homo sapiens 93-101 16978784-6 2006 The simvastatin treatment significantly diminished the microglial CCL5 expression induced by IFN-beta alone or by IFN-beta/TNF-alpha combination. Simvastatin 4-15 interferon beta 1 Homo sapiens 114-122 16978784-7 2006 In the presence of simvastatin, the IFN-beta-induced activation of Janus kinase (Jak)-signal transducer and activator of transcription (STAT) pathway was attenuated, although this compound had little or no effect on the TNF-alpha-evoked activation of nuclear factor kappaB and c-Jun N-terminal kinase pathways. Simvastatin 19-30 interferon beta 1 Homo sapiens 36-44 16978784-9 2006 Taken together, these results suggest that simvastatin suppresses the IFN-beta-induced expression of CCL5 via down-regulation of Jak-STAT signaling pathway. Simvastatin 43-54 interferon beta 1 Homo sapiens 70-78 16959222-5 2006 Interferon (IFN)-beta and -gamma treatment induced IFN-stimulated responsive element (ISRE) transcriptional activity, which was efficiently inhibited by curcumin pre-treatment. Curcumin 153-161 interferon beta 1 Homo sapiens 0-21 16978828-0 2006 Involvement of IFNbeta on IFNgamma and nitric oxide (NO) production by bone marrow (BM) cells in response to lipopolysaccharide. Nitric Oxide 39-51 interferon beta 1 Homo sapiens 15-22 16978828-6 2006 However, only IFNbeta appears to be critical on nitric oxide production. Nitric Oxide 48-60 interferon beta 1 Homo sapiens 14-21 16978828-8 2006 In conclusion, IFNbeta appears to be critical on IFNgamma- and nitric oxide production by BM cells in response to LPS, through a mechanism that is dependent on Thy1.2+CD3+ IFNgamma-producing cells. Nitric Oxide 63-75 interferon beta 1 Homo sapiens 15-22 17015750-9 2006 Conversely, administration of recombinant IFN-beta resulted in reduced leukotriene B4 levels and decreased peritoneal neutrophil recruitment and activation. Leukotriene B4 71-85 interferon beta 1 Homo sapiens 42-50 16961130-11 2006 CONCLUSIONS: The combination of ACNU-carboplatin-vincristine-IFNbeta chemotherapy and radiotherapy is safe and well tolerated, and may prolong survival in patients with glioblastoma multiforme. acnu-carboplatin 32-48 interferon beta 1 Homo sapiens 61-68 16961130-11 2006 CONCLUSIONS: The combination of ACNU-carboplatin-vincristine-IFNbeta chemotherapy and radiotherapy is safe and well tolerated, and may prolong survival in patients with glioblastoma multiforme. Vincristine 49-60 interferon beta 1 Homo sapiens 61-68 16961130-1 2006 OBJECT: This Phase II study was performed to determine the safety, tolerability, and efficacy of combining nimustine (ACNU)-carboplatin-vincristine-Interferon-beta (IFNbeta) chemotherapy. Carboplatin 124-135 interferon beta 1 Homo sapiens 165-172 16801630-3 2006 Treatment of human ACHN renal cell carcinoma (RCC) and A375 melanoma cells with the DNA demethylating nucleoside analog 5-AZA-2"-deoxycytidine (5-AZA-dC) synergistically augmented antiproliferative effects of IFN- alpha (alpha) 2 and IFN-beta (beta). Decitabine 120-142 interferon beta 1 Homo sapiens 234-242 16801630-3 2006 Treatment of human ACHN renal cell carcinoma (RCC) and A375 melanoma cells with the DNA demethylating nucleoside analog 5-AZA-2"-deoxycytidine (5-AZA-dC) synergistically augmented antiproliferative effects of IFN- alpha (alpha) 2 and IFN-beta (beta). Decitabine 144-152 interferon beta 1 Homo sapiens 234-242 16838652-2 2006 Since approved as a therapeutic drug for brain tumor originally produced in Japan, interferon-beta has been reported to be effective when it was used alone, in combination with chemo-radiotherapy (ACNU/MCNU as a nitrosourea derivative chemodrug, and radiation for 60 Gy totally). Nimustine 197-201 interferon beta 1 Homo sapiens 83-98 16670125-5 2006 Our aim was to investigate the effects of dexamethasone on STAT4 activation by IFN-beta and IL-12 in human T cell blasts. Dexamethasone 42-55 interferon beta 1 Homo sapiens 79-87 16670125-6 2006 We report that dexamethasone decreases IL-12-induced STAT4 phosphorylation and IFN-gamma production and enhances IFN-beta-induced STAT4 activation and IL-10 production. Dexamethasone 15-28 interferon beta 1 Homo sapiens 113-121 16838652-2 2006 Since approved as a therapeutic drug for brain tumor originally produced in Japan, interferon-beta has been reported to be effective when it was used alone, in combination with chemo-radiotherapy (ACNU/MCNU as a nitrosourea derivative chemodrug, and radiation for 60 Gy totally). ranimustine 202-206 interferon beta 1 Homo sapiens 83-98 16838652-2 2006 Since approved as a therapeutic drug for brain tumor originally produced in Japan, interferon-beta has been reported to be effective when it was used alone, in combination with chemo-radiotherapy (ACNU/MCNU as a nitrosourea derivative chemodrug, and radiation for 60 Gy totally). Nitrosourea Compounds 212-223 interferon beta 1 Homo sapiens 83-98 16838652-4 2006 For example, as a fundamental study, temozolomide is an enthusiastic chemodrug to enhance the anti-tumor effect of interferon-beta when it is combined, pre-clinical and clinical trial will be scheduled. Temozolomide 37-49 interferon beta 1 Homo sapiens 115-130 16707574-4 2006 We also show that MAVS/IPS-1-dependent IFN-beta promoter activity in HCV-infected cells is fully restored by the nonstructural protein 3 (NS3) protease inhibitor BILN2061. BILN 2061 162-170 interferon beta 1 Homo sapiens 39-47 16704888-9 2006 IFN-alpha and IFN-beta, but not TNF-alpha or IL-6, were able to mimic the adjuvant effects of poly (I:C). poly 94-98 interferon beta 1 Homo sapiens 14-22 16674604-0 2006 Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Glatiramer Acetate 0-18 interferon beta 1 Homo sapiens 48-63 16674604-10 2006 Switching to GA can benefit patients who discontinue IFN-beta therapy. Glatiramer Acetate 13-15 interferon beta 1 Homo sapiens 53-61 16399790-9 2006 Pretreatment with wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, was able to abate the effect of DE(as) on poly(I:C)-induced IFN-beta expression. Wortmannin 18-28 interferon beta 1 Homo sapiens 145-153 16399790-9 2006 Pretreatment with wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, was able to abate the effect of DE(as) on poly(I:C)-induced IFN-beta expression. Poly I 127-133 interferon beta 1 Homo sapiens 145-153 16399790-9 2006 Pretreatment with wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, was able to abate the effect of DE(as) on poly(I:C)-induced IFN-beta expression. Carbon 134-135 interferon beta 1 Homo sapiens 145-153 16624932-2 2006 Here, we describe that the IFN-beta released upon stimulation with lipopolysaccharide (LPS) or polyinosinic:polycytidylic acid (poly I:C) is responsible for a rapid and sustained signal transducer and activator of transcription 1 and 2 activation and expression of IFN-stimulated genes, such as the transcription factor IFN regulatory factor 7 and the chemokine CXC chemokine ligand 10. Poly C 108-126 interferon beta 1 Homo sapiens 27-35 16466595-10 2006 The odds of relapse during a NAb+ period are between 1.51 and 1.58 (p < 0.03) with the time to first relapse being shortened by an average of 244 days after 12 months of IFN-beta therapy. nab 29-32 interferon beta 1 Homo sapiens 173-181 16764338-0 2006 The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients. Norepinephrine 4-18 interferon beta 1 Homo sapiens 70-85 16764338-7 2006 This is the first report of the effects of IFN-beta administration on intracellular catecholamines in MS patients. Catecholamines 84-98 interferon beta 1 Homo sapiens 43-51 16764345-10 2006 For 63% of patients treated with immunosuppressive or immunomodulatory therapies, oral levocarnitine adjunction decreased fatigue intensity, especially in patients treated with cyclophosphamide and interferon beta. Carnitine 87-100 interferon beta 1 Homo sapiens 198-213 16421230-8 2006 Polyinosine-polycytidylic acid also induced production of interferon-beta and chemokine C-C motif ligand 5, whereas CpG DNA did not. polyinosine-polycytidylic acid 0-30 interferon beta 1 Homo sapiens 58-106 16556466-1 2006 In this study, we investigated the affinity, determined by a relative affinity assay, using increasing concentrations of sodium-isothiocyanate to disrupt the antigen antibody binding of neutralizing and non-neutralizing antibodies against interferon-beta (IFNbeta)-1a and -1b in 73 serum samples of MS patients treated with IFNbeta-1a or -1b. sodium thiocyanate 121-142 interferon beta 1 Homo sapiens 239-254 16324719-7 2006 In contrast, Ramos cells, which do not constitutively express PKR, present an increased resistance to mercury when PKR expression is induced by polyIC or interferon-beta treatment. Mercury 102-109 interferon beta 1 Homo sapiens 154-169 16210696-9 2006 Further studies demonstrated that 2-aminopurine, a specific inhibitor double-stranded RNA-dependent protein kinase, could block both IFN-beta production and RV-induced gene expression. 2-Aminopurine 34-47 interferon beta 1 Homo sapiens 133-141 16103093-3 2005 The combination IFN-beta and irinotecan (CPT-11) cooperatively inhibits cell growth and IRF-5 synergizes with it to further promote apoptosis. Irinotecan 41-47 interferon beta 1 Homo sapiens 16-24 16608106-7 2006 The results of interferon beta trials in patients with CIS showed significant benefit of the treatment in decreasing risk of CDMS development. cdms 125-129 interferon beta 1 Homo sapiens 15-30 16339068-2 2005 Neopterin production under specific conditions in vitro has also been obtained upon stimulation with IFN-alpha and/or IFN-beta. Neopterin 0-9 interferon beta 1 Homo sapiens 118-126 16226271-8 2005 One of these CIS, designated 00/572, containing CHO cell-derived IFN-beta and formulated with both bovine casein and human serum albumin, could be assigned a potency, consistent for all assay types, of 40,000 international units (IU) per ampoule relative to the IU of the 2nd IS of IFN-beta, Gb23-902-531. cho 48-51 interferon beta 1 Homo sapiens 65-73 16226271-10 2005 However, greater inter-laboratory variations in estimates were evident from comparisons of Gb23-902-531 or 00/572 with either the 1st IS for E. coli-derived, non-glycosylated, IFN-beta with serine substitution at position 17 (IFN-beta Ser 17 mutein), Gxb02-901-535, or with a CIS (00/574) containing IFN-beta Ser 17 mutein. Serine 190-196 interferon beta 1 Homo sapiens 176-184 16146492-1 2005 OBJECTIVES: Glatiramer acetate (GA) is routinely used in multiple sclerosis (MS) patients who cannot tolerate or fail to respond to beta-interferon (IFN-beta). Glatiramer Acetate 12-30 interferon beta 1 Homo sapiens 149-157 16146492-1 2005 OBJECTIVES: Glatiramer acetate (GA) is routinely used in multiple sclerosis (MS) patients who cannot tolerate or fail to respond to beta-interferon (IFN-beta). Glatiramer Acetate 32-34 interferon beta 1 Homo sapiens 149-157 16166452-8 2005 Combining gemcitabine with cytokine immunogene therapy using IFN-beta markedly enhanced antitumor efficacy. gemcitabine 10-21 interferon beta 1 Homo sapiens 61-69 16157744-14 2005 We hypothesize that interferon beta may exert its effect on brain atrophy in part by reducing a cascade of events that involve iron deposition as a mediator of neurotoxicity or as a disease epiphenomenon. Iron 127-131 interferon beta 1 Homo sapiens 20-35 16140920-0 2005 IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Temozolomide 104-116 interferon beta 1 Homo sapiens 0-8 16140920-4 2005 Here, we show that IFN-beta sensitizes glioma cells that harbor the unmethylated MGMT promoter and are resistant to temozolomide. Temozolomide 116-128 interferon beta 1 Homo sapiens 19-27 16140920-6 2005 Our study suggests that clinical efficacy of temozolomide might be improved by combination with IFN-beta using appropriate doses and schedules of administration. Temozolomide 45-57 interferon beta 1 Homo sapiens 96-104 16187943-3 2005 Although some diseases have been treated successfully with cytokines or anticytokines (i.e., anti-TNF, and to a lesser extent recombinant IL-1 receptor antagonist, in rheumatoid arthritis; IFN-beta in multiple sclerosis), the fact remains that these therapies do not abrogate the concomitant use of steroids or immunosuppressive drugs, and that a significant percentage of patients do not respond to such therapies; these are important limitations. Steroids 299-307 interferon beta 1 Homo sapiens 189-197 16423036-7 2006 Furthermore, incubation of HCECs with an endosomal acidification inhibitor, chloroquine, markedly inhibited poly(I:C)-mediated IFN-beta expression in HCECs. Chloroquine 76-87 interferon beta 1 Homo sapiens 127-135 16423036-7 2006 Furthermore, incubation of HCECs with an endosomal acidification inhibitor, chloroquine, markedly inhibited poly(I:C)-mediated IFN-beta expression in HCECs. Poly I-C 108-117 interferon beta 1 Homo sapiens 127-135 16226271-11 2005 Indeed, variations in potency estimates for preparations containing IFN-beta Ser 17 mutein were sufficiently large to indicate that assays could distinguish preparations of IFN-beta Ser 17 mutein from preparations of glycosylated IFN-beta. Serine 182-185 interferon beta 1 Homo sapiens 173-181 16226271-11 2005 Indeed, variations in potency estimates for preparations containing IFN-beta Ser 17 mutein were sufficiently large to indicate that assays could distinguish preparations of IFN-beta Ser 17 mutein from preparations of glycosylated IFN-beta. Serine 182-185 interferon beta 1 Homo sapiens 173-181 16226271-14 2005 CIS 00/572, containing CHO cell-derived, glycosylated IFN-beta, was clearly shown to be suitable to serve as a primary standard for glycosylated forms of IFN-beta, especially clinical grade IFN-beta-1a products. cho 23-26 interferon beta 1 Homo sapiens 54-62 16241970-11 2005 In patient with NABs, measurements should be repeated, and therapy with IFN-beta should be discontinued in patients with high titres of NABs sustained at repeated measurements with 3- to 6-month intervals (Level A recommendation). nabs 136-140 interferon beta 1 Homo sapiens 72-80 15940386-1 2005 The aim of the present study was to evaluate the efficacy of the combination of cyclophosphamide (CTX) and interferon beta (IFN beta) in a group of relapsing remitting (RR) multiple sclerosis (MS) patients who experienced treatment failure during IFN beta therapy. Cyclophosphamide 80-96 interferon beta 1 Homo sapiens 247-255 16188991-10 2005 They produced IFN-beta after treatment with poly(I:C) but not with lipopolysaccharide. poly 44-48 interferon beta 1 Homo sapiens 14-22 16193896-0 2005 A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Cyclophosphamide 55-71 interferon beta 1 Homo sapiens 118-133 16193896-1 2005 OBJECTIVE: To evaluate the efficacy and safety of combination therapy with pulse cyclophosphamide given with methylprednisolone (MP) and interferon beta (IFNbeta)-Ia in multiple sclerosis (MS) patients with active disease during IFNbeta monotherapy. Cyclophosphamide 81-97 interferon beta 1 Homo sapiens 137-152 16193896-1 2005 OBJECTIVE: To evaluate the efficacy and safety of combination therapy with pulse cyclophosphamide given with methylprednisolone (MP) and interferon beta (IFNbeta)-Ia in multiple sclerosis (MS) patients with active disease during IFNbeta monotherapy. Cyclophosphamide 81-97 interferon beta 1 Homo sapiens 154-161 15845391-5 2005 While polyI:C induced IFN-beta, far stronger than human fibroblasts, and TLR3 gene expression in HCEC, LPS stimulation did not. Poly I-C 6-13 interferon beta 1 Homo sapiens 22-30 16053472-0 2005 Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients. Tryptophan 28-38 interferon beta 1 Homo sapiens 0-15 15940673-3 2005 First, treatment of monocyte-derived dendritic cells (DC) with wortmannin or LY294002 was found to enhance IFN-beta expression upon TLR3 or TLR4 engagement. Wortmannin 63-73 interferon beta 1 Homo sapiens 107-115 15940673-3 2005 First, treatment of monocyte-derived dendritic cells (DC) with wortmannin or LY294002 was found to enhance IFN-beta expression upon TLR3 or TLR4 engagement. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 interferon beta 1 Homo sapiens 107-115 16022584-4 2005 By contrast, reduced levels of D3R and renewed dopamine-associated regulatory functions were found in PBMCs from IFN-beta treated MS patients. Dopamine 47-55 interferon beta 1 Homo sapiens 113-121 15845500-10 2005 IFN-beta polyclonal antibody and IFN-alpha/beta receptor 1 antibody significantly reduced nitric oxide release. Nitric Oxide 90-102 interferon beta 1 Homo sapiens 0-8 15728246-7 2005 The half-life of IFI16 protein was found to be significantly increased in H2O2-treated cells compared with IFN-beta-treated cells (t1/2 = 120 min vs. > 30 min in H2O2- vs. IFN-beta-treated cells, respectively). Hydrogen Peroxide 74-78 interferon beta 1 Homo sapiens 175-183 15833366-0 2005 Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis. Catecholamines 55-69 interferon beta 1 Homo sapiens 21-36 15833373-0 2005 Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta. Mitoxantrone 0-12 interferon beta 1 Homo sapiens 86-94 15833373-1 2005 We assessed the action of mitoxantrone (MX) when given as rescue therapy in patients with relapsing-remitting (RR) multiple sclerosis (MS), whose disease activity worsens despite IFN-beta treatment. Mitoxantrone 26-38 interferon beta 1 Homo sapiens 179-187 15885616-8 2005 Gaseous acetaldehyde-inducible IFN-beta production management was fully reversible while maintaining cell viability at over 95% during the entire process. Acetaldehyde 8-20 interferon beta 1 Homo sapiens 31-39 16060397-0 2005 Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) and ribavirin improves the rate of eradication of the virus by less than 20% in patients with genotype 1b and a high viral load. Ribavirin 187-196 interferon beta 1 Homo sapiens 0-15 15752772-6 2005 The SD.IFN-beta also induced p53 and phosphorylation of p53 at Ser(15). Serine 63-66 interferon beta 1 Homo sapiens 7-15 15778392-9 2005 Similarly, IFN-alpha pretreatment strongly enhanced poly(I:C)-induced activation of IFN-beta, IL-28, and IL-29 genes also in HUVECs. Poly I-C 52-61 interferon beta 1 Homo sapiens 84-92 15651905-3 2005 These results were supported by MRI findings that showed significantly smaller increases in the volume of brain lesions and the number of new/enlarging and gadolinium-enhancing lesions in interferon-beta-1a recipients than in those receiving placebo. Gadolinium 156-166 interferon beta 1 Homo sapiens 188-203 15740178-1 2005 Several disease-modifying agents (DMAs) are approved for the treatment of multiple sclerosis, including three interferon (IFN)-beta products, glatiramer acetate and mitoxantrone. Dimethyl acetylsuccinate 34-38 interferon beta 1 Homo sapiens 110-131 15589048-3 2005 Pretreatment with RU486 blocked morphine-induced increases in IFN-beta, and reversed the suppression of IFN-gamma. Mifepristone 18-23 interferon beta 1 Homo sapiens 62-70 15589048-3 2005 Pretreatment with RU486 blocked morphine-induced increases in IFN-beta, and reversed the suppression of IFN-gamma. Morphine 32-40 interferon beta 1 Homo sapiens 62-70 15589055-6 2005 In the present study, we further characterize IFN-beta-modulated DC by using recently identified blood DC antigens (BDCA), and investigate their ability to produce type I IFN in response to virus stimulation. bdca 116-120 interferon beta 1 Homo sapiens 46-54 15728510-7 2005 Although both inhibitors of PI3K and MEK1 diminished the Ser(727) phosphorylation of STAT1 induced by IFN-beta, only Ly294002 inhibited sIL-1Ra production. Serine 57-60 interferon beta 1 Homo sapiens 102-110 15803376-1 2005 Previous investigators have reported encouraging results for malignant gliomas treated using a combination of human interferon beta (IFN-beta) with nimustine hydrochloride (ACNU) and radiation therapy (termed IAR therapy). Nimustine 148-171 interferon beta 1 Homo sapiens 133-141 15385586-7 2005 However, the membrane response to IFN-beta in the subthreshold range was prevented by ZD7288 (a specific blocker of I(h)) but not by Ni2+, carbachol, or bicuculline, pointing to a dependence on an intact I(h). ICI D2788 86-92 interferon beta 1 Homo sapiens 34-42 15516717-5 2004 The amount of IFN-beta protein increased by IV-infection, and DNA fragmentation was inhibited with anti-IFN-beta antibody and PKR inhibitor (2-aminopurine). 2-Aminopurine 141-154 interferon beta 1 Homo sapiens 14-22 15571491-4 2004 The third formulation of IFN-beta, known as IFN-beta(1b), consists of a modified amino acid sequence containing a cysteine to serine mutation at amino acid 17 and a deletion of the amino terminal methionine. Methionine 196-206 interferon beta 1 Homo sapiens 25-33 15571491-4 2004 The third formulation of IFN-beta, known as IFN-beta(1b), consists of a modified amino acid sequence containing a cysteine to serine mutation at amino acid 17 and a deletion of the amino terminal methionine. Methionine 196-206 interferon beta 1 Homo sapiens 44-52 15314118-6 2004 The two remaining IFN beta biological non-responders were NAb-. nab 58-61 interferon beta 1 Homo sapiens 18-26 15502819-5 2004 AIR-controlled interferon-beta production in transgenic CHO-K1-derived serum-free suspension cultures could be modulated by fine-tuning inflow and outflow of acetaldehyde-containing gas during standard bioreactor operation. Acetaldehyde 158-170 interferon beta 1 Homo sapiens 15-30 15464838-2 2004 To identify the domain of VP35 responsible for interferon antagonism, we generated mutations within the VP35 gene and found that a C-terminal basic amino acid motif is required for inhibition of ISG56 reporter gene expression as well as IFN-beta production. Amino Acids, Basic 142-158 interferon beta 1 Homo sapiens 237-245 15342205-2 2004 In this study we found that isoproterenol reduces T-cell proliferation and IFNgamma secretion in PBMCs cultures from healthy controls and IFNbeta-treated but not untreated MS patients. Isoproterenol 28-41 interferon beta 1 Homo sapiens 138-145 15194680-4 2004 To our surprise, treatment of cells with the HDAC inhibitor, trichostatin A (TSA), inhibits selected interferon beta (IFNbeta)-stimulated immediate early genes that are activated by the transcription factors Stat1 and Stat2. trichostatin A 61-75 interferon beta 1 Homo sapiens 101-116 15194680-4 2004 To our surprise, treatment of cells with the HDAC inhibitor, trichostatin A (TSA), inhibits selected interferon beta (IFNbeta)-stimulated immediate early genes that are activated by the transcription factors Stat1 and Stat2. trichostatin A 61-75 interferon beta 1 Homo sapiens 118-125 15194680-4 2004 To our surprise, treatment of cells with the HDAC inhibitor, trichostatin A (TSA), inhibits selected interferon beta (IFNbeta)-stimulated immediate early genes that are activated by the transcription factors Stat1 and Stat2. trichostatin A 77-80 interferon beta 1 Homo sapiens 101-116 15194680-4 2004 To our surprise, treatment of cells with the HDAC inhibitor, trichostatin A (TSA), inhibits selected interferon beta (IFNbeta)-stimulated immediate early genes that are activated by the transcription factors Stat1 and Stat2. trichostatin A 77-80 interferon beta 1 Homo sapiens 118-125 15194680-5 2004 However, IFNbeta activation of IRF-1, which requires tyrosine-phosphorylated Stat1 homodimers binding to a gamma interferon activation sequence in its promoter is not affected by TSA. Tyrosine 53-61 interferon beta 1 Homo sapiens 9-16 15253685-6 2004 Data from clinical trials of IFNbeta products indicate that clinical efficacy of IFNbeta is reduced in NAb-positive patients. nab 103-106 interferon beta 1 Homo sapiens 29-36 15241362-5 2004 RESULTS: Viruses and polyI:C induced IFN-alpha and IFN-beta production. polyi:c 21-28 interferon beta 1 Homo sapiens 51-59 15559606-3 2004 The aim of the study was the appreciation of BAb occurrence during the treatment of MS by the use of different types of interferon beta and their impact on clinical efficacy. bab 45-48 interferon beta 1 Homo sapiens 120-135 15559606-7 2004 All preparations of IFN-beta induced appearance of BAb, but frequency of developing BAb to IFN-beta varied according to the IFN beta given. bab 51-54 interferon beta 1 Homo sapiens 20-28 15559606-7 2004 All preparations of IFN-beta induced appearance of BAb, but frequency of developing BAb to IFN-beta varied according to the IFN beta given. bab 84-87 interferon beta 1 Homo sapiens 20-28 15559606-7 2004 All preparations of IFN-beta induced appearance of BAb, but frequency of developing BAb to IFN-beta varied according to the IFN beta given. bab 84-87 interferon beta 1 Homo sapiens 91-99 15559606-7 2004 All preparations of IFN-beta induced appearance of BAb, but frequency of developing BAb to IFN-beta varied according to the IFN beta given. bab 84-87 interferon beta 1 Homo sapiens 124-132 15559606-8 2004 The high levels of BAb appeared significant frequently in patients treated with IFN-beta 1-b than in patients treated with both preparations of IFN-beta 1-a. bab 19-22 interferon beta 1 Homo sapiens 80-88 15559606-8 2004 The high levels of BAb appeared significant frequently in patients treated with IFN-beta 1-b than in patients treated with both preparations of IFN-beta 1-a. bab 19-22 interferon beta 1 Homo sapiens 144-152 15184610-7 2004 During IFNbeta treatment, both NAb+ and NAb- patients showed a reduction in relapse rate; this reduction (25%) was not significant in NAb+ patients but was significant (67%; p < 0.0001) in NAb- patients. nab 31-34 interferon beta 1 Homo sapiens 7-14 15184610-7 2004 During IFNbeta treatment, both NAb+ and NAb- patients showed a reduction in relapse rate; this reduction (25%) was not significant in NAb+ patients but was significant (67%; p < 0.0001) in NAb- patients. nab 40-43 interferon beta 1 Homo sapiens 7-14 15184610-7 2004 During IFNbeta treatment, both NAb+ and NAb- patients showed a reduction in relapse rate; this reduction (25%) was not significant in NAb+ patients but was significant (67%; p < 0.0001) in NAb- patients. nab 40-43 interferon beta 1 Homo sapiens 7-14 15184610-7 2004 During IFNbeta treatment, both NAb+ and NAb- patients showed a reduction in relapse rate; this reduction (25%) was not significant in NAb+ patients but was significant (67%; p < 0.0001) in NAb- patients. nab 40-43 interferon beta 1 Homo sapiens 7-14 15173074-0 2004 Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma. phosphorothioate oligodeoxynucleotides 38-76 interferon beta 1 Homo sapiens 180-206 15173074-7 2004 Treatment of PC3 cells with either IFN-beta or -gamma recapitulated some of the aspects of the molecular and phenotypic changes observed after treatment with a G3139/Lipofectin complex. oblimersen 160-165 interferon beta 1 Homo sapiens 35-43 15173074-7 2004 Treatment of PC3 cells with either IFN-beta or -gamma recapitulated some of the aspects of the molecular and phenotypic changes observed after treatment with a G3139/Lipofectin complex. 1,2-dielaidoylphosphatidylethanolamine 166-176 interferon beta 1 Homo sapiens 35-43 15264109-3 2004 This article reviews the long-term data from large phase III clinical trials showing that NAbs can reduce the clinical efficacy of IFNbeta in patients with MS; patients who have a positive result on NAb testing have a higher relapse rate and more disease activity, as measured by brain MRI, than do patients with a negative result. nab 90-93 interferon beta 1 Homo sapiens 131-138 15264110-1 2004 Treatment of multiple sclerosis (MS) with interferon beta (IFNbeta) can be associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs). babs 130-134 interferon beta 1 Homo sapiens 42-57 15264110-1 2004 Treatment of multiple sclerosis (MS) with interferon beta (IFNbeta) can be associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs). babs 130-134 interferon beta 1 Homo sapiens 59-66 15264110-2 2004 NAbs are a subset of BAbs that prevent IFNbeta from effectively binding to or activating its receptor, thereby blocking its biologic effects and inhibiting its therapeutic effects. babs 21-25 interferon beta 1 Homo sapiens 39-46 15549353-1 2004 A proportion of people with multiple sclerosis (MS) treated with interferon (IFN) a develop neutralising anti-IFN beta antibodies (NABs). nabs 131-135 interferon beta 1 Homo sapiens 110-118 15549353-4 2004 In patients treated with IFN beta in whom NABs persist for a significant period of time, their presence is associated with a reduction in both the biological effects and clinical efficacy. nabs 42-46 interferon beta 1 Homo sapiens 25-33 15549353-6 2004 The persistence of NABs appears to be linked to the type of IFN beta treatment as well as the titre of antibodies. nabs 19-23 interferon beta 1 Homo sapiens 60-68 15549353-7 2004 The overall efficacy of IFN beta and, hence, of any biological disease-modifying treatment (DMT) would be substantially improved if the development of NABs could be prevented or reversed. nabs 151-155 interferon beta 1 Homo sapiens 24-32 15549353-10 2004 As a corollary, the therapeutic efficacy of IFN beta could be maximised if patients who tolerate higher-dose preparations could be prevented from developing persistent NABs. nabs 168-172 interferon beta 1 Homo sapiens 44-52 15549353-11 2004 Strategies employed to prevent or reverse the development of NABs with other biological compounds (e. g. insulin, factor VIII, IFN beta, recombinant human erythropoietin) include improvements in the manufacturing process, immunosuppression, induction of tolerance and deimmunisation, and these should be considered in relation to biological DMT therapy as part of future clinical studies. nabs 61-65 interferon beta 1 Homo sapiens 127-135 15273882-2 2004 Thus, our aim has been to describe the modifications of the plasma levels of total cholesterol and triglyceride due to treatment with interferon-beta in multiple sclerosis (MS) patients and to determine their relationship with the disease activity. Cholesterol 83-94 interferon beta 1 Homo sapiens 134-149 15273882-2 2004 Thus, our aim has been to describe the modifications of the plasma levels of total cholesterol and triglyceride due to treatment with interferon-beta in multiple sclerosis (MS) patients and to determine their relationship with the disease activity. Triglycerides 99-111 interferon beta 1 Homo sapiens 134-149 15261560-5 2004 Finally the association between methylprednisolone and interferon beta (IFNbeta) leads the recovery of active lesions at greater extent and reduces the formation of neutralizing antibodies (NABs) against IFNbeta in patients with RRMS. Methylprednisolone 32-50 interferon beta 1 Homo sapiens 55-80 15261560-5 2004 Finally the association between methylprednisolone and interferon beta (IFNbeta) leads the recovery of active lesions at greater extent and reduces the formation of neutralizing antibodies (NABs) against IFNbeta in patients with RRMS. Methylprednisolone 32-50 interferon beta 1 Homo sapiens 72-79 15261564-0 2004 A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. Cyclophosphamide 62-78 interferon beta 1 Homo sapiens 171-186 15261565-0 2004 Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. Cyclophosphamide 41-57 interferon beta 1 Homo sapiens 61-69 15261565-10 2004 Pulse cyclophosphamide decreases the number of Gd+ lesions in patients with active disease on IFN-beta compared to pulse methylprednisolone alone. Cyclophosphamide 6-22 interferon beta 1 Homo sapiens 94-102 15226270-7 2004 Furthermore, alanine scanning of the linker region demonstrated that the Phe(732), Leu(742) and Gly(743) in the TLR3 cytoplasmic linker region are essential for ligand-induced NF-kappaB and IFN-beta promoter activation. Phenylalanine 73-76 interferon beta 1 Homo sapiens 190-198 15226270-7 2004 Furthermore, alanine scanning of the linker region demonstrated that the Phe(732), Leu(742) and Gly(743) in the TLR3 cytoplasmic linker region are essential for ligand-induced NF-kappaB and IFN-beta promoter activation. Glycine 96-99 interferon beta 1 Homo sapiens 190-198 15265658-8 2004 RPE cells treated with poly I:C produced IFN-beta but not IFN-alpha, and this was inhibited by the treatment of RPE cells with anti-TLR 3 antibody. Poly I-C 23-31 interferon beta 1 Homo sapiens 41-49 15282384-2 2004 METHODS: A study was undertaken to determine whether treatment with inhaled fluticasone propionate (FP; 250 microg twice daily) for 2 weeks could modulate production of IL-15 or IFN-beta and thereby affect T cell survival in bronchial tissue of 10 patients with mild/moderate asthma. Fluticasone 76-98 interferon beta 1 Homo sapiens 178-186 15253685-6 2004 Data from clinical trials of IFNbeta products indicate that clinical efficacy of IFNbeta is reduced in NAb-positive patients. nab 103-106 interferon beta 1 Homo sapiens 81-88 14996551-5 2004 However, IFNbeta significantly and dose-dependently enhanced the production of inflammatory mediators for demyelination, such as TNFalpha, IL-1beta, IL-6, and nitric oxide (NO). Nitric Oxide 159-171 interferon beta 1 Homo sapiens 9-16 15007146-0 2004 Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients. Cholesterol 36-47 interferon beta 1 Homo sapiens 0-15 14600148-3 2004 In naive cells, the ISG54 gene is activated via IFN beta-stimulated formation of ISGF3, a heterotrimeric DNA binding complex consisting of p48 (IRF9) and tyrosine-phosphorylated Stat1 and Stat2. Tyrosine 154-162 interferon beta 1 Homo sapiens 48-56 14991072-6 2004 One mechanism by which hematopoietic progenitors are developmentally impaired is through the Cl 13-induced production of IFN-alpha and IFN-beta (IFN-alpha/beta). cl 13 93-98 interferon beta 1 Homo sapiens 135-143 15015010-7 2004 Over the course of the study, 83% of patients developed BAbs to IFNbeta-1b, 13% to IM IFNbeta-1a, and 47 % to SC IFNbeta-1a. babs 56-60 interferon beta 1 Homo sapiens 64-71 15015010-8 2004 Forty percent of patients developed NAbs to IFNbeta-1b, 6.7% to IM IFNbeta-1a, and 26.7% to SC IFNbeta-1a. 1b 52-54 interferon beta 1 Homo sapiens 44-51 15015010-13 2004 These findings demonstrate that high titers of both BAbs and NAbs reduce the clinical efficacy of IFNbeta in patients with RRMS, which is important for the long-term efficacy of these drugs. babs 52-56 interferon beta 1 Homo sapiens 98-105 17516727-1 2004 BACKGROUND AND OBJECTIVE: During the last decade, several agents have proven to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS), for example interferon-beta (IFNbeta) and glatiramer acetate. Glatiramer Acetate 202-220 interferon beta 1 Homo sapiens 172-187 14653852-0 2004 Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis? Neopterin 9-18 interferon beta 1 Homo sapiens 55-70 14653852-1 2004 BACKGROUND: Interferon beta (INFbeta) may induce the expression of several proteins, including neopterin, considered a biological marker of INFbeta activity. Neopterin 95-104 interferon beta 1 Homo sapiens 12-27 14631124-10 2004 Despite some limitations of our study design, the information regarding efficacy, safety and tolerance of the association of AZA and IFN-beta is most encouraging. Azathioprine 125-128 interferon beta 1 Homo sapiens 133-141 15045868-1 2004 Patients with multiple sclerosis receiving interferon beta (IFN) may develop neutralizing anti-interferon beta antibodies (NABs). nabs 123-127 interferon beta 1 Homo sapiens 43-58 15045868-1 2004 Patients with multiple sclerosis receiving interferon beta (IFN) may develop neutralizing anti-interferon beta antibodies (NABs). nabs 123-127 interferon beta 1 Homo sapiens 95-110 15331919-1 2004 OBJECTIVE: The protocol was designed to examine the biological effects and clinical activity of interferon-beta in patients with platinum/taxane-resistant ovarian cancer. Platinum 129-137 interferon beta 1 Homo sapiens 96-111 15331919-1 2004 OBJECTIVE: The protocol was designed to examine the biological effects and clinical activity of interferon-beta in patients with platinum/taxane-resistant ovarian cancer. taxane 138-144 interferon beta 1 Homo sapiens 96-111 15045868-4 2004 Differences of immunogenicity between the interferon beta products with regard to their structure, formulation, dose, route of administration were presented and the influence of NABs on the biological and clinical activity of IFN beta therapy was shown. nabs 178-182 interferon beta 1 Homo sapiens 226-234 14654475-6 2003 As for IFN-alpha, synergistic effects were observed when combined with 5-FU and DOX on PLC/PRF/5 cells only, whereas IFN-beta showed synergistic effects with 5-FU and CDDP on HuH7 and PLC/PRF/5 cell lines. Fluorouracil 158-162 interferon beta 1 Homo sapiens 117-125 14654475-6 2003 As for IFN-alpha, synergistic effects were observed when combined with 5-FU and DOX on PLC/PRF/5 cells only, whereas IFN-beta showed synergistic effects with 5-FU and CDDP on HuH7 and PLC/PRF/5 cell lines. Cisplatin 167-171 interferon beta 1 Homo sapiens 117-125 12944401-8 2003 On the other hand, Dex significantly decreased the endogenous production of interferon-beta, and this cytokine depressed the RANKL-elicited DNA binding of NF-kappaB and AP-1, as well as osteoclast formation. Dexamethasone 19-22 interferon beta 1 Homo sapiens 76-91 12944401-9 2003 Thus, the down-regulation of inhibitory cytokines such as interferon-beta by Dex may allow the osteoclast progenitors to be freed from the suppression of osteoclastogenesis, resulting in an increased number of osteoclasts, as is observed in the early phase of GC-induced osteoporosis. Dexamethasone 77-80 interferon beta 1 Homo sapiens 58-73 14575692-1 2003 PolyI:C, a synthetic double-stranded (ds)RNA, and viruses act on cells to induce IFN-beta which is a key molecule for anti-viral response. Poly I-C 0-7 interferon beta 1 Homo sapiens 81-89 14599789-8 2003 However, the IFN-beta promoter was not activated in cells that were first preinfected for 1 h with rSV5-WT and then subsequently infected with rSV5-P/V-CPI-. Phosphorus 148-149 interferon beta 1 Homo sapiens 13-21 17516727-1 2004 BACKGROUND AND OBJECTIVE: During the last decade, several agents have proven to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS), for example interferon-beta (IFNbeta) and glatiramer acetate. Glatiramer Acetate 202-220 interferon beta 1 Homo sapiens 189-196 12909305-3 2003 In MS, recombinant Interferon-beta (rIFNbeta) is effective in reducing gadolinium contrast-enhancing lesions on magnetic resonance imaging and this suggests that it may reduce BBB damage or even restore its integrity by different mechanisms that include interference with both AM and MMP pathways. Gadolinium 71-81 interferon beta 1 Homo sapiens 19-34 14614543-1 2003 To find an effective and quick way of purifying and identifying recombinant human IFN-beta (rhIFN-beta) expressed in yeast Pichia pastoris, Blue Sepharose 6 fast flow (Blue S6FF) and immunological affinity chromatography (IAC) were compared in this report. Sepharose 145-154 interferon beta 1 Homo sapiens 82-90 12759354-2 2003 We have previously shown that IFNalpha and IFNbeta induce phosphorylation of insulin receptor substrate proteins and downstream engagement of the phosphatidylinositol (PI) 3"-kinase pathway. Phosphatidylinositols 146-166 interferon beta 1 Homo sapiens 43-50 12867595-1 2003 GRIM-19 (gene associated with retinoid-IFN-induced mortality 19), isolated as a cell death activator in a genetic screen used to define mechanisms involved in IFN-beta- and retinoic acid-induced cell death, codes for a approximately 16-kDa protein that induces apoptosis in a number of cell lines. Retinoids 30-38 interferon beta 1 Homo sapiens 159-167 12759354-4 2003 Our data demonstrate that p70 S6K is rapidly phosphorylated on threonine 421 and serine 424 and is activated during treatment of cells with IFNalpha or IFNbeta. Threonine 63-72 interferon beta 1 Homo sapiens 152-159 12759354-4 2003 Our data demonstrate that p70 S6K is rapidly phosphorylated on threonine 421 and serine 424 and is activated during treatment of cells with IFNalpha or IFNbeta. Serine 81-87 interferon beta 1 Homo sapiens 152-159 12835817-10 2003 CONCLUSIONS: For a typical patient with RRMS, treatment with copaxone would be more efficient than interferons and would dominate (would be more efficacious with lower costs) interferon beta. Glatiramer Acetate 61-69 interferon beta 1 Homo sapiens 175-190 12804771-6 2003 In contrast, tyrosine phosphorylation of both STAT1 and STAT2 was inhibited in these cells after IFN-beta stimulation. Tyrosine 13-21 interferon beta 1 Homo sapiens 97-105 12746884-0 2003 Production of interferon-beta by fibroblast cells on membranes prepared with RGD-containing peptides. Peptides 92-100 interferon beta 1 Homo sapiens 14-29 12746884-1 2003 The production of interferon-beta by NB1-RGB fibroblast cells cultured on protein and peptide membranes prepared from silk fibroin, motif peptides of silk fibroin [(AG)(n)] containing arginine-glycine-aspartic acid (RGD) peptide, and Pronectin was investigated. arginyl-glycyl-aspartic acid 184-214 interferon beta 1 Homo sapiens 18-33 12746884-3 2003 The highest production of interferon-beta was observed when the cells were cultured on (AG)(6)RGD(AG)(7) membranes prepared with hexafluoroacetone (HFA) as the casting solvent. hexafluoroacetone 129-146 interferon beta 1 Homo sapiens 26-41 12746884-3 2003 The highest production of interferon-beta was observed when the cells were cultured on (AG)(6)RGD(AG)(7) membranes prepared with hexafluoroacetone (HFA) as the casting solvent. hexafluoroacetone 148-151 interferon beta 1 Homo sapiens 26-41 12746884-4 2003 On RGD-containing peptide membranes more centrally located in the peptides, the cells produced more interferon-beta when the peptide membranes were prepared with HFA as the casting solvent. hexafluoroacetone 162-165 interferon beta 1 Homo sapiens 100-115 12746884-7 2003 The blocking of integrin beta(1) on the cells by anti-integrin beta(1) antibody prevented the enhanced production of interferon-beta on (AG)(6)RGD(AG)(7) membranes prepared with HFA. hexafluoroacetone 178-181 interferon beta 1 Homo sapiens 117-132 12847277-9 2003 The antiapoptotic actions of IFN-beta were targeted at an early stage of neutrophil apoptosis, occurring upstream of mitochondrial permeability transition, and were phosphatidylinositol 3-kinase (PI3K) dependent, as they were blocked by the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 256-264 interferon beta 1 Homo sapiens 29-37 14656689-2 2003 Our RIPA showed good agreement with a reference RIPA (mean difference, -3.2 +/- 10.6 AU), and detected BAB to both IFN-beta-1a and IFN-beta-1b. bab 103-106 interferon beta 1 Homo sapiens 115-123 14656689-2 2003 Our RIPA showed good agreement with a reference RIPA (mean difference, -3.2 +/- 10.6 AU), and detected BAB to both IFN-beta-1a and IFN-beta-1b. bab 103-106 interferon beta 1 Homo sapiens 131-139 14656689-5 2003 BAB were found at higher concentrations, and more frequently detected, in IFN-beta-1b- than in IFN-beta-1a-treated patients, and, at highest titres, preferentially in patients who were positive for NAB. bab 0-3 interferon beta 1 Homo sapiens 74-82 14656689-5 2003 BAB were found at higher concentrations, and more frequently detected, in IFN-beta-1b- than in IFN-beta-1a-treated patients, and, at highest titres, preferentially in patients who were positive for NAB. bab 0-3 interferon beta 1 Homo sapiens 95-103 12764058-6 2003 Furthermore, the tetracycline minocycline, which has a known blocking effect in experimental autoimmune encephalomyelitis, an in vivo model of acute inflammation in multiple sclerosis, and other MMP inhibitors prevent the in vitro degradation of IFN-beta by gelatinase B. tetracycline minocycline 17-41 interferon beta 1 Homo sapiens 246-254 12764062-4 2003 Here we address the in vitro and ex vivo RNA expression profile under one approved therapy of multiple sclerosis, interferon-beta (IFN-beta, Betaseron), by cDNA microarrays and demonstrate that non-responder and responder phenotypes to IFN-beta as assessed by longitudinal gadolinium-enhanced MRI scans and clinical disease activity differ in their ex vivo gene expression profile. Gadolinium 273-283 interferon beta 1 Homo sapiens 114-129 14579493-6 2003 Interferon beta (Avonex, Rebif, Betaferon/Betaseron) and Glatirameracetate (Copaxone) offer effective therapeutic options for the long-term treatment of relapsing-remitting MS. With Mitoxantron (Ralenova) being recently approved by the EMEA for the treatment of secondary-progressive and progressive-relapsing MS an effective therapeutic option is now available also for this group of patients. Mitoxantrone 182-193 interferon beta 1 Homo sapiens 0-15 12500976-0 2003 Nuclear factor-kappa B and mitogen-activated protein kinases mediate nitric oxide-enhanced transcriptional expression of interferon-beta. Nitric Oxide 69-81 interferon beta 1 Homo sapiens 121-136 12719586-11 2003 Because IFN-beta expression itself was reduced in the ribavirin-treated cells, we further investigated the mechanism for up-regulation of the IFN-signaling pathway. Ribavirin 54-63 interferon beta 1 Homo sapiens 8-16 12628246-5 2003 Acetylation of the lysine residue in the second AT-hook, which corresponds to Lys65 of HMGA1, has little effect on the DNA binding; so it appears that repression of the hIFNbeta gene, which follows this modification, is not a direct result of the abrogation of DNA binding. Lysine 19-25 interferon beta 1 Homo sapiens 169-177 12500976-9 2003 DEA/NO and an additional NO donor, MAHMA/NO, are further demonstrated to enhance the transcriptional expression of the IFN-beta gene. dea 0-3 interferon beta 1 Homo sapiens 119-127 12600939-3 2003 Most importantly, in UBP43-deficient cells, IFN-beta induces a prolonged Stat1 tyrosine phosphorylation, DNA binding, and IFN-mediated gene activation. Tyrosine 79-87 interferon beta 1 Homo sapiens 44-52 12807338-7 2003 In addition, EPs 7630 stimulated the synthesis of IFN-beta in MG 63 cells as demonstrated by a specific enzyme immunoassay. exophthalmos producing substance 13-16 interferon beta 1 Homo sapiens 50-58 12580868-5 2003 It was necessary to stop IFN-beta in three cases; these patients still require carbimazole after several months. Carbimazole 79-90 interferon beta 1 Homo sapiens 25-33 12521562-4 2003 In relapsing-remitting multiple sclerosis (RRMS), there is overwhelming Class I data from large clinical trials that supports the use of interferon-beta-1a (IFNbeta-1a), interferon-beta-1b (IFNbeta-1b), and glatiramer acetate. Glatiramer Acetate 207-225 interferon beta 1 Homo sapiens 137-152 12639296-9 2003 At a molar dose equivalent to one-half the dose of IFN-beta, Albuferon beta elicited comparable neopterin responses and significantly higher 2",5"-OAS mRNA levels in rhesus monkeys. albuferon beta 61-75 interferon beta 1 Homo sapiens 51-59 12622455-2 2003 Interferon-beta, ACNU as nimustine hydrochloride and radiotherapy (IAR) is a common therapy for malignant glioma in Japan. Nimustine 17-21 interferon beta 1 Homo sapiens 0-15 12581542-4 2002 OBJECTIVE: This article reviews the potential mechanisms of action of IFN beta products and GA in the context of their regulatory effects on autoimmune components that may be of importance in MS. METHODS: MEDLINE and Current Contents/Clinical Medicine were searched for articles published in English from 1993 to the present using the search terms interferon beta, glatiramer acetate, and multiple sclerosis. Glatiramer Acetate 365-383 interferon beta 1 Homo sapiens 70-78 12479933-3 2002 SR was observed in 9 (18%) and non-response in 41 (82%) with the IFN beta induction/IFN alpha therapy, and in 3 (6.1%) and 46 (93.9%) with IFN alpha monotherapy, respectively. Strontium 0-2 interferon beta 1 Homo sapiens 65-73 12488496-8 2002 In distinction to monocytes/macrophages, neopterin production in DC was highly sensitive to IFN-alpha and IFN-beta. Neopterin 41-50 interferon beta 1 Homo sapiens 106-114 12474988-3 2002 IFNbeta has a significant anti-proliferative effect on GA-induced lymphoproliferation in vitro. Glatiramer Acetate 55-57 interferon beta 1 Homo sapiens 0-7 12474988-12 2002 The Th1/Th0/Th2 distribution of GA-TCL was 7%/30%/63% for the GA+IFNbeta group, 8%/9%/83% for the GA group, compared to 48%/21%/31% pre-GA treatment. Glatiramer Acetate 32-34 interferon beta 1 Homo sapiens 65-72 12474988-12 2002 The Th1/Th0/Th2 distribution of GA-TCL was 7%/30%/63% for the GA+IFNbeta group, 8%/9%/83% for the GA group, compared to 48%/21%/31% pre-GA treatment. Triclosan 35-38 interferon beta 1 Homo sapiens 65-72 12474988-13 2002 All five GA-TCL from the IFNbeta-1a monotherapy patients were Th2-biased. ga-tcl 9-15 interferon beta 1 Homo sapiens 25-32 12474988-13 2002 All five GA-TCL from the IFNbeta-1a monotherapy patients were Th2-biased. 1a 33-35 interferon beta 1 Homo sapiens 25-32 14746240-3 2003 The aim of the study was to evaluate firstly, BAb occurrence in interferon beta 1-a (IFN beta 1-a)-treated MS patients and secondly, BAb impact on clinical efficacy of this medication. bab 46-49 interferon beta 1 Homo sapiens 64-79 14746240-9 2003 A similar number of patients with high BAb levels was seen throughout the study during the IFN-beta treatment. bab 39-42 interferon beta 1 Homo sapiens 91-99 12482656-3 2002 In the absence of the viral V protein cysteine-rich C-terminal domain, IFN-beta mRNA is strongly induced and the transcription factors NF-kappaB and IRF-3 are activated significantly. Cysteine 38-46 interferon beta 1 Homo sapiens 71-79 12482656-6 2002 Blocking of the induction of IFN-beta by dsRNA requires the C-terminal cysteine-rich domain, a feature that is highly conserved among paramyxoviruses. Cysteine 71-79 interferon beta 1 Homo sapiens 29-37 12419248-2 2002 We found that only a small subset of lysines in histones H4 and H3 are acetylated in vivo by the GCN5 acetyltransferase during activation of the IFN-beta gene. Lysine 37-44 interferon beta 1 Homo sapiens 145-153 12391192-8 2002 Finally, biosensor-based binding kinetic analysis revealed that IFN-kappa, like IFN-beta, binds strongly to heparin (K(d): 2.1 nM), suggesting that the cytokine can be retained close to the local site of production. Heparin 108-115 interferon beta 1 Homo sapiens 80-88